22921020_3	Chemical	5,12	steroid
22921020_3	Gene_or_protein	65,70	SFRS3
22921020_3	Gene_or_protein	75,80	FKBP4
22921020_3	Pharmacodynamic_phenotype	5,21	steroid response
22921020_3	Limited_variation	50,64,75,80	alleles in the FKBP4
22921020_3	Limited_variation	50,70	alleles in the SFRS3
22684019_11	Chemical	26,32	IM3829
22684019_11	Disease	73,84	lung cancer
22684019_11	Phenotype	120,143	high expression of Nrf2
22684019_11	Gene_or_protein	139,143	Nrf2
22862823_4	Gene_or_protein	57,62	GATA4
22862823_4	Chemical	67,74	alcohol
22862823_4	Limited_variation	142,152	rs13273672
22862823_4	Disease	67,85	alcohol dependence
15947090_8	Limited_variation	19,34	CYP2C9 genotype
15947090_8	Gene_or_protein	19,25	CYP2C9
15947090_8	Chemical	64,74	S-warfarin
15947090_8	Chemical	85,93	warfarin
15947090_8	Chemical	166,177	R- warfarin
15947090_8	Pharmacokinetic_phenotype	64,74,94,103	S-warfarin clearance
15947090_8	Pharmacokinetic_phenotype	166,187	R- warfarin clearance
15947090_8	Pharmacokinetic_phenotype	79,103	total warfarin clearance
15947090_8	Phenotype	0,3	Age
15947090_8	Phenotype	6,12	height
15947090_8	Phenotype	119,122	age
15947090_8	Phenotype	127,136	body size
23792568_2	Chemical	0,9	Sorafenib
23792568_2	Gene_or_protein	48,52	BRAF
23792568_2	Disease	241,253	brain cancer
23792568_2	Disease	167,179	liver cancer
23792568_2	Disease	48,68	BRAF mutant melanoma
23792568_2	Disease	222,229,247,253	thyroid cancer
23792568_2	Disease	232,236,247,253	lung cancer
23792568_2	Limited_variation	48,59	BRAF mutant
23792568_2	Chemical	76,98	multi-kinase inhibitor
23792568_2	Disease	143,149,173,179	kidney cancer
24325099_2	Gene_or_protein	91,105	hepatic lipase
24325099_2	Gene_or_protein	113,117	LIPC
24325099_2	Chemical	177,189	carbohydrate
24325099_2	Genomic_factor	72,110	promoter region of hepatic lipase gene
24325099_2	Limited_variation	45,119	250G/A polymorphism in the promoter region of hepatic lipase gene ( LIPC )
24325099_2	Phenotype	123,142	serum lipid profile
24325099_2	Phenotype	171,198	high- carbohydrate /low-fat
24325099_2	Phenotype	201,206	HC/LF
24325099_2	Phenotype	217,237	serum lipid profiles
17105675_6	Limited_variation	33,39	A-241G
17105675_6	Chemical	76,87	risperidone
17105675_6	Limited_variation	363,372	rs1076562
17105675_6	Limited_variation	375,380	T939C
17105675_6	Chemical	443,454	risperidone
17105675_6	Pharmacodynamic_phenotype	64,97	efficacy of risperidone treatment
17105675_6	Limited_variation	338,352	-141 C Ins/Del
17105675_6	Limited_variation	355,360	TaqIB
17105675_6	Limited_variation	385,390	TaqIA
17105675_6	Pharmacodynamic_phenotype	431,454	response to risperidone
17105675_6	Limited_variation	134,142	A allele
17105675_6	Limited_variation	190,198	G allele
20172524_1	Pharmacodynamic_phenotype	11,47	effects of magnesium lithospermate B
20172524_1	Chemical	22,47	magnesium lithospermate B
20172524_1	Disease	56,80	diabetic atherosclerosis
20172524_1	Gene_or_protein	85,100	Nrf2 -ARE- NQO1
20172524_1	Genomic_factor	85,124	Nrf2 -ARE- NQO1 transcriptional pathway
17412797_15	Limited_variation	134,162	transferrin genetic variants
17412797_15	Gene_or_protein	134,145	transferrin
17412797_15	Disease	47,60	alcohol abuse
17412797_15	Gene_or_protein	27,30	CDT
19817501_20	Gene_or_protein	14,20	CYP2D6
19817501_20	Pharmacokinetic_phenotype	133,149,169,185	activity towards dextromethorphan
19817501_20	Pharmacokinetic_phenotype	133,149,188,199	activity towards risperidone
19817501_20	Pharmacokinetic_phenotype	133,149,202,209	activity towards codeine
19817501_20	Pharmacokinetic_phenotype	133,149,214,225	activity towards haloperidol
19817501_20	Haplotype	14,25	CYP2D6 * 17
19817501_20	Phenotype	68,84	reduced function
19817501_20	Chemical	150,160	substrates
19817501_20	Pharmacokinetic_phenotype	133,160	activity towards substrates
19817501_20	Chemical	169,185	dextromethorphan
19817501_20	Chemical	188,199	risperidone
19817501_20	Chemical	202,209	codeine
19817501_20	Chemical	214,225	haloperidol
15544431_6	Gene_or_protein	144,150	CYP2A6
15544431_6	Chemical	243,289	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
15544431_6	Chemical	292,295	NNK
15544431_6	Chemical	319,330	nitrosamine
15544431_6	Gene_or_protein	403,409	CYP2A6
15544431_6	Gene_or_protein	100,106	CYP2A8
15544431_6	Chemical	369,372	NNK
22298798_1	Chemical	45,56	clopidogrel
22298798_1	Gene_or_protein	18,23	ABCB1
22298798_1	Limited_variation	18,30	ABCB1 C3435T
22298798_1	Pharmacodynamic_phenotype	45,65	clopidogrel response
22298798_1	Disease	77,93	stent thrombosis
22298798_1	Disease	117,134	coronary stenting
25870087_1	Chemical	36,42	AUY922
25870087_1	Gene_or_protein	20,25	HSP90
25870087_1	Chemical	47,56	Erlotinib
25870087_1	Gene_or_protein	61,65	EGFR
25870087_1	Gene_or_protein	114,146	Epidermal Growth Factor Receptor
25870087_1	Limited_variation	61,73	EGFR -Mutant
25870087_1	Disease	61,85	EGFR -Mutant Lung Cancer
25870087_1	Chemical	114,173	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
25870087_1	Chemical	20,35	HSP90 Inhibitor
25870087_1	Pharmacodynamic_phenotype	91,173	Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
21351275_1	Disease	39,53	thyroid cancer
21351275_1	Gene_or_protein	73,76	MEK
21351275_1	Chemical	153,165	temsirolimus
21351275_1	Gene_or_protein	138,142	mTOR
21351275_1	Gene_or_protein	0,4	BRAF
21351275_1	Limited_variation	0,13	BRAF mutation
21351275_1	Phenotype	0,59	BRAF mutation -selective inhibition of thyroid cancer cells
21351275_1	Chemical	73,86	MEK inhibitor
21351275_1	Chemical	87,94	RDEA119
21351275_1	Phenotype	99,128	genetic-potentiated synergism
21351275_1	Chemical	138,152	mTOR inhibitor
11245458_9	Gene_or_protein	28,31	p53
11245458_9	Chemical	104,107	DDP
11245458_9	Gene_or_protein	36,39	MMR
11245458_9	Pharmacodynamic_phenotype	84,107	cytotoxic effect of DDP
11245458_9	Disease	152,163	colon cance
19019258_1	Disease	21,34	breast cancer
19019258_1	Gene_or_protein	55,61	CYP2D6
19019258_1	Chemical	89,98	tamoxifen
19019258_1	Pharmacokinetic_phenotype	89,109	tamoxifen metabolism
19019258_1	Pharmacodynamic_phenotype	89,98,114,127	tamoxifen drug response
18797455_1	Gene_or_protein	0,5	GSTP1
18797455_1	Limited_variation	0,28	GSTP1 Ile105Val polymorphism
18797455_1	Chemical	112,122	irinotecan
18797455_1	Disease	74,78	MCRC
18797455_1	Phenotype	45,70	progression-free survival
18797455_1	Disease	146,163	Colorectal Cancer
25043824_3	Chemical	31,40	serotonin
25043824_3	Limited_variation	67,92	variation in the 5-HTTLPR
25043824_3	Gene_or_protein	84,92	5-HTTLPR
25043824_3	Pharmacokinetic_phenotype	31,51	serotonin metabolism
12070798_4	Gene_or_protein	48,56	c-erbB-2
12070798_4	Chemical	159,170	carboplatin
12070798_4	Chemical	174,183	cisplatin
12070798_4	Chemical	188,204	cyclophosphamide
12070798_4	Phenotype	66,74	survival
12070798_4	Chemical	141,170	chemotherapy with carboplatin
12070798_4	Chemical	141,158,174,204	chemotherapy with cisplatin and cyclophosphamide
12070798_4	Phenotype	34,61	expression of c-erbB-2 mRNA
12070798_4	Genomic_factor	48,61	c-erbB-2 mRNA
25474278_1	Phenotype	51,65	p53 expression
25474278_1	Gene_or_protein	51,54	p53
25474278_1	Disease	69,97	metastatic colorectal cancer
25474278_1	Chemical	111,122	oxaliplatin
25474278_1	Chemical	127,143	fluoropyrimidine
25474278_1	Chemical	111,163	oxaliplatin and fluoropyrimidine -based chemotherapy
25474278_1	Genomic_factor	20,46	microsatellite instability
19014491_7	Limited_variation	115,129	SIRT1 variants
19014491_7	Gene_or_protein	115,120	SIRT1
19014491_7	Phenotype	168,174	weight
19014491_7	Phenotype	177,185	body fat
19014491_7	Phenotype	217,230	blood glucose
19014491_7	Pharmacodynamic_phenotype	233,252	insulin sensitivity
19014491_7	Phenotype	255,272	insulin secretion
19014491_7	Phenotype	277,286	liver fat
19014491_7	Phenotype	150,165	anthropometrics
19014491_7	Phenotype	189,214	metabolic characteristics
19014491_7	Chemical	233,240	insulin
25941087_7	Chemical	88,97	ritodrine
25941087_7	Gene_or_protein	9,16	SULT1A3
25941087_7	Pharmacokinetic_phenotype	62,97	sulfating activity toward ritodrine
24841934_9	Chemical	8,18	folic acid
24841934_9	Gene_or_protein	86,91	MTHFR
24841934_9	Limited_variation	86,97	MTHFR C677T
24841934_9	Disease	148,151	ARM
24841934_9	Disease	168,171	ARM
9142901_2	Chemical	28,40	somatostatin
9142901_2	Phenotype	54,67,93,98	expression of c-fos
9142901_2	Gene_or_protein	93,98	c-fos
25841872_2	Chemical	7,16	Ezetimibe
25841872_2	Gene_or_protein	133,139	NPC1L1
25841872_2	Gene_or_protein	100,130	Niemann-Pick C1-Like protein 1
25841872_2	Pharmacodynamic_phenotype	25,85	plasma levels of low-density lipoprotein ( LDL ) cholesterol
18573584_4	Chemical	52,63	haloperidol
18573584_4	Chemical	67,78	risperidone
18573584_4	Disease	111,124	schizophrenia
18573584_4	Phenotype	186,222	relapse of these psychotic disorders
18573584_4	Disease	203,222	psychotic disorders
18573584_4	Disease	127,143	schizophreniform
18573584_4	Limited_variation	291,315	5-HTTLPR L and S alleles
18573584_4	Limited_variation	377,381	La/g
18573584_4	Disease	147,172	schizoaffective disorders
18573584_4	Limited_variation	332,374	A/G functional variant within the L alelle
17404720_1	Limited_variation	27,44	MDR1 polymorphism
17404720_1	Gene_or_protein	27,31	MDR1
17404720_1	Chemical	48,55	digoxin
17404720_1	Pharmacokinetic_phenotype	48,82	digoxin pharmacokinetic parameters
26481697_2	Chemical	5,17	chemotherapy
26481697_2	Chemical	22,81	epidermal growth factor receptor tyrosine kinase inhibitors
26481697_2	Gene_or_protein	22,54	epidermal growth factor receptor
26481697_2	Gene_or_protein	84,88	EGFR
26481697_2	Chemical	84,93	EGFR TKIs
26481697_2	Disease	136,162	non-small cell lung cancer
26481697_2	Disease	165,170	NSCLC
26481697_2	Pharmacodynamic_phenotype	183,191	efficacy
21302482_2	Disease	42,63	blood stasis syndrome
21302482_2	Disease	66,69	BSS
21302482_2	Limited_variation	74,99	CYP2C19 gene polymorphism
21302482_2	Gene_or_protein	74,81	CYP2C19
21302482_2	Pharmacodynamic_phenotype	105,127	clopidogrel resistance
21302482_2	Chemical	105,116	clopidogrel
21302482_2	Pharmacodynamic_phenotype	130,132	CR
21302482_2	Phenotype	139,157	post-PCI prognosis
10580024_9	Phenotype	85,105	TPMT enzyme activity
10580024_9	Gene_or_protein	85,89	TPMT
10580024_9	Chemical	157,173	6-mercaptopurine
10580024_9	Pharmacodynamic_phenotype	33,70	thioguanine nucleotide concentrations
10580024_9	Phenotype	14,17	sex
10580024_9	Chemical	33,44	thioguanine
10580024_9	Pharmacodynamic_phenotype	149,173	dose of 6-mercaptopurine
22179112_4	Gene_or_protein	11,15	Rhes
22179112_4	Gene_or_protein	55,59	mTOR
22179112_4	Chemical	134,140	L-DOPA
22179112_4	Gene_or_protein	190,194	Rhes
22179112_4	Limited_variation	11,25	Rhes ( - / - )
22179112_4	Pharmacodynamic_phenotype	113,130	motor improvement
22179112_4	Chemical	190,209	Rhes -binding drugs
22179112_4	Phenotype	46,69	striatal mTOR signaling
22179112_4	Disease	85,95	dyskinesia
22179112_4	Pharmacodynamic_phenotype	113,140	motor improvement on L-DOPA
22015057_6	Chemical	101,110	sunitinib
22015057_6	Limited_variation	162,171	rs2305948
22015057_6	Gene_or_protein	153,159	VEGFR2
22015057_6	Limited_variation	176,185	rs1870377
22015057_6	Limited_variation	199,207	rs307826
22015057_6	Gene_or_protein	190,196	VEGFR3
22015057_6	Limited_variation	210,218	rs448012
22015057_6	Limited_variation	225,233	rs307821
22015057_6	Gene_or_protein	238,245	PDGFR-a
22015057_6	Limited_variation	248,258	rs35597368
22015057_6	Limited_variation	272,281	rs2010963
22015057_6	Gene_or_protein	263,269	VEGF-A
22015057_6	Limited_variation	284,292	rs699947
22015057_6	Limited_variation	299,308	rs1570360
22015057_6	Gene_or_protein	313,316	IL8
22015057_6	Limited_variation	319,328	rs1126647
22015057_6	Gene_or_protein	333,339	CYP3A4
22015057_6	Limited_variation	342,351	rs2740574
22015057_6	Gene_or_protein	356,362	CYP3A5
22015057_6	Limited_variation	365,373	rs776746
22015057_6	Limited_variation	386,395	rs1045642
22015057_6	Gene_or_protein	378,383	ABCB1
22015057_6	Limited_variation	398,407	rs1128503
22015057_6	Limited_variation	414,423	rs2032582
22015057_6	Gene_or_protein	432,437	ABCB2
22015057_6	Limited_variation	440,449	rs2231142
22015057_6	Phenotype	12,27	RECIST response
22015057_6	Phenotype	30,55	progression-free survival
22015057_6	Phenotype	58,61	PFS
22015057_6	Phenotype	66,82	overall survival
22015057_6	Pharmacodynamic_phenotype	89,110	toxicity of sunitinib
22015057_6	Limited_variation	123,136	polymorphisms
15470329_7	Gene_or_protein	0,27	beta 1 -Adrenergic receptor
15470329_7	Limited_variation	0,50	beta 1 -Adrenergic receptor polymorphisms Ser49Gly
15470329_7	Chemical	171,181	metoprolol
15470329_7	Limited_variation	0,41,55,65	beta 1 -Adrenergic receptor polymorphisms Arg 389Gly
15470329_7	Pharmacokinetic_phenotype	121,136,155,181	pharmacokinetic relationship of metoprolol
15470329_7	Pharmacodynamic_phenotype	139,181	pharmacodynamic relationship of metoprolol
19559544_5	Phenotype	0,20	Pdyn gene deficiency
19559544_5	Gene_or_protein	0,4	Pdyn
19559544_5	Chemical	33,43	nalbuphine
19559544_5	Gene_or_protein	113,118	c-Fos
19559544_5	Pharmacodynamic_phenotype	33,99	nalbuphine -induced behavioral sensitization of locomotor activity
19559544_5	Phenotype	104,129	accumbal c-Fos expression
19559544_5	Pharmacodynamic_phenotype	53,99	behavioral sensitization of locomotor activity
23894460_7	Gene_or_protein	0,4	Egfr
23894460_7	Gene_or_protein	80,83	p53
23894460_7	Chemical	106,122	cyclophosphamide
23894460_7	Limited_variation	0,11	Egfr mutant
23894460_7	Phenotype	42,55	proliferation
23894460_7	Phenotype	58,67	apoptosis
23894460_7	Phenotype	80,99	p53 -positive cells
17217931_1	Chemical	91,102	sumatriptan
17217931_1	Gene_or_protein	24,45	serotonin 1B receptor
17217931_1	Genomic_factor	24,54	serotonin 1B receptor promoter
17217931_1	Disease	116,134	alcohol -dependent
17217931_1	Genomic_variation	0,54	Diplotypes of the human serotonin 1B receptor promoter
17217931_1	Pharmacodynamic_phenotype	63,102	growth hormone responses to sumatriptan
12796525_2	Gene_or_protein	86,106	dopamine transporter
12796525_2	Gene_or_protein	114,117	DAT
12796525_2	Gene_or_protein	51,68	dopamine receptor
12796525_2	Limited_variation	30,74	polymorphisms in the dopamine receptor genes
12796525_2	Pharmacodynamic_phenotype	138,165	adverse effects of L - dopa
12796525_2	Limited_variation	30,43,79,111	polymorphisms in the dopamine transporter gene
12796525_2	Chemical	157,165	L - dopa
19655247_7	Gene_or_protein	114,120	SLC6A4
19655247_7	Chemical	159,168	alosetron
19655247_7	Gene_or_protein	142,147	5-HT3
19655247_7	Gene_or_protein	177,182	5-HT4
19655247_7	Chemical	193,202	tegaserod
19655247_7	Chemical	142,158	5-HT3 antagonist
19655247_7	Chemical	177,190	5-HT4 agonist
19655247_7	Pharmacodynamic_phenotype	125,168	responses to the 5-HT3 antagonist alosetron
19655247_7	Pharmacodynamic_phenotype	125,137,173,202	responses to the 5-HT4 agonist , tegaserod
19655247_7	Pharmacodynamic_phenotype	75,94	response to therapy
19374522_1	Gene_or_protein	0,6	CYP2D6
19374522_1	Chemical	56,67	risperidone
19374522_1	Limited_variation	0,17	CYP2D6 genotyping
26698676_2	Disease	162,173	infertility
26698676_2	Disease	222,236	ovarian cancer
26698676_2	Limited_variation	256,261,271,279	BRCA1 mutation
26698676_2	Gene_or_protein	256,261	BRCA1
26698676_2	Gene_or_protein	265,270	BRCA2
26698676_2	Chemical	86,130	selective estrogen receptor [ ER ] modulator
26698676_2	Chemical	133,145	gonadotropin
26698676_2	Limited_variation	265,279	BRCA2 mutation
26698676_2	Chemical	56,76	fertility medication
19843683_7	Chemical	58,66	8-oxoGua
19843683_7	Gene_or_protein	107,124	hOGG1 glycosylase
19843683_7	Pharmacokinetic_phenotype	50,66	urinary 8-oxoGua
22948856_1	Chemical	44,55	pridopidine
22948856_1	Gene_or_protein	96,102	CYP2D6
22948856_1	Pharmacodynamic_phenotype	20,55	tolerability profile of pridopidine
22948856_1	Pharmacokinetic_phenotype	0,15,41,55	Pharmacokinetic of pridopidine
22948856_1	Pharmacokinetic_phenotype	86,115	extensive CYP2D6 metabolizers
22948856_1	Pharmacokinetic_phenotype	77,81,96,115	poor CYP2D6 metabolizers
16257348_2	Chemical	62,72	tryptophan
16257348_2	Gene_or_protein	105,109	TPH1
16257348_2	Limited_variation	105,115	TPH1 A218C
16257348_2	Phenotype	127,150	age of alcoholism onset
16257348_2	Gene_or_protein	62,84	tryptophan hydroxylase
16257348_2	Limited_variation	62,102	tryptophan hydroxylase gene polymorphism
16257348_2	Disease	134,144	alcoholism
22234350_11	Haplotype	51,68	NFATc4 haplotypes
22234350_11	Gene_or_protein	51,57	NFATc4
22234350_11	Disease	163,168	NODAT
22234350_11	Chemical	87,91	CNI-
22495427_3	Gene_or_protein	85,88	XDH
22495427_3	Gene_or_protein	91,95	AOX1
22495427_3	Gene_or_protein	102,107	MOCOS
22495427_3	Pharmacodynamic_phenotype	161,178	drug side effects
22495427_3	Chemical	236,248	azathioprine
22495427_3	Chemical	251,254	AZA
22495427_3	Disease	194,211	kidney transplant
22495427_3	Limited_variation	41,88	single nucleotide polymorphisms ( SNPs ) in XDH
22495427_3	Limited_variation	41,84,91,95	single nucleotide polymorphisms ( SNPs ) in AOX1
22495427_3	Limited_variation	41,84,102,107	single nucleotide polymorphisms ( SNPs ) in MOCOS
22495427_3	Chemical	279,304	immunosuppressive regimen
22461642_7	Chemical	14,22	oridonin
22461642_7	Phenotype	37,60	activity of c-Kit ( + )
22461642_7	Gene_or_protein	49,54	c-Kit
22461642_7	Limited_variation	49,60	c-Kit ( + )
24638003_10	Chemical	30,38	imatinib
24638003_10	Limited_variation	97,117	KIT exon 11 deletion
24638003_10	Gene_or_protein	97,100	KIT
24638003_10	Limited_variation	142,163	KIT exon 11 insertion
24638003_10	Gene_or_protein	142,145	KIT
24638003_10	Limited_variation	184,203	KIT exon 9 mutation
24638003_10	Gene_or_protein	184,187	KIT
24638003_10	Limited_variation	206,221	PDGFRA mutation
24638003_10	Gene_or_protein	206,212	PDGFRA
24638003_10	Phenotype	74,77	RFS
24638003_10	Limited_variation	142,153,167,181	KIT exon 11 point mutation
24638003_10	Limited_variation	227,236	wild-type
24638003_10	Disease	227,242	wild-type tumor
24638003_10	Disease	97,117,237,242	KIT exon 11 deletion tumor
24638003_10	Disease	142,163,237,242	KIT exon 11 insertion tumor
24638003_10	Disease	142,153,167,181,237,242	KIT exon 11 point mutation tumor
24638003_10	Disease	184,203,237,242	KIT exon 9 mutation tumor
24638003_10	Disease	206,221,237,242	PDGFRA mutation tumor
24638003_10	Genomic_factor	97,108	KIT exon 11
8018460_1	Chemical	0,11	Maprotiline
8018460_1	Pharmacokinetic_phenotype	98,127	hydroxylation of debrisoquine
8018460_1	Gene_or_protein	79,85	CYP2D6
8018460_1	Chemical	115,127	debrisoquine
8018460_1	Pharmacokinetic_phenotype	0,22	Maprotiline metabolism
8018460_1	Limited_variation	79,97	CYP2D6 polymorphic
8018460_1	Pharmacokinetic_phenotype	79,127	CYP2D6 polymorphic hydroxylation of debrisoquine
15016420_6	Chemical	13,24	propranolol
15016420_6	Phenotype	63,93	suppression of NK cytotoxicity
15016420_6	Disease	81,93	cytotoxicity
15016420_6	Phenotype	130,144	Fos expression
15016420_6	Gene_or_protein	130,133	Fos
7753410_9	Chemical	4,43	angiotensin II -AT1 receptor antagonist
7753410_9	Chemical	46,54	losartan
7753410_9	Chemical	111,125	angiotensin II
7753410_9	Pharmacodynamic_phenotype	142,205	angiotensin II -induced immediate early gene protein expression
7753410_9	Chemical	142,156	angiotensin II
7753410_9	Gene_or_protein	4,32	angiotensin II -AT1 receptor
7753410_9	Pharmacodynamic_phenotype	166,205	immediate early gene protein expression
7635999_7	Limited_variation	11,26	CYP2D6 genotype
7635999_7	Gene_or_protein	11,17	CYP2D6
7635999_7	Chemical	52,64	debrisoquine
7635999_7	Pharmacokinetic_phenotype	41,78	ultrarapid debrisoquine hydroxylation
22206814_8	Gene_or_protein	20,23	PXR
22206814_8	Chemical	41,53	okadaic acid
22206814_8	Chemical	127,141	pectenotoxin-2
22206814_8	Chemical	83,93	CiVDR/PXRa
11320258_1	Chemical	24,31	cocaine
11320258_1	Gene_or_protein	50,58,73,84	dopamine transporter
11320258_1	Gene_or_protein	63,84	serotonin transporter
11320258_1	Chemical	105,112	cocaine
11320258_1	Genomic_variation	63,94	serotonin transporter knockouts
11320258_1	Genomic_variation	50,58,85,94	dopamine knockouts
11320258_1	Phenotype	105,129	cocaine place preference
17014716_6	Gene_or_protein	20,23	CD4
17014716_6	Chemical	70,80	prostratin
17014716_6	Gene_or_protein	89,98	Cyclin T1
17014716_6	Gene_or_protein	140,149	Cyclin T1
17014716_6	Gene_or_protein	154,179	Cyclin-dependent kinase-9
17014716_6	Gene_or_protein	182,186	CDK9
17014716_6	Gene_or_protein	101,107	P-TEFb
17014716_6	Genomic_factor	89,107	Cyclin T1 / P-TEFb
17014716_6	Gene_or_protein	203,206	Tat
17014716_6	Gene_or_protein	121,127	kinase
1315265_5	Chemical	151,164	dexamethasone
1315265_5	Gene_or_protein	187,190	Fos
1315265_5	Gene_or_protein	61,84	glucocorticoid receptor
1315265_5	Phenotype	187,194	Fos -LI
1315265_5	Chemical	124,148	synthetic glucocorticoid
24120259_13	Limited_variation	34,49	CYP3A5 genotype
24120259_13	Gene_or_protein	34,40	CYP3A5
24120259_13	Pharmacodynamic_phenotype	137,145	toxicity
24120259_13	Chemical	173,183	tacrolimus
24120259_13	Chemical	93,120	immunosuppressive treatment
24120259_13	Pharmacodynamic_phenotype	164,192	doses of tacrolimus required
24120259_13	Disease	248,265	kidney transplant
17151111_6	Gene_or_protein	52,55	GP2
17151111_6	Limited_variation	15,26,42,75	mutation of N -linked GP2 glycosylation sites
17151111_6	Phenotype	106,118,138,143	antigenicity of GP
17151111_6	Phenotype	123,143	immunogenicity of GP
17151111_6	Gene_or_protein	141,143	GP
17151111_6	Genomic_factor	52,75	GP2 glycosylation sites
18024866_6	Chemical	10,19	Tamoxifen
18024866_6	Gene_or_protein	51,57	CYP2D6
18024866_6	Phenotype	184,212	recurrences of breast cancer
18024866_6	Disease	199,212	breast cancer
18024866_6	Haplotype	51,69	CYP2D6 alleles * 4
18024866_6	Haplotype	51,65,72,75	CYP2D6 alleles * 5
18024866_6	Haplotype	51,65,78,82	CYP2D6 alleles * 10
18024866_6	Haplotype	51,65,85,89	CYP2D6 alleles * 41
18024866_6	Phenotype	223,243	relapse-free periods
18024866_6	Phenotype	322,347	event-free survival rates
18024866_6	Pharmacodynamic_phenotype	111,159	impaired formation of antiestrogenic metabolites
22289787_11	Chemical	14,22	VPA / HU
22289787_11	Phenotype	54,64,95,102	expression of EGFR
22289787_11	Gene_or_protein	98,102	EGFR
22289787_11	Phenotype	69,102	cell surface localization of EGFR
22289787_11	Chemical	14,17	VPA
22289787_11	Chemical	20,22	HU
26220844_12	Limited_variation	18,38	TT genotype of STMN1
26220844_12	Gene_or_protein	33,38	STMN1
26220844_12	Chemical	109,127	platinum compounds
26220844_12	Chemical	132,143	vinorelbine
26220844_12	Disease	163,168	NSCLC
26220844_12	Chemical	87,99	chemotherapy
26220844_12	Chemical	109,143	platinum compounds and vinorelbine
21118736_18	Gene_or_protein	14,20	CYP3A5
21118736_18	Chemical	60,70	tacrolimus
21118736_18	Disease	125,128	DGF
21118736_18	Gene_or_protein	140,146	CYP3A5
21118736_18	Disease	165,168	DGF
21118736_18	Haplotype	14,24	CYP3A5 * 3
21118736_18	Haplotype	140,150	CYP3A5 * 1
21118736_18	Pharmacodynamic_phenotype	60,88	tacrolimus dose requirements
21118736_18	Pharmacodynamic_phenotype	193,210	dose requirements
25940539_9	Chemical	25,33	CUDC-101
25940539_9	Gene_or_protein	78,81	p21
25940539_9	Gene_or_protein	86,96	E-cadherin
25940539_9	Gene_or_protein	136,140	XIAP
25940539_9	Gene_or_protein	143,152	b-catenin
25940539_9	Gene_or_protein	155,165	N-cadherin
25940539_9	Gene_or_protein	172,180	Vimentin
25940539_9	Pharmacodynamic_phenotype	4,33	anticancer effect of CUDC-101
25940539_9	Gene_or_protein	125,133	survivin
25940539_9	Phenotype	54,81	increased expression of p21
25940539_9	Phenotype	54,77,86,96	increased expression of E-cadherin
25940539_9	Phenotype	103,133	reduced expression of survivin
25940539_9	Phenotype	103,124,136,140	reduced expression of XIAP
25940539_9	Phenotype	103,124,143,152	reduced expression of b-catenin
25940539_9	Phenotype	103,124,155,165	reduced expression of N-cadherin
25940539_9	Phenotype	103,124,172,180	reduced expression of Vimentin
23394127_3	Gene_or_protein	64,68	NAT2
23394127_3	Gene_or_protein	75,94	cytochrome P450 2E1
23394127_3	Gene_or_protein	97,103	CYP2E1
23394127_3	Chemical	153,156	INH
23394127_3	Gene_or_protein	39,61	N-acetyl transferase 2
23394127_3	Pharmacodynamic_phenotype	113,156	hepatotoxicity of patients treated with INH
25487141_10	Limited_variation	64,89	CYP3A5 gene polymorphisms
25487141_10	Gene_or_protein	64,70	CYP3A5
25487141_10	Limited_variation	96,127	IL-18 A-607C gene polymorphisms
25487141_10	Gene_or_protein	96,101	IL-18
25487141_10	Chemical	165,175	tacrolimus
25487141_10	Gene_or_protein	44,54	hemoglobin
25487141_10	Gene_or_protein	57,59	Hb
25487141_10	Phenotype	38,41	age
25487141_10	Pharmacodynamic_phenotype	165,186	tacrolimus C/D ratios
10529724_11	Gene_or_protein	26,30	nNOS
10529724_11	Pharmacodynamic_phenotype	75,113	METH -induced behavioral sensitization
10529724_11	Chemical	75,79	METH
10529724_11	Gene_or_protein	44,48	iNOS
10529724_11	Phenotype	44,59	iNOS deficiency
10529724_11	Phenotype	26,41	nNOS deficiency
10529724_11	Pharmacodynamic_phenotype	89,113	behavioral sensitization
25007187_2	Chemical	84,100	6-mercaptopurine
25007187_2	Gene_or_protein	118,122	TPMT
25007187_2	Chemical	127,139	methotrexate
25007187_2	Chemical	142,145	MTX
25007187_2	Gene_or_protein	169,174	ABCB1
25007187_2	Gene_or_protein	180,184	MDR1
25007187_2	Gene_or_protein	189,194	ABCC2
25007187_2	Gene_or_protein	197,204	SLC19A1
25007187_2	Gene_or_protein	210,214	RFC1
25007187_2	Gene_or_protein	223,230	SLCO1B1
25007187_2	Chemical	241,244	MTX
25007187_2	Gene_or_protein	259,264	MTHFR
25007187_2	Gene_or_protein	269,273	TYMS
25007187_2	Chemical	362,365	MTX
25007187_2	Pharmacokinetic_phenotype	362,375	MTX clearance
25007187_2	Pharmacodynamic_phenotype	336,354	treatment toxicity
25007187_2	Pharmacokinetic_phenotype	84,115	6-mercaptopurine detoxification
25007187_2	Pharmacokinetic_phenotype	127,158	methotrexate ( MTX ) metabolism
25007187_2	Pharmacodynamic_phenotype	241,251	MTX effect
25007187_2	Limited_variation	304,317	polymorphisms
25007187_2	Limited_variation	49,71	polymorphisms in genes
20107067_3	Limited_variation	25,39	deletion of SR
20107067_3	Gene_or_protein	37,39	SR
20107067_3	Chemical	68,76	D-serine
20107067_3	Disease	104,117	neurotoxicity
20107067_3	Disease	122,128	stroke
20107067_3	Gene_or_protein	80,93	NMDA receptor
20107067_3	Disease	80,117	NMDA receptor -mediated neurotoxicity
20107067_3	Disease	80,103,122,128	NMDA receptor -mediated stroke
26091798_14	Gene_or_protein	31,34	p53
26091798_14	Chemical	69,76	arsenic
26091798_14	Chemical	80,86	Cr(VI)
26091798_14	Disease	194,205	lung cancer
26091798_14	Chemical	168,175	arsenic
26091798_14	Chemical	179,185	Cr(VI)
26091798_14	Disease	179,205	Cr(VI) induced lung cancer
26091798_14	Disease	168,175,186,205	arsenic induced lung cancer
17495880_6	Chemical	54,64	tacrolimus
17495880_6	Gene_or_protein	92,98	CYP3A4
17495880_6	Gene_or_protein	105,111	CYP3A5
17495880_6	Gene_or_protein	120,126	CYP3A4
17495880_6	Gene_or_protein	134,140	CYP3A5
17495880_6	Chemical	174,184	tacrolimus
17495880_6	Haplotype	92,102	CYP3A4 * 1
17495880_6	Haplotype	105,115	CYP3A5 * 1
17495880_6	Haplotype	120,131	CYP3A4 * 1B
17495880_6	Haplotype	134,144	CYP3A5 * 1
17495880_6	Pharmacodynamic_phenotype	174,208	tacrolimus -related nephrotoxicity
17495880_6	Pharmacodynamic_phenotype	242,277	concentrations of toxic metabolites
17495880_6	Haplotype	92,115,145,154	CYP3A4 * 1 / CYP3A5 * 1 genotypes
17495880_6	Haplotype	120,154	CYP3A4 * 1B / CYP3A5 * 1 genotypes
17495880_6	Pharmacodynamic_phenotype	194,208	nephrotoxicity
21457551_10	Chemical	48,56	estrogen
21457551_10	Disease	118,131	breast cancer
21457551_10	Limited_variation	186,195	rs4149013
21457551_10	Gene_or_protein	199,206	SLCO1B1
21457551_10	Chemical	59,68	progestin
21457551_10	Chemical	39,76	combined estrogen - progestin therapy
21457551_10	Chemical	79,82	EPT
21457551_10	Phenotype	112,114	OR
11692082_6	Chemical	64,74	ivermectin
11692082_6	Phenotype	106,121	mdr1 expression
11692082_6	Gene_or_protein	106,110	mdr1
11692082_6	Chemical	6,16	ivermectin
11692082_6	Pharmacodynamic_phenotype	64,93	ivermectin -sensitive collies
11692082_6	Gene_or_protein	36,40	P-gp
20528747_6	Gene_or_protein	46,65	membrane type-1 MMP
20528747_6	Gene_or_protein	68,75	MT1-MMP
20528747_6	Gene_or_protein	121,146	tissue inhibitor of MMP-2
20528747_6	Gene_or_protein	149,155	TIMP-2
20528747_6	Chemical	171,181	theaflavin
20528747_6	Phenotype	206,222	MMP-2 activation
20528747_6	Gene_or_protein	206,211	MMP-2
20528747_6	Phenotype	24,77	protein expression of membrane type-1 MMP ( MT1-MMP )
20528747_6	Phenotype	99,157	protein expression of tissue inhibitor of MMP-2 ( TIMP-2 )
20528747_6	Phenotype	15,19,32,77	mRNA expression of membrane type-1 MMP ( MT1-MMP )
20528747_6	Phenotype	90,94,107,157	mRNA expression of tissue inhibitor of MMP-2 ( TIMP-2 )
21445620_10	Gene_or_protein	34,38	COMT
21445620_10	Chemical	107,111	EGCG
21445620_10	Limited_variation	34,58	COMT Val ( 158/108 ) Met
21445620_10	Pharmacokinetic_phenotype	107,122	EGCG absorption
21445620_10	Pharmacokinetic_phenotype	107,111,127,138	EGCG elimination
16015387_9	Limited_variation	20,40	KIT exon 8 mutations
16015387_9	Gene_or_protein	20,23	KIT
16015387_9	Chemical	164,172	imatinib
16015387_9	Gene_or_protein	83,89	kinase
16015387_9	Phenotype	83,100	kinase activation
16015387_9	Pharmacodynamic_phenotype	146,172	concentrations of imatinib
16015387_9	Genomic_factor	20,30	KIT exon 8
27522730_20	Limited_variation	43,76	interleukin 28B gene polymorphism
27522730_20	Gene_or_protein	43,58	interleukin 28B
27522730_20	Chemical	186,210	pegylated interferon a-2
27522730_20	Chemical	215,224	ribavirin
27522730_20	Chemical	177,224	AVT with pegylated interferon a-2 and ribavirin
27522730_20	Disease	135,143	fibrosis
27522730_20	Phenotype	115,118,135,143	SVR fibrosis
27522730_20	Phenotype	123,143	dynamics of fibrosis
27522730_20	Disease	161,166	CHC-I
27522730_20	Chemical	287,310	interferon-free therapy
24204751_5	Gene_or_protein	0,4	CFTR
24204751_5	Chemical	106,110	cAMP
24204751_5	Chemical	60,81	b-adrenergic cocktail
24204751_5	Gene_or_protein	126,146	muscarinic receptors
24204751_5	Phenotype	0,25	CFTR -dependent secretion
24204751_5	Phenotype	28,35	C-sweat
19442155_4	Chemical	65,72	lithium
19442155_4	Gene_or_protein	208,244	inositol polyphosphate-1-phosphatase
19442155_4	Gene_or_protein	247,253	IPPase
19442155_4	Gene_or_protein	294,304	GSK-3 beta
19442155_4	Gene_or_protein	169,194	inositol mono phosphatase
19442155_4	Gene_or_protein	197,203	IMPase
19442155_4	Gene_or_protein	260,291	glycogen sinthase kinase 3 beta
19344737_12	Disease	81,97	conduct disorder
19344737_12	Disease	128,139	impulsivity
19344737_12	Chemical	158,165	alcohol
19344737_12	Gene_or_protein	240,244	DRD2
19344737_12	Disease	146,176	problematic alcohol / drug use
19344737_12	Limited_variation	215,244	A1 carrier status of the DRD2
19344737_12	Chemical	168,172	drug
23467639_5	Chemical	11,18	aspirin
23467639_5	Gene_or_protein	21,26	P2Y12
23467639_5	Disease	133,141	bleeding
23467639_5	Chemical	21,37	P2Y12 inhibitors
23467639_5	Chemical	48,66	antiplatelet drugs
23467639_5	Phenotype	91,122	inhibition of platelet function
17949449_9	Disease	30,57	Dukes ' C colorectal cancer
17949449_9	Disease	115,121	tumour
17949449_9	Chemical	136,140	5-FU
17949449_9	Limited_variation	172,191	p53 mutation status
17949449_9	Gene_or_protein	172,175	p53
17949449_9	Chemical	136,169	5-FU -based adjuvant chemotherapy
17949449_9	Phenotype	265,289	metastasis-free survival
17949449_9	Disease	81,99	surgical resection
17949449_9	Phenotype	253,260,281,289	overall survival
27027150_2	Disease	42,50	melanoma
27027150_2	Disease	65,71	tumors
27027150_2	Limited_variation	82,92,103,112	BRAF V600E mutations
27027150_2	Gene_or_protein	82,86	BRAF
27027150_2	Limited_variation	82,86,97,112	BRAF V600K mutations
27027150_2	Chemical	115,130	BRAF inhibitors
27027150_2	Chemical	139,149	dabrafenib
20153935_3	Limited_variation	4,9	A118G
20153935_3	Limited_variation	12,16	N40D
20153935_3	Limited_variation	74,78	C77G
20153935_3	Limited_variation	81,85	P26R
20153935_3	Phenotype	271,311	predilection towards alcohol consumption
20153935_3	Chemical	292,299	alcohol
20153935_3	Phenotype	207,229	physiological measures
20153935_3	Phenotype	241,260	behavioral measures
20153935_3	Phenotype	162,176	ligand binding
22205192_1	Chemical	76,83	codeine
22205192_1	Gene_or_protein	110,129	cytochrome P450 2D6
22205192_1	Gene_or_protein	132,138	CYP2D6
22205192_1	Limited_variation	110,149	cytochrome P450 2D6 ( CYP2D6 ) genotype
24597986_7	Limited_variation	20,29	RFC1 G80A
24597986_7	Gene_or_protein	20,24	RFC1
24597986_7	Chemical	80,83	MTX
24597986_7	Pharmacodynamic_phenotype	80,101	MTX -related toxicity
24597986_7	Disease	115,118	ALL
24597986_7	Pharmacodynamic_phenotype	93,101	toxicity
22175791_7	Gene_or_protein	29,34	GSTT1
22175791_7	Chemical	112,116	APAP
22175791_7	Gene_or_protein	152,157	GSTP1
22175791_7	Chemical	221,225	APAP
22175791_7	Limited_variation	29,63	GSTT1 homozygous deletion genotype
22175791_7	Disease	112,126	APAP poisoning
22175791_7	Limited_variation	152,185	GSTP1 homozygous variant genotype
22175791_7	Disease	221,234	APAP poisoned
22588330_3	Chemical	54,66	nitric oxide
22588330_3	Chemical	71,89	prostaglandin E(2)
22588330_3	Phenotype	147,201	expression of inducible nitric oxide synthase ( iNOS )
22588330_3	Gene_or_protein	161,192	inducible nitric oxide synthase
22588330_3	Gene_or_protein	195,199	iNOS
22588330_3	Gene_or_protein	225,230	COX-2
22588330_3	Gene_or_protein	206,222	cyclooxygenase 2
22588330_3	Chemical	27,30	LDF
22588330_3	Phenotype	147,160,206,232	expression of cyclooxygenase 2 ( COX-2 )
22588330_3	Pharmacodynamic_phenotype	41,66,90,100	LPS -induced nitric oxide production
22588330_3	Pharmacodynamic_phenotype	71,100	prostaglandin E(2) production
22588330_3	Chemical	41,44	LPS
22588330_3	Pharmacodynamic_phenotype	41,53,71,100	LPS -induced prostaglandin E(2) production
22588330_3	Pharmacodynamic_phenotype	54,66,90,100	nitric oxide production
24088005_4	Gene_or_protein	49,56	CYP2C19
24088005_4	Phenotype	77,97	platelet aggregation
24088005_4	Chemical	122,133	clopidogrel
24088005_4	Haplotype	49,60	CYP2C19 * 2
11923351_9	Limited_variation	33,42	T69N /S/A
11923351_9	Chemical	90,100	zidovudine
15638955_4	Gene_or_protein	18,50	epidermal growth factor receptor
15638955_4	Gene_or_protein	53,57	EGFR
15638955_4	Disease	255,281	non-small-cell lung cancer
15638955_4	Disease	284,289	NSCLC
15638955_4	Chemical	105,168	inhibitors of the tyrosine kinase ( TK ) domain of the receptor
15638955_4	Gene_or_protein	141,143	TK
15638955_4	Gene_or_protein	123,138	tyrosine kinase
15638955_4	Chemical	65,86	monoclonal antibodies
15638955_4	Pharmacodynamic_phenotype	217,237	antitumor activities
21676217_3	Gene_or_protein	0,4	HER2
21676217_3	Chemical	43,52	lapatinib
21676217_3	Gene_or_protein	94,98	HER2
21676217_3	Disease	94,124	HER2 -- positive breast cancer
21676217_3	Chemical	27,38	trastuzumab
21676217_3	Chemical	0,26	HER2 -related target drugs
21676217_3	Phenotype	94,110	HER2 -- positive
17121920_9	Gene_or_protein	80,84	XIAP
17121920_9	Chemical	115,128	mithramycin A
17121920_9	Phenotype	148,174	transcription of XIAP gene
17121920_9	Gene_or_protein	165,169	XIAP
17121920_9	Gene_or_protein	197,200	Sp1
17121920_9	Phenotype	197,224	Sp1 binding to its promoter
17121920_9	Genomic_factor	80,93	XIAP promoter
22027477_9	Genomic_factor	54,60	MSI -H
22027477_9	Gene_or_protein	80,84	BRAF
22027477_9	Disease	94,97	CRC
22027477_9	Chemical	0,3	PMH
22027477_9	Limited_variation	80,93	BRAF -mutated
22027477_9	Phenotype	63,76	CIMP-positive
22027477_9	Disease	54,60,94,97	MSI -H CRC
22027477_9	Disease	63,76,94,97	CIMP-positive CRC
22027477_9	Disease	80,97	BRAF -mutated CRC
23012624_2	Limited_variation	26,71	inosine triphosphatase ( ITPA ) gene variants
23012624_2	Gene_or_protein	26,48	inosine triphosphatase
23012624_2	Gene_or_protein	51,55	ITPA
23012624_2	Pharmacodynamic_phenotype	107,113	anemia
23012624_2	Chemical	88,97	ribavirin
23012624_2	Disease	138,157	chronic hepatitis C
23012624_2	Pharmacodynamic_phenotype	88,113	ribavirin -induced anemia
18855539_7	Gene_or_protein	39,44	HLA-B
18855539_7	Chemical	120,128	abacavir
18855539_7	Haplotype	39,51	HLA-B * 5701
18855539_7	Pharmacodynamic_phenotype	120,155	abacavir hypersensitivity reactions
21912425_8	Limited_variation	19,28	rs9263726
21912425_8	Chemical	61,72	allopurinol
21912425_8	Pharmacodynamic_phenotype	82,91	SJS / TEN
21912425_8	Pharmacodynamic_phenotype	61,91	allopurinol -related SJS / TEN
10677041_7	Gene_or_protein	10,15	DOR-1
10677041_7	Gene_or_protein	122,127	DOR-1
10677041_7	Limited_variation	10,22	DOR-1 mutant
10677041_7	Chemical	66,74	morphine
10677041_7	Pharmacodynamic_phenotype	43,74	analgesic tolerance to morphine
18695635_12	Chemical	41,45	MPAG
18695635_12	Gene_or_protein	96,103	SLCO1B1
18695635_12	Limited_variation	108,129	SLCO1B3 polymorphisms
18695635_12	Gene_or_protein	108,115	SLCO1B3
18695635_12	Limited_variation	141,158	UGT polymorphisms
18695635_12	Gene_or_protein	141,144	UGT
18695635_12	Pharmacokinetic_phenotype	41,62	MPAG pharmacokinetics
18695635_12	Limited_variation	96,103,116,129	SLCO1B1 polymorphisms
19229528_4	Gene_or_protein	78,82	TPMT
19229528_4	Limited_variation	87,110	ITPA gene polymorphisms
19229528_4	Gene_or_protein	87,91	ITPA
19229528_4	Chemical	192,204	azathioprine
19229528_4	Chemical	207,210	AZA
19229528_4	Limited_variation	78,82,92,110	TPMT gene polymorphisms
19229528_4	Pharmacodynamic_phenotype	115,131	drug intolerance
19229528_4	Disease	151,167	renal transplant
20555338_2	Limited_variation	174,183	rs9923231
20555338_2	Chemical	149,157	warfarin
20555338_2	Gene_or_protein	167,173	VKORC1
20555338_2	Limited_variation	193,202	rs1799853
20555338_2	Gene_or_protein	186,192	CYP2C9
20555338_2	Limited_variation	212,221	rs1057910
20555338_2	Gene_or_protein	205,211	CYP2C9
20555338_2	Gene_or_protein	226,232	CYP4F2
20555338_2	Limited_variation	233,242	rs2108622
20555338_2	Pharmacodynamic_phenotype	149,164	warfarin dosing
20555338_2	Limited_variation	108,129	genetic polymorphisms
20731819_13	Gene_or_protein	30,36	CYP2D6
20731819_13	Chemical	184,193	tamoxifen
20731819_13	Chemical	202,211	tamoxifen
20731819_13	Haplotype	30,40	CYP2D6 * 4
20731819_13	Phenotype	163,167	BCSS
20731819_13	Phenotype	107,124	clinical outcomes
18589174_8	Chemical	36,39	TAC
18589174_8	Gene_or_protein	63,68	MDR-1
18589174_8	Genomic_variation	63,76	MDR-1 -3435CC
18589174_8	Pharmacodynamic_phenotype	11,20	C/D ratio
25145853_6	Chemical	15,30	TLR9 ligand CpG
25145853_6	Gene_or_protein	15,19	TLR9
25145853_6	Gene_or_protein	124,127	Th2
25145853_6	Phenotype	135,147	Th1 response
25145853_6	Gene_or_protein	135,138	Th1
25145853_6	Phenotype	168,200	change in the IgG2a : IgG1 ratio
25145853_6	Gene_or_protein	182,187	IgG2a
25145853_6	Gene_or_protein	190,194	IgG1
25145853_6	Pharmacodynamic_phenotype	79,96	antibody response
25145853_6	Chemical	0,51	Conjugation of TLR9 ligand CpG to LDH nanoparticles
25145853_6	Chemical	34,37	LDH
25145853_6	Phenotype	124,127,139,147	Th2 response
10377355_6	Chemical	0,14	Norepinephrine
10377355_6	Phenotype	70,92	CRH neurons in the PVN
10377355_6	Chemical	17,19	NE
10377355_6	Gene_or_protein	70,73	CRH
26060059_10	Limited_variation	0,28	IL28B rs8099917 / rs12979860
26060059_10	Gene_or_protein	0,5	IL28B
26060059_10	Disease	59,75	MC -positive HCV
26060059_10	Chemical	90,111	PEG-IFN and ribavirin
26060059_10	Chemical	102,111	ribavirin
26060059_10	Disease	217,220	HCV
26060059_10	Limited_variation	118,132	TT/CC genotype
26060059_10	Phenotype	152,155	SVR
26060059_10	Limited_variation	162,167	TG/TC
26060059_10	Phenotype	173,180	non-SVR
26060059_10	Disease	72,75	HCV
26060059_10	Disease	211,220	MC in HCV
26060059_10	Limited_variation	183,188	TT/CC
26060059_10	Chemical	90,97	PEG-IFN
26060059_10	Disease	59,61	MC
26060059_10	Disease	211,213	MC
26666244_1	Chemical	33,40	AZD6244
26666244_1	Chemical	19,30	selumetinib
26666244_1	Chemical	43,54	ARRY-142866
26666244_1	Gene_or_protein	61,67	MEK1/2
26666244_1	Disease	113,136	refractory solid tumors
26666244_1	Disease	141,170	KRAS mutant colorectal cancer
26666244_1	Gene_or_protein	141,145	KRAS
26666244_1	Chemical	61,77	MEK1/2 inhibitor
26666244_1	Chemical	100,109	cetuximab
26666244_1	Limited_variation	141,152	KRAS mutant
26666244_1	Chemical	19,30,80,109	selumetinib in combination with cetuximab
17667795_9	Chemical	46,57	haloperidol
17667795_9	Limited_variation	100,114	CYP2D6 alleles
17667795_9	Gene_or_protein	100,106	CYP2D6
17667795_9	Pharmacodynamic_phenotype	46,78	haloperidol plasma concentration
17034599_14	Limited_variation	9,33	variants in the ATM gene
17034599_14	Gene_or_protein	25,28	ATM
17034599_14	Pharmacodynamic_phenotype	120,150	adverse radiotherapy responses
23543259_1	Limited_variation	10,28	eNOS polymorphisms
23543259_1	Gene_or_protein	10,14	eNOS
23543259_1	Chemical	32,42	salbutamol
23543259_1	Pharmacodynamic_phenotype	32,84	salbutamol evoked endothelium dependent vasodilation
23543259_1	Pharmacodynamic_phenotype	50,84	endothelium dependent vasodilation
21389156_11	Limited_variation	4,13	rs8099917
21389156_11	Chemical	80,88	PEG -IFN
21389156_11	Pharmacodynamic_phenotype	64,104	response to the PEG -IFN / RBV treatment
21389156_11	Disease	120,139	chronic hepatitis C
21389156_11	Chemical	91,94	RBV
21389156_11	Chemical	80,94	PEG -IFN / RBV
26086150_11	Pharmacodynamic_phenotype	46,79	co-trimoxazole -induced SJS / TEN
26086150_11	Chemical	46,60	co-trimoxazole
26086150_11	Gene_or_protein	106,111	HLA-B
26086150_11	Gene_or_protein	122,127	HLA-C
26086150_11	Gene_or_protein	142,147	HLA-C
26086150_11	Haplotype	106,119	HLA-B * 15:02
26086150_11	Haplotype	122,135	HLA-C * 06:02
26086150_11	Haplotype	142,155	HLA-C * 08:01
26086150_11	Pharmacodynamic_phenotype	70,79	SJS / TEN
24465960_12	Gene_or_protein	0,6	CYP3A5
24465960_12	Gene_or_protein	13,19	CYP3A4
24465960_12	Gene_or_protein	27,33	CYP3A4
24465960_12	Limited_variation	27,47	CYP3A4 rs4646437 T>C
24465960_12	Gene_or_protein	52,57	IL-10
24465960_12	Limited_variation	52,71	IL-10 rs1800871 C>T
24465960_12	Chemical	150,160	tacrolimus
24465960_12	Haplotype	0,10	CYP3A5 * 3
24465960_12	Haplotype	13,24	CYP3A4 * 1G
24465960_12	Pharmacokinetic_phenotype	150,171	tacrolimus metabolism
24465960_12	Disease	186,202	renal transplant
17116677_8	Limited_variation	43,48	D123G
17116677_8	Limited_variation	51,56	F227L
17116677_8	Limited_variation	63,68	T369I
17116677_8	Phenotype	126,154	concentrations of VRX-480773
17116677_8	Chemical	144,154	VRX-480773
26575001_3	Chemical	0,8	Afatinib
26575001_3	Gene_or_protein	55,59	EGFR
26575001_3	Gene_or_protein	62,68	ErbB-2
26575001_3	Gene_or_protein	75,81	ErbB-4
26575001_3	Chemical	92,101	erlotinib
26575001_3	Gene_or_protein	145,149	EGFR
16242410_4	Genomic_factor	7,20	cFos promoter
16242410_4	Gene_or_protein	7,11	cFos
16242410_4	Chemical	179,186	cocaine
16242410_4	Gene_or_protein	208,212	cFos
16242410_4	Pharmacodynamic_phenotype	23,42	H4 hyperacetylation
16242410_4	Pharmacodynamic_phenotype	108,129	histone modifications
16242410_4	Chemical	77,84	cocaine
16242410_4	Chemical	153,160	cocaine
25122903_3	Limited_variation	50,76	intronic SNP ( rs9479757 )
25122903_3	Chemical	98,104	heroin
25122903_3	Chemical	138,144	heroin
25122903_3	Disease	98,114	heroin addiction
25122903_3	Disease	138,152	heroin addicts
21817190_8	Limited_variation	18,38	variants of the ITPA
21817190_8	Gene_or_protein	34,38	ITPA
21817190_8	Disease	74,92	haemolytic anaemia
21817190_8	Chemical	97,100	RBV
21817190_8	Chemical	170,177	PEG-IFN
21817190_8	Chemical	182,185	RBV
21817190_8	Limited_variation	247,280	TT genotype at rs8099917 of IL28B
21817190_8	Gene_or_protein	275,280	IL28B
21817190_8	Pharmacodynamic_phenotype	154,185	SVR by standard PEG-IFN and RBV
21817190_8	Pharmacodynamic_phenotype	97,115	RBV dose reduction
21817190_8	Limited_variation	262,271	rs8099917
21817190_8	Chemical	170,185	PEG-IFN and RBV
20947785_6	Limited_variation	46,72	NPHS2 pathogenic mutations
20947785_6	Gene_or_protein	46,51	NPHS2
20947785_6	Disease	154,158	SRNS
20947785_6	Disease	114,151	steroid -resistant nephrotic syndrome
20947785_6	Chemical	114,121	steroid
9488225_8	Chemical	26,35	captopril
9488225_8	Gene_or_protein	136,140	Bk2r
9488225_8	Limited_variation	136,146	Bk2r - / -
9488225_8	Disease	122,125	SBP
9488225_8	Limited_variation	150,157	J129 Sv
24947927_1	Gene_or_protein	56,59	MEK
24947927_1	Chemical	70,79	RO4987655
24947927_1	Chemical	82,91	CH4987655
24947927_1	Disease	129,135	cancer
24947927_1	Limited_variation	141,159	RAS- RAF mutations
24947927_1	Gene_or_protein	141,149	RAS- RAF
24947927_1	Chemical	56,69	MEK inhibitor
15154117_7	Haplotype	69,85	CHRNA4 haplotype
15154117_7	Gene_or_protein	69,75	CHRNA4
15154117_7	Chemical	170,178	nicotine
15154117_7	Disease	170,188	nicotine addiction
15154117_7	Phenotype	280,284,317,323	FTND scores
15154117_7	Phenotype	313,323	RTQ scores
15154117_7	Haplotype	88,94	GCTATA
17358097_9	Limited_variation	36,51	CYP3A5 genotype
17358097_9	Gene_or_protein	36,42	CYP3A5
17358097_9	Chemical	119,131	lansoprazole
17358097_9	Pharmacokinetic_phenotype	87,131	enantioselective disposition of lansoprazole
12153842_2	Gene_or_protein	82,86	ADH2
12153842_2	Haplotype	82,90	ADH2 * 2
12153842_2	Gene_or_protein	109,130	alcohol dehydrogenase
12153842_2	Phenotype	158,172	heavy drinking
16245360_6	Chemical	43,50	CpG ODN
16245360_6	Phenotype	130,168	development of Th2 -mediated responses
16245360_6	Gene_or_protein	145,148	Th2
19784640_11	Gene_or_protein	22,28	CYP3A4
19784640_11	Chemical	62,70	fentanyl
19784640_11	Gene_or_protein	150,156	CYP3A4
19784640_11	Gene_or_protein	200,206	CYP3A4
19784640_11	Haplotype	22,40	CYP3A4 * 1G / * 1G
19784640_11	Phenotype	110,114	pain
19784640_11	Haplotype	150,166	CYP3A4 * 1 / * 1
19784640_11	Haplotype	200,217	CYP3A4 * 1 / * 1G
23071495_3	Chemical	0,10	Bucindolol
23071495_3	Limited_variation	79,162	polymorphisms in the primary target ( b ( 1 ) adrenergic receptor [ AR ] Arg389 Gly
23071495_3	Gene_or_protein	125,144	adrenergic receptor
23071495_3	Pharmacodynamic_phenotype	0,10,54,62	Bucindolol efficacy
23071495_3	Limited_variation	79,99,189,280	polymorphisms in the a secondary target modifier ( a ( 2C ) AR Ins [ wild-type ( Wt ) ] 322-325 deletion [ Del ]
23071495_3	Chemical	16,25	b-blocker
23071495_3	Chemical	28,47	sympatholytic agent
23071495_3	Gene_or_protein	147,149	AR
23071495_3	Gene_or_protein	228,230	AR
26678339_4	Gene_or_protein	103,107	IDH1
26678339_4	Disease	103,121	IDH1 mutant cancer
26678339_4	Gene_or_protein	141,145	IDH1
26678339_4	Limited_variation	103,114	IDH1 mutant
26678339_4	Phenotype	183,230	vulnerability to depletion of the coenzyme NAD+
26678339_4	Chemical	18,47	metabolic therapeutic targets
26678339_4	Gene_or_protein	226,230	NAD+
18568343_13	Limited_variation	28,34,46,54	UGT1A8 variants
18568343_13	Limited_variation	39,54	UGT1A9 variants
18568343_13	Pharmacokinetic_phenotype	58,72	MPA metabolism
18568343_13	Chemical	58,61	MPA
18568343_13	Chemical	111,132	calcineurin inhibitor
18568343_13	Gene_or_protein	111,122	calcineurin
18568343_13	Gene_or_protein	28,34	UGT1A8
18568343_13	Gene_or_protein	39,45	UGT1A9
19114005_9	Disease	26,32	glioma
19114005_9	Chemical	39,50	cilengitide
19114005_9	Phenotype	61,83	phosphorylation of FAK
19114005_9	Gene_or_protein	80,83	FAK
19114005_9	Gene_or_protein	86,89	Src
19114005_9	Gene_or_protein	94,97	Akt
19114005_9	Phenotype	61,79,94,97	phosphorylation of Akt
19114005_9	Phenotype	61,79,86,89	phosphorylation of Src
9006118_1	Chemical	32,49	manganese sulfate
9006118_1	Chemical	54,67	5-azacytidine
9006118_1	Gene_or_protein	102,107	c-myc
9006118_1	Phenotype	83,107	overexpressing the c-myc
9006118_1	Pharmacodynamic_phenotype	14,49	transformation by manganese sulfate
9006118_1	Pharmacodynamic_phenotype	14,31,54,67	transformation by 5-azacytidine
17143476_3	Gene_or_protein	90,94	CHFR
17143476_3	Pharmacodynamic_phenotype	179,201	sensitivity to taxanes
17143476_3	Chemical	194,201	taxanes
17143476_3	Disease	205,223	endometrial cancer
17143476_3	Gene_or_protein	97,148	checkpoint with forkhead-associated and ring finger
17143476_3	Phenotype	66,150	hypermethylation of the CHFR ( checkpoint with forkhead-associated and ring finger )
17143476_3	Gene_or_protein	151,174	mitotic checkpoint gene
8904964_10	Gene_or_protein	59,63	ADH2
8904964_10	Chemical	109,116	alcohol
8904964_10	Haplotype	145,153	ADH2 * 1
8904964_10	Gene_or_protein	145,149	ADH2
8904964_10	Haplotype	59,67	ADH2 * 3
8904964_10	Pharmacokinetic_phenotype	109,128	alcohol elimination
27228223_9	Chemical	46,57	oseltamivir
27228223_9	Limited_variation	179,192	CES1 variants
27228223_9	Gene_or_protein	179,183	CES1
27228223_9	Limited_variation	207,212	G143E
27228223_9	Pharmacokinetic_phenotype	46,68	oseltamivir activation
19748123_12	Chemical	25,33	WY14,643
19748123_12	Gene_or_protein	90,99	Cyclin B1
19748123_12	Phenotype	71,99	mRNA expression of Cyclin B1
19748123_12	Phenotype	59,66,76,99	protein expression of Cyclin B1
17286538_5	Phenotype	15,30	CYP2A6 activity
17286538_5	Gene_or_protein	15,21	CYP2A6
17286538_5	Chemical	56,64	coumarin
17286538_5	Pharmacokinetic_phenotype	44,64	shunting of coumarin
21192345_5	Gene_or_protein	36,41	EPHX1
21192345_5	Chemical	152,160	warfarin
21192345_5	Phenotype	168,205	stable international normalized ratio
21192345_5	Genomic_factor	27,41	exons of EPHX1
22076562_5	Chemical	38,50	lansoprazole
22076562_5	Phenotype	97,113	CYP2C19 activity
22076562_5	Gene_or_protein	97,104	CYP2C19
10070957_8	Limited_variation	41,55	A2/A2 genotype
10070957_8	Chemical	83,90	estrone
10070957_8	Chemical	116,125	estradiol
10070957_8	Chemical	151,163	testosterone
10070957_8	Chemical	188,203	androstenedione
10070957_8	Chemical	229,251	dehydroepiandrosterone
10070957_8	Chemical	281,311	dehydroepiandrosterone sulfate
10070957_8	Limited_variation	363,377	A1/A1 genotype
10070957_8	Pharmacodynamic_phenotype	73,90	levels of estrone
10070957_8	Pharmacodynamic_phenotype	73,82,116,125	levels of estradiol
10070957_8	Pharmacodynamic_phenotype	73,82,151,163	levels of testosterone
10070957_8	Pharmacodynamic_phenotype	73,82,188,203	levels of androstenedione
10070957_8	Pharmacodynamic_phenotype	73,82,229,251	levels of dehydroepiandrosterone
10070957_8	Pharmacodynamic_phenotype	73,82,281,311	levels of dehydroepiandrosterone sulfate
23679233_4	Gene_or_protein	94,98	HER2
23679233_4	Disease	186,200	breast cancers
23679233_4	Chemical	254,264	paclitaxel
23679233_4	Chemical	267,282	cyclophosphamid
23679233_4	Chemical	285,295	epirubicin
23679233_4	Chemical	298,310	fluorouracil
23679233_4	Chemical	317,328	trastuzumab
23679233_4	Chemical	224,248	neoadjuvant chemotherapy
23679233_4	Genomic_variation	10,29	Genomic alterations
21731042_5	Chemical	0,6	Folate
21731042_5	Gene_or_protein	120,125	MTHFR
21731042_5	Limited_variation	120,131	MTHFR C677T
24342753_5	Chemical	96,103	4a- PDD
24342753_5	Limited_variation	0,17,33,52	Substituting F617 in TM5 with leucine
24342753_5	Pharmacodynamic_phenotype	61,80	channel sensitivity
24342753_5	Limited_variation	0,12,20,24,33,52	Substituting Y621 in TM5 with leucine
24342753_5	Gene_or_protein	36,39	TM5
24342753_5	Limited_variation	0,12,28,52	Substituting F624 in TM5 with leucine
24342753_5	Phenotype	177,216	activation in response to cell swelling
24342753_5	Limited_variation	142,147	F617L
24342753_5	Limited_variation	152,157	Y621L
21052032_12	Gene_or_protein	17,21	MC1R
21052032_12	Disease	52,77	major depressive disorder
21052032_12	Pharmacodynamic_phenotype	97,120	response to desipramine
21052032_12	Chemical	109,120	desipramine
25871911_11	Gene_or_protein	77,79	ER
25871911_11	Gene_or_protein	124,128	HER2
25871911_11	Pharmacodynamic_phenotype	199,228	sensitivity to 5-fluorouracil
25871911_11	Chemical	214,228	5-fluorouracil
25871911_11	Genomic_factor	244,280	deficiencies in chromatin remodeling
25871911_11	Disease	77,89,139,149	ER -positive metastases
25871911_11	Genomic_variation	285,315	homologous recombination genes
25871911_11	Chemical	92,109	endocrine therapy
25871911_11	Disease	124,149	HER2 -negative metastases
25871911_11	Phenotype	77,89	ER -positive
25871911_11	Phenotype	124,138	HER2 -negative
23103366_1	Limited_variation	19,28,47,78	Arg194Trp polymorphisms of the XRCC1 gene
23103366_1	Limited_variation	37,78	Arg399Gln polymorphisms of the XRCC1 gene
23103366_1	Gene_or_protein	68,73	XRCC1
23103366_1	Disease	161,174	breast cancer
23103366_1	Chemical	120,136	adjuvant therapy
23103366_1	Pharmacodynamic_phenotype	108,136	response to adjuvant therapy
20127344_13	Gene_or_protein	19,23	IDH1
20127344_13	Chemical	54,59	NADPH
20127344_13	Chemical	83,88	NADPH
20127344_13	Limited_variation	11,23	mutated IDH1
20127344_13	Pharmacodynamic_phenotype	83,95	NADPH levels
23570465_7	Chemical	47,56	tamoxifen
23570465_7	Phenotype	124,147	reduced CYP2D6 activity
23570465_7	Gene_or_protein	132,138	CYP2D6
23570465_7	Disease	204,217	breast cancer
23570465_7	Phenotype	204,237	breast cancer -specific mortality
23570465_7	Phenotype	175,185	recurrence
14631118_5	Gene_or_protein	115,124	PPARalpha
14631118_5	Chemical	191,199	Wy-14643
14631118_5	Gene_or_protein	220,229	PPARalpha
14631118_5	Chemical	22,48	EA extract of bitter gourd
25264278_1	Chemical	0,7	Wogonin
25264278_1	Disease	48,68	myelogenous leukemia
25264278_1	Phenotype	106,121	MRP1 expression
25264278_1	Gene_or_protein	106,110	MRP1
25264278_1	Genomic_factor	136,145	Nrf2 /ARE
25264278_1	Pharmacodynamic_phenotype	17,38	multi-drug resistance
25264278_1	Gene_or_protein	136,140	Nrf2
27097961_8	Gene_or_protein	34,37	NAA
27097961_8	Gene_or_protein	40,42	Cr
27097961_8	Gene_or_protein	48,51	Cho
27097961_8	Chemical	89,92	MPH
27097961_8	Limited_variation	128,156	DAT1 gene VNTR polymorphisms
27097961_8	Gene_or_protein	128,132	DAT1
27097961_8	Phenotype	48,58	Cho levels
27097961_8	Phenotype	40,42,52,58	Cr levels
27097961_8	Phenotype	34,37,52,58	NAA levels
18729643_4	Gene_or_protein	75,103	catechol-O-methyltransferase
18729643_4	Chemical	49,57	dopamine
18729643_4	Gene_or_protein	106,110	COMT
18729643_4	Limited_variation	106,120	COMT Val158Met
18729643_4	Disease	161,168	anxiety
18729643_4	Disease	178,185	anxiety
18729643_4	Limited_variation	9,16,75,103	variant catechol-O-methyltransferase
18729643_4	Phenotype	178,206	anxiety -related temperament
18729643_4	Phenotype	211,256	altered neural responses to affective stimuli
22892524_4	Limited_variation	172,177	N236T
22892524_4	Limited_variation	188,195	A181V/T
22892524_4	Chemical	205,208	TDF
22892524_4	Gene_or_protein	88,102	HBV polymerase
22892524_4	Limited_variation	88,116	HBV polymerase gene variants
22892524_4	Chemical	163,166	ADV
22892524_4	Pharmacodynamic_phenotype	144,166	resistance against ADV
20078613_12	Chemical	34,37	Oxa
20078613_12	Gene_or_protein	180,183	XPD
20078613_12	Gene_or_protein	148,153	GSTpi
20078613_12	Limited_variation	148,167	GSTpi 105 Val / Val
20078613_12	Limited_variation	180,190	XPD 751Lys
20078613_12	Phenotype	78,103	progression-free survival
20078613_12	Pharmacodynamic_phenotype	34,54	Oxa pharmacodynamics
20078613_12	Pharmacodynamic_phenotype	120,127	outcome
21172311_1	Limited_variation	24,51	5- HTR1B gene polymorphisms
21172311_1	Gene_or_protein	24,32	5- HTR1B
21172311_1	Disease	56,74	alcohol dependence
21172311_1	Chemical	56,63	alcohol
21635144_12	Phenotype	23,38	CYP3A4 activity
21635144_12	Gene_or_protein	23,29	CYP3A4
21635144_12	Gene_or_protein	54,60	CYP3A4
21635144_12	Chemical	155,165	tacrolimus
21635144_12	Gene_or_protein	189,195	CYP3A5
21635144_12	Haplotype	54,71	CYP3A4 * 1 / * 1G
21635144_12	Pharmacokinetic_phenotype	155,182	tacrolimus pharmacokinetics
21635144_12	Limited_variation	97,109	polymorphism
23407558_2	Gene_or_protein	70,102	epidermal growth factor receptor
23407558_2	Gene_or_protein	105,109	EGFR
23407558_2	Gene_or_protein	168,172	EGFR
23407558_2	Chemical	112,138	tyrosine kinase inhibitors
23407558_2	Chemical	141,144	TKI
23407558_2	Limited_variation	168,180	EGFR -mutant
23407558_2	Pharmacodynamic_phenotype	37,47	resistance
23407558_2	Gene_or_protein	112,127	tyrosine kinase
23407558_2	Disease	168,193	EGFR -mutant lung cancers
23407558_2	Chemical	70,138	epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors
14515062_8	Gene_or_protein	34,39	IL-1B
14515062_8	Limited_variation	34,48	IL-1B allele 2
14515062_8	Pharmacodynamic_phenotype	105,142	adenosine -stimulated myocardial flow
14515062_8	Pharmacodynamic_phenotype	145,149	ASMF
14515062_8	Pharmacodynamic_phenotype	127,142	myocardial flow
14515062_8	Phenotype	96,101,127,142	basal myocardial flow
14515062_8	Chemical	105,114	adenosine
15205357_10	Chemical	0,4	DFMO
15205357_10	Gene_or_protein	68,76	ER-alpha
15205357_10	Phenotype	40,76	methylated CpG sites in the ER-alpha
15358623_4	Chemical	64,72	warfarin
15358623_4	Limited_variation	104,125	VKORC1 gene mutations
15358623_4	Gene_or_protein	104,110	VKORC1
15358623_4	Pharmacodynamic_phenotype	187,212	anticoagulation intensity
15358623_4	Pharmacodynamic_phenotype	140,153	doses of drug
15358623_4	Pharmacodynamic_phenotype	43,58	anticoagulation
2753981_6	Gene_or_protein	77,81	cAMP
2753981_6	Chemical	163,174	1,25-(OH)2D
2753981_6	Pharmacodynamic_phenotype	38,51	serum calcium
2753981_6	Pharmacodynamic_phenotype	64,81	nephrogenous cAMP
2753981_6	Pharmacodynamic_phenotype	157,174	serum 1,25-(OH)2D
2753981_6	Chemical	6,20	PTH - ( 1-34 )
2753981_6	Pharmacodynamic_phenotype	94,122	renal phosphate reabsorption
21869714_2	Disease	68,94	non-small cell lung cancer
21869714_2	Disease	97,102	NSCLC
21869714_2	Gene_or_protein	181,213	epidermal growth factor receptor
21869714_2	Gene_or_protein	216,220	EGFR
21869714_2	Limited_variation	326,340	EGFR mutations
21869714_2	Gene_or_protein	326,330	EGFR
21869714_2	Phenotype	146,171	progression-free survival
21869714_2	Chemical	181,248	epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor
21869714_2	Gene_or_protein	223,238	tyrosine kinase
21869714_2	Chemical	285,297	chemotherapy
21869714_2	Pharmacodynamic_phenotype	128,141	response rate
16467864_3	Limited_variation	9,23	AML1 mutations
16467864_3	Gene_or_protein	9,13	AML1
16467864_3	Disease	83,91	MDS /AML
16467864_3	Genomic_variation	120,139	genetic alterations
21596890_6	Chemical	17,21	CDCA
21596890_6	Gene_or_protein	42,49	C /EBPb
21596890_6	Phenotype	81,96	phosphorylation
21596890_6	Phenotype	99,119	nuclear accumulation
21596890_6	Phenotype	126,136	expression
15692831_8	Phenotype	87,99	mEH activity
15692831_8	Gene_or_protein	87,90	mEH
15692831_8	Gene_or_protein	140,145	EPHX1
15692831_8	Chemical	169,180	CBZ-epoxide
15692831_8	Pharmacokinetic_phenotype	6,42	plasma CBZ-diol / CBZ-epoxide ratios
15692831_8	Pharmacokinetic_phenotype	45,66	diol / epoxide ratios
15692831_8	Genomic_variation	121,151	diplotypes in each EPHX1 block
15692831_8	Pharmacokinetic_phenotype	169,191	CBZ-epoxide metabolism
15692831_8	Chemical	13,21	CBZ-diol
15692831_8	Chemical	24,35	CBZ-epoxide
25137520_6	Limited_variation	60,73	SNPs in TNF-a
25137520_6	Gene_or_protein	68,73	TNF-a
25137520_6	Gene_or_protein	76,81	TNF-b
25137520_6	Gene_or_protein	92,95	VDR
25137520_6	Gene_or_protein	98,101	MBP
25137520_6	Gene_or_protein	108,112	APOE
25137520_6	Chemical	126,133	mercury
25137520_6	Chemical	119,123	lead
25137520_6	Chemical	139,147	solvents
25137520_6	Gene_or_protein	84,89	TCA-b
25137520_6	Limited_variation	60,67,76,81	SNPs in TNF-b
25137520_6	Limited_variation	60,67,84,89	SNPs in TCA-b
25137520_6	Limited_variation	60,67,92,95	SNPs in VDR
25137520_6	Limited_variation	60,67,98,101	SNPs in MBP
25137520_6	Limited_variation	60,67,108,112	SNPs in APOE
17452407_12	Disease	36,40	ESRD
17452407_12	Gene_or_protein	59,66	ERalpha
17452407_12	Limited_variation	59,78	ERalpha Ser10Ser CC
17452407_12	Chemical	130,142	triglyceride
17452407_12	Disease	112,115	PEW
17452407_12	Chemical	158,165	albumin
17452407_12	Chemical	176,181	hsCRP
17452407_12	Phenotype	98,115	prevalence of PEW
17452407_12	Pharmacodynamic_phenotype	124,142	serum triglyceride
17452407_12	Pharmacodynamic_phenotype	152,165	serum albumin
17452407_12	Pharmacodynamic_phenotype	176,188	hsCRP levels
17412797_2	Gene_or_protein	51,54	CDT
17412797_2	Chemical	85,92	alcohol
17412797_2	Gene_or_protein	13,48	Carbohydrate -deficient transferrin
17412797_2	Disease	85,98	alcohol abuse
6938173_4	Phenotype	111,114,127,139	ABO blood groups
6938173_4	Phenotype	117,119,127,139	Rh blood groups
6938173_4	Chemical	240,251	lead oxides
6938173_4	Phenotype	124,139	MN blood groups
6938173_4	Phenotype	155,175	ability to taste PTC
6938173_4	Phenotype	178,191	ear lobe type
6938173_4	Phenotype	196,212	mid-digital hair
6938173_4	Genomic_factor	75,93	chromosomic damage
6938173_4	Genomic_variation	21,40	genetic variability
20655300_4	Gene_or_protein	71,75	BDNF
20655300_4	Chemical	133,139	heroin
20655300_4	Limited_variation	71,84	BDNF val66met
20655300_4	Phenotype	115,145	ages of onset for heroin abuse
20655300_4	Disease	133,145	heroin abuse
21047202_5	Limited_variation	15,38	polymorphisms in CYP3A5
21047202_5	Gene_or_protein	32,38	CYP3A5
21047202_5	Limited_variation	47,69	polymorphism in CYP3A4
21047202_5	Gene_or_protein	63,69	CYP3A4
21047202_5	Chemical	122,132	tacrolimus
21047202_5	Pharmacodynamic_phenotype	122,144	tacrolimus stable dose
17968354_8	Pharmacodynamic_phenotype	47,68	dystrophin expression
17968354_8	Gene_or_protein	47,57	dystrophin
17968354_8	Chemical	8,16	PNA-AAV6
17968354_8	Chemical	0,3	PNA
17968354_8	Chemical	0,38	PNA and PNA-AAV6 , PNA-AAV8 conjugates
17968354_8	Chemical	19,27	PNA-AAV8
26940072_9	Gene_or_protein	4,10	VKORC1
26940072_9	Pharmacodynamic_phenotype	17,36	daily warfarin dose
26940072_9	Limited_variation	108,117	rs9923231
26940072_9	Limited_variation	120,129	rs9934438
26940072_9	Limited_variation	134,143	rs2884737
26940072_9	Chemical	23,31	warfarin
26940072_9	Limited_variation	167,185	wild-type genotype
26940072_9	Pharmacodynamic_phenotype	186,212	requiring the highest dose
26791794_9	Disease	32,38	tumors
26791794_9	Gene_or_protein	92,98	PIK3CA
26791794_9	Gene_or_protein	137,143	PIK3CA
26791794_9	Limited_variation	137,157	PIK3CA - p.Glu542Lys
26791794_9	Chemical	187,197	crizotinib
26791794_9	Gene_or_protein	216,222	PIK3CA
26791794_9	Phenotype	48,76	high level MET amplification
26791794_9	Limited_variation	216,234	PIK3CA co-mutation
26791794_9	Pharmacodynamic_phenotype	250,267	clinical response
26791794_9	Gene_or_protein	59,62	MET
26791794_9	Limited_variation	82,98	wild-type PIK3CA
26791794_9	Limited_variation	102,131	MET exon 14 skipping mutation
26791794_9	Gene_or_protein	102,105	MET
26791794_9	Pharmacodynamic_phenotype	174,197	responses to crizotinib
26791794_9	Genomic_variation	59,76	MET amplification
26791794_9	Genomic_factor	102,113	MET exon 14
19067682_10	Limited_variation	0,27	CYP3A5 genetic polymorphism
19067682_10	Gene_or_protein	0,6	CYP3A5
19067682_10	Chemical	52,62	tacrolimus
19067682_10	Pharmacodynamic_phenotype	52,86	tacrolimus -related nephrotoxicity
19067682_10	Pharmacodynamic_phenotype	72,86	nephrotoxicity
17998284_10	Gene_or_protein	14,18	KRAS
17998284_10	Chemical	66,69	CTX
17998284_10	Limited_variation	14,28	KRAS WT status
17998284_10	Phenotype	46,62	survival benefit
17998284_10	Disease	78,82	mCRC
19366808_3	Chemical	46,55	sorafenib
19366808_3	Gene_or_protein	183,190	BCR/ABL
19366808_3	Gene_or_protein	211,224	interleukin-3
19366808_3	Phenotype	65,78	proliferation
19366808_3	Phenotype	91,100	apoptosis
19366808_3	Chemical	24,45	multikinase inhibitor
20442314_9	Gene_or_protein	15,22	Bcr-Abl
20442314_9	Chemical	111,119	imatinib
20442314_9	Phenotype	62,96	death activated by spindle defects
20442314_9	Phenotype	15,40	Bcr-Abl -expressing cells
17392718_12	Chemical	24,33	talinolol
17392718_12	Phenotype	82,97	MDR1 expression
17392718_12	Gene_or_protein	82,86	MDR1
17392718_12	Chemical	10,13	SJW
17392718_12	Chemical	116,119	SJW
17392718_12	Gene_or_protein	163,177	P-glycoprotein
17392718_12	Pharmacokinetic_phenotype	24,37	talinolol AUC
23020798_1	Limited_variation	0,22	Polymorphisms in ERCC1
23020798_1	Gene_or_protein	17,22	ERCC1
23020798_1	Gene_or_protein	25,29	GSTs
23020798_1	Gene_or_protein	32,34	TS
23020798_1	Gene_or_protein	39,44	MTHFR
23020798_1	Phenotype	53,88	clinical outcomes of gastric cancer
23020798_1	Limited_variation	0,16,32,34	Polymorphisms in TS
23020798_1	Limited_variation	0,16,39,44	Polymorphisms in MTHFR
23020798_1	Limited_variation	0,16,25,29	Polymorphisms in GSTs
23020798_1	Chemical	111,145	platinum /5-Fu -based chemotherapy
23020798_1	Disease	74,88	gastric cancer
23020798_1	Chemical	111,125	platinum /5-Fu
23302800_3	Disease	22,28	tumour
23302800_3	Gene_or_protein	76,80	BRAF
23302800_3	Disease	76,98	BRAF -mutated melanoma
23302800_3	Pharmacodynamic_phenotype	111,149	response to treatment with vemurafenib
23302800_3	Gene_or_protein	195,199	BRAF
23302800_3	Phenotype	203,223	melanoma maintenance
23302800_3	Phenotype	22,39	tumour regression
23302800_3	Phenotype	44,61	improved survival
23302800_3	Limited_variation	76,89	BRAF -mutated
23302800_3	Chemical	138,149	vemurafenib
23302800_3	Disease	203,211	melanoma
10223459_12	Chemical	47,59	clotrimazole
10223459_12	Disease	151,163	glioblastoma
10223459_12	Chemical	238,247	cisplatin
10223459_12	Phenotype	69,87	cell proliferation
10223459_12	Limited_variation	260,273	wild-type p53
10223459_12	Pharmacodynamic_phenotype	218,247	antitumor effect of cisplatin
10223459_12	Phenotype	260,293	wild-type p53 -mediated apoptosis
10223459_12	Gene_or_protein	270,273	p53
10223459_12	Phenotype	103,124	morphological changes
26505133_3	Chemical	0,9	Sorafenib
26505133_3	Gene_or_protein	56,60	FLT3
26505133_3	Disease	106,114	leukemia
26505133_3	Gene_or_protein	93,97	FLT3
26505133_3	Disease	93,114	FLT3 mutated leukemia
26505133_3	Chemical	15,41	oral multikinase inhibitor
26505133_3	Limited_variation	93,105	FLT3 mutated
21309949_1	Gene_or_protein	0,4	COMT
21309949_1	Gene_or_protein	9,14	ALDH2
21309949_1	Chemical	85,92	alcohol
21309949_1	Limited_variation	0,4,15,28	COMT polymorphisms
21309949_1	Limited_variation	9,28	ALDH2 polymorphisms
21309949_1	Phenotype	54,92	implicit drinking motives with alcohol
22035418_1	Gene_or_protein	28,32	NME1
22035418_1	Limited_variation	4,81	T_T genotype within the NME1 promoter single nucleotide polymorphism -835 C/T
22035418_1	Chemical	122,132	cytarabine
22035418_1	Disease	172,194	acute myeloid leukemia
22035418_1	Pharmacodynamic_phenotype	122,154	cytarabine induced neurotoxicity
22035418_1	Genomic_factor	28,41	NME1 promoter
22035418_1	Pharmacodynamic_phenotype	141,154	neurotoxicity
23029188_2	Gene_or_protein	122,127	IL28B
23029188_2	Chemical	212,221	ribavirin
23029188_2	Chemical	224,227	RBV
23029188_2	Limited_variation	73,132	single nucleotide polymorphisms ( SNP ) near the IL28B gene
23029188_2	Pharmacodynamic_phenotype	137,229	response to the combined treatments of pegylated-interferon ( PegIFN ) and ribavirin ( RBV )
23029188_2	Chemical	176,196	pegylated-interferon
23029188_2	Chemical	199,205	PegIFN
23029188_2	Disease	241,244	HCV
23029188_2	Chemical	153,229	combined treatments of pegylated-interferon ( PegIFN ) and ribavirin ( RBV )
17250611_11	Limited_variation	16,33	allele of TAS2R16
17250611_11	Gene_or_protein	26,33	TAS2R16
17250611_11	Chemical	75,82	alcohol
17250611_11	Disease	75,93	alcohol dependence
17250611_11	Phenotype	124,145	mean Maxdrinks scores
9607827_2	Limited_variation	62,67	Q151M
9607827_2	Pharmacodynamic_phenotype	89,124	multi- dideoxynucleoside resistance
9607827_2	Chemical	96,113	dideoxynucleoside
9607827_2	Pharmacodynamic_phenotype	127,130	MDR
9607827_2	Limited_variation	2,45	set of five reverse transcriptase mutations
9607827_2	Disease	136,171	human immunodeficiency virus type 1
9607827_2	Disease	174,179	HIV-1
19414633_2	Chemical	18,29	clopidogrel
19414633_2	Chemical	34,43	prasugrel
19414633_2	Gene_or_protein	95,110	cytochrome P450
19414633_2	Gene_or_protein	113,116	CYP
16821082_1	Gene_or_protein	24,28	CCT5
16821082_1	Gene_or_protein	31,35	RGS3
16821082_1	Gene_or_protein	42,46	YKT6
16821082_1	Gene_or_protein	69,72	p53
16821082_1	Chemical	106,115	docetaxel
16821082_1	Disease	125,139	breast cancers
16821082_1	Disease	69,88	p53 -mutated tumors
16821082_1	Pharmacodynamic_phenotype	92,115	resistance to docetaxel
16821082_1	Limited_variation	69,81	p53 -mutated
19127598_11	Phenotype	44,66	COX-2 mRNA suppression
19127598_11	Gene_or_protein	44,49	COX-2
19127598_11	Phenotype	69,89	p21 mRNA stimulation
19127598_11	Gene_or_protein	69,72	p21
19127598_11	Chemical	100,110	isoflavone
19127598_11	Pharmacodynamic_phenotype	94,117	serum isoflavone levels
19127598_11	Genomic_factor	44,54	COX-2 mRNA
19127598_11	Genomic_factor	69,77	p21 mRNA
25366762_3	Gene_or_protein	98,104	GRIN2A
25366762_3	Chemical	216,222	heroin
25366762_3	Disease	216,232	heroin addiction
25366762_3	Gene_or_protein	51,95	glutamate receptor , N-methyl D-aspartate 2A
25366762_3	Gene_or_protein	132,188	2A subunit of the N-methyl D-aspartate ( NMDA ) receptor
25366762_3	Limited_variation	0,111	Genetic polymorphisms in functional regions of the glutamate receptor , N-methyl D-aspartate 2A ( GRIN2A ) gene
10585223_5	Gene_or_protein	37,42	mdr1a
10585223_5	Gene_or_protein	57,62	mdr1a
10585223_5	Chemical	157,164	digoxin
10585223_5	Limited_variation	37,52	mdr1a ( + / + )
10585223_5	Limited_variation	57,72	mdr1a ( - / - )
10585223_5	Pharmacokinetic_phenotype	157,177	digoxin accumulation
10585223_5	Pharmacokinetic_phenotype	0,33	Brain concentration-time profiles
9259617_1	Pharmacodynamic_phenotype	4,26	effect of aflatoxin B1
9259617_1	Gene_or_protein	73,105	transforming growth factor-alpha
9259617_1	Chemical	109,113	CCl4
9259617_1	Pharmacodynamic_phenotype	109,138	CCl4 induced rat liver injury
9259617_1	Chemical	14,26	aflatoxin B1
9259617_1	Phenotype	34,68	expression of early response genes
9259617_1	Pharmacodynamic_phenotype	126,138	liver injury
9259617_1	Phenotype	34,47,73,105	expression of transforming growth factor-alpha
22961402_1	Limited_variation	0,18	CD55 polymorphisms
22961402_1	Gene_or_protein	0,4	CD55
22961402_1	Chemical	31,38	aspirin
22961402_1	Pharmacodynamic_phenotype	31,72	aspirin - exacerbated respiratory disease
22961402_1	Pharmacodynamic_phenotype	53,72	respiratory disease
25251606_7	Gene_or_protein	81,87	MARCKS
25251606_7	Phenotype	102,122	content of PI(4,5)P2
25251606_7	Chemical	113,122	PI(4,5)P2
25251606_7	Phenotype	164,188	behavioral abnormalities
25643589_10	Chemical	12,38	lenalidomide / azacitidine
25643589_10	Chemical	27,38	azacitidine
25643589_10	Limited_variation	121,134	NPM1 mutation
25643589_10	Gene_or_protein	121,125	NPM1
25643589_10	Chemical	12,24	lenalidomide
25643589_10	Phenotype	53,88	function of cytotoxic T lymphocytes
12456499_2	Limited_variation	98,131	one within subunit A ( Val34Leu )
12456499_2	Pharmacodynamic_phenotype	191,224	prothrombotic effects of estrogen
12456499_2	Chemical	335,362	hormone replacement therapy
12456499_2	Disease	275,301	arterial thrombotic events
12456499_2	Limited_variation	136,169	one within subunit B ( His95Arg )
12456499_2	Chemical	216,224	estrogen
12456499_2	Gene_or_protein	58,81	coagulation factor XIII
12456499_2	Limited_variation	58,95	coagulation factor XIII polymorphisms
17961161_11	Gene_or_protein	14,19	ERCC1
17961161_11	Chemical	85,113	platinum -based chemotherapy
17961161_11	Gene_or_protein	140,145	ERCC1
17961161_11	Phenotype	241,249	survival
17961161_11	Pharmacodynamic_phenotype	73,113	response to platinum -based chemotherapy
17961161_11	Disease	14,36	ERCC1 -negative tumors
17961161_11	Disease	140,162	ERCC1 -positive tumors
17961161_11	Chemical	85,93	platinum
17961161_11	Phenotype	14,29	ERCC1 -negative
17961161_11	Phenotype	140,155	ERCC1 -positive
17961161_11	Pharmacodynamic_phenotype	188,202	response rates
21562147_9	Limited_variation	64,84	SNPs in the POR gene
21562147_9	Gene_or_protein	76,79	POR
21562147_9	Chemical	138,146	warfarin
21562147_9	Pharmacodynamic_phenotype	138,163	warfarin maintenance dose
18079739_5	Chemical	50,57	ITF2357
18079739_5	Limited_variation	111,124	JAK2 (V617F )
18079739_5	Gene_or_protein	192,196	JAK2
18079739_5	Gene_or_protein	111,115	JAK2
18079739_5	Gene_or_protein	136,142	pSTAT5
18079739_5	Gene_or_protein	147,153	pSTAT3
18079739_5	Limited_variation	182,196	wild-type JAK2
18079739_5	Limited_variation	182,191,200,204	wild-type STAT
18079739_5	Gene_or_protein	200,204	STAT
15910869_1	Gene_or_protein	27,57	cholesterol 7alpha-hydroxylase
15910869_1	Gene_or_protein	73,89	apolipoprotein E
15910869_1	Chemical	131,143	atorvastatin
15910869_1	Limited_variation	2,57	promoter polymorphism in cholesterol 7alpha-hydroxylase
15910869_1	Limited_variation	73,98	apolipoprotein E genotype
15910869_1	Pharmacodynamic_phenotype	106,143	LDL-lowering response to atorvastatin
15910869_1	Genomic_factor	2,10	promoter
26369533_2	Disease	13,26	Breast cancer
26369533_2	Phenotype	51,74	reduced CYP2D6 activity
26369533_2	Gene_or_protein	59,65	CYP2D6
26369533_2	Chemical	135,144	tamoxifen
26369533_2	Pharmacodynamic_phenotype	96,112	endoxifen levels
26369533_2	Chemical	96,105	endoxifen
26369533_2	Phenotype	41,47,59,74	absent CYP2D6 activity
23358500_5	Limited_variation	50,70	CHRNA5 polymorphisms
23358500_5	Gene_or_protein	50,56	CHRNA5
23358500_5	Chemical	128,136	nicotine
23358500_5	Chemical	151,159	nicotine
23358500_5	Chemical	197,205	nicotine
23358500_5	Phenotype	75,93	smoking topography
23358500_5	Chemical	187,194	placebo
8807668_1	Chemical	35,50	(S)-mephenytoin
8807668_1	Haplotype	74,95	haplotypes of CYP2C19
8807668_1	Gene_or_protein	88,95	CYP2C19
8807668_1	Pharmacokinetic_phenotype	14,50	poor metabolizers of (S)-mephenytoin
21628721_5	Gene_or_protein	22,29	CYP2C19
21628721_5	Chemical	231,242	clopidogrel
21628721_5	Haplotype	22,33	CYP2C19 * 2
21628721_5	Phenotype	49,66	platelet function
21628721_5	Disease	283,300	coronary stenting
16359408_4	Gene_or_protein	50,56	CYP2C8
16359408_4	Chemical	82,105	N-desethylaminodiaquine
16359408_4	Chemical	13,15	AQ
16359408_4	Gene_or_protein	34,49	cytochrome P450
24123531_7	Gene_or_protein	46,50	EGFR
24123531_7	Gene_or_protein	55,59	KRAS
24123531_7	Pharmacodynamic_phenotype	74,95	erlotinib sensitivity
24123531_7	Chemical	74,83	erlotinib
24123531_7	Chemical	110,119	erlotinib
24123531_7	Limited_variation	162,180	HRAS G12D mutation
24123531_7	Gene_or_protein	162,166	HRAS
24123531_7	Limited_variation	32,50	wild-type for EGFR
24123531_7	Limited_variation	32,45,55,59	wild-type for KRAS
24123531_7	Pharmacodynamic_phenotype	110,140	erlotinib -resistant cell line
23091097_11	Limited_variation	49,61	ATM mutation
23091097_11	Gene_or_protein	49,52	ATM
23091097_11	Chemical	184,201	alkylating agents
23091097_11	Chemical	206,220	purine analogs
23091097_11	Genomic_variation	32,44	11q deletion
23091097_11	Phenotype	131,147	overall survival
23091097_11	Disease	65,68	CLL
23091097_11	Chemical	184,220	alkylating agents and purine analogs
17980418_4	Gene_or_protein	45,50	FCER2
17980418_4	Chemical	130,140	budesonide
17980418_4	Disease	156,172	Childhood Asthma
17980418_4	Limited_variation	45,82	FCER2 single nucleotide polymorphisms
12005453_12	Chemical	58,66	butyrate
12005453_12	Gene_or_protein	99,104	GLUT2
12005453_12	Gene_or_protein	109,120	proglucagon
12005453_12	Phenotype	109,131	proglucagon expression
12005453_12	Chemical	158,163	SCFAs
12005453_12	Phenotype	99,104,121,131	GLUT2 expression
8998185_4	Phenotype	67,89	p53 protein expression
8998185_4	Gene_or_protein	67,70	p53
8998185_4	Disease	97,103	tumors
8998185_4	Disease	138,153	prostate cancer
8998185_4	Chemical	230,247	androgen blockade
22974536_2	Disease	73,97	acute coronary syndromes
22974536_2	Disease	100,103	ACS
22974536_2	Gene_or_protein	138,145	CYP2C19
22974536_2	Chemical	188,203	thienopyridines
22974536_2	Pharmacodynamic_phenotype	232,254	adverse cardiac events
22974536_2	Chemical	260,271	clopidogrel
22974536_2	Chemical	287,296	prasugrel
22974536_2	Haplotype	138,149	CYP2C19 * 2
20101393_3	Chemical	75,82	ecstasy
20101393_3	Disease	91,101	depressive
20101393_3	Disease	104,111	anxiety
20101393_3	Limited_variation	183,224	polymorphism of the serotonin transporter
20101393_3	Gene_or_protein	203,224	serotonin transporter
20101393_3	Disease	249,259	depression
20101393_3	Disease	264,281	anxiety disorders
26299806_7	Chemical	42,49	fisetin
26299806_7	Chemical	54,63	sorafenib
26299806_7	Gene_or_protein	69,72	RAF
26299806_7	Phenotype	148,160	tumor growth
26299806_7	Chemical	42,63	fisetin and sorafenib
26299806_7	Phenotype	113,131	cell proliferation
26299806_7	Phenotype	134,143	apoptosis
26299806_7	Chemical	69,82	RAF inhibitor
24521898_3	Chemical	47,55	warfarin
24521898_3	Gene_or_protein	113,119	CYP2C9
24521898_3	Gene_or_protein	122,128	VKORC1
24521898_3	Gene_or_protein	133,139	CYP4F2
24521898_3	Pharmacodynamic_phenotype	47,70	warfarin hypersensitive
15952058_9	Chemical	0,9	Tamoxifen
15952058_9	Gene_or_protein	33,40	UGT2B15
15952058_9	Phenotype	109,117	survival
15952058_9	Phenotype	79,97	risk of recurrence
15952058_9	Limited_variation	33,64	UGT2B15 high activity genotypes
10568834_5	Phenotype	8,26	p53 overexpression
10568834_5	Gene_or_protein	8,11	p53
10568834_5	Chemical	208,222	5-fluorouracil
10568834_5	Chemical	227,237	levamisole
10568834_5	Phenotype	81,97	patient survival
10568834_5	Limited_variation	8,11,31,39	p53 mutation
10568834_5	Chemical	190,237	chemotherapy with 5-fluorouracil and levamisole
17529886_13	Limited_variation	0,6,18,36	UGT1A7 I399 polymorphisms
17529886_13	Gene_or_protein	0,6	UGT1A7
17529886_13	Gene_or_protein	11,17	UGT1A9
17529886_13	Chemical	89,92	MPA
17529886_13	Limited_variation	11,36	UGT1A9 I399 polymorphisms
17529886_13	Pharmacokinetic_phenotype	89,109	MPA pharmacokinetics
25143362_5	Disease	31,49	muscular dystrophy
25143362_5	Gene_or_protein	92,101	dysferlin
25143362_5	Chemical	132,142	bortezomib
25143362_5	Phenotype	157,177	dysferlin expression
25143362_5	Gene_or_protein	157,166	dysferlin
25143362_5	Limited_variation	59,101	homozygous Arg555Trp mutation in dysferlin
25143362_5	Chemical	111,131	proteasome inhibitor
24948056_9	Gene_or_protein	67,71	TLR9
24948056_9	Phenotype	116,141	immunity to S. pneumoniae
24948056_9	Chemical	55,61	PC-BSA
24948056_9	Chemical	34,82	EC immunization with PC-BSA plus TLR9 ligand CpG
24948056_9	Chemical	67,82	TLR9 ligand CpG
25523423_4	Gene_or_protein	47,69	APPswe , PSEN1dE985Dbo
25523423_4	Gene_or_protein	72,79	APP/PS1
25523423_4	Disease	97,99	AD
25523423_4	Chemical	158,170	Bryostatin-1
25523423_4	Phenotype	182,200	cognitive deficits
8923461_9	Gene_or_protein	10,15	c-fos
8923461_9	Gene_or_protein	20,25	c-jun
8923461_9	Gene_or_protein	58,67	TNF alpha
8923461_9	Chemical	99,102	DEX
8923461_9	Phenotype	0,15,26,34	Levels of c-fos proteins
8923461_9	Phenotype	0,9,20,34	Levels of c-jun proteins
11016647_4	Disease	42,48	tumors
11016647_4	Phenotype	88,111	depletion of tumor MGMT
11016647_4	Gene_or_protein	107,111	MGMT
11016647_4	Disease	101,111	tumor MGMT
11016647_4	Chemical	117,133	O6-benzylguanine
11016647_4	Chemical	136,140	6-BG
11016647_4	Chemical	263,267	6-BG
11016647_4	Gene_or_protein	279,283	MGMT
11016647_4	Limited_variation	263,291	6-BG -resistant MGMT mutants
11016647_4	Phenotype	147,178	protection of sensitive tissues
23301703_1	Chemical	18,24	GZD824
23301703_1	Gene_or_protein	111,144	breakpoint cluster region-Abelson
23301703_1	Gene_or_protein	147,154	Bcr-Abl
23301703_1	Pharmacodynamic_phenotype	178,243	clinically acquired mutation -induced resistance against imatinib
23301703_1	Chemical	235,243	imatinib
23301703_1	Pharmacodynamic_phenotype	216,243	resistance against imatinib
23301703_1	Limited_variation	198,206	mutation
26716652_7	Chemical	0,6	RY10-4
26716652_7	Chemical	12,16	DAPT
26716652_7	Gene_or_protein	45,49	HER2
26716652_7	Chemical	101,107	RY10-4
26716652_7	Chemical	122,126	DAPT
26716652_7	Chemical	0,16	RY10-4 plus DAPT
26716652_7	Phenotype	27,36	apoptosis
26716652_7	Phenotype	163,172	apoptosis
26716652_7	Phenotype	45,65	HER2 -overexpressing
22753902_3	Chemical	137,147	cytarabine
22753902_3	Chemical	150,163	anthracycline
22753902_3	Disease	193,199	Cancer
22753902_3	Disease	204,212	Leukemia
22753902_3	Limited_variation	259,274	RUNX1 mutations
22753902_3	Gene_or_protein	259,264	RUNX1
22753902_3	Disease	107,113	CN-AML
22753902_3	Chemical	137,163	cytarabine / anthracycline
18075464_1	Disease	102,128	nonischemic cardiomyopathy
18075464_1	Disease	143,156	heart failure
18075464_1	Chemical	186,196	carvedilol
18075464_1	Limited_variation	0,38	Arg389Gly- beta1 -adrenergic receptors
18075464_1	Phenotype	64,98	left ventricular systolic function
18075464_1	Gene_or_protein	11,38	beta1 -adrenergic receptors
15975707_3	Genomic_factor	32,46	hTERT promoter
15975707_3	Chemical	94,105	polyphenols
15975707_3	Chemical	108,138	(-)-epigallocatechin-3-gallate
15975707_3	Chemical	152,172	(-)-epigallocatechin
15975707_3	Phenotype	202,221	hTERT transcription
15975707_3	Gene_or_protein	202,207	hTERT
15975707_3	Pharmacodynamic_phenotype	79,105	effects of tea polyphenols
15975707_3	Chemical	141,145	EGCG
15975707_3	Chemical	175,178	EGC
15975707_3	Pharmacodynamic_phenotype	79,89,152,180	effects of (-)-epigallocatechin ( EGC )
15975707_3	Pharmacodynamic_phenotype	79,89,108,147	effects of (-)-epigallocatechin-3-gallate ( EGCG )
15975707_3	Gene_or_protein	32,37	hTERT
18349701_12	Chemical	33,41	pindolol
18349701_12	Chemical	93,100	lithium
18349701_12	Limited_variation	147,165	5-HTTLPR genotypes
18349701_12	Limited_variation	44,54	s/s-allele
18349701_12	Pharmacodynamic_phenotype	80,113	benefit from lithium augmentation
16390351_6	Chemical	202,213	repaglinide
16390351_6	Gene_or_protein	283,289	CYP2C8
16390351_6	Haplotype	283,300	CYP2C8 * 3 mutant
16390351_6	Pharmacokinetic_phenotype	22,30,202,213	mean AUC repaglinide
16390351_6	Pharmacodynamic_phenotype	119,133,202,213	mean C ( max ) repaglinide
16390351_6	Haplotype	322,332	wild-types
18977767_5	Gene_or_protein	59,63	SkM1
18977767_5	Gene_or_protein	106,112	Nav1.5
18977767_5	Gene_or_protein	210,216	Nav1.5
18977767_5	Pharmacodynamic_phenotype	229,261	tetrodotoxin ( TTX ) sensitivity
18977767_5	Chemical	229,241	tetrodotoxin
18977767_5	Chemical	244,247	TTX
18977767_5	Limited_variation	181,195,210,216	point mutation Nav1.5
18977767_5	Gene_or_protein	26,56	skeletal Na(+) channel isoform
18977767_5	Gene_or_protein	74,103	cardiac Na(+) channel isoform
10678749_3	Chemical	85,95	quinpirole
10678749_3	Pharmacodynamic_phenotype	134,159	striatal c-Fos expression
10678749_3	Chemical	116,124	RU-24969
10678749_3	Gene_or_protein	143,148	c-Fos
10678749_3	Pharmacodynamic_phenotype	116,159	RU-24969 -induced striatal c-Fos expression
10678749_3	Chemical	60,84	D2-like dopamine agonist
28035401_6	Gene_or_protein	35,40	HDAC6
28035401_6	Pharmacodynamic_phenotype	44,66	vemurafenib resistance
28035401_6	Chemical	44,55	vemurafenib
17719176_3	Limited_variation	25,43	WFS1 polymorphisms
17719176_3	Gene_or_protein	25,29	WFS1
17719176_3	Disease	47,74	medication overuse headache
17719176_3	Disease	77,80	MOH
17719176_3	Disease	87,113	chronic headache condition
17719176_3	Disease	168,171	MOH
17719176_3	Limited_variation	189,216	WFS1 His611Arg polymorphism
17719176_3	Gene_or_protein	189,193	WFS1
17719176_3	Limited_variation	275,284	Arg / Arg
17719176_3	Limited_variation	287,290	R/R
17719176_3	Limited_variation	297,304	non-R/R
17719176_3	Phenotype	254,271	clinical features
17719176_3	Disease	137,150	drugs overuse
20401433_11	Gene_or_protein	29,34	ADH1C
20401433_11	Gene_or_protein	43,48	ADH1B
20401433_11	Gene_or_protein	65,70	ADH1C
20401433_11	Gene_or_protein	85,90	ADH1B
20401433_11	Chemical	117,124	alcohol
20401433_11	Haplotype	29,38	ADH1C * 1
20401433_11	Haplotype	43,52	ADH1B * 1
20401433_11	Disease	117,135	alcohol dependence
20401433_11	Haplotype	65,80	ADH1C * 1 / * 1
20401433_11	Haplotype	85,100	ADH1B * 1 / * 1
22030088_4	Limited_variation	73,85	UGT1A6 T181A
22030088_4	Gene_or_protein	73,79	UGT1A6
22030088_4	Limited_variation	73,79,90,95	UGT1A6 R184S
22030088_4	Disease	133,140	Adenoma
22030088_4	Chemical	157,166	Celecoxib
22030088_4	Chemical	234,241	aspirin
22030088_4	Disease	259,267	adenomas
22030088_4	Chemical	339,348	celecoxib
22030088_4	Chemical	26,57	combining aspirin and celecoxib
22030088_4	Chemical	36,43	aspirin
22030088_4	Chemical	48,57	celecoxib
22030088_4	Pharmacodynamic_phenotype	16,57	effect of combining aspirin and celecoxib
22030088_4	Chemical	286,293	placebo
25657029_9	Gene_or_protein	45,49	MIA2
25657029_9	Limited_variation	45,67	MIA2 ( I141M ) variant
25657029_9	Phenotype	78,97	high levels of ERN1
25657029_9	Gene_or_protein	93,97	ERN1
25657029_9	Pharmacodynamic_phenotype	112,136	sensitive to gemcitabine
25657029_9	Chemical	125,136	gemcitabine
25657029_9	Disease	14,18	PDAC
10877911_6	Gene_or_protein	25,68	glial cell line-derived neurotrophic factor
10877911_6	Gene_or_protein	71,75	GDNF
10877911_6	Chemical	126,143	6-hydroxydopamine
10877911_6	Disease	153,172	Parkinson's disease
26167638_1	Limited_variation	0,16,30,51	VKORC1 - 1639G/A Genetic Polymorphisms
26167638_1	Gene_or_protein	0,6	VKORC1
26167638_1	Limited_variation	0,8,21,51	VKORC1 - 1173 C/T Genetic Polymorphisms
26167638_1	Chemical	88,96	Warfarin
26167638_1	Pharmacodynamic_phenotype	88,113	Warfarin Maintenance Dose
16963807_2	Chemical	57,65	curcumin
16963807_2	Phenotype	86,109	LDL receptor expression
16963807_2	Gene_or_protein	86,98	LDL receptor
16963807_2	Chemical	114,120	sterol
16963807_2	Chemical	321,327	sterol
16963807_2	Pharmacodynamic_phenotype	47,65	effect of curcumin
16963807_2	Gene_or_protein	245,271	green fluorescence protein
16963807_2	Gene_or_protein	274,277	GFP
16963807_2	Gene_or_protein	321,348	sterol regulatory element-1
16963807_2	Gene_or_protein	351,356	SRE-1
22948856_4	Chemical	54,65	pridopidine
22948856_4	Pharmacokinetic_phenotype	27,65	pharmacokinetic profile of pridopidine
22948856_4	Gene_or_protein	125,131	CYP2D6
22948856_4	Pharmacokinetic_phenotype	120,144	poor CYP2D6 metabolizers
22948856_4	Pharmacodynamic_phenotype	91,106	dose adjustment
12835613_12	Gene_or_protein	34,41	CYP2C19
12835613_12	Chemical	102,114	carisoprodol
12835613_12	Pharmacokinetic_phenotype	89,114	metabolizing carisoprodol
12835613_12	Haplotype	34,51	CYP2C19 * 1 / * 2
12835613_12	Pharmacokinetic_phenotype	152,177	intermediate metabolizers
25522765_1	Chemical	27,36	Erlotinib
25522765_1	Phenotype	46,82	Growth of Non-Small Cell Lung Cancer
25522765_1	Disease	56,82	Non-Small Cell Lung Cancer
25522765_1	Limited_variation	99,113	EGFR Mutations
25522765_1	Gene_or_protein	99,103	EGFR
25522765_1	Phenotype	118,136	HGF Overexpression
25522765_1	Gene_or_protein	118,121	HGF
25522765_1	Chemical	10,21	Onartuzumab
25522765_1	Chemical	10,36	Onartuzumab with Erlotinib
21932012_4	Disease	0,4	GACI
21932012_4	Limited_variation	18,45	mutations in the ENPP1 gene
21932012_4	Gene_or_protein	35,40	ENPP1
21932012_4	Chemical	91,114	inorganic pyrophosphate
21932012_4	Chemical	117,122	PP(i)
21932012_4	Chemical	149,163	hydroxyapatite
24265036_2	Chemical	3,12	tamoxifen
24265036_2	Disease	22,35	breast cancer
24265036_2	Gene_or_protein	108,125	estrogen receptor
24265036_2	Gene_or_protein	198,215	estrogen receptor
24265036_2	Phenotype	63,74	hot flashes
24265036_2	Phenotype	108,136	estrogen receptor antagonism
24265036_2	Limited_variation	150,171,198,215	genetic variations of estrogen receptor
24265036_2	Limited_variation	150,189	genetic variations of metabolic enzymes
24265036_2	Gene_or_protein	172,189	metabolic enzymes
26273667_5	Chemical	103,117	sulphonylureas
26273667_5	Chemical	120,130	biguanides
26273667_5	Gene_or_protein	133,150	alpha glucosidase
26273667_5	Chemical	168,186	thiazolidinediones
26273667_5	Disease	225,238	hyperglycemia
26273667_5	Chemical	133,161	alpha glucosidase inhibitors
15610939_3	Phenotype	12,43	5-HTT uptake ( function ) level
15610939_3	Gene_or_protein	12,17	5-HTT
15610939_3	Chemical	48,58	paroxetine
15610939_3	Gene_or_protein	120,125	5-HTT
15610939_3	Phenotype	120,141	5-HTT expression rate
15610939_3	Limited_variation	148,150,165,174	LL genotypes
15610939_3	Limited_variation	153,155,165,174	LS genotypes
15610939_3	Limited_variation	162,174	SS genotypes
15610939_3	Phenotype	48,66	paroxetine binding
15610939_3	Disease	95,105	alcoholics
19300499_1	Gene_or_protein	41,47	VKORC1
19300499_1	Gene_or_protein	50,56	CYP2C9
19300499_1	Gene_or_protein	63,69	CYP4F2
19300499_1	Pharmacodynamic_phenotype	107,120	warfarin dose
19300499_1	Chemical	107,115	warfarin
22506971_7	Gene_or_protein	66,86	dopamine transporter
22506971_7	Gene_or_protein	89,92	DAT
22506971_7	Chemical	131,138	alcohol
22506971_7	Chemical	181,188	alcohol
22506971_7	Phenotype	26,94	hypermethylation of the promoter of the dopamine transporter ( DAT )
22506971_7	Disease	131,149	alcohol dependence
22506971_7	Disease	181,196	alcohol craving
22506971_7	Genomic_factor	50,86	promoter of the dopamine transporter
25862379_3	Chemical	32,40	dopamine
25862379_3	Gene_or_protein	68,88	dopamine transporter
25862379_3	Pharmacodynamic_phenotype	18,54	extracellular dopamine concentration
25862379_3	Chemical	68,76	dopamine
25695221_15	Chemical	15,24	Gefitinib
25695221_15	Limited_variation	181,200	EGFR gene mutations
25695221_15	Gene_or_protein	181,185	EGFR
25695221_15	Limited_variation	225,256	EGFR exon 19 deletion mutations
25695221_15	Gene_or_protein	225,229	EGFR
25695221_15	Chemical	45,56	bevacizumab
25695221_15	Disease	159,164	NSCLC
25695221_15	Chemical	15,56	Gefitinib in combination with bevacizumab
25695221_15	Genomic_factor	225,237	EGFR exon 19
23245376_1	Limited_variation	29,39	NRXN3 SNPs
23245376_1	Gene_or_protein	29,34	NRXN3
23245376_1	Disease	45,76	borderline personality disorder
23245376_1	Disease	45,113	borderline personality disorder phenotypes in heroin dependent cases
23245376_1	Chemical	91,97	heroin
23245376_1	Disease	91,107	heroin dependent
9563874_17	Gene_or_protein	46,50	EGFR
9563874_17	Gene_or_protein	113,117	EGFR
9563874_17	Chemical	136,150	cAMP analogues
9563874_17	Disease	205,211	cancer
9563874_17	Gene_or_protein	55,59	PKAI
9563874_17	Chemical	74,96	pharmacological agents
9563874_17	Chemical	107,131	anti- EGFR blocking MAbs
9563874_17	Pharmacodynamic_phenotype	159,195	cooperative antiproliferative effect
18628428_8	Disease	22,35	breast cancer
18628428_8	Chemical	52,55	E+P
18628428_8	Limited_variation	121,139	CYP1A1 Ile(462)Val
18628428_8	Gene_or_protein	121,127	CYP1A1
18628428_8	Gene_or_protein	142,148	CYP1A1
18628428_8	Limited_variation	156,174	CYP1B1 Asn(453)Ser
18628428_8	Gene_or_protein	156,162	CYP1B1
18628428_8	Gene_or_protein	181,184	PGR
18628428_8	Limited_variation	181,196	PGR Val(660)Leu
18628428_8	Limited_variation	142,153	CYP1A1 MspI
18628428_8	Pharmacodynamic_phenotype	22,55	breast cancer associated with E+P
18628428_8	Limited_variation	228,260	homozygous for the common allele
10087449_9	Phenotype	0,43	PACAP -induced expression of the c-fos gene
10087449_9	Gene_or_protein	0,5	PACAP
10087449_9	Gene_or_protein	33,43	c-fos gene
10087449_9	Chemical	121,143	PACAP - ( 6-38 ) - NH2
10087449_9	Chemical	93,118	PACAP receptor antagonist
10087449_9	Gene_or_protein	93,98	PACAP
10087449_9	Gene_or_protein	121,126	PACAP
27916449_4	Limited_variation	26,49	GNAO1 missense mutation
27916449_4	Gene_or_protein	26,31	GNAO1
27916449_4	Chemical	74,84	topiramate
27916449_4	Disease	130,136	chorea
27916449_4	Phenotype	57,71	age of 18years
11561767_10	Gene_or_protein	0,4	MUC1
11561767_10	Disease	23,30	tumours
11561767_10	Chemical	71,80	tamoxifen
11561767_10	Chemical	138,147	tamoxifen
11561767_10	Phenotype	0,11	MUC1 levels
21114867_1	Gene_or_protein	29,62	endothelial nitric oxide synthase
21114867_1	Disease	112,138	non-small-cell lung cancer
21114867_1	Chemical	161,197	platinum -based doublet chemotherapy
21114867_1	Limited_variation	8,62	polymorphisms in the endothelial nitric oxide synthase
21114867_1	Phenotype	83,99	overall survival
21114867_1	Chemical	161,169	platinum
17492376_9	Disease	14,28	Breast cancers
17492376_9	Gene_or_protein	35,40	BRCA1
17492376_9	Chemical	91,100	docetaxel
17492376_9	Pharmacodynamic_phenotype	76,100	sensitivity to docetaxel
21639946_8	Gene_or_protein	79,85	CYP2C9
21639946_8	Gene_or_protein	92,98	CYP2C9
21639946_8	Limited_variation	106,115	rs9332127
21639946_8	Limited_variation	127,136	rs2108622
21639946_8	Gene_or_protein	120,126	CYP4F2
21639946_8	Limited_variation	144,154	rs12714145
21639946_8	Gene_or_protein	139,143	GGCX
21639946_8	Limited_variation	163,172	rs4653436
21639946_8	Gene_or_protein	157,162	EPHX1
21639946_8	Limited_variation	182,191	rs1799809
21639946_8	Gene_or_protein	177,181	PROC
21639946_8	Pharmacodynamic_phenotype	197,217	warfarin sensitivity
21639946_8	Chemical	197,205	warfarin
21639946_8	Haplotype	79,89	CYP2C9 * 3
21639946_8	Limited_variation	92,103	CYP2C9 C-65
21919924_3	Chemical	15,22	alcohol
21919924_3	Disease	36,38	AD
21919924_3	Genomic_factor	69,89	3 ' region of GABRA2
21919924_3	Gene_or_protein	83,89	GABRA2
21919924_3	Gene_or_protein	235,241	GABRG1
21919924_3	Disease	15,33	alcohol dependence
22661198_3	Limited_variation	56,121	T102C polymorphism in the 5-HT receptor subtype 2A gene ( HTR2A )
22661198_3	Gene_or_protein	82,106	5-HT receptor subtype 2A
22661198_3	Gene_or_protein	114,119	HTR2A
22661198_3	Chemical	126,133	alcohol
22661198_3	Disease	126,144	alcohol dependence
15083067_2	Chemical	0,9	Bupropion
15083067_2	Gene_or_protein	53,80	cytochrome P450 ( CYP ) 2B6
15083067_2	Phenotype	141,151	expression
15083067_2	Pharmacokinetic_phenotype	156,165	catalysis
24495780_6	Limited_variation	25,34	rs4795893
24495780_6	Limited_variation	37,46	rs1024611
24495780_6	Limited_variation	49,55	rs4586
24495780_6	Limited_variation	60,69	rs2857657
24495780_6	Gene_or_protein	99,103	CCL2
24495780_6	Disease	244,257	schizophrenic
24495780_6	Chemical	347,358	risperidone
24495780_6	Phenotype	153,189	Positive and Negative Syndrome Scale
24495780_6	Phenotype	192,197	PANSS
24495780_6	Limited_variation	18,22	SNPs
24098690_10	Disease	47,57	restenosis
24098690_10	Limited_variation	65,80	ACE DD genotype
24098690_10	Gene_or_protein	65,68	ACE
22348413_9	Chemical	0,12	Itraconazole
22348413_9	Gene_or_protein	44,50	CYP3A4
22348413_9	Chemical	101,110	midazolam
22348413_9	Chemical	113,122	triazolam
22348413_9	Chemical	125,134	buspirone
22348413_9	Chemical	137,147	lovastatin
22348413_9	Chemical	150,161	simvastatin
22348413_9	Chemical	166,175	oxycodone
22348413_9	Chemical	186,196	rifampicin
22348413_9	Pharmacodynamic_phenotype	78,89,101,110	exposure to midazolam
22348413_9	Pharmacodynamic_phenotype	78,89,113,122	exposure to triazolam
22348413_9	Pharmacodynamic_phenotype	78,89,125,134	exposure to buspirone
22348413_9	Pharmacodynamic_phenotype	78,89,137,147	exposure to lovastatin
22348413_9	Pharmacodynamic_phenotype	78,89,150,161	exposure to simvastatin
22348413_9	Pharmacodynamic_phenotype	78,89,166,175	exposure to oxycodone
22348413_9	Chemical	30,50	inhibitors of CYP3A4
22348413_9	Pharmacodynamic_phenotype	219,240	plasma concentrations
27569869_5	Chemical	0,12	Capecitabine
27569869_5	Chemical	29,33	5-FU
27569869_5	Gene_or_protein	43,46	CDA
27569869_5	Gene_or_protein	51,55	TYMP
27569869_5	Limited_variation	67,78	SNPs in CDA
27569869_5	Gene_or_protein	75,78	CDA
27569869_5	Gene_or_protein	83,87	CES2
27569869_5	Gene_or_protein	37,40	CES
27569869_5	Limited_variation	67,74,83,87	SNPs in CES2
27569869_5	Pharmacodynamic_phenotype	121,129	efficacy
27569869_5	Pharmacodynamic_phenotype	134,142	toxicity
18589587_5	Disease	56,64	toxicity
18589587_5	Phenotype	82,131	inhibition of cytochrome P450 ( CYP450 ) isoforms
18589587_5	Gene_or_protein	96,111	cytochrome P450
18589587_5	Gene_or_protein	114,120	CYP450
18589587_5	Chemical	135,144	isoniazid
18589587_5	Gene_or_protein	147,154	CYP2C19
18589587_5	Gene_or_protein	157,162	CYP3A
18589587_5	Chemical	182,185	INH
18589587_5	Pharmacokinetic_phenotype	18,34	slow acetylation
18589587_5	Pharmacodynamic_phenotype	182,209	INH plasmatic concentration
18852012_19	Chemical	132,149	5-aminosalicylate
18852012_19	Gene_or_protein	125,129	NAT1
18852012_19	Chemical	154,173	p-aminobenzoic acid
18852012_19	Gene_or_protein	186,190	NAT2
18852012_19	Chemical	193,208	sulphamethazine
18852012_19	Chemical	92,129	substrate specificities of human NAT1
18852012_19	Chemical	92,118,180,190	substrate specificities of human NAT2
25696877_6	Chemical	36,47	clopidogrel
25696877_6	Limited_variation	122,154	CYP2C19 loss-of-function alleles
25696877_6	Gene_or_protein	122,129	CYP2C19
25696877_6	Disease	262,282	cardiovascular death
25696877_6	Disease	285,306	myocardial infarction
25696877_6	Disease	312,318	stroke
25696877_6	Phenotype	187,218	adverse cardiovascular outcomes
25696877_6	Disease	361,377	stent thrombosis
25696877_6	Disease	66,100	percutaneous coronary intervention
12517791_13	Limited_variation	46,57	AR mutation
12517791_13	Gene_or_protein	46,48	AR
12517791_13	Disease	91,94	AWS
12517791_13	Chemical	112,121	flutamide
12517791_13	Chemical	208,220	bicalutamide
12517791_13	Disease	170,183	refractory PC
19531897_9	Limited_variation	14,35	CYP2C19 polymorphisms
19531897_9	Gene_or_protein	14,21	CYP2C19
19531897_9	Chemical	94,105	clopidogrel
19531897_9	Pharmacodynamic_phenotype	71,105	antiplatelet effect of clopidogrel
16314758_1	Gene_or_protein	37,43	Homer1
16314758_1	Limited_variation	17,48	polymorphism in the Homer1 gene
16314758_1	Disease	54,72	cocaine dependence
16314758_1	Chemical	54,61	cocaine
15967990_10	Phenotype	126,147	TPMT protein function
15967990_10	Gene_or_protein	126,130	TPMT
15967990_10	Chemical	192,202	thiopurine
15967990_10	Pharmacodynamic_phenotype	180,202	response to thiopurine
15967990_10	Limited_variation	105,118	polymorphisms
15710601_1	Chemical	0,10	Evodiamine
15710601_1	Phenotype	83,113	IkappaBalpha kinase activation
15710601_1	Gene_or_protein	83,95	IkappaBalpha
15710601_1	Phenotype	48,68	NF-kappaB activation
15710601_1	Gene_or_protein	48,57	NF-kappaB
15710601_1	Gene_or_protein	136,145	NF-kappaB
15710601_1	Phenotype	136,170,186,201	NF-kappaB -regulated antiapoptotic gene expression
15710601_1	Phenotype	136,156,175,201	NF-kappaB -regulated metastatic gene expression
15710601_1	Phenotype	218,227	apoptosis
15710601_1	Phenotype	245,253	invasion
23097010_11	Limited_variation	22,49	POR 28 genetic polymorphism
23097010_11	Gene_or_protein	22,25	POR
23097010_11	Chemical	122,132	tacrolimus
23097010_11	Limited_variation	145,174	CYP3A5 3 genetic polymorphism
23097010_11	Gene_or_protein	145,151	CYP3A5
23097010_11	Pharmacodynamic_phenotype	107,132	variability of tacrolimus
17851539_6	Phenotype	27,43	c-Fos activation
17851539_6	Gene_or_protein	27,32	c-Fos
17851539_6	Chemical	67,74	ethanol
17851539_6	Gene_or_protein	175,180	c-Jun
17851539_6	Gene_or_protein	200,238	extracellular signal-regulated kinases
17851539_6	Gene_or_protein	243,268	c-Jun N -terminal kinases
23360489_5	Disease	12,23	lung cancer
23360489_5	Gene_or_protein	66,71	c-Met
23360489_5	Chemical	113,120	SU11274
23360489_5	Gene_or_protein	92,97	c-Met
23360489_5	Gene_or_protein	132,136	EGFR
23360489_5	Genomic_variation	44,71	gene amplification of c-Met
23360489_5	Chemical	132,152	EGFR -targeted drugs
23360489_5	Pharmacodynamic_phenotype	75,87,113,120	sensitive to SU11274
23360489_5	Pharmacodynamic_phenotype	75,84,125,152	sensitive not to EGFR -targeted drugs
23360489_5	Chemical	92,112	c-Met -targeted drug
21916909_1	Gene_or_protein	15,20	ABCB1
21916909_1	Gene_or_protein	23,29	CYP3A4
21916909_1	Gene_or_protein	40,46	CYP3A5
21916909_1	Chemical	90,100	tacrolimus
21916909_1	Haplotype	23,35	CYP3A4 * 18B
21916909_1	Haplotype	40,50	CYP3A5 * 3
21916909_1	Pharmacokinetic_phenotype	70,100	pharmacokinetics of tacrolimus
23012624_1	Limited_variation	9,13,24,33	ITPA genotypes
23012624_1	Gene_or_protein	9,13	ITPA
23012624_1	Limited_variation	18,33	IL28B genotypes
23012624_1	Gene_or_protein	18,23	IL28B
23012624_1	Chemical	79,107	peginterferon plus ribavirin
23012624_1	Disease	37,56	chronic hepatitis C
23012624_1	Chemical	79,92	peginterferon
23012624_1	Chemical	98,107	ribavirin
16773681_6	Gene_or_protein	252,282	thiopurine S-methyltransferase
16773681_6	Gene_or_protein	285,289	TPMT
16773681_6	Chemical	341,351	thiopurine
16773681_6	Disease	162,165	IBD
16773681_6	Limited_variation	252,310	thiopurine S-methyltransferase ( TPMT ) gene polymorphisms
16773681_6	Pharmacodynamic_phenotype	315,351	hematological toxicity of thiopurine
16773681_6	Pharmacodynamic_phenotype	315,337	hematological toxicity
23082737_9	Chemical	14,25	vemurafenib
23082737_9	Disease	80,88	melanoma
23082737_9	Disease	108,114	tumors
23082737_9	Limited_variation	130,152	BRAF (V600E ) mutation
23082737_9	Phenotype	57,104	abnormal signaling for melanoma cellular growth
23082737_9	Gene_or_protein	130,134	BRAF
23175182_5	Gene_or_protein	14,28	mGlu3 receptor
23175182_5	Pharmacodynamic_phenotype	57,77	action of paclitaxel
23175182_5	Pharmacodynamic_phenotype	57,66,80,89	action of etoposide
23175182_5	Pharmacodynamic_phenotype	57,66,92,104	action of cis-platinum
23175182_5	Pharmacodynamic_phenotype	57,66,111,121	action of irinotecan
23175182_5	Chemical	14,37	mGlu3 receptor blockade
23175182_5	Chemical	67,77	paclitaxel
23175182_5	Chemical	80,89	etoposide
23175182_5	Chemical	92,104	cis-platinum
23175182_5	Chemical	111,121	irinotecan
26341921_8	Gene_or_protein	44,48	EGFR
26341921_8	Chemical	108,116	afatinib
26341921_8	Limited_variation	173,187	EGFR ( L858R )
26341921_8	Gene_or_protein	173,177	EGFR
26341921_8	Phenotype	227,240	tumor relapse
26341921_8	Disease	198,218	lung adenocarcinomas
26341921_8	Disease	227,232	tumor
26341921_8	Chemical	122,131	cetuximab
26341921_8	Chemical	108,131	afatinib plus cetuximab
26341921_8	Pharmacodynamic_phenotype	245,260	drug-resistance
26341921_8	Disease	44,68	EGFR -mutant lung cancer
26341921_8	Chemical	288,292	TKIs
26341921_8	Limited_variation	44,56	EGFR -mutant
26341921_8	Disease	173,218	EGFR ( L858R ) - induced lung adenocarcinomas
25319571_4	Chemical	56,86	(S)-3,5-dihydroxyphenylglycine
25319571_4	Gene_or_protein	175,179	Drd1
25319571_4	Gene_or_protein	192,196	Drd2
25319571_4	Chemical	89,93	DHPG
25319571_4	Chemical	34,86	group I mGluR agonist (S)-3,5-dihydroxyphenylglycine
25319571_4	Disease	113,116	LTD
25319571_4	Limited_variation	152,161,175,185	wild-type Drd1 -eGFP
25319571_4	Limited_variation	164,185	hemizygous Drd1 -eGFP
25319571_4	Limited_variation	152,161,192,202	wild-type Drd2 -eGFP
25319571_4	Limited_variation	164,174,192,202	hemizygous Drd2 -eGFP
24387766_10	Phenotype	109,131	expression of hepcidin
24387766_10	Gene_or_protein	123,131	hepcidin
24387766_10	Chemical	44,66	black soyabean extract
24387766_10	Pharmacokinetic_phenotype	77,90	Fe metabolism
24387766_10	Chemical	77,79	Fe
15813023_1	Phenotype	12,39	MDR1 polymorphic expression
15813023_1	Gene_or_protein	12,16	MDR1
15813023_1	Chemical	63,77	cyclosporine A
15813023_1	Pharmacokinetic_phenotype	48,77	disposition of cyclosporine A
18252229_3	Gene_or_protein	0,6	CYP2C9
18252229_3	Haplotype	17,24	p.R144C
18252229_3	Gene_or_protein	29,35	CYP2C9
18252229_3	Haplotype	46,53	p.I359L
18252229_3	Genomic_factor	66,81	VKORC1 promoter
18252229_3	Gene_or_protein	66,72	VKORC1
18252229_3	Chemical	150,158	warfarin
18252229_3	Limited_variation	221,246	VKORC1 missense mutations
18252229_3	Gene_or_protein	221,227	VKORC1
18252229_3	Chemical	251,259	warfarin
18252229_3	Pharmacodynamic_phenotype	150,172	warfarin " sensitive "
18252229_3	Pharmacodynamic_phenotype	251,273	warfarin " resistant "
18252229_3	Haplotype	0,14	CYP2C9 ( * ) 2
18252229_3	Haplotype	29,43	CYP2C9 ( * ) 3
18252229_3	Limited_variation	66,112	VKORC1 promoter ( g.-1639G-->A ) polymorphisms
18252229_3	Pharmacodynamic_phenotype	286,298	higher doses
18252229_3	Pharmacodynamic_phenotype	185,196	lower doses
23778325_1	Gene_or_protein	72,76	COX2
23778325_1	Chemical	89,98	celecoxib
23778325_1	Limited_variation	10,31	genetic polymorphisms
23778325_1	Disease	35,42	adenoma
23778325_1	Phenotype	35,53	adenoma recurrence
23778325_1	Pharmacodynamic_phenotype	58,66,89,98	toxicity celecoxib
23778325_1	Chemical	72,86	COX2 inhibitor
23778325_1	Pharmacodynamic_phenotype	58,86	toxicity in a COX2 inhibitor
18666383_4	Limited_variation	27,48	polymorphisms of TPMT
18666383_4	Gene_or_protein	44,48	TPMT
18666383_4	Chemical	94,104	thiopurine
18666383_4	Pharmacodynamic_phenotype	64,104	clinical impact on the use of thiopurine
20121554_4	Disease	57,85	acute lymphoblastic leukemia
20121554_4	Gene_or_protein	103,138	methylenetetrahydrofolate reductase
20121554_4	Limited_variation	92,153	homozygous methylenetetrahydrofolate reductase C677T mutation
20121554_4	Chemical	179,191	methotrexate
20121554_4	Disease	214,240	cerebral venous thrombosis
20121554_4	Chemical	269,281	methotrexate
20121554_4	Pharmacodynamic_phenotype	179,209	methotrexate -induced toxicity
20121554_4	Pharmacodynamic_phenotype	201,209	toxicity
21346370_3	Gene_or_protein	37,44	SLC22A2
21346370_3	Gene_or_protein	94,98	OCT2
21346370_3	Chemical	295,302	aspirin
21346370_3	Gene_or_protein	0,34	Solute carrier family 22, member 2
21346370_3	Gene_or_protein	63,91	organic cation transporter 2
21346370_3	Chemical	228,242	prostaglandins
10098858_5	Chemical	35,46	amphetamine
10098858_5	Phenotype	50,65	RGS2 expression
10098858_5	Gene_or_protein	50,54	RGS2
10098858_5	Chemical	111,122	amphetamine
10098858_5	Pharmacodynamic_phenotype	15,46	effects of repeated amphetamine
22955794_3	Limited_variation	0,54	Variation in the cytochrome P450 2C19 ( CYP2C19 ) gene
22955794_3	Gene_or_protein	17,37	cytochrome P450 2C19
22955794_3	Gene_or_protein	40,47	CYP2C19
22955794_3	Gene_or_protein	70,77	CYP2C19
22955794_3	Chemical	147,158	clopidogrel
22955794_3	Pharmacodynamic_phenotype	126,158	variable response to clopidogrel
11417444_12	Chemical	25,37	azathioprine
11417444_12	Phenotype	44,57	TPMT activity
11417444_12	Gene_or_protein	44,48	TPMT
11417444_12	Chemical	124,136	azathioprine
27025877_4	Phenotype	0,15	JAK2 inhibition
27025877_4	Gene_or_protein	0,4	JAK2
27025877_4	Pharmacodynamic_phenotype	25,68	sensitivity to the EGFR inhibitor erlotinib
27025877_4	Chemical	59,68	erlotinib
27025877_4	Gene_or_protein	44,48	EGFR
27025877_4	Gene_or_protein	122,126	EGFR
27025877_4	Disease	122,161	EGFR -mutant TKI -resistant lung cancer
27025877_4	Chemical	44,58	EGFR inhibitor
27025877_4	Limited_variation	122,134	EGFR -mutant
27025877_4	Chemical	72,75	TKI
27025877_4	Chemical	135,138	TKI
27025877_4	Phenotype	72,86	TKI -resistant
19932784_15	Disease	27,50	acute coronary syndrome
19932784_15	Disease	53,70	diabetes mellitus
19932784_15	Gene_or_protein	77,84	CYP2C19
19932784_15	Chemical	143,154	clopidogrel
19932784_15	Phenotype	16,24	high BMI
19932784_15	Haplotype	77,86	CYP2C19 2
19932784_15	Pharmacodynamic_phenotype	107,111	HTPR
16473917_1	Limited_variation	11,41	CYP1A2 deficiency polymorphism
16473917_1	Gene_or_protein	11,17	CYP1A2
16473917_1	Chemical	87,151	4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one
16473917_1	Chemical	154,162	YM-64227
16473917_1	Pharmacokinetic_phenotype	67,164	pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one ( YM-64227 )
16473917_1	Chemical	169,203	phosphodiesterase type 4 inhibitor
22572645_4	Chemical	51,57	folate
22572645_4	Chemical	113,123	folic acid
22572645_4	Limited_variation	164,178	MTHFR genotype
22572645_4	Gene_or_protein	164,169	MTHFR
22572645_4	Phenotype	69,83	child problems
22572645_4	Pharmacodynamic_phenotype	51,64	folate status
19147553_3	Chemical	0,8	Nutlin-3
19147553_3	Gene_or_protein	14,18	MDM2
19147553_3	Gene_or_protein	94,97	p53
19147553_3	Disease	110,116	cancer
19147553_3	Chemical	14,28	MDM2 inhibitor
19147553_3	Chemical	77,97	activator of the p53
19566775_5	Limited_variation	46,81	rs16147 of the NPY gene ( -485C>T )
19566775_5	Gene_or_protein	61,64	NPY
19566775_5	Limited_variation	14,45,86,128	single nucleotide polymorphisms rs7687423 of the NPY receptor Y1 ( NPY1R )
19566775_5	Gene_or_protein	121,126	NPY1R
19566775_5	Chemical	169,184	methamphetamine
19566775_5	Disease	200,209	psychosis
19566775_5	Gene_or_protein	103,118	NPY receptor Y1
19566775_5	Disease	169,195	methamphetamine dependence
19566775_5	Limited_variation	14,81	single nucleotide polymorphisms rs16147 of the NPY gene ( -485C>T )
19566775_5	Limited_variation	86,95	rs7687423
24966969_2	Limited_variation	0,73	Single nucleotide polymorphisms ( SNPs ) of VKORC ( 1173T/C , rs9934438 )
24966969_2	Limited_variation	0,43,78,108	Single nucleotide polymorphisms ( SNPs ) of CYP2C9 ( 1075A/C , rs1057910 )
24966969_2	Gene_or_protein	78,84	CYP2C9
24966969_2	Pharmacodynamic_phenotype	147,170	sensitivity of warfarin
24966969_2	Chemical	162,170	warfarin
24966969_2	Gene_or_protein	44,49	VKORC
10223777_10	Gene_or_protein	169,175	CYP2D6
10223777_10	Limited_variation	148,166	R296C polymorphism
10223777_10	Gene_or_protein	182,188	CYP2D6
10223777_10	Pharmacodynamic_phenotype	39,59	plasma concentration
10223777_10	Pharmacokinetic_phenotype	71,112	urinary alpha-hydroxymetoprolol excretion
10223777_10	Haplotype	169,179	CYP2D6 * 1
10223777_10	Haplotype	182,192	CYP2D6 * 2
10223777_10	Chemical	79,102	alpha-hydroxymetoprolol
9654649_8	Chemical	0,5	G-Rg1
9654649_8	Gene_or_protein	65,67	GR
9654649_8	Pharmacodynamic_phenotype	103,116	effect of Dex
9654649_8	Phenotype	51,75	intracellular GR content
9654649_8	Chemical	113,116	Dex
21135276_3	Gene_or_protein	71,75	HER2
21135276_3	Chemical	104,113	lapatinib
21135276_3	Gene_or_protein	154,158	HER2
21135276_3	Gene_or_protein	223,227	HER2
21135276_3	Gene_or_protein	28,68	human epidermal growth factor receptor 2
21135276_3	Chemical	0,11	Trastuzumab
21135276_3	Gene_or_protein	119,151	epidermal growth factor receptor
21135276_3	Chemical	119,184	epidermal growth factor receptor / HER2 tyrosine kinase inhibitor
21135276_3	Disease	223,258	HER2 -overexpressing breast cancers
21135276_3	Chemical	28,97	human epidermal growth factor receptor 2 ( HER2 ) monoclonal antibody
21135276_3	Phenotype	223,243	HER2 -overexpressing
14654539_7	Chemical	87,101	5-fluorouracil
14654539_7	Chemical	106,115	mitomycin
14654539_7	Gene_or_protein	165,168	p53
14654539_7	Limited_variation	120,176	mutations affecting the L2/L3 domains of the p53 protein
14654539_7	Pharmacodynamic_phenotype	67,101	lack of response to 5-fluorouracil
14654539_7	Pharmacodynamic_phenotype	67,86,106,115	lack of response to mitomycin
21508389_3	Gene_or_protein	36,47	Kirsten ras
21508389_3	Gene_or_protein	50,54	KRAS
21508389_3	Disease	77,94	colorectal tumour
21508389_3	Chemical	104,115	oxaliplatin
21508389_3	Chemical	120,132	capecitabine
21508389_3	Gene_or_protein	172,176	TP53
21508389_3	Gene_or_protein	148,169	tumour suppressor p53
21508389_3	Limited_variation	138,178	wild-type tumour suppressor p53 ( TP53 )
11956176_1	Chemical	0,14	Cyclosporine a
11956176_1	Chemical	19,24	FK506
11956176_1	Phenotype	33,97	transcriptional activity of the human mineralocorticoid receptor
11956176_1	Gene_or_protein	71,97	mineralocorticoid receptor
11956176_1	Pharmacodynamic_phenotype	142,164	aldosterone resistance
11956176_1	Chemical	142,153	aldosterone
11956176_1	Disease	168,190	kidney transplantation
24597466_4	Gene_or_protein	28,33	HLA-B
24597466_4	Chemical	77,80	CBZ
24597466_4	Gene_or_protein	179,184	HLA-B
24597466_4	Pharmacodynamic_phenotype	226,251	hypersensitivity syndrome
24597466_4	Chemical	213,216	CBZ
24597466_4	Pharmacodynamic_phenotype	254,257	HSS
24597466_4	Disease	263,286	maculopapular exanthema
24597466_4	Disease	289,292	MPE
24597466_4	Pharmacodynamic_phenotype	77,157	CBZ -induced Stevens-Johnson syndrome / toxic epidermal necrolysis ( SJS / TEN )
24597466_4	Pharmacodynamic_phenotype	146,155	SJS / TEN
24597466_4	Haplotype	28,41	HLA-B * 15:02
24597466_4	Limited_variation	179,192	HLA-B * 15:02
24597466_4	Pharmacodynamic_phenotype	213,251	CBZ -induced hypersensitivity syndrome
24597466_4	Pharmacodynamic_phenotype	90,143	Stevens-Johnson syndrome / toxic epidermal necrolysis
17986837_5	Limited_variation	4,15	TPH1 779A/C
17986837_5	Gene_or_protein	4,8	TPH1
17986837_5	Disease	102,121	nicotine dependence
17986837_5	Chemical	102,110	nicotine
15226679_4	Limited_variation	48,65	genotypes of MDR1
15226679_4	Gene_or_protein	61,65	MDR1
15226679_4	Gene_or_protein	70,94	cytochrome P450 (CYP) 3A
15226679_4	Chemical	182,192	tacrolimus
15226679_4	Limited_variation	48,60,70,94	genotypes of cytochrome P450 (CYP) 3A
15226679_4	Phenotype	158,173	mRNA expression
15226679_4	Pharmacodynamic_phenotype	182,225	tacrolimus concentration/dose ( C/D ) ratio
15226679_4	Disease	256,277	liver transplantation
16818870_9	Gene_or_protein	207,235	catechol-O-methyltransferase
16818870_9	Limited_variation	207,259	catechol-O-methyltransferase Val158Met polymorphisms
16818870_9	Chemical	284,294	raclopride
16818870_9	Phenotype	284,312	raclopride binding potential
16818870_9	Genomic_variation	74,128	dopamine transporter variable nucleotide tandem repeat
16818870_9	Limited_variation	131,152	D2 receptor Taq A1/A2
16818870_9	Genomic_variation	155,200	D4 receptor variable nucleotide tandem repeat
16818870_9	Genomic_variation	24,67	Gene variants of dopamine system components
16818870_9	Gene_or_protein	74,94	dopamine transporter
16818870_9	Gene_or_protein	131,146	D2 receptor Taq
16818870_9	Gene_or_protein	155,166	D4 receptor
8099817_5	Phenotype	32,61	expression of preprodynorphin
8099817_5	Gene_or_protein	46,61	preprodynorphin
8099817_5	Gene_or_protein	72,77	c-fos
8099817_5	Chemical	131,138	cocaine
8099817_5	Phenotype	32,45,72,77	expression of c-fos
8099817_5	Phenotype	131,158	cocaine self-administration
16419387_1	Haplotype	75,99	cytochrome P450 3A4 * 1B
16419387_1	Chemical	119,127	fentanyl
16419387_1	Haplotype	75,90,104,111	cytochrome P450 3A5 * 3
16419387_1	Gene_or_protein	75,94	cytochrome P450 3A4
16419387_1	Gene_or_protein	75,90,104,107	cytochrome P450 3A5
16419387_1	Pharmacodynamic_phenotype	51,61	toxicology
26791794_6	Gene_or_protein	97,103	PIK3CA
26791794_6	Limited_variation	97,117	PIK3CA - p.Glu545Lys
26791794_6	Chemical	146,156	crizotinib
26791794_6	Gene_or_protein	50,53	MET
26791794_6	Limited_variation	50,79	MET exon 14 skipping mutation
26791794_6	Pharmacodynamic_phenotype	191,199	response
26791794_6	Genomic_factor	50,61	MET exon 14
22329763_1	Gene_or_protein	0,38	17-Hydroxysteroid dehydrogenase type 5
22329763_1	Gene_or_protein	67,74	HSD17B5
22329763_1	Disease	128,132	PCOS
22329763_1	Limited_variation	59,74	-71 A/G HSD17B5
22329763_1	Chemical	100,118	oral contraceptive
22329763_1	Limited_variation	0,80	17-Hydroxysteroid dehydrogenase type 5 gene polymorphism ( -71 A/G HSD17B5 SNP )
24598368_5	Disease	65,84	anaplastic lymphoma
24598368_5	Chemical	104,114	crizotinib
24598368_5	Disease	184,210	non-small cell lung cancer
24598368_5	Disease	226,232	tumors
24598368_5	Gene_or_protein	242,246	EML4
24598368_5	Gene_or_protein	249,252	ALK
24598368_5	Genomic_variation	242,267	EML4 / ALK translocations
24598368_5	Chemical	65,101	anaplastic lymphoma kinase inhibitor
24598368_5	Pharmacodynamic_phenotype	148,161	response rate
15247556_13	Chemical	0,9	Phenytoin
15247556_13	Chemical	30,33	LPV
15247556_13	Phenotype	48,64	CYP3A4 induction
15247556_13	Gene_or_protein	48,54	CYP3A4
15247556_13	Chemical	115,118	RTV
15247556_13	Pharmacokinetic_phenotype	30,43	LPV clearance
21503919_2	Gene_or_protein	110,114	ITPA
21503919_2	Chemical	177,186	ribavirin
21503919_2	Disease	225,266	chronic hepatitis C virus (HCV) infection
21503919_2	Gene_or_protein	71,107	inosine triphosphate pyrophosphatase
21503919_2	Chemical	157,171	peg-interferon
21503919_2	Chemical	157,198	peg-interferon plus ribavirin combination
21503919_2	Limited_variation	25,116	single nucleotide polymorphism ( SNP ) in the inosine triphosphate pyrophosphatase ( ITPA )
21503919_2	Phenotype	126,149	reduction of hemoglobin
17700364_10	Limited_variation	14,54	Single nucleotide polymorphisms of ABCA1
17700364_10	Gene_or_protein	49,54	ABCA1
17700364_10	Limited_variation	14,48,57,62	Single nucleotide polymorphisms of APOA5
17700364_10	Gene_or_protein	65,70	APOC3
17700364_10	Gene_or_protein	73,77	APOE
17700364_10	Gene_or_protein	84,88	CETP
17700364_10	Limited_variation	14,48,65,70	Single nucleotide polymorphisms of APOC3
17700364_10	Limited_variation	14,48,73,77	Single nucleotide polymorphisms of APOE
17700364_10	Limited_variation	14,48,84,88	Single nucleotide polymorphisms of CETP
17700364_10	Phenotype	127,171	high-density lipoprotein- cholesterol levels
17700364_10	Phenotype	103,122	plasma triglyceride
17700364_10	Gene_or_protein	57,62	APOA5
17700364_10	Chemical	179,193	antiretroviral
23942539_1	Limited_variation	13,54	dihydropyrimidine dehydrogenase genotypes
23942539_1	Gene_or_protein	13,44	dihydropyrimidine dehydrogenase
23942539_1	Chemical	72,86	5-fluorouracil
23942539_1	Disease	101,118	colorectal cancer
8834233_1	Gene_or_protein	40,61	alcohol dehydrogenase
8834233_1	Pharmacodynamic_phenotype	78,97	alcohol sensitivity
8834233_1	Chemical	78,85	alcohol
8834233_1	Limited_variation	20,74	polymorphism in the alcohol dehydrogenase beta subunit
8834233_1	Genomic_factor	40,74	alcohol dehydrogenase beta subunit
18602406_7	Gene_or_protein	3,8	beta3
18602406_7	Chemical	65,79	valerenic acid
18602406_7	Pharmacodynamic_phenotype	42,79	anxiolytic activity of valerenic acid
18602406_7	Limited_variation	3,32	beta3 ( N265M ) point-mutated
10628896_8	Chemical	0,11	Haloperidol
10628896_8	Gene_or_protein	30,36	CYP3A4
10628896_8	Gene_or_protein	85,91	CYP2D6
12419746_1	Chemical	75,85	paclitaxel
12419746_1	Chemical	88,93	Taxol
12419746_1	Chemical	99,108	docetaxel
12419746_1	Chemical	111,119	Taxotere
12419746_1	Gene_or_protein	125,129	HER2
12419746_1	Chemical	35,46	trastuzumab
12419746_1	Chemical	49,58	Herceptin
12419746_1	Disease	125,161	HER2 -expressing human breast cancer
12419746_1	Chemical	35,95	trastuzumab ( Herceptin ) combined with paclitaxel ( Taxol )
12419746_1	Chemical	35,74,99,121	trastuzumab ( Herceptin ) combined with docetaxel ( Taxotere )
12419746_1	Phenotype	125,141	HER2 -expressing
24766650_6	Chemical	60,66	heroin
24766650_6	Limited_variation	125,204	missense SNP rs5376 ( Asn334Ser ) in the galanin receptor type 1 gene ( GALR1 )
24766650_6	Gene_or_protein	166,189	galanin receptor type 1
24766650_6	Gene_or_protein	197,202	GALR1
24766650_6	Limited_variation	224,252	FKBP5 intronic SNP rs1360780
24766650_6	Gene_or_protein	224,229	FKBP5
24766650_6	Disease	60,76	heroin addiction
24766650_6	Limited_variation	9,13	SNPs
22118006_7	Gene_or_protein	4,11	CYP2C19
22118006_7	Disease	140,163	coronary artery disease
22118006_7	Chemical	174,185	clopidogrel
22118006_7	Haplotype	4,15	CYP2C19 * 2
22118006_7	Disease	74,76	ST
22118006_7	Disease	87,111	coronary stent placement
22588607_3	Limited_variation	78,89	p.Gly143Glu
22588607_3	Limited_variation	92,103	rs121912777
22588607_3	Chemical	156,167	oseltamivir
22588607_3	Limited_variation	187,195	c.428G>A
22588607_3	Gene_or_protein	62,66	CES1
22588607_3	Limited_variation	62,75	CES1 c.428G>A
15188667_7	Disease	5,10	GISTs
15188667_7	Chemical	22,39	imatinib mesylate
15188667_7	Gene_or_protein	74,77	KIT
15188667_7	Gene_or_protein	82,88	PDGFRA
15188667_7	Disease	159,163	GIST
23503720_9	Chemical	29,38	silibinin
23503720_9	Gene_or_protein	71,76	Smad2
23503720_9	Gene_or_protein	81,86	Smad3
23503720_9	Gene_or_protein	109,115	TGF-b1
23503720_9	Phenotype	54,76	translocation of Smad2
23503720_9	Phenotype	54,70,81,86	translocation of Smad3
23503720_9	Disease	125,129	HSFs
18058343_7	Chemical	24,33	bupropion
18058343_7	Limited_variation	112,136	DRD2 Taq1 A2/A2 genotype
18058343_7	Gene_or_protein	112,116	DRD2
18058343_7	Phenotype	55,72	smoking cessation
22509987_5	Limited_variation	38,73	genetic variation in COMT Val158Met
22509987_5	Gene_or_protein	59,63	COMT
22509987_5	Gene_or_protein	78,82	DRD2
22509987_5	Gene_or_protein	85,90	ANKK1
22509987_5	Chemical	153,160	alcohol
22509987_5	Disease	153,171	alcohol dependence
22509987_5	Limited_variation	78,96	DRD2 / ANKK1 Taq1A
21280081_10	Pharmacodynamic_phenotype	0,29	COMT inhibition by entacapone
21280081_10	Gene_or_protein	0,4	COMT
21280081_10	Chemical	19,29	entacapone
21280081_10	Gene_or_protein	44,48	COMT
21280081_10	Gene_or_protein	64,68	COMT
21280081_10	Limited_variation	44,55	COMT ( HH )
21280081_10	Limited_variation	64,75	COMT ( LL )
23246478_11	Phenotype	113,152	prostate specific antigen concentration
23246478_11	Gene_or_protein	113,138	prostate specific antigen
23246478_11	Limited_variation	41,72	single nucleotide polymorphisms
25594941_4	Limited_variation	0,9	rs9923231
25594941_4	Gene_or_protein	12,18	VKORC1
25594941_4	Limited_variation	23,29	rs7294
25594941_4	Gene_or_protein	32,38	VKORC1
25594941_4	Limited_variation	43,52	rs1057910
25594941_4	Gene_or_protein	55,61	CYP2C9
25594941_4	Limited_variation	66,75	rs2108622
25594941_4	Gene_or_protein	78,84	CYP4F2
25594941_4	Limited_variation	93,101	rs699664
25594941_4	Gene_or_protein	104,108	GGCX
25594941_4	Pharmacodynamic_phenotype	127,142	warfarin action
25594941_4	Chemical	173,182	vitamin K
25594941_4	Chemical	313,321	warfarin
25594941_4	Pharmacokinetic_phenotype	293,321	pharmacokinetics of warfarin
25594941_4	Pharmacodynamic_phenotype	272,288,310,321	pharmacodynamics of warfarin
25594941_4	Pharmacodynamic_phenotype	161,182	circulatory vitamin K
25594941_4	Chemical	127,135	warfarin
16800828_1	Gene_or_protein	17,24	GABABR1
16800828_1	Limited_variation	17,31	GABABR1 T1974C
16800828_1	Limited_variation	34,41	rs29230
16800828_1	Disease	111,121	alcoholism
16800828_1	Chemical	125,132	alcohol
16800828_1	Gene_or_protein	51,65	GABAB receptor
16800828_1	Phenotype	125,152	alcohol withdrawal seizures
8487953_6	Phenotype	46,67	expression of KROX-24
8487953_6	Gene_or_protein	60,67	KROX-24
8487953_6	Chemical	92,98	MK-801
8487953_6	Gene_or_protein	173,176	FOS
8487953_6	Gene_or_protein	181,184	JUN
8487953_6	Phenotype	135,176	expression pattern similar to that of FOS
8487953_6	Phenotype	135,172,181,184	expression pattern similar to that of JUN
24956250_1	Gene_or_protein	23,28	HLA-B
24956250_1	Pharmacodynamic_phenotype	69,94	abacavir hypersensitivity
24956250_1	Chemical	69,77	abacavir
24956250_1	Haplotype	23,36	HLA-B * 57:01
20922562_4	Limited_variation	45,67	polymorphisms of KIF3A
20922562_4	Gene_or_protein	62,67	KIF3A
20922562_4	Disease	103,106	AIA
20922562_4	Chemical	225,232	aspirin
20922562_4	Phenotype	174,205	forced expiratory volume at 1 s
20922562_4	Phenotype	208,217	FEV ( 1 )
27040858_7	Chemical	42,50	Icotinib
27040858_7	Chemical	59,69	crizotinib
27040858_7	Limited_variation	92,105	EGFR mutation
27040858_7	Gene_or_protein	92,96	EGFR
27040858_7	Gene_or_protein	135,139	ROS1
27040858_7	Limited_variation	151,164	KRAS mutation
27040858_7	Gene_or_protein	151,155	KRAS
27040858_7	Pharmacodynamic_phenotype	30,50	response to Icotinib
27040858_7	Pharmacodynamic_phenotype	30,41,59,69	response to crizotinib
27040858_7	Genomic_factor	135,146	ROS1 fusion
19813492_5	Gene_or_protein	29,48	cytochrome P450 3A4
19813492_5	Gene_or_protein	89,108	cytochrome P450 3A4
19813492_5	Chemical	151,161	tacrolimus
19813492_5	Chemical	77,108	inducers of cytochrome P450 3A4
19813492_5	Chemical	15,48	substrates of cytochrome P450 3A4
19813492_5	Pharmacodynamic_phenotype	133,161	interactions with tacrolimus
19813492_5	Chemical	62,72,86,108	inhibitors of cytochrome P450 3A4
26086150_9	Chemical	14,28	co-trimoxazole
26086150_9	Gene_or_protein	69,74	HLA-B
26086150_9	Gene_or_protein	85,90	HLA-C
26086150_9	Gene_or_protein	104,109	HLA-C
26086150_9	Pharmacodynamic_phenotype	14,47	co-trimoxazole -induced SJS / TEN
26086150_9	Haplotype	69,82	HLA-B * 15:02
26086150_9	Haplotype	85,98	HLA-C * 06:02
26086150_9	Haplotype	104,117	HLA-C * 08:01
26086150_9	Pharmacodynamic_phenotype	38,47	SJS / TEN
21801714_9	Gene_or_protein	3,7	Nrf2
21801714_9	Chemical	26,29	Cln
21801714_9	Phenotype	48,63	UGT1A1 activity
21801714_9	Gene_or_protein	48,54	UGT1A1
21801714_9	Gene_or_protein	75,79	Nrf2
21801714_9	Genomic_variation	3,17	Nrf2 knock-out
27378608_1	Chemical	114,123	lapatinib
27378608_1	Gene_or_protein	127,131	HER2
27378608_1	Gene_or_protein	0,36	Immunoglobulin G fragment C receptor
27378608_1	Limited_variation	0,50	Immunoglobulin G fragment C receptor polymorphisms
27378608_1	Pharmacodynamic_phenotype	55,123	efficacy of preoperative chemotherapy plus trastuzumab and lapatinib
27378608_1	Chemical	98,109	trastuzumab
27378608_1	Disease	127,155	HER2 -positive breast cancer
27378608_1	Chemical	80,92	chemotherapy
27378608_1	Chemical	80,123	chemotherapy plus trastuzumab and lapatinib
27378608_1	Phenotype	127,141	HER2 -positive
12218660_1	Limited_variation	23,70	polymorphisms in the serotonin transporter gene
12218660_1	Gene_or_protein	44,65	serotonin transporter
12218660_1	Chemical	93,100	cocaine
12218660_1	Disease	93,111	cocaine dependence
26736037_7	Gene_or_protein	4,8	CREB
26736037_7	Chemical	126,141	methamphetamine
26736037_7	Gene_or_protein	188,192	CREB
26736037_7	Chemical	243,258	methamphetamine
26736037_7	Phenotype	77,106	chronic use of multiple drugs
26736037_7	Pharmacodynamic_phenotype	274,306	outcomes of outpatient treatment
26736037_7	Phenotype	217,258	pretreatment frequency of methamphetamine
26736037_7	Phenotype	42,65	gene expression changes
26736037_7	Phenotype	110,115	abuse
19377049_12	Gene_or_protein	30,34	DHFR
19377049_12	Chemical	50,65	corticosteroids
19377049_12	Gene_or_protein	92,96	AML1
19377049_12	Gene_or_protein	99,102	ETO
19377049_12	Phenotype	92,112	AML1 - ETO -positive
19377049_12	Chemical	30,45	DHFR inhibitors
19377049_12	Disease	92,120	AML1 - ETO -positive disease
7875180_1	Chemical	0,10	Metoprolol
7875180_1	Chemical	51,63	debrizoquine
7875180_1	Limited_variation	51,97	debrizoquine oxidation ( CYP2D6 ) polymorphism
7875180_1	Gene_or_protein	76,82	CYP2D6
7875180_1	Pharmacokinetic_phenotype	0,30	Metoprolol alpha-hydroxylation
7875180_1	Pharmacokinetic_phenotype	51,73	debrizoquine oxidation
23275005_7	Chemical	33,38	4-HNE
23275005_7	Gene_or_protein	172,176	Nrf2
23275005_7	Chemical	276,281	4-HNE
23275005_7	Genomic_factor	172,182	Nrf2 - ARE
23275005_7	Chemical	172,204	Nrf2 - ARE -activating compounds
23275005_7	Pharmacodynamic_phenotype	224,234,273,281	resistance to 4-HNE
23275005_7	Genomic_factor	92,103,119,137	complex I - driven respiration
23275005_7	Genomic_factor	107,137	complex II- driven respiration
17445431_11	Gene_or_protein	13,17	DPYD
17445431_11	Gene_or_protein	59,63	DPYD
17445431_11	Chemical	84,88	5-FU
17445431_11	Chemical	148,152	5-FU
17445431_11	Pharmacodynamic_phenotype	157,182	chemotherapeutic toxicity
17445431_11	Disease	212,229	colonic carcinoma
17445431_11	Phenotype	59,79	DPYD enzyme activity
17445431_11	Pharmacokinetic_phenotype	84,104	5-FU dyes metabolism
17445431_11	Pharmacokinetic_phenotype	132,152	accumulation of 5-FU
17445431_11	Haplotype	13,21	DPYD * 5
17445431_11	Chemical	157,173	chemotherapeutic
17445431_11	Disease	200,207,220,229	gastric carcinoma
21975350_4	Gene_or_protein	0,6	CYP2A6
21975350_4	Gene_or_protein	11,16	CYP3A
21975350_4	Chemical	35,44	letrozole
21975350_4	Pharmacokinetic_phenotype	35,55	letrozole metabolism
25872644_1	Limited_variation	20,41	ADORA2A polymorphisms
25872644_1	Gene_or_protein	20,27	ADORA2A
25872644_1	Chemical	45,53	levodopa
25872644_1	Disease	77,96	Parkinson's disease
25872644_1	Pharmacodynamic_phenotype	45,73	levodopa -induced dyskinesia
25872644_1	Disease	63,73	dyskinesia
16395124_1	Gene_or_protein	35,41	GABRA2
16395124_1	Chemical	52,59	alcohol
16395124_1	Disease	52,70	alcohol dependence
23982262_11	Chemical	22,32	nevirapine
23982262_11	Limited_variation	70,79	rs3745274
23982262_11	Gene_or_protein	55,61	CYP2B6
23982262_11	Limited_variation	82,87	Q172H
23982262_11	Pharmacokinetic_phenotype	22,36	nevirapine AUC
23982262_11	Limited_variation	55,67	CYP2B6 516TT
24519039_8	Chemical	48,57	ribavirin
24519039_8	Limited_variation	84,105	polymorphisms at ITPA
24519039_8	Gene_or_protein	101,105	ITPA
24519039_8	Disease	132,151	chronic hepatitis C
24519039_8	Pharmacodynamic_phenotype	110,128	treatment efficacy
24519039_8	Phenotype	172,184	relapse risk
19514905_1	Gene_or_protein	0,5	HLA-B
19514905_1	Chemical	32,40	abacavir
19514905_1	Haplotype	0,12	HLA-B * 5701
23909652_2	Chemical	0,11	Vemurafenib
23909652_2	Gene_or_protein	26,30	BRAF
23909652_2	Disease	172,192	metastatic melanomas
23909652_2	Gene_or_protein	208,212	BRAF
23909652_2	Limited_variation	208,218	BRAF V600E
23909652_2	Gene_or_protein	33,81	v-raf murine sarcoma viral oncogene homologue B1
23909652_2	Chemical	26,100	BRAF ( v-raf murine sarcoma viral oncogene homologue B1 ) kinase inhibitor
23909652_2	Phenotype	146,154	survival
23909652_2	Chemical	112,131	targeted biotherapy
18983505_3	Chemical	68,78	paroxetine
18983505_3	Gene_or_protein	104,125	serotonin transporter
18983505_3	Gene_or_protein	133,139	SLC6A4
18983505_3	Phenotype	180,197	platelet function
18983505_3	Limited_variation	104,163	serotonin transporter gene ( SLC6A4 ) promoter polymorphism
18983505_3	Limited_variation	166,174	5-HTTLPR
18983505_3	Genomic_factor	104,130,142,150	serotonin transporter gene promoter
18983505_3	Pharmacodynamic_phenotype	43,78	dose-response effects of paroxetine
16944116_13	Limited_variation	14,29	CYP2D6 genotype
16944116_13	Gene_or_protein	14,20	CYP2D6
16944116_13	Chemical	101,111	flecainide
16944116_13	Disease	155,187	supraventricular tachyarrhythmia
16944116_13	Phenotype	57,68	body weight
16944116_13	Phenotype	71,74	age
16944116_13	Phenotype	77,80	sex
16944116_13	Pharmacokinetic_phenotype	101,128	flecainide pharmacokinetics
16944116_13	Phenotype	87,90	Scr
16944116_13	Pharmacokinetic_phenotype	40,43	IMs
15379981_6	Chemical	14,22	lycopene
15379981_6	Gene_or_protein	82,86	CD80
15379981_6	Gene_or_protein	91,95	CD86
15379981_6	Gene_or_protein	102,142	major histocompatibility complex type II
15379981_6	Phenotype	42,97	expression of costimulatory molecules ( CD80 and CD86 )
15379981_6	Phenotype	42,55,102,142	expression of major histocompatibility complex type II
15379981_6	Gene_or_protein	56,79	costimulatory molecules
15589566_1	Limited_variation	38,55	5-HTTLPR S allele
15589566_1	Gene_or_protein	38,46	5-HTTLPR
15589566_1	Chemical	80,87	alcohol
15589566_1	Disease	80,98	alcohol -dependent
15589566_1	Phenotype	60,76	suicide attempts
22995156_8	Phenotype	17,21	B-Cd
22995156_8	Limited_variation	76,101	MT1A rs11076161 A-alleles
22995156_8	Gene_or_protein	76,80	MT1A
22995156_8	Phenotype	119,140	highly polluted group
22995156_8	Limited_variation	81,91	rs11076161
22995156_8	Phenotype	193,196	age
22995156_8	Phenotype	199,202	sex
22995156_8	Phenotype	209,216	smoking
24355137_1	Limited_variation	19,35	5-HTR2A -1438A/G
24355137_1	Gene_or_protein	55,59	MAOA
24355137_1	Disease	114,145	borderline personality disorder
24355137_1	Chemical	156,162	heroin
24355137_1	Gene_or_protein	19,26	5-HTR2A
24355137_1	Limited_variation	38,52	COMT Val158Met
24355137_1	Limited_variation	55,64	MAOA -LPR
24355137_1	Limited_variation	67,75	DAT VNTR
24355137_1	Limited_variation	80,90	5-HTT VNTR
24355137_1	Disease	156,173	heroin -dependent
24355137_1	Gene_or_protein	38,42	COMT
24355137_1	Gene_or_protein	67,70	DAT
24355137_1	Gene_or_protein	80,85	5-HTT
19442155_5	Chemical	26,33	lithium
19442155_5	Gene_or_protein	124,134	GSK-3 beta
19442155_5	Chemical	153,160	lithium
19442155_5	Pharmacodynamic_phenotype	94,112	inositol depletion
19442155_5	Chemical	94,102	inositol
19442155_5	Pharmacodynamic_phenotype	153,167	lithium action
1734875_1	Chemical	24,44	phosphatidylinositol
1734875_1	Gene_or_protein	48,53	c-myc
1734875_1	Disease	48,87	c-myc gene-expressed human renal cancer
1734875_1	Phenotype	48,68	c-myc gene-expressed
26485092_1	Chemical	32,42	Tacrolimus
26485092_1	Limited_variation	127,141	CYP3A5 Alleles
26485092_1	Gene_or_protein	127,133	CYP3A5
26485092_1	Pharmacodynamic_phenotype	32,57	Tacrolimus Concentrations
14570538_1	Limited_variation	11,31,45,58	dopamine transporter polymorphisms
14570538_1	Gene_or_protein	11,31	dopamine transporter
14570538_1	Gene_or_protein	11,19,36,44	dopamine receptor
14570538_1	Limited_variation	36,58	receptor polymorphisms
14570538_1	Chemical	85,94	bupropion
14570538_1	Phenotype	62,79	smoking cessation
24692733_2	Gene_or_protein	141,145	KRAS
24692733_2	Gene_or_protein	207,211	BRAF
24692733_2	Gene_or_protein	216,222	PIK3CA
24692733_2	Limited_variation	141,155	KRAS wild-type
24692733_2	Disease	156,160	mCRC
24692733_2	Chemical	128,135	FOLFIRI
24692733_2	Chemical	83,125	folinic acid / 5-fluorouracil / irinotecan
24692733_2	Chemical	68,77	cetuximab
24692733_2	Disease	141,160	KRAS wild-type mCRC
24692733_2	Chemical	68,125	cetuximab plus folinic acid / 5-fluorouracil / irinotecan
17030231_1	Chemical	0,10	Salmeterol
17030231_1	Gene_or_protein	39,64	beta2-adrenergic receptor
17030231_1	Disease	102,108	asthma
17030231_1	Pharmacodynamic_phenotype	0,19	Salmeterol response
17030231_1	Limited_variation	39,73	beta2-adrenergic receptor genotype
21955998_9	Chemical	89,92	BSC
21955998_9	Gene_or_protein	107,111	EGFR
21955998_9	Chemical	101,120,137,140	anti- EGFR mAb with BSC
21955998_9	Disease	243,264	wild-type KRAS tumors
21955998_9	Gene_or_protein	253,257	KRAS
21955998_9	Chemical	73,85	chemotherapy
21955998_9	Chemical	101,133	anti- EGFR mAb with chemotherapy
21955998_9	Phenotype	161,172,183,190	progression of mCRC
21955998_9	Phenotype	177,190	death of mCRC
21955998_9	Limited_variation	243,257	wild-type KRAS
21955998_9	Chemical	101,115	anti- EGFR mAb
21955998_9	Disease	186,190	mCRC
26045855_1	Gene_or_protein	0,4	BRAF
26045855_1	Limited_variation	0,19	BRAF (V600 ) mutant
26045855_1	Disease	0,46	BRAF (V600 ) mutant non-small-cell lung cancer
26045855_1	Chemical	60,71	Vemurafenib
26045855_1	Pharmacodynamic_phenotype	47,71	resistant to Vemurafenib
20628391_2	Gene_or_protein	27,47	thymidylate synthase
20628391_2	Gene_or_protein	50,54	TYMS
20628391_2	Limited_variation	61,124	UDP-glucoronosyltransferase 1A ( UGT1A ) germline polymorphisms
20628391_2	Gene_or_protein	61,91	UDP-glucoronosyltransferase 1A
20628391_2	Gene_or_protein	94,99	UGT1A
20628391_2	Disease	163,166	CRC
20628391_2	Disease	143,160	colorectal cancer
20628391_2	Chemical	191,201	irinotecan
20628391_2	Chemical	207,221	5-fluorouracil
20628391_2	Chemical	224,234	irinotecan
20628391_2	Phenotype	132,168	outcome of colorectal cancer ( CRC )
20628391_2	Limited_variation	27,56,102,124	thymidylate synthase ( TYMS ) germline polymorphisms
20628391_2	Chemical	237,240	5FU
20628391_2	Chemical	191,221	irinotecan plus 5-fluorouracil
20628391_2	Chemical	224,240	irinotecan / 5FU
21873787_2	Gene_or_protein	66,98	RAS association domain family 1A
21873787_2	Gene_or_protein	101,108	RASSF1A
21873787_2	Disease	128,162	advanced epithelial ovarian cancer
21873787_2	Chemical	192,201	cisplatin
21873787_2	Phenotype	44,110	methylation status of RAS association domain family 1A ( RASSF1A )
21873787_2	Pharmacodynamic_phenotype	180,227	efficacy of cisplatin based neoadjuvant therapy
21873787_2	Chemical	192,227	cisplatin based neoadjuvant therapy
19067682_7	Chemical	35,45	tacrolimus
19067682_7	Gene_or_protein	86,92	CYP3A5
19067682_7	Gene_or_protein	124,130	CYP3A5
19067682_7	Haplotype	86,102	CYP3A5 * 1 / * 1
19067682_7	Haplotype	124,140	CYP3A5 * 3 / * 3
19067682_7	Disease	17,32	transplantation
19067682_7	Pharmacodynamic_phenotype	35,56	tacrolimus daily dose
10656431_13	Chemical	18,28	paclitaxel
10656431_13	Phenotype	91,105	p53 deficiency
10656431_13	Gene_or_protein	91,94	p53
10656431_13	Phenotype	66,83	lack of G1 arrest
10656431_13	Pharmacodynamic_phenotype	4,28	efficiency of paclitaxel
25792135_8	Gene_or_protein	20,25	BICD1
25792135_8	Chemical	82,92	creatinine
25792135_8	Pharmacodynamic_phenotype	82,107	creatinine concentrations
25792135_8	Limited_variation	10,55	rs2630578 BICD1 gene polymorphism CC genotype
25792135_8	Limited_variation	129,131	CC
25792135_8	Limited_variation	136,138	GC
16799968_5	Disease	61,73	liver injury
16799968_5	Gene_or_protein	130,133	CAR
16799968_5	Chemical	113,120	TCPOBOP
16799968_5	Gene_or_protein	151,154	CAR
16799968_5	Phenotype	38,58	hepatocyte apoptosis
16799968_5	Limited_variation	130,139	CAR + / +
16799968_5	Limited_variation	151,160	CAR - / -
16799968_5	Phenotype	87,97	fatalities
16799968_5	Chemical	32,35	Jo2
15180166_10	Chemical	31,44	acetaminophen
15180166_10	Chemical	47,72	acetaminophen glucuronide
15180166_10	Gene_or_protein	76,82	UGT1A1
15180166_10	Limited_variation	76,93	UGT1A1 -wildtypes
15180166_10	Limited_variation	76,82,96,109	UGT1A1 heterozygotes
15180166_10	Limited_variation	76,82,114,121	UGT1A1 mutants
15180166_10	Pharmacokinetic_phenotype	4,72	metabolic ratios unchanged acetaminophen / acetaminophen glucuronide
19095777_1	Gene_or_protein	0,32	Epidermal growth factor receptor
19095777_1	Limited_variation	52,66	K-ras mutation
19095777_1	Gene_or_protein	52,57	K-ras
19095777_1	Chemical	121,125	5-FU
19095777_1	Disease	168,181	rectal cancer
19095777_1	Genomic_variation	0,49	Epidermal growth factor receptor gene copy number
19095777_1	Chemical	109,118	cetuximab
19095777_1	Pharmacodynamic_phenotype	71,118	pathological response to preoperative cetuximab
19095777_1	Pharmacodynamic_phenotype	71,108,121,125	pathological response to preoperative 5-FU
19095777_1	Pharmacodynamic_phenotype	71,108,130,147	pathological response to preoperative radiation therapy
19095777_1	Chemical	130,147	radiation therapy
12966314_1	Gene_or_protein	20,40	dopamine receptor D1
12966314_1	Chemical	89,96	alcohol
12966314_1	Limited_variation	20,63	dopamine receptor D1 gene DdeI polymorphism
12966314_1	Phenotype	68,85	sensation seeking
12966314_1	Disease	89,107	alcohol -dependent
18377430_8	Chemical	29,40	doxorubicin
18377430_8	Limited_variation	101,128	ABCG2 c.421C>A polymorphism
18377430_8	Gene_or_protein	101,106	ABCG2
18377430_8	Pharmacokinetic_phenotype	29,56	doxorubicin pharmacokinetic
27590272_3	Gene_or_protein	104,108	OCT2
27590272_3	Gene_or_protein	147,152	MATE1
27590272_3	Gene_or_protein	201,206	ABCB1
27590272_3	Gene_or_protein	259,264	ABCC2
27590272_3	Chemical	356,370	platinum drugs
27590272_3	Gene_or_protein	73,101	organic cation transporter 2
27590272_3	Gene_or_protein	113,144	multidrug and toxin extrusion 1
27590272_3	Gene_or_protein	157,198	ATP-binding cassette subfamily B member 1
27590272_3	Gene_or_protein	215,256	ATP-binding cassette subfamily C member 2
27590272_3	Pharmacodynamic_phenotype	324,332,353,370	efficacy of platinum drugs
27590272_3	Pharmacodynamic_phenotype	337,370	adverse effects of platinum drugs
27590272_3	Limited_variation	273,294	genetic polymorphisms
17267549_4	Gene_or_protein	44,57	Kv1.5 channel
17267549_4	Gene_or_protein	65,70	KCNA5
17267549_4	Chemical	202,217	4-aminopyridine
17267549_4	Phenotype	22,72	overexpression of the Kv1.5 channel gene ( KCNA5 )
17267549_4	Pharmacodynamic_phenotype	189,217	sensitive to 4-aminopyridine
7944879_2	Chemical	83,92	clozapine
7944879_2	Gene_or_protein	130,150	D4 dopamine receptor
7944879_2	Gene_or_protein	153,157	DRD4
7944879_2	Pharmacodynamic_phenotype	71,92	response to clozapine
7944879_2	Limited_variation	130,150,160,167	D4 dopamine receptor alleles
16759339_3	Limited_variation	92,148	Ser9Gly ( BalI ) polymorphism in exon 1 of the DRD3 gene
16759339_3	Chemical	155,162	alcohol
16759339_3	Disease	231,241	alcoholism
16759339_3	Limited_variation	16,83	-141 C Ins/Del polymorphism in the promoter region of the DRD2 gene
16759339_3	Gene_or_protein	74,78	DRD2
16759339_3	Gene_or_protein	139,143	DRD3
16759339_3	Disease	155,173	alcohol -dependent
16759339_3	Genomic_factor	204,241	genetic predisposition for alcoholism
16759339_3	Genomic_factor	51,83	promoter region of the DRD2 gene
16759339_3	Genomic_factor	125,148	exon 1 of the DRD3 gene
23258095_8	Chemical	69,72	PEG
23258095_8	Gene_or_protein	75,81	IFNa-2
23258095_8	Disease	112,115	HCC
23258095_8	Limited_variation	147,156	IL28B SNP
23258095_8	Gene_or_protein	147,152	IL28B
23258095_8	Disease	184,187	CHC
23258095_8	Chemical	69,83	PEG - IFNa-2 a
24728879_2	Gene_or_protein	57,64	(HLA)-B
24728879_2	Pharmacodynamic_phenotype	84,151	allopurinol -associated severe cutaneous adverse reactions ( SCAR )
24728879_2	Chemical	84,95	allopurinol
24728879_2	Pharmacokinetic_phenotype	145,149	SCAR
24728879_2	Haplotype	57,72	(HLA)-B * 58:01
24728879_2	Pharmacodynamic_phenotype	108,142	severe cutaneous adverse reactions
23846846_3	Limited_variation	31,56	DPYSL2 gene polymorphisms
23846846_3	Gene_or_protein	31,37	DPYSL2
23846846_3	Disease	97,99	AD
23846846_3	Disease	76,94	alcohol dependence
23846846_3	Chemical	76,83	alcohol
11893774_7	Chemical	14,22	estrogen
11893774_7	Gene_or_protein	76,78	HL
11893774_7	Pharmacodynamic_phenotype	14,37	estrogen responsiveness
11893774_7	Genomic_factor	55,87	-1557 / -1175 of the HL promoter
19251742_7	Chemical	94,99	SrCl2
19251742_7	Gene_or_protein	311,320	gammaH2AX
19251742_7	Phenotype	174,215	methylation status of histone H3 lysine 9
19251742_7	Genomic_variation	218,239	low chromosome damage
25227813_15	Limited_variation	14,25	mutant EGFR
25227813_15	Gene_or_protein	21,25	EGFR
25227813_15	Chemical	46,54	icotinib
25227813_15	Disease	111,127	tumor metastasis
25227813_15	Pharmacodynamic_phenotype	39,68	higher icotinib concentration
25227813_15	Phenotype	90,93	PFS
25227813_15	Phenotype	98,100	OS
17563401_7	Limited_variation	0,74	Polymorphisms in 3-hydroxy-3-methylglutaryl-coenzyme A reductase ( HMGCR )
17563401_7	Gene_or_protein	67,72	HMGCR
17563401_7	Gene_or_protein	17,64	3-hydroxy-3-methylglutaryl-coenzyme A reductase
17563401_7	Chemical	121,132	pravastatin
17563401_7	Chemical	202,213	fluvastatin
17563401_7	Pharmacodynamic_phenotype	109,132	efficacy of pravastatin
17563401_7	Pharmacodynamic_phenotype	170,213	reduction of LDL cholesterol by fluvastatin
17563401_7	Pharmacodynamic_phenotype	170,198	reduction of LDL cholesterol
16815314_8	Chemical	55,65	metoprolol
16815314_8	Limited_variation	200,209	Arg389Arg
16815314_8	Limited_variation	212,221	Gly389Arg
16815314_8	Limited_variation	228,237	Gly389Gly
16815314_8	Pharmacodynamic_phenotype	14,80	descent of systolic blood pressure after metoprolol administration
16815314_8	Pharmacodynamic_phenotype	25,48	systolic blood pressure
15094935_9	Limited_variation	0,17	CYP2C9 genotyping
15094935_9	Gene_or_protein	0,6	CYP2C9
15094935_9	Chemical	90,98	warfarin
15094935_9	Pharmacodynamic_phenotype	90,118	warfarin dosage requirements
18378882_9	Chemical	98,106	levodopa
18378882_9	Limited_variation	13,18	MUT +
18378882_9	Phenotype	44,55	axial signs
18378882_9	Limited_variation	73,78	MUT -
18378882_9	Pharmacodynamic_phenotype	98,106,137,158	levodopa resistant axial signs
18378882_9	Disease	255,262	surgery
19366808_1	Chemical	0,9	Sorafenib
19366808_1	Gene_or_protein	61,68	BCR/ABL
19366808_1	Phenotype	18,27	apoptosis
19366808_1	Phenotype	50,68	expressing BCR/ABL
19366808_1	Phenotype	87,102	kinase activity
22821000_4	Chemical	221,265	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
22821000_4	Chemical	268,272	MPTP
22821000_4	Disease	328,345	Parkinson disease
22821000_4	Gene_or_protein	24,30	Ranbp2
22821000_4	Genomic_variation	24,49	Ranbp2 haploinsufficiency
22821000_4	Phenotype	76,156	manifestations linked to tyrosine -hydroxylase ( TH ( + ) ) dopaminergic neurons
22821000_4	Gene_or_protein	125,133	TH ( + )
22821000_4	Gene_or_protein	101,122	tyrosine -hydroxylase
22821000_4	Chemical	279,302	parkinsonian neurotoxin
22821000_4	Phenotype	76,100,161,185	manifestations linked to glial cells of the brain
22821000_4	Phenotype	76,100,190,196	manifestations linked to retina
21149285_6	Limited_variation	35,48	HLA-A alleles
21149285_6	Gene_or_protein	35,40	HLA-A
21149285_6	Chemical	119,122	CBZ
21149285_6	Chemical	125,128	CBZ
21149285_6	Gene_or_protein	165,170	HLA-A
21149285_6	Chemical	231,234	CBZ
21149285_6	Chemical	289,292	CBZ
21149285_6	Gene_or_protein	477,482	HLA-A
21149285_6	Chemical	514,517	CBZ
21149285_6	Pharmacodynamic_phenotype	92,97	cADRs
21149285_6	Haplotype	165,177	HLA-A * 3101
21149285_6	Pharmacodynamic_phenotype	231,249	CBZ -induced cADRs
21149285_6	Haplotype	477,489	HLA-A * 3101
21149285_6	Pharmacodynamic_phenotype	514,532	CBZ -induced cADRs
21149285_6	Pharmacodynamic_phenotype	244,249	cADRs
21149285_6	Pharmacodynamic_phenotype	527,532	cADRs
12150448_4	Gene_or_protein	39,48	HER-2/neu
12150448_4	Gene_or_protein	51,55	HER2
12150448_4	Gene_or_protein	180,184	HER2
12150448_4	Phenotype	258,261	DTH
12150448_4	Pharmacodynamic_phenotype	160,200	immunogenicity of a HER2 peptide vaccine
12150448_4	Chemical	180,200	HER2 peptide vaccine
12150448_4	Chemical	292,300	antigens
12150448_4	Phenotype	225,242	immune competence
12150448_4	Disease	39,79,92,99	HER-2/neu ( HER2 ) overexpressing breast cancers
12150448_4	Disease	39,72,84,99	HER-2/neu ( HER2 ) overexpressing ovarian cancers
12150448_4	Phenotype	39,72	HER-2/neu ( HER2 ) overexpressing
17952745_4	Chemical	81,93	temozolomide
17952745_4	Gene_or_protein	222,226	MGMT
17952745_4	Phenotype	222,254	MGMT promotor methylation status
17952745_4	Genomic_variation	202,208	1p/19q
17952745_4	Phenotype	127,135	survival
17952745_4	Genomic_factor	222,235	MGMT promotor
27883280_1	Chemical	17,27	irinotecan
27883280_1	Disease	51,62	lung cancer
27883280_1	Gene_or_protein	81,87	UGT1A1
27883280_1	Haplotype	81,92	UGT1A1 * 28
27883280_1	Haplotype	81,87,96,99	UGT1A1 * 6
1225820_10	Gene_or_protein	86,90	ChF1
1225820_10	Gene_or_protein	95,99	ChS1
1225820_10	Phenotype	128,140,160,174	synthesis of cholinesterase
1225820_10	Gene_or_protein	160,174	cholinesterase
1225820_10	Disease	263,269	apnoea
1225820_10	Chemical	249,262	suxamethonium
1225820_10	Limited_variation	207,230	ChU1 ChD1 heterozygotes
1225820_10	Gene_or_protein	212,216	ChD1
1225820_10	Pharmacodynamic_phenotype	249,269	suxamethonium apnoea
1225820_10	Gene_or_protein	207,211	ChU1
23101464_3	Gene_or_protein	64,68	PDYN
23101464_3	Gene_or_protein	73,78	OPRK1
23101464_3	Chemical	92,99	alcohol
23101464_3	Phenotype	309,341	intensity of depressive symptoms
23101464_3	Disease	322,341	depressive symptoms
23101464_3	Disease	92,110	alcohol -dependent
23101464_3	Limited_variation	16,59,73,78	single nucleotide polymorphisms ( SNPs ) in OPRK1
23101464_3	Limited_variation	16,68	single nucleotide polymorphisms ( SNPs ) in the PDYN
23101464_3	Disease	286,296	depression
23101464_3	Phenotype	168,184	negative craving
20191296_1	Gene_or_protein	23,27	POMC
20191296_1	Chemical	72,79	alcohol
20191296_1	Phenotype	0,41	DNA methylation of the POMC gene promoter
20191296_1	Phenotype	61,90	craving in alcohol dependence
20191296_1	Genomic_factor	23,41	POMC gene promoter
20191296_1	Disease	72,90	alcohol dependence
22217332_2	Disease	123,129	polyps
22217332_2	Gene_or_protein	184,189	EMID2
22217332_2	Disease	245,257	nasal polyps
22217332_2	Chemical	272,279	aspirin
22217332_2	Gene_or_protein	136,181	emilin/multimerin domain-containing protein 2
22217332_2	Phenotype	46,76	protruded extracellular matrix
22217332_2	Disease	19,41	subepithelial fibrosis
22217332_2	Pharmacodynamic_phenotype	272,295	aspirin -hypersensitive
22217332_2	Disease	261,267	asthma
24022708_2	Chemical	146,158	lansoprazole
24022708_2	Chemical	161,164	LSZ
24022708_2	Gene_or_protein	237,244	CYP2C19
24022708_2	Chemical	313,316	LSZ
24022708_2	Chemical	337,360	5'-hydroxy lansoprazole
24022708_2	Chemical	363,367	HLSZ
24022708_2	Chemical	374,395	lansoprazole sulphone
24022708_2	Chemical	438,441	LSZ
24022708_2	Gene_or_protein	46,50	MDRI
24022708_2	Gene_or_protein	34,41	CYP2C19
24022708_2	Chemical	398,402	LSZS
24022708_2	Limited_variation	46,57	MDRI C3435T
24022708_2	Pharmacokinetic_phenotype	115,166	pharmacokinetic variability of lansoprazole ( LSZ )
24022708_2	Gene_or_protein	249,253	MDRI
24022708_2	Limited_variation	249,274	MDRI C3435T polymorphisms
24022708_2	Pharmacokinetic_phenotype	282,316	pharmacokinetics difference of LSZ
24022708_2	Limited_variation	21,41	genotypes of CYP2C19
24022708_2	Limited_variation	237,244,261,274	CYP2C19 polymorphisms
24022708_2	Pharmacodynamic_phenotype	282,312,337,369	pharmacokinetics difference of 5'-hydroxy lansoprazole ( HLSZ )
24022708_2	Pharmacodynamic_phenotype	282,312,374,404	pharmacokinetics difference of lansoprazole sulphone ( LSZS )
24055295_8	Chemical	15,21	JTC801
24055295_8	Gene_or_protein	73,76	FLG
24055295_8	Gene_or_protein	162,170	loricrin
24055295_8	Gene_or_protein	173,183	keratin 10
24055295_8	Gene_or_protein	190,208	transglutaminase 1
24055295_8	Phenotype	35,39,63,76	mRNA levels of FLG
24055295_8	Phenotype	44,76	protein expression levels of FLG
24055295_8	Phenotype	89,103,162,170	mRNA levels of loricrin
24055295_8	Phenotype	89,103,173,183	mRNA levels of keratin 10
24055295_8	Phenotype	89,103,190,208	mRNA levels of transglutaminase 1
24055295_8	Phenotype	89,149	mRNA levels of other makers for keratinocyte differentiation
21388237_3	Disease	98,108	Depression
21388237_3	Chemical	247,259	escitalopram
21388237_3	Chemical	273,286	nortriptyline
21388237_3	Gene_or_protein	131,152	serotonin transporter
21388237_3	Limited_variation	131,188	serotonin transporter gene promoter polymorphism 5-HTTLPR
21388237_3	Chemical	262,266	SSRI
21388237_3	Chemical	289,313	tricyclic antidepressant
21388237_3	Phenotype	192,207	sexual function
21388237_3	Genomic_factor	131,166	serotonin transporter gene promoter
18525109_3	Chemical	46,54	brazilin
18525109_3	Gene_or_protein	126,142	heme oxygenase-1
18525109_3	Gene_or_protein	145,149	HO-1
18525109_3	Chemical	29,41	C. sappan L.
18525109_3	Gene_or_protein	102,112	luciferase
18525109_3	Phenotype	102,121	luciferase activity
18525109_3	Phenotype	126,162	heme oxygenase-1 ( HO-1 ) expression
21747412_4	Limited_variation	38,52	MTHFR genotype
21747412_4	Gene_or_protein	38,43	MTHFR
21747412_4	Chemical	69,72	MTX
21747412_4	Disease	124,127	ALL
21747412_4	Disease	153,156	ALL
21747412_4	Pharmacodynamic_phenotype	69,79	MTX dosage
21498394_2	Gene_or_protein	35,66	dihydropyrimidine dehydrogenase
21498394_2	Chemical	144,156	capecitabine
21498394_2	Limited_variation	35,114	dihydropyrimidine dehydrogenase ( DPD ) single nucleotide polymorphisms ( SNP )
21498394_2	Haplotype	35,74,119,129	dihydropyrimidine dehydrogenase ( DPD ) haplotypes
21498394_2	Pharmacodynamic_phenotype	133,156	outcome of capecitabine
21498394_2	Gene_or_protein	69,72	DPD
15063162_7	Chemical	27,39	nitric oxide
15063162_7	Gene_or_protein	92,97	c-Fos
15063162_7	Chemical	75,82	lithium
15063162_7	Gene_or_protein	100,104	ICER
15063162_7	Chemical	158,170	nitric oxide
15063162_7	Chemical	213,225	nitric oxide
15063162_7	Chemical	229,236	lithium
15063162_7	Pharmacodynamic_phenotype	75,115	lithium -induced c-Fos / ICER expression
15063162_7	Pharmacodynamic_phenotype	229,275	lithium -induced activation of adrenal medulla
15063162_7	Pharmacokinetic_phenotype	92,115	c-Fos / ICER expression
15063162_7	Pharmacodynamic_phenotype	246,275	activation of adrenal medulla
18978522_8	Gene_or_protein	0,6	CYP3A7
18978522_8	Chemical	60,72	cyclosporine
18978522_8	Haplotype	0,11	CYP3A7 * 1C
18978522_8	Pharmacodynamic_phenotype	60,83	cyclosporine daily dose
18978522_8	Disease	112,127	transplantation
25242669_6	Gene_or_protein	69,73	EGFR
25242669_6	Gene_or_protein	118,122	EGFR
25242669_6	Chemical	319,328	gefitinib
25242669_6	Gene_or_protein	344,348	EGFR
25242669_6	Gene_or_protein	467,471	EGFR
25242669_6	Chemical	467,477	EGFR -TKIs
25242669_6	Disease	69,88	EGFR -mutated NSCLC
25242669_6	Chemical	118,127	EGFR -TKI
25242669_6	Disease	344,363	EGFR -mutated NSCLC
25242669_6	Chemical	408,454	TKI followed by a subsequent line of treatment
15896496_1	Limited_variation	30,101	( Val66Met ) polymorphism in the brain-derived neurotrophic factor gene
15896496_1	Gene_or_protein	63,96	brain-derived neurotrophic factor
15896496_1	Disease	107,125	alcohol dependence
15896496_1	Phenotype	130,146	extreme violence
15896496_1	Chemical	107,114	alcohol
11555846_6	Limited_variation	47,88	Gln27Glu beta ( 2 ) - adrenergic receptor
11555846_6	Chemical	163,170	glucose
11555846_6	Limited_variation	92,149	Pro12Ala peroxisome proliferator-activated receptor gamma
11555846_6	Gene_or_protein	101,149	peroxisome proliferator-activated receptor gamma
11555846_6	Gene_or_protein	56,88	beta ( 2 ) - adrenergic receptor
11555846_6	Pharmacokinetic_phenotype	174,200	insulin kinetic parameters
11555846_6	Chemical	174,181	insulin
11555846_6	Pharmacokinetic_phenotype	163,170,182,200	glucose kinetic parameters
20022477_10	Limited_variation	43,69	CCR3 genetic polymorphisms
20022477_10	Gene_or_protein	43,47	CCR3
20022477_10	Disease	111,115	AERD
20022477_10	Chemical	204,211	aspirin
20022477_10	Pharmacodynamic_phenotype	204,228	aspirin hypersensitivity
20025435_2	Limited_variation	39,77	polymorphisms in alcohol dehydrogenase
20025435_2	Gene_or_protein	80,84	ADH2
20025435_2	Gene_or_protein	87,92	ADH1B
20025435_2	Gene_or_protein	99,121	aldehyde dehydrogenase
20025435_2	Gene_or_protein	124,129	ALDH2
20025435_2	Chemical	142,149	alcohol
20025435_2	Chemical	234,241	alcohol
20025435_2	Disease	142,160	alcohol dependence
20025435_2	Gene_or_protein	56,77	alcohol dehydrogenase
20025435_2	Limited_variation	39,55,99,121	polymorphisms in aldehyde dehydrogenase
20025435_2	Disease	234,252	alcohol dependence
22735459_10	Gene_or_protein	40,46	CYP2C9
22735459_10	Gene_or_protein	61,67	CYP2C9
22735459_10	Chemical	132,138	E-3174
22735459_10	Chemical	144,152	losartan
22735459_10	Chemical	183,191	losartan
22735459_10	Gene_or_protein	214,220	CYP2C9
22735459_10	Gene_or_protein	235,241	CYP2C9
22735459_10	Haplotype	40,56	CYP2C9 * 1 / * 3
22735459_10	Haplotype	61,78	CYP2C9 * 1 / * 13
22735459_10	Pharmacodynamic_phenotype	172,191	effects of losartan
22735459_10	Pharmacokinetic_phenotype	119,152	formation of E-3174 from losartan
22735459_10	Haplotype	214,230	CYP2C9 * 1 / * 3
22735459_10	Haplotype	235,252	CYP2C9 * 1 / * 13
15608594_4	Limited_variation	47,65	A118G polymorphism
15608594_4	Chemical	115,122	alcohol
15608594_4	Pharmacodynamic_phenotype	85,122	sensitivity to the effects of alcohol
24394004_5	Genomic_factor	29,39	MSI status
24394004_5	Chemical	73,84	oxaliplatin
24394004_5	Pharmacodynamic_phenotype	48,59,73,104	efficacy of oxaliplatin -based chemotherapy
24394004_5	Chemical	73,104	oxaliplatin -based chemotherapy
27096382_17	Limited_variation	33,49	IL36RN mutations
27096382_17	Gene_or_protein	33,39	IL36RN
27096382_17	Chemical	104,122	retinoid acitretin
27096382_17	Pharmacodynamic_phenotype	5,13	response
25351929_1	Chemical	31,40	lapatinib
25351929_1	Chemical	45,56	vinorelbine
25351929_1	Disease	90,129	HER2 -positive metastatic breast cancer
25351929_1	Gene_or_protein	90,94	HER2
25351929_1	Chemical	31,56	lapatinib and vinorelbine
25351929_1	Phenotype	90,104	HER2 -positive
20079691_13	Gene_or_protein	27,31	HER2
20079691_13	Gene_or_protein	34,39	TOP2A
20079691_13	Chemical	168,182	anthracyclines
20079691_13	Genomic_variation	59,78	Ch17CEP duplication
20079691_13	Pharmacodynamic_phenotype	155,182	benefit from anthracyclines
20079691_13	Genomic_factor	43,56	chromosome 17
12563177_9	Pharmacokinetic_phenotype	64,94	PON1 activity towards diazoxon
12563177_9	Gene_or_protein	64,68	PON1
12563177_9	Chemical	86,94	diazoxon
12563177_9	Limited_variation	5,37	combination of R and L genotypes
12563177_9	Limited_variation	26,27	L
12563177_9	Limited_variation	20,21	R
12563177_9	Pharmacokinetic_phenotype	64,77	PON1 activity
22896000_13	Chemical	0,11	Omacetaxine
22896000_13	Disease	59,62	CML
22896000_13	Limited_variation	77,91	T315I mutation
23515680_8	Limited_variation	9,15	C1236T
23515680_8	Limited_variation	20,26	C3435T
23515680_8	Chemical	30,41	venlafaxine
23515680_8	Pharmacodynamic_phenotype	99,111	intoxication
23515680_8	Pharmacodynamic_phenotype	122,139	non-intoxications
25270523_1	Gene_or_protein	12,38	anaplastic lymphoma kinase
25270523_1	Disease	56,77	sarcomatoid carcinoma
25270523_1	Chemical	119,129	crizotinib
25270523_1	Genomic_variation	12,52	anaplastic lymphoma kinase translocation
25270523_1	Pharmacodynamic_phenotype	109,129	effect of crizotinib
23645737_3	Gene_or_protein	36,60	adenosine deaminase-like
23645737_3	Gene_or_protein	63,67	ADAL
23645737_3	Chemical	113,120	GS-9219
23645737_3	Pharmacokinetic_phenotype	85,120	intracellular activation of GS-9219
22521649_2	Gene_or_protein	13,45	Epidermal growth factor receptor
22521649_2	Gene_or_protein	48,52	EGFR
22521649_2	Disease	68,94	non-small cell lung cancer
22521649_2	Disease	97,102	NSCLC
22521649_2	Pharmacodynamic_phenotype	146,206	response to EGFR - tyrosine kinase inhibitors ( EGFR -TKIs )
22521649_2	Gene_or_protein	158,162	EGFR
22521649_2	Chemical	158,191	EGFR - tyrosine kinase inhibitors
22521649_2	Gene_or_protein	194,198	EGFR
22521649_2	Chemical	194,204	EGFR -TKIs
22521649_2	Limited_variation	13,64	Epidermal growth factor receptor ( EGFR ) mutations
11882352_1	Chemical	68,72	TCDD
11882352_1	Pharmacodynamic_phenotype	56,72	toxicity of TCDD
11882352_1	Gene_or_protein	88,94	c- src
11882352_1	Phenotype	11,26	src -deficiency
11882352_1	Gene_or_protein	11,14	src
11882352_1	Genomic_variation	88,103	c- src knockout
17636396_11	Chemical	80,100,119,140	anthracycline -based adjuvant chemotherapy
17636396_11	Chemical	105,140	taxane -based adjuvant chemotherapy
17636396_11	Phenotype	158,174	HER2 /neu status
17636396_11	Gene_or_protein	158,167	HER2 /neu
17636396_11	Disease	196,223	HER2 /neu -positive cancers
17636396_11	Gene_or_protein	196,205	HER2 /neu
17636396_11	Disease	277,304	HER2 /neu -negative cancers
17636396_11	Gene_or_protein	277,286	HER2 /neu
17636396_11	Phenotype	196,215	HER2 /neu -positive
17636396_11	Phenotype	277,296	HER2 /neu -negative
17636396_11	Chemical	80,93	anthracycline
17636396_11	Chemical	105,111	taxane
19636338_15	Gene_or_protein	7,13	CYP1A2
19636338_15	Chemical	97,107	olanzapine
19636338_15	Haplotype	7,18	CYP1A2 * 1F
19636338_15	Pharmacodynamic_phenotype	97,128	olanzapine serum concentrations
19636338_15	Pharmacodynamic_phenotype	145,163	treatment response
16407894_1	Genomic_variation	0,16	Knockout of ERK1
16407894_1	Chemical	26,33	cocaine
16407894_1	Pharmacodynamic_phenotype	26,73	cocaine -evoked immediate early gene expression
16407894_1	Phenotype	78,99	behavioral plasticity
16407894_1	Gene_or_protein	12,16	ERK1
16893904_1	Gene_or_protein	69,79	huntingtin
16893904_1	Disease	103,111	toxicity
16893904_1	Disease	115,135	Huntington's disease
16893904_1	Phenotype	69,90	huntingtin misfolding
16893904_1	Chemical	18,42	epigallocatechin-gallate
18429967_1	Chemical	8,18	tacrolimus
18429967_1	Gene_or_protein	50,56	CYP3A5
18429967_1	Pharmacokinetic_phenotype	8,45	tacrolimus circadian pharmacokinetics
18429967_1	Disease	122,138	renal transplant
23991619_3	Disease	14,17	APL
23991619_3	Gene_or_protein	40,43	PML
23991619_3	Gene_or_protein	53,57	bcr1
23991619_3	Gene_or_protein	64,67	WT1
23991619_3	Genomic_variation	40,59	PML / RARa ( bcr1 )
23991619_3	Genomic_variation	188,213	t ( 2 ; 3 ) ( p25 ; q21 )
23991619_3	Genomic_variation	218,245	t ( 15 ; 17 ) ( q22 ; q21 )
23991619_3	Gene_or_protein	97,121	Fms-like tyrosine kinase
23991619_3	Genomic_variation	97,159	Fms-like tyrosine kinase -internal tandem duplication mutation
23991619_3	Gene_or_protein	46,50	RARa
23991619_3	Phenotype	26,73	overexpressed PML / RARa ( bcr1 ) and WT1 genes
25303981_7	Limited_variation	41,70	DTNBP1 rs3213207 polymorphism
25303981_7	Disease	125,151	methamphetamine dependence
25303981_7	Gene_or_protein	41,47	DTNBP1
25303981_7	Chemical	125,140	methamphetamine
10102685_7	Chemical	43,46	STZ
10102685_7	Chemical	26,40	streptozotocin
10102685_7	Gene_or_protein	192,196	iNOS
10102685_7	Phenotype	120,152	blood glucose levels > 11 mmol/l
10102685_7	Limited_variation	192,202	iNOS - / -
14999690_13	Gene_or_protein	116,124	TNFalpha
14999690_13	Chemical	202,209	ethanol
14999690_13	Gene_or_protein	134,137	Ras
14999690_13	Phenotype	116,148	TNFalpha -induced Ras activation
14999690_13	Phenotype	55,86	hepatocellular oxidative stress
14999690_13	Phenotype	96,106	cell death
14999690_13	Phenotype	134,148	Ras activation
14999690_13	Phenotype	165,186	hepatic proliferation
14999690_13	Pharmacodynamic_phenotype	202,231	ethanol -induced liver injury
14999690_13	Pharmacodynamic_phenotype	219,231	liver injury
14506398_11	Gene_or_protein	74,81	ALDH1A1
14506398_11	Gene_or_protein	90,97	ALDH1A1
14506398_11	Haplotype	74,85	ALDH1A1 * 2
14506398_11	Haplotype	90,101	ALDH1A1 * 3
14506398_11	Disease	142,152	alcoholics
18186959_9	Chemical	49,58	erlotinib
18186959_9	Gene_or_protein	116,120	EGFR
18186959_9	Pharmacodynamic_phenotype	20,37	cell cycle arrest
18186959_9	Limited_variation	106,120	wild-type EGFR
18186959_9	Pharmacodynamic_phenotype	130,156	pharmacodynamic separation
25071141_1	Gene_or_protein	23,27	PI3K
25071141_1	Gene_or_protein	30,33	AKT
25071141_1	Chemical	55,64	tamoxifen
25071141_1	Chemical	65,75	exemestane
25071141_1	Chemical	55,75	tamoxifen exemestane
25060417_1	Chemical	12,22	diflunisal
25060417_1	Phenotype	26,47	autonomic dysfunction
25060417_1	Disease	62,93	familial amyloid polyneuropathy
25060417_1	Gene_or_protein	96,99	TTR
25060417_1	Limited_variation	96,108	TTR Val30Met
25060417_1	Pharmacodynamic_phenotype	0,22	Efficacy of diflunisal
22072145_4	Limited_variation	60,79	MMP-2 polymorphisms
22072145_4	Gene_or_protein	60,65	MMP-2
22072145_4	Disease	159,184	nonsmall cell lung cancer
22072145_4	Disease	187,192	NSCLC
22072145_4	Pharmacodynamic_phenotype	85,103	treatment efficacy
22072145_4	Chemical	227,255	platinum -based chemotherapy
22072145_4	Disease	126,141	severe toxicity
22072145_4	Chemical	227,235	platinum
23708314_10	Chemical	24,28	CRAd
23708314_10	Gene_or_protein	166,171	TRAIL
23708314_10	Gene_or_protein	174,177	DR5
23708314_10	Gene_or_protein	180,189	caspase-3
23708314_10	Gene_or_protein	194,203	caspase-8
23708314_10	Phenotype	152,171,204,208	expression of TRAIL mRNA
23708314_10	Phenotype	152,165,174,177,204,208	expression of DR5 mRNA
23708314_10	Phenotype	152,165,180,189,204,208	expression of caspase-3 mRNA
23708314_10	Phenotype	152,165,194,208	expression of caspase-8 mRNA
23708314_10	Phenotype	75,93	cell proliferation
23708314_10	Phenotype	105,119	cell apoptosis
23708314_10	Genomic_factor	194,208	caspase-8 mRNA
23708314_10	Genomic_factor	180,189,204,208	caspase-3 mRNA
23708314_10	Genomic_factor	174,177,204,208	DR5 mRNA
23708314_10	Genomic_factor	166,171,204,208	TRAIL mRNA
23708314_10	Phenotype	152,171,213,221	expression of TRAIL proteins
23708314_10	Phenotype	152,165,174,177,213,221	expression of DR5 proteins
23708314_10	Phenotype	152,165,180,189,213,221	expression of caspase-3 proteins
23708314_10	Phenotype	152,165,194,203,213,221	expression of caspase-8 proteins
24240480_7	Limited_variation	14,33	ABCB1 polymorphisms
24240480_7	Gene_or_protein	14,19	ABCB1
24240480_7	Limited_variation	14,19,44,53	ABCB1 c.1236C>T
24240480_7	Limited_variation	14,19,56,67	ABCB1 c.2677G>T/A
24240480_7	Limited_variation	14,19,74,83	ABCB1 c.3435C>T
24240480_7	Chemical	116,126	quetiapine
24240480_7	Gene_or_protein	185,190	ABCB1
24240480_7	Pharmacodynamic_phenotype	99,126	plasma levels of quetiapine
24240480_7	Limited_variation	185,199	ABCB1 genotype
24240480_7	Pharmacokinetic_phenotype	137,163	pharmacokinetic parameters
20648600_11	Chemical	0,3	LAM
20648600_11	Limited_variation	34,39	L180M
20648600_11	Limited_variation	45,50	M204V
20648600_11	Disease	106,113	viremia
20648600_11	Pharmacodynamic_phenotype	0,14	LAM resistance
20648600_11	Limited_variation	0,52	LAM resistance substitutions ( rt L180M + rt M204V )
17042920_1	Limited_variation	19,42	polymorphisms of CYP3A4
17042920_1	Gene_or_protein	36,42	CYP3A4
17042920_1	Gene_or_protein	45,51	CYP3A5
17042920_1	Gene_or_protein	56,60	MDR1
17042920_1	Chemical	64,76	cyclosporine
17042920_1	Limited_variation	11,35,45,51	genetic polymorphisms of CYP3A5
17042920_1	Limited_variation	11,35,56,60	genetic polymorphisms of MDR1
17042920_1	Pharmacokinetic_phenotype	64,93	cyclosporine pharmacokinetics
17042920_1	Disease	100,121	renal transplantation
12052467_7	Limited_variation	116,142	Stromelysin-1 polymorphism
12052467_7	Gene_or_protein	116,129	Stromelysin-1
12052467_7	Limited_variation	145,152,162,203	-455G/A polymorphisms of the beta-fibrinogen gene
12052467_7	Limited_variation	157,203	TaqI polymorphisms of the beta-fibrinogen gene
12052467_7	Gene_or_protein	183,198	beta-fibrinogen
12052467_7	Gene_or_protein	206,211	apoE4
12052467_7	Limited_variation	214,263	Asp(9)Asn mutation in the lipoprotein lipase gene
12052467_7	Gene_or_protein	240,258	lipoprotein lipase
12052467_7	Gene_or_protein	298,312	hepatic lipase
12052467_7	Gene_or_protein	326,329	ACE
12052467_7	Gene_or_protein	66,100	Cholesteryl Ester Transfer Protein
12052467_7	Limited_variation	66,113	Cholesteryl Ester Transfer Protein polymorphism
12052467_7	Chemical	392,399	statins
12052467_7	Pharmacodynamic_phenotype	381,399	effects of statins
12052467_7	Limited_variation	270,317	-514 CT polymorphism in the hepatic lipase gene
12052467_7	Limited_variation	326,348	ACE deletion type gene
22026499_9	Gene_or_protein	59,63	SGCE
22026499_9	Disease	77,95	myoclonus dystonia
22026499_9	Disease	125,143	myoclonus dystonia
22026499_9	Pharmacodynamic_phenotype	160,185	alcohol -induced dystonia
22026499_9	Limited_variation	43,63	mutation in the SGCE
22026499_9	Chemical	160,167	alcohol
22026499_9	Pharmacodynamic_phenotype	177,185	dystonia
18467506_7	Phenotype	8,23	SCF mRNA levels
18467506_7	Gene_or_protein	8,11	SCF
18467506_7	Chemical	30,34	APAP
18467506_7	Chemical	97,101	APAP
18467506_7	Genomic_factor	8,16	SCF mRNA
18467506_7	Pharmacodynamic_phenotype	30,41	APAP injury
21338584_3	Phenotype	39,55	PDYN mRNA levels
21338584_3	Gene_or_protein	39,43	PDYN
21338584_3	Limited_variation	184,210	PDYN promoter SNP genotype
21338584_3	Gene_or_protein	184,188	PDYN
21338584_3	Chemical	214,221	alcohol
21338584_3	Phenotype	161,179	addictive behavior
21338584_3	Phenotype	140,157	cognitive control
21338584_3	Disease	214,232	alcohol -dependent
21338584_3	Genomic_factor	39,48	PDYN mRNA
21338584_3	Genomic_factor	184,197	PDYN promoter
19695401_14	Chemical	13,25	azathioprine
19695401_14	Gene_or_protein	90,94	TPMT
19695401_14	Haplotype	77,105	heterozygous TPMT * 1 / * 3C
19695401_14	Pharmacodynamic_phenotype	35,51	myelosuppression
19695401_14	Pharmacodynamic_phenotype	13,51	azathioprine -induced myelosuppression
19695401_14	Limited_variation	171,189	wild-type genotype
26946441_13	Chemical	92,101	oxycodone
26946441_13	Limited_variation	177,187	OPRK1 SNPs
26946441_13	Gene_or_protein	177,182	OPRK1
26946441_13	Pharmacodynamic_phenotype	70,101	analgesic response of oxycodone
26946441_13	Phenotype	147,167	muscle cuff pressure
26946441_13	Limited_variation	21,34	polymorphisms
15116260_11	Chemical	47,58	pravastatin
15116260_11	Gene_or_protein	19,36	HMG CoA reductase
15116260_11	Phenotype	67,106	progression of coronary atherosclerosis
15116260_11	Disease	82,106	coronary atherosclerosis
15116260_11	Chemical	19,46	HMG CoA reductase inhibitor
15116260_11	Phenotype	111,125	adverse events
27097364_3	Chemical	41,52	raltegravir
27097364_3	Limited_variation	72,111	single nucleotide polymorphism of ABCB1
27097364_3	Gene_or_protein	106,111	ABCB1
27097364_3	Gene_or_protein	116,121	ABCG2
27097364_3	Pharmacodynamic_phenotype	41,67	raltegravir concentrations
27097364_3	Limited_variation	72,105,116,121	single nucleotide polymorphism of ABCG2
16407894_3	Gene_or_protein	32,35	ERK
16407894_3	Chemical	138,145	cocaine
16407894_3	Gene_or_protein	26,29	MEK
16407894_3	Gene_or_protein	20,23	Raf
16407894_3	Gene_or_protein	4,7	Ras
16407894_3	Pharmacodynamic_phenotype	96,106,127,145	behavioral actions of cocaine
16407894_3	Pharmacodynamic_phenotype	111,145	neurobiological actions of cocaine
16407894_3	Genomic_factor	4,68	Ras -controlled Raf - MEK - ERK protein kinase signaling cascade
16407894_3	Gene_or_protein	44,50	kinase
12855658_2	Chemical	41,51	paclitaxel
12855658_2	Chemical	74,84	paclitaxel
12855658_2	Disease	118,132	ovarian cancer
12855658_2	Disease	169,182	cancer testis
12855658_2	Gene_or_protein	193,228	Taxol resistance -associated gene 3
12855658_2	Gene_or_protein	231,237	TRAG-3
12855658_2	Pharmacodynamic_phenotype	41,62	paclitaxel resistance
12855658_2	Gene_or_protein	41,68	paclitaxel resistance genes
12855658_2	Gene_or_protein	169,190	cancer testis antigen
12855658_2	Chemical	193,198	Taxol
12855658_2	Pharmacodynamic_phenotype	193,209	Taxol resistance
12855658_2	Pharmacodynamic_phenotype	74,95	paclitaxel -resistant
17559417_5	Chemical	84,91	cocaine
17559417_5	Gene_or_protein	160,169	5-HT(3A )
17559417_5	Gene_or_protein	191,200	5-HT(3A )
17559417_5	Pharmacodynamic_phenotype	42,91	effects of acute and chronic intermittent cocaine
17559417_5	Limited_variation	131,188	deletion of the gene for the 5-HT(3A ) - receptor subunit
17559417_5	Limited_variation	191,206	5-HT(3A ) - / -
10628896_5	Gene_or_protein	14,17	CYP
10628896_5	Gene_or_protein	51,57	CYP3A4
10628896_5	Chemical	124,135	haloperidol
10628896_5	Pharmacokinetic_phenotype	14,39	CYP -mediated disposition
22528326_10	Limited_variation	7,16	rs2108622
22528326_10	Gene_or_protein	0,6	CYP4F2
22528326_10	Chemical	62,70	warfarin
22528326_10	Pharmacodynamic_phenotype	62,82	warfarin stable dose
15322730_3	Chemical	0,9	Serotonin
15322730_3	Chemical	40,49	serotonin
15322730_3	Limited_variation	178,186	5-HTTLPR
15322730_3	Gene_or_protein	64,69	5-HTT
15322730_3	Gene_or_protein	40,61	serotonin transporter
15322730_3	Pharmacokinetic_phenotype	0,18	Serotonin reuptake
15322730_3	Limited_variation	88,130	functional insertion/deletion polymorphism
22634097_7	Gene_or_protein	35,40	RAD51
22634097_7	Limited_variation	35,59	RAD51 G172T polymorphism
22634097_7	Disease	73,88	cervical cancer
22634097_7	Chemical	114,142	platinum -based chemotherapy
22634097_7	Chemical	114,122	platinum
20136445_1	Pharmacodynamic_phenotype	36,75	hydrogen peroxide -induced p53 activity
20136445_1	Chemical	36,53	hydrogen peroxide
20136445_1	Gene_or_protein	63,66	p53
20136445_1	Chemical	19,32	polyphenolics
20136445_1	Pharmacodynamic_phenotype	63,75	p53 activity
25486952_12	Disease	11,14	PMF
25486952_12	Gene_or_protein	63,67	JAK2
25486952_12	Chemical	63,78	JAK2 inhibitors
17516068_1	Chemical	36,48	capecitabine
17516068_1	Disease	67,112	HER2 -overexpressing metastatic breast cancer
17516068_1	Gene_or_protein	67,71	HER2
17516068_1	Chemical	20,48	trastuzumab and capecitabine
17516068_1	Chemical	20,31	trastuzumab
17516068_1	Phenotype	67,87	HER2 -overexpressing
17516068_1	Disease	121,134	Breast Cancer
10949117_3	Gene_or_protein	57,61	hMOR
10949117_3	Chemical	103,110	alcohol
10949117_3	Limited_variation	57,77	hMOR exon 1 variants
10949117_3	Disease	103,121	alcohol dependence
10949117_3	Genomic_factor	57,68	hMOR exon 1
24601977_7	Limited_variation	6,21	CYP2C9 genotype
24601977_7	Gene_or_protein	6,12	CYP2C9
24601977_7	Limited_variation	24,39	VKORC1 genotype
24601977_7	Gene_or_protein	24,30	VKORC1
24601977_7	Phenotype	50,68	VKORC1 interaction
24601977_7	Gene_or_protein	50,56	VKORC1
24601977_7	Pharmacodynamic_phenotype	91,116	warfarin dose variability
24601977_7	Chemical	91,99	warfarin
24601977_7	Phenotype	0,3	Age
24601977_7	Phenotype	44,47	age
21182896_4	Gene_or_protein	22,46	tryptophan hydroxylase 2
21182896_4	Chemical	94,101	alcohol
21182896_4	Disease	82,89	suicide
21182896_4	Phenotype	94,118	alcohol -related suicide
25303299_10	Gene_or_protein	14,19	MTHFR
25303299_10	Gene_or_protein	30,35	ABCB1
25303299_10	Limited_variation	30,42	ABCB1 C3435T
25303299_10	Chemical	93,96	MTX
25303299_10	Limited_variation	14,25	MTHFR C677T
25303299_10	Pharmacodynamic_phenotype	93,118	MTX plasma concentrations
15897724_4	Disease	40,52	macrocytosis
15897724_4	Limited_variation	67,84	ALDH-2/2 genotype
15897724_4	Gene_or_protein	67,75	ALDH-2/2
15897724_4	Chemical	108,120	acetaldehyde
15897724_4	Pharmacokinetic_phenotype	108,133	acetaldehyde accumulation
21642685_12	Disease	43,51	melanoma
21642685_12	Gene_or_protein	62,65	KIT
21642685_12	Chemical	95,112	imatinib mesylate
21642685_12	Genomic_variation	62,77	KIT alterations
21642685_12	Pharmacodynamic_phenotype	124,154	significant clinical responses
18355347_4	Chemical	45,48	CsA
18355347_4	Disease	105,107	GO
18355347_4	Chemical	117,127	tacrolimus
18355347_4	Disease	167,169	GO
18355347_4	Disease	137,147	transplant
18355347_4	Disease	58,74	renal transplant
19429175_2	Chemical	9,17	morphine
19429175_2	Chemical	22,28	heroin
19429175_2	Gene_or_protein	89,94	MOR-1
19429175_2	Gene_or_protein	54,73	mu-opioid receptors
19429175_2	Pharmacodynamic_phenotype	22,38	heroin analgesia
19429175_2	Pharmacodynamic_phenotype	9,17,29,38	morphine analgesia
25121365_3	Gene_or_protein	164,168	P-gp
25121365_3	Pharmacodynamic_phenotype	17,45	variability in drug response
25121365_3	Gene_or_protein	144,161	drug transporters
25121365_3	Limited_variation	67,141	genetic polymorphism in genes encoding different drug metabolizing enzymes
25121365_3	Gene_or_protein	116,141	drug metabolizing enzymes
25121365_3	Gene_or_protein	177,184	enzymes
25121365_3	Limited_variation	67,115,144,170	genetic polymorphism in genes encoding different drug transporters ( P-gp )
25121365_3	Limited_variation	67,115,177,184	genetic polymorphism in genes encoding different enzymes
17708140_6	Chemical	18,26	warfarin
17708140_6	Gene_or_protein	99,114	cytochrome P450
17708140_6	Chemical	29,44	antidepressants
17708140_6	Chemical	47,60	antiepileptic
17708140_6	Chemical	73,80	statins
27382939_13	Gene_or_protein	13,18	IL28B
27382939_13	Chemical	32,39	PEG-IFN
27382939_13	Disease	66,79	CHD infection
27382939_13	Pharmacodynamic_phenotype	32,48	PEG-IFN response
20597903_1	Limited_variation	15,31	SLC6A12 variants
20597903_1	Gene_or_protein	15,22	SLC6A12
20597903_1	Chemical	37,44	aspirin
20597903_1	Disease	37,63	aspirin -intolerant asthma
20597903_1	Disease	57,63	asthma
24611967_4	Chemical	42,49	glucose
24611967_4	Gene_or_protein	115,139	alanine aminotransferase
24611967_4	Chemical	187,196	metformin
24611967_4	Chemical	220,229	metformin
24611967_4	Chemical	252,270	carnitine -orotate
24611967_4	Gene_or_protein	67,90	glycosylated hemoglobin
24611967_4	Gene_or_protein	93,98	HbA1c
24611967_4	Gene_or_protein	142,145	ALT
21109266_2	Disease	0,13	Pompe disease
21109266_2	Gene_or_protein	66,69	GAA
21109266_2	Chemical	103,110	glucose
21109266_2	Gene_or_protein	45,63	acid a-glucosidase
21109266_2	Chemical	89,97	glycogen
21109266_2	Phenotype	31,63	deficiency of acid a-glucosidase
18980981_6	Chemical	52,61	erlotinib
18980981_6	Gene_or_protein	73,77	EGFR
18980981_6	Disease	86,91	NSCLC
18980981_6	Chemical	152,160	platinum
18980981_6	Disease	194,199	NSCLC
18980981_6	Chemical	260,269	erlotinib
18980981_6	Pharmacodynamic_phenotype	248,269	response to erlotinib
18980981_6	Limited_variation	73,85	EGFR -mutant
18980981_6	Pharmacodynamic_phenotype	52,72	erlotinib -sensitive
18980981_6	Chemical	194,212	NSCLC chemotherapy
16721582_1	Phenotype	0,25	Recurrence of proteinuria
16721582_1	Disease	14,25	proteinuria
16721582_1	Disease	55,107	NPHS2 -associated focal segmental glomerulosclerosis
16721582_1	Gene_or_protein	55,60	NPHS2
16721582_1	Chemical	130,143	cyclosporin A
16721582_1	Chemical	147,156	sirolimus
16721582_1	Disease	41,51	transplant
20034695_6	Chemical	0,14	Cholestyramine
20034695_6	Disease	48,62	sitosterolemia
20034695_6	Gene_or_protein	65,70	ABCG5
20034695_6	Genomic_variation	65,84	ABCG5 /8 deficiency
23186157_3	Gene_or_protein	10,13	Abl
23186157_3	Disease	95,104	leukemias
23186157_3	Chemical	0,31	Selective Abl kinase inhibitors
23186157_3	Phenotype	88,104	Ph (+) leukemias
23186157_3	Limited_variation	88,94	Ph (+)
10750555_2	Gene_or_protein	0,31	Transforming growth factor beta
10750555_2	Gene_or_protein	34,42	TGF-beta
10750555_2	Chemical	136,144	estrogen
10750555_2	Chemical	149,158	vitamin D
10750555_2	Phenotype	74,89	bone metabolism
12777962_9	Chemical	52,60	nicotine
12777962_9	Chemical	70,77	alcohol
12777962_9	Gene_or_protein	116,122	CYP2E1
12777962_9	Haplotype	116,127	CYP2E1 * 1D
12777962_9	Disease	39,60	dependent on nicotine
12777962_9	Disease	39,51,70,77	dependent on alcohol
12777962_9	Chemical	246,254	nicotine
12777962_9	Disease	233,254	dependent on nicotine
18385200_4	Phenotype	0,5,15,29	C-MYC protein levels
18385200_4	Gene_or_protein	0,5	C-MYC
18385200_4	Gene_or_protein	10,14	DHFR
18385200_4	Chemical	125,128	MTX
18385200_4	Phenotype	10,29	DHFR protein levels
18385200_4	Chemical	191,208	four-drug regimen
18385200_4	Chemical	125,144	MTX -based protocol
10655277_2	Disease	26,51	chronic hepatitis B virus
10655277_2	Gene_or_protein	62,87	antibody to hepatitis B e
10655277_2	Gene_or_protein	136,156	alanine transaminase
10655277_2	Chemical	213,222	IFN-alpha
10655277_2	Chemical	292,301	ribavirin
10655277_2	Chemical	306,315	IFN-alpha
10655277_2	Gene_or_protein	98,106	anti-HBe
10655277_2	Limited_variation	111,129	HBV DNA positivity
10655277_2	Gene_or_protein	159,162	ALT
10655277_2	Phenotype	136,174	alanine transaminase ( ALT ) elevation
10655277_2	Chemical	195,210	interferon alfa
10655277_2	Chemical	267,315	combination therapy with ribavirin and IFN-alpha
10655277_2	Disease	54,57	HBV
2755460_1	Phenotype	0,29	Proenkephalin gene expression
2755460_1	Gene_or_protein	0,13	Proenkephalin
2755460_1	Chemical	68,77	estradiol
20179610_15	Limited_variation	0,6	A2143G
20179610_15	Pharmacodynamic_phenotype	58,83	clarithromycin resistance
20179610_15	Chemical	58,72	clarithromycin
20179610_15	Limited_variation	24,41	23S rRNA mutation
20179610_15	Genomic_factor	24,32	23S rRNA
20179610_15	Pharmacodynamic_phenotype	101,131	H. pylori eradication efficacy
22088980_6	Gene_or_protein	32,39	CYP2C19
22088980_6	Chemical	107,118	clopidogrel
22088980_6	Haplotype	32,43	CYP2C19 * 2
9592111_5	Chemical	53,60	alcohol
9592111_5	Phenotype	179,201	NGFI-B mRNA expression
9592111_5	Gene_or_protein	179,185	NGFI-B
9592111_5	Genomic_factor	179,190	NGFI-B mRNA
9592111_5	Chemical	247,251	ACTH
9592111_5	Pharmacokinetic_phenotype	247,261	ACTH secretion
25877443_1	Gene_or_protein	15,20	HLA-B
25877443_1	Pharmacodynamic_phenotype	42,85	abacavir -induced hypersensitivity reaction
25877443_1	Chemical	42,50	abacavir
25877443_1	Haplotype	15,27	HLA-B * 5701
25877443_1	Pharmacodynamic_phenotype	60,85	hypersensitivity reaction
12107202_1	Chemical	0,19	Hydrochlorothiazide
12107202_1	Gene_or_protein	130,154	calcium-sensing receptor
12107202_1	Limited_variation	96,159	gain-of-function mutations of the calcium-sensing receptor gene
12107202_1	Pharmacokinetic_phenotype	40,65	urinary calcium excretion
16338277_3	Chemical	44,66	5-HT ( 3 ) antagonists
16338277_3	Gene_or_protein	188,249	adenosine triphosphate -binding cassette subfamily B member 1
16338277_3	Gene_or_protein	252,257	ABCB1
16338277_3	Pharmacodynamic_phenotype	30,66	resistance to 5-HT ( 3 ) antagonists
16338277_3	Limited_variation	90,135,188,259	single-nucleotide polymorphism ( 3435C>T ) in adenosine triphosphate -binding cassette subfamily B member 1 ( ABCB1 )
16338277_3	Gene_or_protein	164,187	drug efflux transporter
14635204_12	Limited_variation	44,71	HFE coding region mutations
14635204_12	Gene_or_protein	44,47	HFE
14635204_12	Chemical	119,123	iron
14635204_12	Disease	150,153	SCD
14635204_12	Phenotype	119,132	iron overload
14635204_12	Chemical	164,191	chronic transfusion therapy
14635204_12	Genomic_factor	44,61	HFE coding region
15196685_4	Chemical	69,78	capsaicin
15196685_4	Phenotype	91,107	c-fos expression
15196685_4	Gene_or_protein	91,96	c-fos
20973798_3	Chemical	52,61	gefitinib
20973798_3	Chemical	66,75	erlotinib
20973798_3	Limited_variation	134,148	EGFR mutations
20973798_3	Gene_or_protein	134,138	EGFR
20973798_3	Disease	109,114	NSCLC
20973798_3	Phenotype	184,187	PFS
20973798_3	Phenotype	156,181	progression-free survival
20973798_3	Pharmacodynamic_phenotype	83,92	responses
22835516_5	Disease	9,36	malignant pleural effusions
22835516_5	Limited_variation	54,67	EGFR mutation
22835516_5	Gene_or_protein	54,58	EGFR
22835516_5	Disease	82,99	pleural effusions
22835516_5	Chemical	136,145	gefitinib
22835516_5	Chemical	152,161	erlotinib
22835516_5	Limited_variation	179,192	EGFR mutation
22835516_5	Gene_or_protein	179,183	EGFR
22835516_5	Chemical	121,133	chemotherapy
24277619_9	Limited_variation	5,10	rs671
24277619_9	Pharmacodynamic_phenotype	98,115	flushing response
24277619_9	Disease	207,209	AD
24277619_9	Disease	258,260	AD
24277619_9	Limited_variation	41,44	SNP
24277619_9	Chemical	122,129	alcohol
25042383_3	Gene_or_protein	66,71	TOP2A
25042383_3	Chemical	110,123	anthracycline
25042383_3	Disease	162,175	breast cancer
25042383_3	Pharmacodynamic_phenotype	85,123	efficacy of neo-adjuvant anthracycline
26437921_9	Chemical	92,101	methadone
26437921_9	Limited_variation	126,132	rs6265
26437921_9	Limited_variation	224,233	rs1799978
26437921_9	Phenotype	62,101	continued opioid use while on methadone
26437921_9	Limited_variation	6,22	genetic variants
20621700_3	Limited_variation	28,48	IL-28B polymorphisms
20621700_3	Gene_or_protein	28,34	IL-28B
20621700_3	Chemical	79,92	peginterferon
20621700_3	Chemical	97,106	ribavirin
20621700_3	Pharmacodynamic_phenotype	52,92	response to treatment with peginterferon
20621700_3	Pharmacodynamic_phenotype	52,78,97,106	response to treatment with ribavirin
25539912_1	Chemical	18,25	lithium
25539912_1	Limited_variation	36,49	TP53 mutation
25539912_1	Gene_or_protein	36,40	TP53
25539912_1	Disease	85,100	medulloblastoma
25539912_1	Phenotype	36,81	TP53 mutation associated radiation resistance
25539912_1	Pharmacodynamic_phenotype	0,25	WNT activation by lithium
25539912_1	Pharmacodynamic_phenotype	0,14	WNT activation
18485328_10	Limited_variation	73,84	p.Gly143Glu
18485328_10	Chemical	188,203	methylphenidate
18485328_10	Limited_variation	89,99	p.Asp260fs
18485328_10	Pharmacokinetic_phenotype	161,203	hydrolytic activity toward methylphenidate
21844885_11	Limited_variation	56,70	VEGF genotypes
21844885_11	Gene_or_protein	56,60	VEGF
21844885_11	Disease	88,116	metastatic colorectal cancer
21844885_11	Chemical	127,137	irinotecan
21844885_11	Chemical	163,174	bevacizumab
21844885_11	Chemical	127,174	irinotecan -based chemotherapy plus bevacizumab
21844885_11	Phenotype	189,191	RR
21844885_11	Phenotype	196,198	OS
21844885_11	Chemical	127,157	irinotecan -based chemotherapy
12165570_5	Gene_or_protein	68,72	CREB
12165570_5	Chemical	114,122	morphine
12165570_5	Chemical	162,169	sucrose
12165570_5	Phenotype	56,72	activity of CREB
12165570_5	Pharmacodynamic_phenotype	114,129	morphine reward
12165570_5	Phenotype	147,169	preference for sucrose
18602074_4	Chemical	0,10	Bisacurone
18602074_4	Phenotype	38,78	TNF-alpha -mediated expression of VCAM-1
18602074_4	Phenotype	58,78	expression of VCAM-1
18602074_4	Gene_or_protein	38,47	TNF-alpha
18602074_4	Gene_or_protein	72,78	VCAM-1
15902904_2	Chemical	53,60	ethanol
15902904_2	Chemical	117,130	acetylcholine
15902904_2	Chemical	205,218	acetylcholine
15902904_2	Gene_or_protein	250,256	CHRNA4
15902904_2	Chemical	315,322	ethanol
15902904_2	Gene_or_protein	195,242	nicotinic acetylcholine receptor alpha4 subunit
15902904_2	Pharmacodynamic_phenotype	269,322	enhancement of nicotinic receptor function by ethanol
15902904_2	Gene_or_protein	86,139	alpha4beta2 neuronal nicotinic acetylcholine receptor
15902904_2	Limited_variation	175,258	polymorphism of the nicotinic acetylcholine receptor alpha4 subunit gene ( CHRNA4 )
15902904_2	Phenotype	74,139	activity of alpha4beta2 neuronal nicotinic acetylcholine receptor
15902904_2	Gene_or_protein	284,302	nicotinic receptor
15902904_2	Pharmacodynamic_phenotype	284,311	nicotinic receptor function
10430972_10	Chemical	31,37	folate
10430972_10	Disease	60,80	hyperhomocysteinemia
10430972_10	Disease	98,102	ESRD
10430972_10	Limited_variation	137,172	677C-->T mutation in the MTHFR gene
10430972_10	Gene_or_protein	162,167	MTHFR
21747412_7	Limited_variation	42,56	MTHFR genotype
21747412_7	Gene_or_protein	42,47	MTHFR
21747412_7	Chemical	86,89	MTX
21747412_7	Disease	125,128	ALL
26385865_6	Gene_or_protein	63,67	POG1
26385865_6	Genomic_variation	14,23,63,67	knockdown POG1
26385865_6	Pharmacodynamic_phenotype	111,136	cytotoxicity of sunitinib
26385865_6	Chemical	127,136	sunitinib
18675355_8	Gene_or_protein	12,17	CD40L
18675355_8	Gene_or_protein	62,67	LFA-1
18675355_8	Gene_or_protein	81,84	CD4
18675355_8	Gene_or_protein	136,141	LFA-1
18675355_8	Chemical	147,157	everolimus
18675355_8	Chemical	161,164	DSG
18675355_8	Gene_or_protein	202,205	CD4
18675355_8	Chemical	120,164	combining anti- LFA-1 with everolimus or DSG
18675355_8	Chemical	130,141	anti- LFA-1
18675355_8	Chemical	6,17	anti- CD40L
18675355_8	Chemical	56,67	anti- LFA-1
18675355_8	Gene_or_protein	89,92	CD8
18675355_8	Phenotype	81,84,93,113	CD4 T cell proliferation
18675355_8	Phenotype	89,92,93,113	CD8 T cell proliferation
18675355_8	Phenotype	202,226	CD4 T cell proliferation
18675355_8	Phenotype	33,53	T cell proliferation
11054768_9	Chemical	21,27	heroin
11054768_9	Limited_variation	137,166	polymorphism in the DRD4 gene
11054768_9	Gene_or_protein	157,161	DRD4
11054768_9	Disease	21,34	heroin -abuse
11054768_9	Haplotype	137,161,176,186	polymorphism in the DRD4 haplotypes
21676164_1	Gene_or_protein	0,5	HLA-B
21676164_1	Pharmacodynamic_phenotype	54,78	Stevens-Johnson syndrome
21676164_1	Chemical	31,44	carbamazepine
21676164_1	Pharmacodynamic_phenotype	83,109	toxic epidermal necrolysis
21676164_1	Disease	132,148	neuropathic pain
21676164_1	Haplotype	0,12	HLA-B * 1502
21676164_1	Pharmacodynamic_phenotype	31,78	carbamazepine -induced Stevens-Johnson syndrome
21676164_1	Pharmacodynamic_phenotype	31,53,83,109	carbamazepine -induced toxic epidermal necrolysis
23306941_1	Chemical	134,147	peginterferon
23306941_1	Chemical	152,161	ribavirin
23306941_1	Limited_variation	190,202	IL28B allele
23306941_1	Disease	83,94	hepatitis C
23306941_1	Limited_variation	83,111	hepatitis C virus genotype 1
23306941_1	Phenotype	14,42	sustained virologic response
27430334_6	Chemical	26,33	AZD4619
27430334_6	Phenotype	44,67	ALT1 protein expression
27430334_6	Gene_or_protein	44,48	ALT1
16731130_12	Phenotype	4,23	expression of Bcl-2
16731130_12	Gene_or_protein	18,23	Bcl-2
16731130_12	Chemical	61,66	CoCl2
16731130_12	Phenotype	150,164	Bax expression
16731130_12	Gene_or_protein	150,153	Bax
19328219_11	Limited_variation	19,27	-1438A/G
19328219_11	Disease	33,51	alcohol dependence
19328219_11	Limited_variation	97,109	5-HTTLPR S/S
19328219_11	Limited_variation	130,142	5-HTTLPR L/S
19328219_11	Limited_variation	164,176	5-HTTLPR L/L
19328219_11	Genomic_factor	97,105	5-HTTLPR
19328219_11	Genomic_factor	130,138	5-HTTLPR
19328219_11	Genomic_factor	164,172	5-HTTLPR
16359811_6	Gene_or_protein	0,4	CREB
16359811_6	Chemical	52,59	cocaine
16359811_6	Chemical	85,92	cocaine
16359811_6	Phenotype	149,160	CREB levels
16359811_6	Gene_or_protein	149,153	CREB
16359811_6	Chemical	198,205	cocaine
16359811_6	Genomic_factor	0,14	CREB antisense
16359811_6	Pharmacodynamic_phenotype	174,205	incentive properties of cocaine
16359811_6	Pharmacodynamic_phenotype	34,59	threshold dose of cocaine
16359811_6	Phenotype	73,112	reinstating cocaine self-administration
12804863_11	Gene_or_protein	43,54	HER-2 / neu
12804863_11	Phenotype	138,168	CD8 + mediated immune response
12804863_11	Pharmacokinetic_phenotype	105,125	CTL epitope delivery
12804863_11	Chemical	67,74	CpG ODN
12804863_11	Gene_or_protein	138,141	CD8
2887298_6	Chemical	23,39	cyclophosphamide
2887298_6	Gene_or_protein	117,120	H-2
2887298_6	Gene_or_protein	124,129	YAC-1
2887298_6	Phenotype	104,129	cell surface H-2 on YAC-1
18364363_1	Gene_or_protein	24,45	serotonin transporter
18364363_1	Chemical	91,98	alcohol
18364363_1	Phenotype	80,109	relapse in alcohol dependence
18364363_1	Limited_variation	4,68	short allele of the serotonin transporter promote r polymorphism
18364363_1	Disease	91,109	alcohol dependence
18364363_1	Genomic_factor	24,53	serotonin transporter promote
11455387_7	Chemical	41,45	PAHs
11455387_7	Phenotype	58,75	expression of Bax
11455387_7	Gene_or_protein	72,75	Bax
11455387_7	Phenotype	101,110	apoptosis
25286744_4	Phenotype	23,38	CYP3A4 activity
25286744_4	Gene_or_protein	23,29	CYP3A4
25286744_4	Chemical	41,50	midazolam
21111586_1	Chemical	2,20	methylene chloride
21111586_1	Phenotype	82,105	activation of caspase-3
21111586_1	Gene_or_protein	96,105	caspase-3
21111586_1	Disease	122,135	breast cancer
21111586_1	Phenotype	60,69	apoptosis
21111586_1	Chemical	33,51	Saururus chinensis
21111586_1	Disease	109,117,129,135	prostate cancer
25978827_4	Chemical	81,88	alcohol
25978827_4	Limited_variation	167,175	rs886003
25978827_4	Limited_variation	206,216	rs17862325
25978827_4	Disease	81,99	alcohol dependence
25978827_4	Limited_variation	14,45	single-nucleotide polymorphisms
24491881_3	Gene_or_protein	25,60	methylenetetrahydrofolate reductase
24491881_3	Gene_or_protein	102,107	MTHFR
24491881_3	Chemical	127,139	homocysteine
24491881_3	Pharmacodynamic_phenotype	127,154	homocysteine ( Hcy ) levels
24491881_3	Gene_or_protein	63,68	MTHFR
24491881_3	Limited_variation	2,75	C-to-T mutation in the methylenetetrahydrofolate reductase ( MTHFR ) gene
24491881_3	Chemical	142,145	Hcy
24491881_3	Phenotype	89,107	thermolabile MTHFR
25039301_4	Gene_or_protein	98,103	OPRM1
25039301_4	Limited_variation	98,109	OPRM1 A118G
25039301_4	Pharmacodynamic_phenotype	132,152	responses to alcohol
25039301_4	Chemical	51,58	ethanol
25039301_4	Chemical	169,176	alcohol
25039301_4	Chemical	145,152	alcohol
18926911_12	Limited_variation	75,131	substitution ( S ) in one HLA-G allele in the HLA-G 0101
18926911_12	Gene_or_protein	101,106	HLA-G
18926911_12	Gene_or_protein	121,126	HLA-G
18926911_12	Haplotype	242,253	HLA-G010403
18926911_12	Haplotype	257,268	HLA- G0105N
18926911_12	Haplotype	121,131	HLA-G 0101
18926911_12	Haplotype	227,239	HLA- G010401
18926911_12	Limited_variation	190,224	substitution ( N/S ) on HLA- G0103
18926911_12	Disease	314,323	rejection
18926911_12	Limited_variation	190,213,227,239	substitution ( N/S ) on HLA- G010401
18926911_12	Limited_variation	190,213,242,253	substitution ( N/S ) on HLA-G010403
18926911_12	Limited_variation	190,213,257,268	substitution ( N/S ) on HLA- G0105N
18926911_12	Haplotype	214,224	HLA- G0103
26039043_12	Gene_or_protein	46,52	CYP3A4
26039043_12	Chemical	87,97	tacrolimus
26039043_12	Chemical	120,130	tacrolimus
26039043_12	Chemical	168,178	tacrolimus
26039043_12	Haplotype	46,57	CYP3A4 * 1B
26039043_12	Pharmacodynamic_phenotype	87,115	tacrolimus dose requirements
26039043_12	Pharmacodynamic_phenotype	120,195	tacrolimus trough concentration/weight-adjusted tacrolimus daily dose ratio
26039043_12	Disease	224,239	transplantation
23149441_14	Limited_variation	29,48	CYP3A5 polymorphism
23149441_14	Gene_or_protein	29,35	CYP3A5
23149441_14	Chemical	64,74	tacrolimus
23149441_14	Limited_variation	120,139	CYP3A5 polymorphism
23149441_14	Gene_or_protein	120,126	CYP3A5
23149441_14	Pharmacodynamic_phenotype	64,86	tacrolimus variability
26415139_12	Limited_variation	15,32	CYP2B6 g.15582C>T
26415139_12	Gene_or_protein	15,21	CYP2B6
26415139_12	Chemical	43,46	EFV
26415139_12	Disease	90,100	HIV / AIDS
26415139_12	Pharmacodynamic_phenotype	36,60	plasma EFV concentration
21507151_2	Gene_or_protein	43,48	OPRM1
21507151_2	Chemical	82,89	alcohol
21507151_2	Chemical	92,99	cocaine
21507151_2	Chemical	104,112	nicotine
21507151_2	Gene_or_protein	4,22	mu-opioid receptor
21507151_2	Chemical	73,79	opiate
21507151_2	Disease	82,89,113,122	alcohol addiction
21507151_2	Disease	73,79,113,122	opiate addiction
21507151_2	Disease	92,99,113,122	cocaine addiction
21507151_2	Disease	104,122	nicotine addiction
18370849_5	Pharmacodynamic_phenotype	29,59	carbamazepine hypersensitivity
18370849_5	Chemical	29,42	carbamazepine
18370849_5	Gene_or_protein	64,69	HLA-B
18370849_5	Haplotype	64,76	HLA-B * 1502
19330906_1	Chemical	0,9	Nebivolol
19330906_1	Gene_or_protein	55,77	estrogen receptor beta
19330906_1	Phenotype	20,46	endothelial cell stiffness
26471290_13	Gene_or_protein	14,18	KRAS
26471290_13	Disease	105,110	NSCLC
26471290_13	Chemical	153,181	platinum -based chemotherapy
26471290_13	Limited_variation	14,21	KRAS MT
26471290_13	Phenotype	55,71	progression-free
26471290_13	Phenotype	76,92	overall survival
26471290_13	Chemical	153,161	platinum
8524236_7	Chemical	40,55	chloramphenicol
8524236_7	Gene_or_protein	106,113	ER/ Sp1
8524236_7	Chemical	146,161	chloramphenicol
8524236_7	Chemical	223,227	TCDD
8524236_7	Gene_or_protein	279,296	ER/ Sp1 - " XRE "
8524236_7	Gene_or_protein	40,82	chloramphenicol acetyltransferase reporter
8524236_7	Limited_variation	96,131	wild-type ER/ Sp1 promoter sequence
8524236_7	Pharmacodynamic_phenotype	134,188	E2 -induced chloramphenicol acetyltransferase activity
8524236_7	Gene_or_protein	146,179	chloramphenicol acetyltransferase
8524236_7	Limited_variation	272,296	mutant ER/ Sp1 - " XRE "
8524236_7	Pharmacodynamic_phenotype	134,179,193,204	E2 -induced chloramphenicol acetyltransferase mRNA levels
8524236_7	Chemical	134,136	E2
8524236_7	Genomic_factor	146,179,193,197	chloramphenicol acetyltransferase mRNA
8524236_7	Pharmacodynamic_phenotype	146,188	chloramphenicol acetyltransferase activity
8524236_7	Pharmacodynamic_phenotype	146,179,193,204	chloramphenicol acetyltransferase mRNA levels
25712669_5	Phenotype	40,61	STAT3 phosphorylation
25712669_5	Gene_or_protein	40,45	STAT3
25712669_5	Chemical	113,120	matrine
25712669_5	Phenotype	0,35	Apoptosis-related molecular changes
25712669_5	Phenotype	66,92	transcriptional activities
25658497_11	Gene_or_protein	151,155	BDNF
25658497_11	Limited_variation	151,164	BDNF Val66Met
25658497_11	Chemical	67,82	antidepressants
25658497_11	Chemical	180,184	SSRI
25658497_11	Limited_variation	209,218	Val / Val
25658497_11	Chemical	232,241	SNRI/ TCA
25658497_11	Limited_variation	246,249	Met
25658497_11	Disease	110,135	major depressive disorder
18006783_9	Gene_or_protein	0,9	Cyclin D1
18006783_9	Chemical	73,82	celecoxib
18006783_9	Gene_or_protein	36,39	Ras
24809685_11	Gene_or_protein	61,66	MAO-A
24809685_11	Phenotype	156,165,188,200	serotonin availability
24809685_11	Phenotype	173,200	norepinephrine availability
24809685_11	Phenotype	47,87	CpG -specific MAO-A gene hypomethylation
24809685_11	Pharmacodynamic_phenotype	232,265	antidepressant treatment response
16475678_9	Chemical	31,41	paclitaxel
16475678_9	Phenotype	91,107	CHFR methylation
16475678_9	Gene_or_protein	91,95	CHFR
16475678_9	Chemical	141,151	paclitaxel
16475678_9	Phenotype	201,217	CHFR methylation
16475678_9	Gene_or_protein	201,205	CHFR
16475678_9	Chemical	230,240	paclitaxel
16475678_9	Pharmacodynamic_phenotype	114,151	partial response ( PR ) to paclitaxel
16475678_9	Pharmacodynamic_phenotype	224,240	PR to paclitaxel
16475678_9	Pharmacodynamic_phenotype	114,130	partial response
16475678_9	Pharmacodynamic_phenotype	133,135	PR
16475678_9	Pharmacodynamic_phenotype	224,226	PR
24265703_7	Limited_variation	14,24	RB1 status
24265703_7	Gene_or_protein	14,17	RB1
24265703_7	Pharmacodynamic_phenotype	40,51,100,109	sensitivity cisplatin
24265703_7	Chemical	100,109	cisplatin
24265703_7	Chemical	121,135	5-fluorouracil
24265703_7	Chemical	138,148	idarubicin
24265703_7	Chemical	151,161	epirubicin
24265703_7	Chemical	164,171	PRIMA-1
24265703_7	Chemical	182,193	fludarabine
24265703_7	Chemical	198,208	PD-0332991
24265703_7	Disease	243,247	TNBC
24265703_7	Chemical	112,116	CDDP
24265703_7	Disease	55,59	TNBC
24265703_7	Pharmacodynamic_phenotype	40,51,66,68,121,135	sensitivity to 5-fluorouracil
24265703_7	Pharmacodynamic_phenotype	40,51,66,68,138,148	sensitivity to idarubicin
24265703_7	Pharmacodynamic_phenotype	40,51,66,68,151,161	sensitivity to epirubicin
24265703_7	Pharmacodynamic_phenotype	40,51,66,68,164,171	sensitivity to PRIMA-1
24265703_7	Pharmacodynamic_phenotype	40,51,66,68,182,193	sensitivity to fludarabine
24265703_7	Pharmacodynamic_phenotype	40,51,66,68,198,208	sensitivity to PD-0332991
24265703_7	Chemical	69,89	multiple other drugs
24265703_7	Pharmacodynamic_phenotype	40,51,66,89	sensitivity to multiple other drugs
27467210_4	Chemical	14,21	AZD6244
27467210_4	Chemical	0,11	Selumetinib
27467210_4	Chemical	24,35	ARRY-142886
27467210_4	Gene_or_protein	77,83	MEK1/2
27467210_4	Gene_or_protein	175,179	KRAS
27467210_4	Limited_variation	175,186	KRAS mutant
27467210_4	Chemical	0,11,128,157	Selumetinib in combination with docetaxel
27467210_4	Disease	175,212	KRAS mutant pretreated advanced NSCLC
24585043_5	Limited_variation	88,97	rs6465084
24585043_5	Chemical	110,117	alcohol
24585043_5	Limited_variation	179,204	A allele of SNP rs6465084
24585043_5	Chemical	208,215	alcohol
24585043_5	Disease	110,128	alcohol -dependent
24585043_5	Disease	208,226	alcohol -dependent
24585043_5	Limited_variation	195,204	rs6465084
15345592_1	Disease	59,87	chronic myelogenous leukemia
15345592_1	Chemical	135,152	imatinib mesylate
15345592_1	Gene_or_protein	13,27	BCR-ABL kinase
15345592_1	Limited_variation	13,37	BCR-ABL kinase mutations
15345592_1	Phenotype	111,131	ytogenetic remission
24830941_7	Gene_or_protein	129,150	Jun N-terminal kinase
24830941_7	Chemical	169,173	tBHQ
24830941_7	Gene_or_protein	197,203	CYP2C9
24830941_7	Chemical	15,32	kinase inhibitors
24830941_7	Gene_or_protein	37,69	mitogen-activated protein kinase
24830941_7	Gene_or_protein	87,124	extracellular signal-regulated kinase
24830941_7	Pharmacodynamic_phenotype	169,203	tBHQ -induced expression of CYP2C9
24830941_7	Pharmacodynamic_phenotype	183,203	expression of CYP2C9
19682085_14	Gene_or_protein	14,18	ITPA
19682085_14	Chemical	71,74	AZA
19682085_14	Phenotype	114,132	flu -like symptoms
19682085_14	Disease	114,117	flu
19682085_14	Limited_variation	14,35	ITPA 94C>A homozygous
19682085_14	Pharmacodynamic_phenotype	71,109	AZA -related gastrointestinal toxicity
19682085_14	Pharmacodynamic_phenotype	84,109	gastrointestinal toxicity
21829065_1	Limited_variation	35,60	KRAS gene mutation status
21829065_1	Gene_or_protein	35,39	KRAS
21829065_1	Chemical	95,105	irinotecan
21829065_1	Disease	169,197	metastatic colorectal cancer
21829065_1	Chemical	80,89	cetuximab
21829065_1	Chemical	80,105	cetuximab plus irinotecan
21829065_1	Pharmacodynamic_phenotype	69,105	benefit of cetuximab plus irinotecan
21829065_1	Chemical	122,134	chemotherapy
15000558_1	Limited_variation	4,47	reverse transcriptase ( RT ) mutation V118I
15000558_1	Chemical	88,96	abacavir
15000558_1	Disease	140,155	HIV-1 infection
15000558_1	Gene_or_protein	4,25	reverse transcriptase
15000558_1	Gene_or_protein	28,30	RT
15000558_1	Chemical	88,128	abacavir -based antiretroviral treatment
15000558_1	Chemical	131,134	ART
15000558_1	Pharmacodynamic_phenotype	67,84	virologic failure
15983922_3	Chemical	28,38	lamivudine
15983922_3	Pharmacodynamic_phenotype	148,169	lamivudine resistance
15983922_3	Chemical	148,158	lamivudine
15983922_3	Pharmacodynamic_phenotype	62,79	viral suppression
15983922_3	Limited_variation	106,121	M184V mutations
26450467_1	Gene_or_protein	24,30	CYP3A5
26450467_1	Gene_or_protein	35,40	MDR-1
26450467_1	Chemical	58,68	Tacrolimus
26450467_1	Pharmacokinetic_phenotype	58,85	Tacrolimus Pharmacokinetics
26450467_1	Limited_variation	24,30,41,54	CYP3A5 Polymorphisms
26450467_1	Limited_variation	35,54	MDR-1 Polymorphisms
22900031_3	Limited_variation	21,64	genetic deletion of Pak1 ( Pak1 ( - / - ) )
22900031_3	Gene_or_protein	41,45	Pak1
22900031_3	Chemical	183,196	acetylcholine
22900031_3	Chemical	199,202	ACh
22900031_3	Gene_or_protein	99,102	Pak
22900031_3	Pharmacodynamic_phenotype	110,133	response of the airways
20878066_6	Phenotype	40,65	knock-down p53 expression
20878066_6	Gene_or_protein	51,54	p53
20878066_6	Chemical	96,106	amifostine
20878066_6	Chemical	122,132	paclitaxel
20878066_6	Gene_or_protein	157,160	p53
20878066_6	Pharmacodynamic_phenotype	122,153	paclitaxel 's anticancer effect
20878066_6	Genomic_variation	157,167	p53 status
20878066_6	Genomic_variation	40,54	knock-down p53
8947308_9	Limited_variation	73,100	deletion of the GST M1 gene
8947308_9	Gene_or_protein	89,95	GST M1
8947308_9	Disease	163,175	liver damage
8947308_9	Chemical	212,219	ethanol
8947308_9	Pharmacodynamic_phenotype	195,219	toxic effects of ethanol
25939871_12	Gene_or_protein	30,37	SLCO1B1
25939871_12	Chemical	99,103	6-MP
25939871_12	Disease	145,148	ALL
25939871_12	Limited_variation	30,49	SLCO1B1 c.521 T > C
25939871_12	Pharmacodynamic_phenotype	81,103	dose reduction of 6-MP
25939871_12	Chemical	119,131	chemotherapy
21172311_2	Gene_or_protein	4,31	human serotonin receptor 1B
21172311_2	Chemical	80,89	serotonin
21172311_2	Gene_or_protein	34,39	HRT1B
21172311_2	Phenotype	80,97	serotonin release
26013962_7	Phenotype	19,36	5-HTT mRNA levels
26013962_7	Gene_or_protein	19,24	5-HTT
26013962_7	Chemical	92,99	cocaine
26013962_7	Phenotype	64,88	executive WM performance
26013962_7	Genomic_factor	19,29	5-HTT mRNA
11888582_12	Chemical	18,26	abacavir
11888582_12	Gene_or_protein	69,74	HLA-B
11888582_12	Disease	144,160	hypersensitivity
11888582_12	Haplotype	69,81	HLA-B * 5701
11888582_12	Gene_or_protein	84,90	HLA-DR
11888582_12	Haplotype	99,107	HLA-DQ 3
11888582_12	Haplotype	84,92	HLA-DR 7
11888582_12	Gene_or_protein	99,105	HLA-DQ
24921970_1	Gene_or_protein	15,19	EGFR
24921970_1	Chemical	15,46	EGFR tyrosine kinase inhibitors
24921970_1	Disease	68,74	cancer
11320258_10	Gene_or_protein	4,13	serotonin
11320258_10	Chemical	28,35	cocaine
11320258_10	Gene_or_protein	46,49	DAT
11320258_10	Chemical	104,111	cocaine
11320258_10	Gene_or_protein	132,135	DAT
11320258_10	Gene_or_protein	138,142	SERT
11320258_10	Genomic_variation	46,58	DAT knockout
11320258_10	Genomic_variation	132,158	DAT / SERT double knockout
11320258_10	Phenotype	4,42	serotonin dependence of cocaine reward
11320258_10	Phenotype	104,128	cocaine place preference
21876500_1	Limited_variation	32,88	Val158Met catechol-O-methyltransferase gene polymorphism
21876500_1	Gene_or_protein	42,70	catechol-O-methyltransferase
21876500_1	Disease	93,119	methamphetamine dependence
21876500_1	Chemical	93,108	methamphetamine
2491158_6	Gene_or_protein	116,119	VH1
2491158_6	Chemical	51,68	phosphorylcholine
2491158_6	Gene_or_protein	132,143	S107 family
15349717_10	Chemical	23,35	azathioprine
15349717_10	Limited_variation	110,137	promoter TPMT polymorphisms
15349717_10	Limited_variation	99,105,119,137	coding TPMT polymorphisms
15349717_10	Pharmacodynamic_phenotype	152,166	dose tolerated
15349717_10	Gene_or_protein	119,123	TPMT
15349717_10	Genomic_factor	110,123	promoter TPMT
15349717_10	Genomic_factor	99,105,119,123	coding TPMT
20122728_2	Limited_variation	12,40	TNF-a promoter polymorphisms
20122728_2	Gene_or_protein	12,17	TNF-a
20122728_2	Disease	63,79	multiple myeloma
20122728_2	Disease	82,84	MM
20122728_2	Chemical	227,238	thalidomide
20122728_2	Chemical	243,256	dexamethasone
20122728_2	Chemical	227,256	thalidomide and dexamethasone
20122728_2	Genomic_factor	12,26	TNF-a promoter
20122728_2	Phenotype	167,183	clinical outcome
20122728_2	Chemical	259,269	Thal + Dex
19796663_8	Pharmacodynamic_phenotype	84,116	apomorphine -induced GH response
19796663_8	Chemical	84,95	apomorphine
19796663_8	Chemical	105,107	GH
19796663_8	Gene_or_protein	129,133	DRD2
19796663_8	Gene_or_protein	138,143	ANKK1
19796663_8	Chemical	147,154	alcohol
19796663_8	Disease	147,165	alcohol -dependent
19796663_8	Limited_variation	121,133	SNPs in DRD2
19796663_8	Limited_variation	121,128,138,143	SNPs in ANKK1
19796663_8	Pharmacodynamic_phenotype	105,116	GH response
26984388_6	Chemical	16,27	cobimetinib
26984388_6	Chemical	33,44	vemurafenib
26984388_6	Gene_or_protein	77,81	BRAF
26984388_6	Limited_variation	77,108	BRAF ( V600 ) mutation-positive
26984388_6	Disease	77,121,136,144	BRAF ( V600 ) mutation-positive unresectable melanoma
26984388_6	Chemical	16,44	cobimetinib plus vemurafenib
26984388_6	Disease	77,108,125,144	BRAF ( V600 ) mutation-positive metastatic melanoma
16818479_12	Limited_variation	14,28	EGFR mutations
16818479_12	Gene_or_protein	14,18	EGFR
16818479_12	Chemical	114,124	paclitaxel
16818479_12	Pharmacodynamic_phenotype	44,55,129,140	response to gemcitabine
16818479_12	Chemical	102,111	platinums
16818479_12	Pharmacodynamic_phenotype	44,55,102,111	response to platinums
16818479_12	Pharmacodynamic_phenotype	44,55,114,124	response to paclitaxel
16818479_12	Chemical	129,140	gemcitabine
16818479_12	Pharmacodynamic_phenotype	44,92	response to conventional chemotherapeutic agents
18645163_6	Phenotype	30,47	CPT II deficiency
18645163_6	Gene_or_protein	30,36	CPT II
18645163_6	Chemical	88,100	triheptanoin
19147553_8	Chemical	11,19	nutlin-3
19147553_8	Chemical	38,51	rhodamine 123
19147553_8	Gene_or_protein	101,105	P-gp
19147553_8	Pharmacokinetic_phenotype	28,51	efflux of rhodamine 123
19147553_8	Chemical	62,79	fluorescence dyes
25885881_4	Chemical	0,11	Thiopurines
25885881_4	Gene_or_protein	20,24	Rac1
25885881_4	Gene_or_protein	29,35	GTPase
25885881_4	Phenotype	51,71	antiapoptotic effect
16719540_4	Chemical	122,134	fluorouracil
16719540_4	Gene_or_protein	296,316	thymidylate synthase
16719540_4	Pharmacokinetic_phenotype	202,218	pharmacokinetics
16719540_4	Pharmacokinetic_phenotype	263,273	metabolism
16719540_4	Gene_or_protein	283,290	targets
16719540_4	Pharmacodynamic_phenotype	165,189	narrow therapeutic index
11368834_10	Limited_variation	25,35	CCK -45C>T
11368834_10	Gene_or_protein	25,28	CCK
11368834_10	Gene_or_protein	40,45	CCKBR
11368834_10	Limited_variation	40,55	CCKBR Val125Ile
11368834_10	Chemical	98,105	alcohol
11368834_10	Disease	98,116	alcohol dependence
20205660_5	Gene_or_protein	131,161	thiopurine S-methyltransferase
20205660_5	Limited_variation	39,82,112,128	genetic polymorphisms of genes encoding for xanthine oxidase
20205660_5	Limited_variation	39,82,131,161	genetic polymorphisms of genes encoding for thiopurine S-methyltransferase
20205660_5	Limited_variation	39,82,164,200	genetic polymorphisms of genes encoding for inosine triphosphate pyrophosphatase
20205660_5	Limited_variation	39,82,203,241	genetic polymorphisms of genes encoding for hypoxanthine phosphoribosyltransferase
20205660_5	Limited_variation	39,109	genetic polymorphisms of genes encoding for glutathione S -tranferases
20205660_5	Gene_or_protein	83,109	glutathione S -tranferases
20205660_5	Gene_or_protein	112,128	xanthine oxidase
20205660_5	Gene_or_protein	164,200	inosine triphosphate pyrophosphatase
20205660_5	Gene_or_protein	203,241	hypoxanthine phosphoribosyltransferase
20205660_5	Gene_or_protein	244,279	inosine monophosphate dehydrogenase
20205660_5	Pharmacodynamic_phenotype	284,304	multidrug resistance
20205660_5	Gene_or_protein	284,313	multidrug resistance proteins
20205660_5	Limited_variation	39,82,244,279	genetic polymorphisms of genes encoding for inosine monophosphate dehydrogenase
20205660_5	Limited_variation	39,82,284,313	genetic polymorphisms of genes encoding for multidrug resistance proteins
20205660_5	Chemical	284,293	multidrug
22011650_9	Chemical	102,111	gefitinib
22011650_9	Gene_or_protein	129,133	EGFR
22011650_9	Gene_or_protein	205,209	EGFR
22011650_9	Phenotype	14,19	HRQoL
22011650_9	Phenotype	24,41	symptom endpoints
22011650_9	Chemical	163,187	carboplatin / paclitaxel
22011650_9	Limited_variation	205,227	EGFR mutation-negative
22011650_9	Limited_variation	129,151	EGFR mutation-positive
22011650_9	Disease	129,158	EGFR mutation-positive tumors
22011650_9	Disease	205,234	EGFR mutation-negative tumors
22011650_9	Pharmacodynamic_phenotype	63,80	efficacy outcomes
22011650_9	Chemical	163,174	carboplatin
22011650_9	Chemical	177,187	paclitaxel
21388909_1	Limited_variation	20,38	ABCB1 polymorphism
21388909_1	Gene_or_protein	20,25	ABCB1
21388909_1	Chemical	55,71	sodium valproate
21388909_1	Disease	95,103	epilepsy
21388909_1	Pharmacodynamic_phenotype	43,71	response to sodium valproate
14582249_5	Gene_or_protein	25,30	GSTT1
14582249_5	Limited_variation	35,53	GSTM1 polymorphism
14582249_5	Gene_or_protein	35,40	GSTM1
14582249_5	Chemical	86,99	1,3-butadiene
14582249_5	Limited_variation	25,30,41,53	GSTT1 polymorphism
14582249_5	Pharmacodynamic_phenotype	61,99	biological indicators of 1,3-butadiene
23774940_5	Pharmacodynamic_phenotype	50,59	SJS / TEN
23774940_5	Chemical	37,40	NVP
23774940_5	Gene_or_protein	123,128	ABCB1
23774940_5	Gene_or_protein	133,139	ABCC10
23774940_5	Gene_or_protein	166,172	CYP2B6
23774940_5	Gene_or_protein	175,181	CYP3A4
23774940_5	Gene_or_protein	186,192	CYP3A5
23774940_5	Pharmacodynamic_phenotype	37,59	NVP -induced SJS / TEN
23774940_5	Limited_variation	186,217	CYP3A5 cytochrome gene variants
23774940_5	Limited_variation	175,181,193,217	CYP3A4 cytochrome gene variants
23774940_5	Limited_variation	166,172,193,217	CYP2B6 cytochrome gene variants
23774940_5	Limited_variation	133,157,209,217	ABCC10 transporter genes variants
23774940_5	Limited_variation	123,128,140,157,209,217	ABCB1 transporter genes variants
22819302_1	Chemical	37,46	silymarin
22819302_1	Chemical	50,61	doxorubicin
22819302_1	Phenotype	116,137	c-myc gene expression
22819302_1	Gene_or_protein	116,121	c-myc
22819302_1	Pharmacodynamic_phenotype	0,10,26,46	Preventive effects of silymarin
22819302_1	Pharmacodynamic_phenotype	50,89	doxorubicin -induced testicular damages
22819302_1	Pharmacodynamic_phenotype	15,46	protective effects of silymarin
22819302_1	Pharmacodynamic_phenotype	71,89	testicular damages
26940072_6	Chemical	65,73	warfarin
26940072_6	Gene_or_protein	93,99	CYP2C9
26940072_6	Gene_or_protein	122,128	VKORC1
26940072_6	Limited_variation	129,138	rs9923231
26940072_6	Limited_variation	141,150	rs9934438
26940072_6	Limited_variation	153,159	rs7294
26940072_6	Limited_variation	164,173	rs2884737
26940072_6	Haplotype	93,103	CYP2C9 * 1
26940072_6	Haplotype	93,99,106,109	CYP2C9 * 2
26940072_6	Haplotype	93,99,114,117	CYP2C9 * 3
12166950_3	Gene_or_protein	116,130	PDGFR receptor
12166950_3	Chemical	186,197	quinazoline
12166950_3	Chemical	55,87	small molecule kinase inhibitors
12166950_3	Gene_or_protein	70,76	kinase
19564049_1	Gene_or_protein	48,52	XBP1
19564049_1	Chemical	118,127	valproate
19564049_1	Disease	131,148	bipolar disorders
19564049_1	Limited_variation	48,60	XBP1 -116C/G
19564049_1	Pharmacodynamic_phenotype	78,89,118,127	response to valproate
22555197_1	Chemical	58,68	irinotecan
22555197_1	Disease	115,143	metastatic colorectal cancer
22555197_1	Limited_variation	163,169,181,194	UGT1A1 polymorphisms
22555197_1	Gene_or_protein	163,169	UGT1A1
22555197_1	Gene_or_protein	174,180	CYP2A6
22555197_1	Limited_variation	174,194	CYP2A6 polymorphisms
22555197_1	Chemical	73,76	S-1
22555197_1	Pharmacodynamic_phenotype	207,215	activity
28423012_11	Phenotype	12,43	induction of 15-PGDH expression
28423012_11	Gene_or_protein	25,32	15-PGDH
28423012_11	Chemical	62,83	15-keto-PGE2 analogue
28423012_11	Disease	135,182	endotoxin-associated liver inflammation /injury
22741564_4	Phenotype	12,62	thiopurine S-methyltransferase ( TPMT ) deficiency
22741564_4	Gene_or_protein	12,42	thiopurine S-methyltransferase
22741564_4	Gene_or_protein	45,49	TPMT
22741564_4	Chemical	136,148	azathioprine
22741564_4	Chemical	152,168	6-mercaptopurine
22741564_4	Disease	216,231	Crohn's disease
22741564_4	Disease	234,236	CD
22741564_4	Pharmacodynamic_phenotype	136,185	azathioprine or 6-mercaptopurine immunomodulation
17989208_5	Gene_or_protein	135,139	HCN1
17989208_5	Chemical	170,180	sulfhydryl
17989208_5	Genomic_variation	55,208	substitutions into the descending portion of the P loop ( residues 339-345 ) of HCN1 -R ( where R is resistance to sulfhydryl -reactive agents ) channels
17989208_5	Pharmacodynamic_phenotype	156,197	resistance to sulfhydryl -reactive agents
27710871_1	Chemical	0,11	Trabectedin
27710871_1	Phenotype	55,70	BRCA deficiency
27710871_1	Gene_or_protein	55,59	BRCA
27710871_1	Chemical	17,29	chemotherapy
20374216_1	Chemical	163,170	alcohol
20374216_1	Gene_or_protein	35,77	corticotropin releasing hormone receptor 1
20374216_1	Gene_or_protein	85,90	CRHR1
20374216_1	Limited_variation	0,92	Single-nucleotide polymorphisms in corticotropin releasing hormone receptor 1 gene ( CRHR1 )
20374216_1	Disease	163,181	alcohol dependence
20374216_1	Phenotype	113,158	quantitative trait of event-related potential
15864124_1	Gene_or_protein	77,108	UDP-glucuronosyltransferase 1A1
15864124_1	Chemical	118,128	irinotecan
15864124_1	Pharmacodynamic_phenotype	118,137	irinotecan toxicity
15864124_1	Limited_variation	8,113	polymorphism in the phenobarbital -responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene
12668130_5	Gene_or_protein	27,32	MnSOD
12668130_5	Gene_or_protein	37,45	Cu/ZnSOD
12668130_5	Phenotype	158,170	infarct size
12668130_5	Disease	158,165	infarct
12668130_5	Chemical	173,188	malondialdehyde
12668130_5	Disease	71,81	I/R injury
12668130_5	Phenotype	127,155	serum creatine kinase levels
12668130_5	Pharmacodynamic_phenotype	173,195	malondialdehyde levels
12668130_5	Phenotype	202,222	apoptotic cell death
12668130_5	Phenotype	8,45	expression of both MnSOD and Cu/ZnSOD
12668130_5	Gene_or_protein	133,148	creatine kinase
27457818_7	Chemical	34,43	clonidine
27457818_7	Limited_variation	76,101	COMT low-activity alleles
27457818_7	Gene_or_protein	76,80	COMT
27457818_7	Chemical	48,55	placebo
20510210_2	Gene_or_protein	120,140	cytochrome P450 2C19
20510210_2	Limited_variation	120,165	cytochrome P450 2C19 ( CYP2C19 ) polymorphism
20510210_2	Gene_or_protein	143,150	CYP2C19
20510210_2	Chemical	193,204	clopidogrel
20510210_2	Pharmacodynamic_phenotype	169,204	antiplatelet effects of clopidogrel
27378608_9	Gene_or_protein	122,126	HER2
27378608_9	Gene_or_protein	34,42	FcyRIIIa
27378608_9	Limited_variation	34,44	FcyRIIIa V
27378608_9	Chemical	92,118	trastuzumab plus lapatinib
27378608_9	Disease	122,131	HER2 + BC
12777962_1	Gene_or_protein	0,6	CYP2E1
12777962_1	Chemical	55,62	alcohol
12777962_1	Chemical	67,75	nicotine
12777962_1	Disease	67,86	nicotine dependence
12777962_1	Haplotype	0,11	CYP2E1 * 1D
12777962_1	Disease	55,62,76,86	alcohol dependence
25726043_14	Disease	14,19	NSCLC
25726043_14	Gene_or_protein	59,63	EGFR
25726043_14	Pharmacodynamic_phenotype	104,125	response to gefitinib
25726043_14	Chemical	116,125	gefitinib
25726043_14	Limited_variation	59,69	EGFR L858R
25726043_14	Phenotype	36,43	smoking
18708376_7	Phenotype	18,48	ESR1 promoter hypermethylation
18708376_7	Gene_or_protein	18,22	ESR1
18708376_7	Phenotype	53,70	low ER expression
18708376_7	Gene_or_protein	57,59	ER
18708376_7	Chemical	160,169	tamoxifen
18708376_7	Phenotype	92,143	atypia in Random Periareolar Fine Needle Aspiration
18708376_7	Genomic_factor	18,31	ESR1 promoter
18382665_13	Limited_variation	121,157	ADH1B regulatory region polymorphism
18382665_13	Gene_or_protein	121,126	ADH1B
18382665_13	Gene_or_protein	202,207	ADH1B
18382665_13	Haplotype	202,215	ADH1B * 47His
18382665_13	Pharmacokinetic_phenotype	31,53	selection distribution
18382665_13	Genomic_factor	121,144	ADH1B regulatory region
11712813_1	Limited_variation	2,32	polymorphism of the XRCC1 gene
11712813_1	Gene_or_protein	22,27	XRCC1
11712813_1	Chemical	58,66	platinum
11712813_1	Disease	95,112	colorectal cancer
11712813_1	Pharmacodynamic_phenotype	46,66	response to platinum
18760346_3	Limited_variation	38,55	Ala- MnSOD allele
18760346_3	Gene_or_protein	43,48	MnSOD
18760346_3	Chemical	83,87	iron
18760346_3	Disease	126,150	hepatocellular carcinoma
18760346_3	Pharmacokinetic_phenotype	75,100	hepatic iron accumulation
18760346_3	Disease	3,22	alcoholic cirrhotic
16929515_2	Gene_or_protein	38,58	thymidylate synthase
16929515_2	Gene_or_protein	61,63	TS
16929515_2	Limited_variation	13,65	DNA polymorphisms in the thymidylate synthase ( TS )
16929515_2	Gene_or_protein	70,111	5,10-methylene-tetrahydrofolate reductase
16929515_2	Gene_or_protein	114,119	MTHFR
16929515_2	Limited_variation	13,37,70,121	DNA polymorphisms in the 5,10-methylene-tetrahydrofolate reductase ( MTHFR )
16929515_2	Disease	194,208	gastric cancer
16929515_2	Phenotype	165,173	survival
16929515_2	Chemical	222,266	5-FU based preoperative chemotherapy ( CTx )
16929515_2	Chemical	222,226	5-FU
16929515_2	Chemical	246,258	chemotherapy
16929515_2	Chemical	261,264	CTx
16929515_2	Pharmacodynamic_phenotype	152,160	response
18784465_9	Gene_or_protein	44,49	HLA-B
18784465_9	Haplotype	44,56	HLA-B * 5701
18784465_9	Phenotype	136,163	quality-adjusted life years
18784465_9	Chemical	10,35	Abacavir -based treatment
18784465_9	Phenotype	101,116	life expectancy
18784465_9	Chemical	10,18	Abacavir
18784465_9	Phenotype	189,202	lifetime cost
26352193_12	Gene_or_protein	11,19	5-HTTLPR
26352193_12	Disease	40,54	social anxiety
26352193_12	Disease	57,64	anxiety
26352193_12	Disease	71,81	depressive
26352193_12	Chemical	92,99	alcohol
26352193_12	Genomic_variation	0,19	Triallelic 5-HTTLPR
26352193_12	Disease	92,110	alcohol -dependent
22571356_5	Gene_or_protein	89,95	VKORC1
22571356_5	Chemical	241,249	warfarin
22571356_5	Phenotype	338,346	bleeding
22571356_5	Limited_variation	0,134	Homozygosity for the -1639 G>A single nucleotide functional promoter polymorphism of the VKORC1 gene ( genotype AA ; 14 5 % of cases )
22571356_5	Pharmacodynamic_phenotype	181,210	time to therapeutic INR > = 2
22571356_5	Pharmacodynamic_phenotype	234,254	stable warfarin dose
22571356_5	Phenotype	297,305	INRs > 5
22571356_5	Limited_variation	411,422	GG genotype
25034231_6	Chemical	5,13	xanthone
25034231_6	Phenotype	33,52	expression of CXCR4
25034231_6	Gene_or_protein	47,52	CXCR4
25034231_6	Disease	56,58	MM
15175841_1	Gene_or_protein	19,24	c-Fos
15175841_1	Chemical	93,101	morphine
15175841_1	Phenotype	0,35	Withdrawal-induced c-Fos expression
19383921_1	Gene_or_protein	0,29	Poly(ADP-ribose) polymerase-1
19383921_1	Gene_or_protein	82,85	p53
19383921_1	Phenotype	128,141	tumor relapse
19383921_1	Chemical	162,173	carboplatin
19383921_1	Chemical	0,39	Poly(ADP-ribose) polymerase-1 inhibitor
19383921_1	Disease	74,108	Brca2 / p53 -mutant mammary tumors
19383921_1	Limited_variation	74,93	Brca2 / p53 -mutant
19383921_1	Gene_or_protein	74,79	Brca2
19383921_1	Disease	128,133	tumor
19182535_2	Gene_or_protein	4,19	tyrosine kinase
19182535_2	Gene_or_protein	22,24	TK
19182535_2	Chemical	39,47	imatinib
19182535_2	Disease	80,92	malignancies
19182535_2	Gene_or_protein	142,147	c-abl
19182535_2	Gene_or_protein	150,155	c-kit
19182535_2	Gene_or_protein	160,166	PDGF-R
19182535_2	Chemical	4,36	tyrosine kinase ( TK ) inhibitor
19182535_2	Gene_or_protein	132,139	kinases
18480244_5	Chemical	50,61	TLR7 ligand
18480244_5	Gene_or_protein	50,54	TLR7
18480244_5	Chemical	112,120	SM360320
18480244_5	Chemical	64,109	9-benzyl-8-hydroxy-2-(2-methoxyethoxy)adenine
18480244_5	Phenotype	168,183	TLR7 activation
18480244_5	Gene_or_protein	168,172	TLR7
18480244_5	Chemical	123,128	1V136
25404639_1	Gene_or_protein	33,36	p50
25404639_1	Chemical	63,76	eriocalyxin B
12504868_8	Gene_or_protein	0,33	Intercellular adhesion molecule-1
12504868_8	Gene_or_protein	181,184	Tat
12504868_8	Phenotype	0,49	Intercellular adhesion molecule-1 gene expression
12504868_8	Chemical	181,203	Tat combined with METH
12504868_8	Chemical	199,203	METH
24092646_1	Gene_or_protein	20,24	MDR1
24092646_1	Gene_or_protein	27,32	EPHX1
24092646_1	Chemical	78,86	warfarin
24092646_1	Gene_or_protein	37,46	protein Z
24092646_1	Pharmacodynamic_phenotype	64,93	modulation of warfarin dosage
24092646_1	Limited_variation	20,24,47,60	MDR1 gene variants
24092646_1	Limited_variation	27,32,47,60	EPHX1 gene variants
24092646_1	Limited_variation	37,60	protein Z gene variants
19615284_8	Gene_or_protein	0,5	BRCA1
19615284_8	Chemical	55,100	anthracycline -based neoadjuvant chemotherapy
19615284_8	Disease	112,125	breast cancer
19615284_8	Phenotype	0,24	BRCA1 methylation status
19615284_8	Chemical	55,68	anthracycline
26216193_4	Chemical	53,67	5-fluorouracil
26216193_4	Chemical	116,137	5-fluorouracil-5-FUDR
26216193_4	Gene_or_protein	219,223	DPYD
26216193_4	Pharmacokinetic_phenotype	96,137	degradation rate of 5-fluorouracil-5-FUDR
26216193_4	Gene_or_protein	180,211	dihydropyrimidine dehydrogenase
26216193_4	Pharmacokinetic_phenotype	53,78	5-fluorouracil metabolism
26216193_4	Limited_variation	159,216	polymorphisms in the dihydropyrimidine dehydrogenase gene
15589566_3	Limited_variation	83,100	5-HTTLPR S allele
15589566_3	Gene_or_protein	83,91	5-HTTLPR
15589566_3	Chemical	104,111	alcohol
15589566_3	Disease	104,122	alcohol -dependent
15589566_3	Phenotype	58,74	suicide attempts
20663035_7	Chemical	15,26	Kainic acid
20663035_7	Phenotype	68,92	expression of c-fos mRNA
20663035_7	Genomic_factor	82,92	c-fos mRNA
20663035_7	Gene_or_protein	82,87	c-fos
22521649_12	Disease	45,56	lung cancer
22521649_12	Gene_or_protein	71,75	EGFR
22521649_12	Chemical	107,113	taxane
22521649_12	Chemical	119,130	gemcitabine
22521649_12	Limited_variation	71,86	EGFR -mutations
22521649_12	Phenotype	98,101	PFS
22521649_12	Chemical	148,179	platinum -based doublet regimen
22521649_12	Chemical	148,156	platinum
25589624_2	Chemical	10,19	Veliparib
25589624_2	Gene_or_protein	24,28	PARP
25589624_2	Chemical	97,113	cyclophosphamide
25589624_2	Gene_or_protein	131,135	BRCA
25589624_2	Chemical	10,19,72,113	Veliparib in combination with oral cyclophosphamide
25589624_2	Disease	131,156	BRCA -mutant solid tumors
25589624_2	Chemical	24,38	PARP inhibitor
25589624_2	Limited_variation	131,143	BRCA -mutant
12700947_8	Gene_or_protein	95,98	CEA
12700947_8	Phenotype	89,107	anti- CEA immunity
12700947_8	Chemical	40,52	CpG ODN 1826
12700947_8	Chemical	25,28	3H1
12700947_8	Chemical	25,52	3H1 mixed with CpG ODN 1826
26325438_9	Chemical	4,14	tacrolimus
26325438_9	Gene_or_protein	26,32	CYP3A5
26325438_9	Limited_variation	17,25	rs776746
26325438_9	Gene_or_protein	47,53	CYP3A5
26325438_9	Gene_or_protein	110,116	CYP3A5
26325438_9	Haplotype	26,42	CYP3A5 * 3 / * 3
26325438_9	Haplotype	47,63	CYP3A5 * 3 / * 1
26325438_9	Haplotype	110,126	CYP3A5 * 1 / * 1
26325438_9	Pharmacodynamic_phenotype	92,104	blood levels
24651609_2	Chemical	79,82	OEA
24651609_2	Chemical	56,76	N-oleoylethanolamine
24651609_2	Gene_or_protein	130,178	peroxisome proliferator-activated receptor alpha
24651609_2	Gene_or_protein	181,186	PPARa
24651609_2	Chemical	203,220	sulfamoyl analogs
19179882_9	Phenotype	21,36	MDR2 expression
19179882_9	Gene_or_protein	21,25	MDR2
19179882_9	Chemical	93,112	phosphatidylcholine
19179882_9	Gene_or_protein	147,151	MDR2
19179882_9	Phenotype	88,120	bile phosphatidylcholine content
19179882_9	Chemical	8,11	TPN
20424113_3	Chemical	50,56	copper
20424113_3	Chemical	59,61	Cu
20424113_3	Chemical	79,82	DSF
20424113_3	Chemical	66,76	disulfiram
20424113_3	Disease	150,163	breast cancer
20424113_3	Genomic_variation	194,207	PIK3CA status
20424113_3	Gene_or_protein	194,200	PIK3CA
20424113_3	Chemical	105,124	antialcoholism drug
20424113_3	Phenotype	150,175	breast cancer cell growth
15259893_9	Chemical	30,40	amprenavir
15259893_9	Limited_variation	67,71	I50V
15259893_9	Chemical	110,119	lopinavir
15259893_9	Pharmacodynamic_phenotype	0,40	Resistance during exposure to amprenavir
15259893_9	Pharmacodynamic_phenotype	96,119	resistance to lopinavir
25894531_2	Gene_or_protein	118,123	ADRB2
25894531_2	Limited_variation	126,135	rs1042713
25894531_2	Limited_variation	142,151	rs1042714
25894531_2	Gene_or_protein	187,193	SCNN1A
25894531_2	Limited_variation	196,205	rs2228576
25894531_2	Pharmacodynamic_phenotype	211,265	cycling performance after the inhalation of salbutamol
25894531_2	Gene_or_protein	88,115	adrenergic b2-receptor gene
25894531_2	Gene_or_protein	158,184	epithelial Na channel gene
25894531_2	Chemical	255,265	salbutamol
25894531_2	Limited_variation	40,115	single nucleotide polymorphisms ( SNPs ) in the adrenergic b2-receptor gene
25894531_2	Limited_variation	40,87,158,184	single nucleotide polymorphisms ( SNPs ) in the epithelial Na channel gene
17089107_1	Gene_or_protein	10,16	CYP2D6
17089107_1	Pharmacodynamic_phenotype	51,62	hypersomnia
17089107_1	Chemical	25,41	H1-antihistamine
17089107_1	Haplotype	10,21	CYP2D6 * 10
17089107_1	Pharmacodynamic_phenotype	25,62	H1-antihistamine -induced hypersomnia
24285256_8	Chemical	30,39	sirolimus
24285256_8	Limited_variation	80,93	ABCB1 1236C>T
24285256_8	Gene_or_protein	80,85	ABCB1
24285256_8	Limited_variation	80,85,96,106	ABCB1 2677G>T /A
24285256_8	Limited_variation	80,85,111,118	ABCB1 3435C>T
24285256_8	Pharmacokinetic_phenotype	30,51	sirolimus C0/D ratios
21790903_11	Limited_variation	141,162	polymorphisms in CNR1
21790903_11	Gene_or_protein	158,162	CNR1
21790903_11	Chemical	238,245	cocaine
21790903_11	Disease	238,255	cocaine addiction
21790903_11	Disease	56,58	CD
21790903_11	Disease	70,84	drugs of abuse
21790903_11	Pharmacodynamic_phenotype	180,218	susceptibility to substance dependence
19299582_7	Chemical	25,33	sirtinol
19299582_7	Gene_or_protein	44,49	SIRT1
19299582_7	Gene_or_protein	79,84	SIRT1
19299582_7	Gene_or_protein	108,113	SIRT1
19299582_7	Gene_or_protein	124,129	SIRT1
19299582_7	Gene_or_protein	148,157	TNF-alpha
19299582_7	Gene_or_protein	198,203	SIRT1
19299582_7	Phenotype	222,241	TNF-alpha secretion
19299582_7	Gene_or_protein	222,231	TNF-alpha
19299582_7	Gene_or_protein	124,135	SIRT1 shRNA
19299582_7	Chemical	44,59	SIRT1 inhibitor
19299582_7	Genomic_variation	65,84	knocking down SIRT1
25035107_1	Phenotype	87,101	MAO-B activity
25035107_1	Gene_or_protein	87,92	MAO-B
25035107_1	Chemical	107,114	alcohol
25035107_1	Chemical	130,137	alcohol
25035107_1	Disease	107,125	alcohol dependence
25035107_1	Phenotype	130,168	alcohol dependence -related phenotypes
25035107_1	Limited_variation	15,73	gene polymorphisms encoding dopaminergic system components
25035107_1	Gene_or_protein	43,73	dopaminergic system components
25035107_1	Disease	130,148	alcohol dependence
21561767_1	Chemical	13,58	5-(arenethynyl) hetero-monocyclic derivatives
21561767_1	Limited_variation	105,128	T315I gatekeeper mutant
21561767_1	Gene_or_protein	83,90	BCR-ABL
8963481_9	Limited_variation	76,95	CYP2D6 polymorphism
8963481_9	Gene_or_protein	76,82	CYP2D6
8963481_9	Chemical	107,123	dextromethorphan
8963481_9	Pharmacokinetic_phenotype	168,185	poor metabolizers
8963481_9	Pharmacokinetic_phenotype	194,216	extensive metabolizers
8963481_9	Phenotype	107,135	dextromethorphan phenotyping
8963481_9	Pharmacokinetic_phenotype	6,32	pharmacokinetic parameters
18666383_8	Phenotype	28,55	low levels of TPMT activity
18666383_8	Gene_or_protein	42,46	TPMT
18666383_8	Pharmacodynamic_phenotype	110,118	toxicity
18666383_8	Chemical	90,100	thiopurine
18666383_8	Pharmacodynamic_phenotype	90,118	thiopurine -induced toxicity
18666383_8	Pharmacodynamic_phenotype	127,143	myelosuppression
18666383_8	Phenotype	216,234	very high activity
11361019_12	Phenotype	27,40	cell survival
11361019_12	Chemical	63,70	CB 1954
11361019_12	Gene_or_protein	100,113	DT-diaphorase
11361019_12	Phenotype	100,122	DT-diaphorase activity
22137367_6	Phenotype	22,33	IGF-1 value
22137367_6	Gene_or_protein	22,27	IGF-1
22137367_6	Chemical	54,57	rGH
26807589_1	Limited_variation	2,41	Single-Nucleotide Polymorphism in ABCC4
26807589_1	Gene_or_protein	36,41	ABCC4
26807589_1	Chemical	61,70	Tenofovir
26807589_1	Disease	61,104	Tenofovir -Related Beta2 -Microglobulinuria
26807589_1	Disease	127,132	HIV-1
22297576_10	Chemical	14,18	5-HT
22297576_10	Chemical	57,61	GABA
22297576_10	Chemical	64,73	glutamate
22297576_10	Chemical	78,81	CRF
22297576_10	Phenotype	102,122	aggressive behaviors
22297576_10	Phenotype	0,26	Modulation of 5-HT neurons
18187595_3	Gene_or_protein	18,25	SLCO1B1
18187595_3	Limited_variation	18,44	SLCO1B1 c. 521 CC genotype
18187595_3	Pharmacokinetic_phenotype	110,173	mean area under the plasma repaglinide concentration-time curve
18187595_3	Chemical	137,148	repaglinide
18187595_3	Pharmacokinetic_phenotype	176,179	AUC
18187595_3	Limited_variation	220,228,263,272	c. 521TC genotypes
18187595_3	Limited_variation	243,251,263,272	c. 521TT genotypes
17178263_13	Gene_or_protein	17,22	PTGS2
17178263_13	Limited_variation	17,61	PTGS2 -765G>C single-nucleotide polymorphism
17178263_13	Gene_or_protein	80,85	COX-2
17178263_13	Chemical	108,117	celecoxib
17178263_13	Pharmacodynamic_phenotype	80,117	COX-2 inhibitory effects of celecoxib
11340648_2	Gene_or_protein	0,14	Neuropeptide Y
11340648_2	Gene_or_protein	17,20	NPY
11340648_2	Chemical	95,103	morphine
11340648_2	Phenotype	75,114	behavioral signs of morphine withdrawal
20303013_3	Gene_or_protein	75,80	GSTM1
20303013_3	Gene_or_protein	83,88	GSTT1
20303013_3	Gene_or_protein	95,100	GSTP1
20303013_3	Limited_variation	61,80	polymorphisms GSTM1
20303013_3	Limited_variation	61,74,83,88	polymorphisms GSTT1
20303013_3	Limited_variation	61,74,95,100	polymorphisms GSTP1
20303013_3	Pharmacodynamic_phenotype	104,122	treatment response
20303013_3	Disease	150,187	de novo diffuse large B-cell lymphoma
20303013_3	Chemical	207,279	rituximab plus cyclophosphamide / doxorubicin / vincristine / prednisone
20303013_3	Chemical	207,216	rituximab
20303013_3	Chemical	222,238	cyclophosphamide
20303013_3	Chemical	241,252	doxorubicin
20303013_3	Chemical	255,266	vincristine
20303013_3	Chemical	269,279	prednisone
23159001_11	Chemical	16,38	icotinib hydrochloride
23159001_11	Limited_variation	103,116	EGFR mutation
23159001_11	Gene_or_protein	103,107	EGFR
23159001_11	Pharmacodynamic_phenotype	4,38	efficacy of icotinib hydrochloride
23159001_11	Phenotype	59,82	ECOG performance status
23159001_11	Phenotype	121,125	rash
23159001_11	Phenotype	85,100	smoking history
23792648_11	Chemical	56,67	doxorubicin
23792648_11	Chemical	70,81	oxaliplatin
23792648_11	Chemical	86,98	methotrexate
23792648_11	Disease	112,129	stomach carcinoma
23792648_11	Gene_or_protein	159,166	BCL2L12
23792648_11	Gene_or_protein	169,172	BAX
23792648_11	Gene_or_protein	179,184	BCL-2
23792648_11	Phenotype	159,166,185,204	BCL2L12 expression profiles
23792648_11	Phenotype	169,172,185,204	BAX expression profiles
23792648_11	Phenotype	179,204	BCL-2 expression profiles
23792648_11	Chemical	254,266	chemotherapy
23792648_11	Phenotype	212,266	molecular signaling pathways triggered by chemotherapy
23792648_11	Pharmacodynamic_phenotype	26,67	growth suppressive effects of doxorubicin
23792648_11	Pharmacodynamic_phenotype	26,52,70,81	growth suppressive effects oxaliplatin
23792648_11	Pharmacodynamic_phenotype	26,52,86,98	growth suppressive effects methotrexate
15900282_1	Limited_variation	7,55	genetic variants of microsomal epoxide hydrolase
15900282_1	Gene_or_protein	27,55	microsomal epoxide hydrolase
15900282_1	Chemical	63,71	warfarin
15900282_1	Gene_or_protein	111,130	cytochrome P450 2C9
15900282_1	Pharmacodynamic_phenotype	63,89	warfarin dose requirements
15900282_1	Pharmacodynamic_phenotype	101,130	effect of cytochrome P450 2C9
23415432_1	Phenotype	0,25	Lipoprotein abnormalities
23415432_1	Phenotype	51,80	lipoprotein lipase deficiency
23415432_1	Gene_or_protein	51,69	lipoprotein lipase
23415432_1	Chemical	121,129	orlistat
15790782_1	Gene_or_protein	0,19	Cytochrome P450 2C9
15790782_1	Gene_or_protein	22,28	CYP2C9
15790782_1	Gene_or_protein	35,62	vitamin K epoxide reductase
15790782_1	Gene_or_protein	65,71	VKORC1
15790782_1	Pharmacodynamic_phenotype	103,128	acenocoumarol sensitivity
15790782_1	Chemical	103,116	acenocoumarol
15790782_1	Limited_variation	0,30,74,83	Cytochrome P450 2C9 ( CYP2C9 ) genotypes
15790782_1	Limited_variation	35,83	vitamin K epoxide reductase ( VKORC1 ) genotypes
15707696_5	Disease	45,60	chronic ethanol
15707696_5	Gene_or_protein	85,88	CpG
15707696_5	Phenotype	186,208	expression of the NR2B
15707696_5	Gene_or_protein	204,208	NR2B
15707696_5	Phenotype	68,88	demethylation in CpG
15707696_5	Genomic_factor	104,125	regions ( 5843-6276 )
15707696_5	Genomic_factor	130,143	( 6477-6763 )
15707696_5	Chemical	53,60	ethanol
19530960_6	Haplotype	0,15	DPYD haplotypes
19530960_6	Gene_or_protein	0,4	DPYD
19530960_6	Chemical	65,69	5-FU
19530960_6	Pharmacodynamic_phenotype	65,78	5-FU toxicity
15834213_3	Gene_or_protein	43,49	GABRA2
15834213_3	Chemical	69,76	alcohol
15834213_3	Chemical	111,118	alcohol
15834213_3	Disease	69,87	alcohol dependence
15834213_3	Disease	111,129	alcohol -dependent
18829024_9	Limited_variation	58,77	StAR gene mutations
18829024_9	Gene_or_protein	58,62	StAR
18829024_9	Chemical	100,109	estrogens
18829024_9	Phenotype	19,28	Pregnancy
18829024_9	Phenotype	128,146	placental function
18084327_10	Chemical	38,45	AZD1152
18084327_10	Disease	65,70	tumor
18084327_10	Gene_or_protein	152,155	p53
18084327_10	Disease	152,173	p53 -deficient cancer
18084327_10	Phenotype	152,166	p53 -deficient
18324624_6	Phenotype	20,33,44,47	expression of MCJ
18324624_6	Gene_or_protein	34,39	MDR-1
18324624_6	Gene_or_protein	44,47	MCJ
18324624_6	Pharmacodynamic_phenotype	65,107	sensitivity of Sk-Ov-3 cells to paclitaxel
18324624_6	Chemical	97,107	paclitaxel
18324624_6	Phenotype	130,147	expression of Src
18324624_6	Gene_or_protein	144,147	Src
18324624_6	Gene_or_protein	150,155	Bcl-2
18324624_6	Gene_or_protein	160,168	Bcl-X(L)
18324624_6	Pharmacodynamic_phenotype	183,226	sensitivity of Sk-Ov-3 cells to carboplatin
18324624_6	Chemical	215,226	carboplatin
18324624_6	Phenotype	20,39	expression of MDR-1
18324624_6	Phenotype	130,143,150,155	expression of Bcl-2
18324624_6	Phenotype	130,143,160,168	expression of Bcl-X(L)
18519658_5	Disease	0,13	Breast cancer
18519658_5	Limited_variation	54,84	Asp299Gly polymorphism of TLR4
18519658_5	Gene_or_protein	80,84	TLR4
18519658_5	Chemical	118,151	anthracycline -based chemotherapy
18519658_5	Chemical	118,131	anthracycline
25687192_2	Limited_variation	26,93	single-nucleotide polymorphism ( SNP ) rs12979860 in the IL28B gene
25687192_2	Limited_variation	65,75	rs12979860
25687192_2	Gene_or_protein	83,88	IL28B
25687192_2	Disease	188,191	CHC
25687192_2	Disease	229,232	CHC
25687192_2	Chemical	337,350	peginterferon
25687192_2	Chemical	356,365	ribavirin
25687192_2	Disease	166,185	chronic hepatitis C
25687192_2	Pharmacodynamic_phenotype	129,193	virological response to treatment of chronic hepatitis C ( CHC )
25687192_2	Chemical	337,365	peginterferon plus ribavirin
25687192_2	Chemical	153,185	treatment of chronic hepatitis C
25687192_2	Limited_variation	251,269	favorable C allele
25687192_2	Pharmacodynamic_phenotype	298,318	virological response
25687192_2	Pharmacodynamic_phenotype	129,149	virological response
16041239_4	Gene_or_protein	85,90	ABCB1
16041239_4	Gene_or_protein	98,103	ABCC1
16041239_4	Gene_or_protein	112,117	ABCC2
16041239_4	Gene_or_protein	130,135	ABCG2
16041239_4	Chemical	251,261	nelfinavir
16041239_4	Limited_variation	77,90	SNPs in ABCB1
16041239_4	Limited_variation	77,81,95,103	SNPs in ABCC1
16041239_4	Limited_variation	77,81,109,117	SNPs in ABCC2
16041239_4	Limited_variation	77,81,127,135	SNPs in ABCG2
16041239_4	Haplotype	153,163	haplotypes
16041239_4	Limited_variation	40,71	single nucleotide polymorphisms
16041239_4	Genomic_variation	208,224	genetic variants
26116794_11	Gene_or_protein	42,48	GABRA2
26116794_11	Pharmacodynamic_phenotype	57,104	alcohol dependence -related aggressive behavior
26116794_11	Chemical	57,64	alcohol
26116794_11	Disease	57,75	alcohol dependence
26116794_11	Phenotype	85,104	aggressive behavior
19820367_1	Limited_variation	26,40	K-ras mutation
19820367_1	Gene_or_protein	26,31	K-ras
19820367_1	Chemical	44,53	tamoxifen
19820367_1	Disease	77,90	breast cancer
22708928_2	Gene_or_protein	36,43	SULT1A1
22708928_2	Gene_or_protein	13,33	Sulfotransferase 1A1
22708928_2	Chemical	81,100	4-hydroxy-tamoxifen
22708928_2	Chemical	103,111	4-OH-TAM
22708928_2	Chemical	164,173	tamoxifen
22708928_2	Chemical	176,179	TAM
22708928_2	Pharmacokinetic_phenotype	66,100	elimination of 4-hydroxy-tamoxifen
15341704_2	Chemical	0,8	Warfarin
15341704_2	Disease	84,106	thromboembolic disease
15341704_2	Gene_or_protein	137,143	CYP2C9
15341704_2	Chemical	30,43	anticoagulant
15341704_2	Gene_or_protein	157,183	hepatic microsomal enzymes
24672032_3	Limited_variation	0,48	IFNL3 ( lambda-3 interferon gene ) polymorphisms
24672032_3	Gene_or_protein	8,27	lambda-3 interferon
24672032_3	Gene_or_protein	0,5	IFNL3
24672032_3	Phenotype	57,78	expression of miR-122
24672032_3	Gene_or_protein	71,78	miR-122
24672032_3	Chemical	188,197	ribavirin
24672032_3	Disease	237,240	CHC
24672032_3	Phenotype	105,135	sustained virological response
24672032_3	Phenotype	138,141	SVR
24672032_3	Chemical	162,197	pegylated interferon plus ribavirin
24672032_3	Disease	223,234	hepatitis C
24672032_3	Chemical	162,182	pegylated interferon
21418871_10	Disease	13,27	Gastric cancer
21418871_10	Limited_variation	42,56	ERCC1 -118 C/C
21418871_10	Gene_or_protein	42,47	ERCC1
21418871_10	Gene_or_protein	70,75	XRCC1
21418871_10	Chemical	122,162	oxaliplatin -based adjuvant chemotherapy
21418871_10	Limited_variation	70,85	XRCC1 -399A / G
21418871_10	Limited_variation	70,75,89,92	XRCC1 A/A
21418871_10	Chemical	122,133	oxaliplatin
23237192_10	Limited_variation	28,36	1494C> T
23237192_10	Disease	89,93	NSHL
23237192_10	Chemical	127,141	aminoglycoside
23237192_10	Phenotype	169,201	hearing of the mutation carriers
23237192_10	Limited_variation	184,192	mutation
24401102_11	Limited_variation	28,34	rs4952
24401102_11	Chemical	70,78	nicotine
24401102_11	Limited_variation	133,143	rs13273442
24401102_11	Disease	70,89	nicotine dependence
24401102_11	Limited_variation	8,25	SNP in the region
18784465_7	Chemical	49,57	abacavir
18784465_7	Chemical	60,70	lamivudine
18784465_7	Chemical	77,86	efavirenz
18784465_7	Gene_or_protein	108,113	HLA-B
18784465_7	Gene_or_protein	153,158	HLA-B
18784465_7	Chemical	191,200	tenofovir
18784465_7	Chemical	203,216	emtricitabine
18784465_7	Chemical	223,232	efavirenz
18784465_7	Limited_variation	108,120	HLA-B * 5701
18784465_7	Limited_variation	153,165	HLA-B * 5701
22935222_7	Chemical	39,49	naringenin
22935222_7	Gene_or_protein	60,66	CYP1B1
22935222_7	Phenotype	91,106	CYP1A1 activity
22935222_7	Gene_or_protein	91,97	CYP1A1
19536092_9	Gene_or_protein	29,32	ATM
19536092_9	Gene_or_protein	37,42	ERCC5
19536092_9	Chemical	72,83	oxaliplatin
19536092_9	Disease	96,99	ACC
19536092_9	Pharmacodynamic_phenotype	72,92	oxaliplatin efficacy
19398669_11	Limited_variation	14,51	Genetic polymorphism 677 C>T on MTHFR
19398669_11	Gene_or_protein	46,51	MTHFR
19398669_11	Chemical	69,75	5-MTHF
19398669_11	Chemical	86,98	homocysteine
19398669_11	Chemical	175,181	5-MTHF
19398669_11	Chemical	187,199	homocysteine
19398669_11	Pharmacodynamic_phenotype	147,181,200,216	chronic effects of vascular 5-MTHF on vascular wall
19398669_11	Pharmacodynamic_phenotype	147,165,187,216	chronic effects of homocysteine on vascular wall
21288822_9	Gene_or_protein	45,51	pfmdr1
21288822_9	Chemical	55,66	amodiaquine
21288822_9	Pharmacodynamic_phenotype	71,92	mefloquine resistance
21288822_9	Chemical	71,81	mefloquine
21288822_9	Gene_or_protein	122,128	pfmdr1
21288822_9	Pharmacodynamic_phenotype	55,66,82,92	amodiaquine resistance
17112802_1	Limited_variation	0,15	CYP2A6 genotype
17112802_1	Gene_or_protein	0,6	CYP2A6
17112802_1	Chemical	63,71	nicotine
17112802_1	Pharmacokinetic_phenotype	39,71	disposition kinetics of nicotine
17112802_1	Pharmacokinetic_phenotype	24,34,51,71	metabolism kinetics of nicotine
27864013_5	Limited_variation	143,166	BRAF ( V600E ) - mutant
27864013_5	Gene_or_protein	143,147	BRAF
27864013_5	Gene_or_protein	170,174	BRAF
27864013_5	Limited_variation	170,193	BRAF ( V600K ) - mutant
27864013_5	Disease	170,213	BRAF ( V600K ) - mutant metastatic melanoma
27864013_5	Chemical	248,258	dabrafenib
27864013_5	Chemical	283,293	trametinib
27864013_5	Disease	143,166,194,213	BRAF ( V600E ) - mutant metastatic melanoma
27864013_5	Chemical	248,258,278,293	dabrafenib plus trametinib
14558439_3	Chemical	19,70	4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline
14558439_3	Gene_or_protein	4,8	JAK3
14558439_3	Chemical	73,88	CAS 202475-60-3
14558439_3	Gene_or_protein	178,182	JAK3
14558439_3	Chemical	91,98	JANEX-1
14558439_3	Chemical	101,109	WHI-P131
14558439_3	Phenotype	126,155	rejection of islet allografts
14558439_3	Chemical	4,18	JAK3 inhibitor
14558439_3	Phenotype	178,200	JAK3 expression status
20015348_11	Chemical	67,70	GCV
20015348_11	Phenotype	112,139	caspase3 protein expression
20015348_11	Gene_or_protein	112,120	caspase3
20015348_11	Chemical	59,64	BI-TK
20015348_11	Chemical	59,70	BI-TK / GCV
16146333_7	Chemical	182,199	estrone-3-sulfate
16146333_7	Chemical	202,243	17beta-estradiol 17-(beta-D-glucuronide )
16146333_7	Chemical	250,262	methotrexate
16146333_7	Pharmacodynamic_phenotype	34,76	resistance against chemotherapeutic agents
16146333_7	Chemical	53,76	chemotherapeutic agents
16146333_7	Gene_or_protein	79,83	BCRP
16146333_7	Chemical	125,142	organic molecules
19273354_4	Disease	64,72	diabetes
19273354_4	Limited_variation	80,94	TCF1 mutations
19273354_4	Gene_or_protein	80,84	TCF1
19273354_4	Pharmacodynamic_phenotype	133,172	hypoglycaemic effects of sulphonylureas
19273354_4	Limited_variation	179,185,195,204	KCNJ11 mutations
19273354_4	Gene_or_protein	179,185	KCNJ11
19273354_4	Gene_or_protein	189,194	ABCC8
19273354_4	Chemical	214,228	sulphonylureas
19273354_4	Limited_variation	189,204	ABCC8 mutations
19273354_4	Chemical	158,172	sulphonylureas
19273354_4	Chemical	253,260	insulin
17919354_6	Limited_variation	18,31	HFE mutations
17919354_6	Gene_or_protein	18,21	HFE
17919354_6	Chemical	34,45	anastrozole
17919354_6	Chemical	50,59	tamoxifen
17919354_6	Disease	144,157	breast cancer
17919354_6	Chemical	76,88	chemotherapy
25350163_8	Limited_variation	39,64	F508del - CFTR homozygous
25350163_8	Gene_or_protein	49,53	CFTR
25350163_8	Disease	39,67	F508del - CFTR homozygous CF
25350163_8	Chemical	83,117	combination of cysteamine and EGCG
25350163_8	Chemical	113,117	EGCG
25350163_8	Gene_or_protein	127,132	BECN1
25350163_8	Phenotype	143,156	SQSTM1 levels
25350163_8	Gene_or_protein	143,149	SQSTM1
25350163_8	Phenotype	170,183	CFTR function
25350163_8	Gene_or_protein	170,174	CFTR
25350163_8	Chemical	253,261	chloride
25350163_8	Gene_or_protein	336,351	TNF / TNF-alpha
25350163_8	Disease	354,359	tumor
25350163_8	Gene_or_protein	390,422	chemokine [C-X-C motif] ligand 8
25350163_8	Gene_or_protein	382,387	CXCL8
25350163_8	Phenotype	459,462,473,487	TNF protein levels
25350163_8	Gene_or_protein	459,462	TNF
25350163_8	Gene_or_protein	467,472	CXCL8
25350163_8	Chemical	98,108	cysteamine
25350163_8	Pharmacodynamic_phenotype	253,285	chloride concentrations in sweat
25350163_8	Phenotype	127,132,150,156	BECN1 levels
25350163_8	Phenotype	323,351,425,436	abundance of TNF / TNF-alpha transcripts
25350163_8	Gene_or_protein	354,375	tumor necrosis factor
25350163_8	Phenotype	323,335,382,387,425,436	abundance of CXCL8 transcripts
25350163_8	Phenotype	467,487	CXCL8 protein levels
16115938_12	Disease	88,93	tumor
16115938_12	Disease	132,138	cancer
16115938_12	Chemical	7,61	antisense PKA RIalpha and CpG immunomer in combination
16115938_12	Chemical	33,46	CpG immunomer
16115938_12	Chemical	88,116	tumor -targeted therapeutics
16115938_12	Chemical	7,28	antisense PKA RIalpha
20028383_1	Chemical	17,27	irinotecan
20028383_1	Chemical	32,45	doxifluridine
20028383_1	Disease	50,78	metastatic colorectal cancer
20028383_1	Gene_or_protein	95,101	UGT1A1
20028383_1	Chemical	17,45	irinotecan and doxifluridine
20028383_1	Haplotype	95,106	UGT1A1 * 28
19884861_11	Limited_variation	25,39	EGFR mutations
19884861_11	Gene_or_protein	25,29	EGFR
19884861_11	Disease	150,155	NSCLC
19884861_11	Chemical	194,203	erlotinib
19884861_11	Chemical	166,175	docetaxel
19884861_11	Phenotype	105,123	favorable outcomes
19884861_11	Chemical	166,203	docetaxel plus intercalated erlotinib
24040330_2	Chemical	46,57	glutathione
24040330_2	Gene_or_protein	99,104	GSTT1
24040330_2	Gene_or_protein	107,112	GSTP1
24040330_2	Limited_variation	115,121	rs1695
24040330_2	Limited_variation	132,138	rs4925
24040330_2	Gene_or_protein	124,129	GSTO1
24040330_2	Gene_or_protein	141,146	GSTO2
24040330_2	Limited_variation	149,157	rs156697
24040330_2	Gene_or_protein	160,165	GSTM1
24040330_2	Gene_or_protein	168,173	GSTA1
24040330_2	Limited_variation	176,185	rs3957357
24040330_2	Disease	239,253	bladder cancer
24040330_2	Gene_or_protein	46,69	glutathione transferase
24040330_2	Gene_or_protein	72,75	GST
24040330_2	Limited_variation	46,96	glutathione transferase ( GST ) gene polymorphisms
24040330_2	Phenotype	197,205	survival
24040330_2	Chemical	291,303	chemotherapy
24040330_2	Pharmacodynamic_phenotype	281,303	effect on chemotherapy
23918539_1	Limited_variation	0,26	Genetic variation in NOS2A
23918539_1	Gene_or_protein	21,26	NOS2A
23918539_1	Chemical	101,110	ribavirin
23918539_1	Disease	123,142	chronic hepatitis C
23918539_1	Pharmacodynamic_phenotype	48,118	sustained virological response to peginterferon plus ribavirin therapy
23918539_1	Chemical	82,95	peginterferon
23918539_1	Chemical	82,118	peginterferon plus ribavirin therapy
12893983_9	Gene_or_protein	32,36	GNB3
12893983_9	Limited_variation	32,55	GNB3 C825T polymorphism
12893983_9	Disease	103,108	obese
12893983_9	Chemical	143,154	sibutramine
19663671_7	Limited_variation	22,31,94,107	c.1236C>T SNPs of ABCB1
19663671_7	Limited_variation	46,55,94,107	c.2677G>T SNPs of ABCB1
19663671_7	Limited_variation	72,81,94,107	c.3435C>T SNPs of ABCB1
19663671_7	Gene_or_protein	102,107	ABCB1
19663671_7	Chemical	166,175	clozapine
19663671_7	Chemical	180,192	norclozapine
19663671_7	Chemical	369,378	clozapine
19663671_7	Pharmacodynamic_phenotype	149,175	plasma levels of clozapine
19663671_7	Pharmacodynamic_phenotype	149,165,180,192	plasma levels of norclozapine
19663671_7	Genomic_factor	34,41	exon 12
19663671_7	Genomic_factor	58,65	exon 21
19663671_7	Genomic_factor	84,91	exon 26
19891556_6	Chemical	47,58	clopidogrel
19891556_6	Limited_variation	113,129	CYP2C19 genotype
19891556_6	Gene_or_protein	113,120	CYP2C19
19891556_6	Chemical	133,144	clopidogrel
19891556_6	Pharmacokinetic_phenotype	133,161	clopidogrel pharmacokinetics
19891556_6	Pharmacodynamic_phenotype	133,144,164,180	clopidogrel pharmacodynamics
19891556_6	Pharmacodynamic_phenotype	133,144,185,202	clopidogrel clinical response
11238813_6	Chemical	4,21	diallyl disulfide
11238813_6	Gene_or_protein	46,51	H-ras
11238813_6	Gene_or_protein	120,123	p21
11238813_6	Gene_or_protein	126,131	H-ras
11238813_6	Pharmacodynamic_phenotype	4,60	diallyl disulfide -mediated inhibition of H-ras oncogene
11238813_6	Phenotype	106,154	inhibition of p21 ( H-ras ) membrane association
11238813_6	Phenotype	73,85	tumor growth
11238813_6	Disease	73,78	tumor
11238813_6	Pharmacodynamic_phenotype	32,60	inhibition of H-ras oncogene
22942289_9	Chemical	31,37	VX-770
22942289_9	Gene_or_protein	55,59	CFTR
19396436_11	Gene_or_protein	14,18	DRD3
19396436_11	Limited_variation	14,40	DRD3 Ser9Gly polymorphisms
19396436_11	Pharmacodynamic_phenotype	91,114	efficacy of pramipexole
19396436_11	Chemical	103,114	pramipexole
19396436_11	Disease	140,142	PD
23736108_9	Gene_or_protein	83,88	TAPBP
23736108_9	Limited_variation	89,98	rs2071888
23736108_9	Limited_variation	192,201	rs1059288
23736108_9	Disease	252,256	AERD
23736108_9	Chemical	275,282	aspirin
23736108_9	Disease	293,299	asthma
23736108_9	Disease	275,299	aspirin -tolerant asthma
26773964_3	Limited_variation	55,74	CYP3A5 polymorphism
26773964_3	Gene_or_protein	55,61	CYP3A5
26773964_3	Phenotype	94,108	CYP3A activity
26773964_3	Gene_or_protein	94,99	CYP3A
26773964_3	Chemical	188,209	4b-hydroxycholesterol
26773964_3	Pharmacodynamic_phenotype	164,209	plasma concentration of 4b-hydroxycholesterol
26773964_3	Disease	122,144	kidney transplantation
22418828_5	Gene_or_protein	22,29	CYP2C19
22418828_5	Chemical	138,150	pantoprazole
22418828_5	Gene_or_protein	180,187	CYP2C19
22418828_5	Haplotype	22,39	CYP2C19 * 2 / * 2
22418828_5	Pharmacodynamic_phenotype	113,150	plasma concentrations of pantoprazole
22418828_5	Haplotype	180,197	CYP2C19 * 1 / * 1
22418828_5	Limited_variation	168,197	wild-type ( CYP2C19 * 1 / * 1
21908221_3	Chemical	49,64	hormone therapy
21908221_3	Chemical	67,69	HT
21908221_3	Chemical	109,115	8-OHdG
21908221_3	Chemical	148,154	8-OHdG
21908221_3	Gene_or_protein	181,185	OGG1
21908221_3	Limited_variation	181,191	OGG1 S326C
21908221_3	Chemical	239,241	HT
21908221_3	Pharmacodynamic_phenotype	101,122	urinary 8-OHdG levels
21908221_3	Pharmacodynamic_phenotype	93,98,109,122	blood 8-OHdG levels
21908221_3	Pharmacodynamic_phenotype	139,154	level of 8-OHdG
19481104_8	Gene_or_protein	50,55	Gsta2
19481104_8	Gene_or_protein	58,65	Sult2a1
19481104_8	Gene_or_protein	68,72	Fgl1
19481104_8	Chemical	148,154	CCl(4)
19481104_8	Gene_or_protein	77,79	C6
19481104_8	Pharmacodynamic_phenotype	148,171	CCl(4) - hepatotoxicity
19391036_8	Gene_or_protein	32,38	A1298C
19391036_8	Limited_variation	54,72	C677T polymorphism
19391036_8	Chemical	92,95	MTX
19391036_8	Pharmacodynamic_phenotype	92,113	MTX -related toxicity
18654768_9	Gene_or_protein	60,67	CYP2C19
18654768_9	Chemical	138,150	escitalopram
18654768_9	Chemical	154,164	omeprazole
18654768_9	Pharmacokinetic_phenotype	154,173	omeprazole kinetics
18654768_9	Pharmacokinetic_phenotype	138,150,165,173	escitalopram kinetics
18654768_9	Chemical	60,78	CYP2C19 substrates
18654768_9	Limited_variation	186,195	genotypes
22401810_16	Limited_variation	19,39	FSHR gene variations
22401810_16	Gene_or_protein	19,23	FSHR
22401810_16	Limited_variation	48,57	Asn680Ser
22401810_16	Limited_variation	72,81	Thr449Ile
22401810_16	Limited_variation	88,97	Ile160Thr
22401810_16	Gene_or_protein	223,226	AMH
22401810_16	Limited_variation	60,69	Ala189Val
22401810_16	Pharmacodynamic_phenotype	143,174	response to fertility treatment
22401810_16	Phenotype	189,208	low ovarian reserve
27217047_12	Gene_or_protein	95,101	CYP3A5
27217047_12	Gene_or_protein	121,127	CYP3A5
27217047_12	Haplotype	121,131	CYP3A5 * 1
27217047_12	Pharmacodynamic_phenotype	18,41	daily dosage of Tac -QD
27217047_12	Haplotype	95,111	CYP3A5 * 3 / * 3
27217047_12	Chemical	34,41	Tac -QD
26418006_3	Chemical	25,36	gemcitabine
26418006_3	Phenotype	58,90	activities of cytidine deaminase
26418006_3	Gene_or_protein	93,96	CDA
26418006_3	Gene_or_protein	72,90	cytidine deaminase
26418006_3	Gene_or_protein	148,153	hENT1
26418006_3	Gene_or_protein	158,178	deoxycytidine kinase
26418006_3	Gene_or_protein	181,184	DCK
26418006_3	Gene_or_protein	193,220	ribonucleotide reductase M1
26418006_3	Gene_or_protein	223,227	RRM1
26418006_3	Gene_or_protein	107,145	equilibrative nucleoside transporter 1
26418006_3	Pharmacodynamic_phenotype	25,45	gemcitabine response
26418006_3	Phenotype	58,71,101,145	activities of human equilibrative nucleoside transporter 1
26418006_3	Phenotype	58,71,158,178	activities of deoxycytidine kinase
26418006_3	Phenotype	58,71,193,220	activities of ribonucleotide reductase M1
19190113_1	Limited_variation	7,33	variation in the DIO2 gene
19190113_1	Gene_or_protein	24,28	DIO2
19190113_1	Chemical	105,114	thyroxine
19190113_1	Chemical	120,136	triiodothyronine
19190113_1	Disease	148,159	hypothyroid
19190113_1	Pharmacodynamic_phenotype	81,136	response to combination thyroxine plus triiodothyronine
19190113_1	Chemical	93,136	combination thyroxine plus triiodothyronine
19190113_1	Phenotype	52,76	psychological well-being
23127338_3	Gene_or_protein	96,101	eIF3a
23127338_3	Limited_variation	129,150	eIF3a mutation status
23127338_3	Gene_or_protein	129,134	eIF3a
23127338_3	Chemical	198,206	platinum
23127338_3	Limited_variation	54,75,85,106	mutations in promoter regions of eIF3a gene
23127338_3	Limited_variation	54,66,80,106	mutations in exon regions of eIF3a gene
23127338_3	Chemical	198,230	platinum -based chemotherapeutic
23127338_3	Disease	231,242	lung cancer
23127338_3	Genomic_factor	80,106	exon regions of eIF3a gene
23127338_3	Genomic_factor	67,75,85,106	promoter regions of eIF3a gene
22329352_1	Chemical	0,11	Thalidomide
22329352_1	Disease	64,71	myeloma
22329352_1	Gene_or_protein	119,154	fibroblast growth factor receptor 3
22329352_1	Phenotype	77,83,105,154	normal expression of fibroblast growth factor receptor 3
22329352_1	Phenotype	35,71	progression-free survival in myeloma
22329352_1	Disease	188,197	Leukaemia
22329352_1	Disease	202,210	Lymphoma
22329352_1	Phenotype	92,154	up-regulated expression of fibroblast growth factor receptor 3
16550163_3	Chemical	79,89	thiopurine
16550163_3	Gene_or_protein	120,124	TPMT
26056325_2	Chemical	13,24	Vemurafenib
26056325_2	Chemical	29,39	dabrafenib
26056325_2	Disease	163,171	melanoma
26056325_2	Limited_variation	176,198	BRAF (V600E ) mutation
26056325_2	Gene_or_protein	176,180	BRAF
26103436_16	Disease	66,69	MCL
26103436_16	Chemical	84,94	bortezomib
26103436_16	Chemical	116,128	lenalidamide
26103436_16	Gene_or_protein	168,192	Bruton's Tyrosine Kinase
26103436_16	Chemical	155,165	Ibruitinib
26103436_16	Gene_or_protein	195,198	BTK
26103436_16	Disease	262,265	MCL
26103436_16	Chemical	97,111	NFkB inhibitor
26103436_16	Chemical	168,210	Bruton's Tyrosine Kinase [ BTK ] inhibitor
26103436_16	Chemical	131,148	anti-angiogenesis
15650426_10	Chemical	11,14	MVA
15650426_10	Gene_or_protein	105,108	Env
15650426_10	Gene_or_protein	62,65	CD8
15650426_10	Gene_or_protein	54,57	CD4
15650426_10	Pharmacodynamic_phenotype	54,57,66,82	CD4 T cell responses
15650426_10	Pharmacodynamic_phenotype	62,82	CD8 T cell responses
15650426_10	Pharmacodynamic_phenotype	99,118	anti- Env Ab titers
17555717_6	Gene_or_protein	10,16	DTNBP1
17555717_6	Pharmacodynamic_phenotype	54,79	methamphetamine psychosis
17555717_6	Chemical	54,69	methamphetamine
17555717_6	Limited_variation	83,105	polymorphisms of P1635
17555717_6	Chemical	100,105	P1635
17555717_6	Limited_variation	83,99,137,141	polymorphisms of SNPA
17555717_6	Haplotype	187,233	haplotype of P1655 ( rs2619539 ) - P1635- SNPA
17555717_6	Gene_or_protein	137,141	SNPA
17555717_6	Limited_variation	108,117	rs3213207
17555717_6	Limited_variation	144,153	rs2619538
17555717_6	Limited_variation	208,217	rs2619539
16819620_6	Gene_or_protein	80,84	DRD4
16819620_6	Chemical	172,179	alcohol
16819620_6	Gene_or_protein	119,124	5-HTT
16819620_6	Gene_or_protein	63,77	DA D4 receptor
16819620_6	Gene_or_protein	95,116	serotonin transporter
16819620_6	Limited_variation	63,86,127,135	DA D4 receptor ( DRD4 ) genotype
16819620_6	Limited_variation	95,135	serotonin transporter ( 5-HTT ) genotype
16819620_6	Chemical	184,191	tobacco
11967152_6	Chemical	65,68	CPP
11967152_6	Gene_or_protein	141,153	alpha CaMKII
11967152_6	Limited_variation	141,169	alpha CaMKII ( T286A + / - )
11967152_6	Limited_variation	99,101	WT
11967152_6	Phenotype	180,214	hippocampal long-term potentiation
11967152_6	Phenotype	217,220	LTP
19179437_6	Chemical	45,51	leptin
19179437_6	Gene_or_protein	68,118	signal transducer and activator of transcription-3
19179437_6	Pharmacodynamic_phenotype	68,129	signal transducer and activator of transcription-3 expression
19179437_6	Pharmacodynamic_phenotype	45,129	leptin -induced robust signal transducer and activator of transcription-3 expression
17559964_9	Limited_variation	16,32	GNB3 CC genotype
17559964_9	Gene_or_protein	16,20	GNB3
17559964_9	Limited_variation	96,112	non- CC genotype
17559964_9	Phenotype	57,60	SVR
22095536_2	Chemical	118,125	PEG-IFN
22095536_2	Gene_or_protein	212,217	IL28B
22095536_2	Chemical	102,115	peginterferon
22095536_2	Chemical	102,153	peginterferon ( PEG-IFN ) and ribavirin combination
22095536_2	Limited_variation	181,222	genetic polymorphisms near the IL28B gene
22095536_2	Phenotype	45,65	early viral dynamics
22095536_2	Pharmacodynamic_phenotype	91,161	outcome of peginterferon ( PEG-IFN ) and ribavirin combination therapy
22095536_2	Chemical	132,141	ribavirin
22095536_2	Pharmacodynamic_phenotype	261,285	response to this therapy
21995595_10	Gene_or_protein	26,30	ENO2
21995595_10	Phenotype	85,113	reduced ENO2 gene expression
21995595_10	Gene_or_protein	93,97	ENO2
21995595_10	Disease	61,78	heroin dependence
21995595_10	Disease	143,160	heroin dependence
21995595_10	Chemical	61,67	heroin
21995595_10	Chemical	143,149	heroin
18647087_1	Chemical	15,35	PEG - PEI copolymers
18647087_1	Chemical	21,24	PEI
18647087_1	Phenotype	88,109	dystrophin expression
18647087_1	Gene_or_protein	88,98	dystrophin
18647087_1	Chemical	15,18	PEG
14604772_9	Gene_or_protein	4,13	TNF-alpha
14604772_9	Chemical	70,79	ibudilast
14604772_9	Phenotype	4,33	TNF-alpha immunoreactive glia
25637161_10	Phenotype	7,44	overexpression of antiapoptotic BCL-2
25637161_10	Gene_or_protein	39,44	BCL-2
25637161_10	Pharmacodynamic_phenotype	81,111	BEZ235 / CQ -induced apoptosis
25637161_10	Pharmacodynamic_phenotype	192,223	BEZ235 / CQ -induced cell death
25637161_10	Chemical	81,92	BEZ235 / CQ
25637161_10	Pharmacodynamic_phenotype	102,111	apoptosis
25637161_10	Pharmacodynamic_phenotype	213,223	cell death
25637161_10	Chemical	192,203	BEZ235 / CQ
24782176_7	Chemical	78,81	MTX
24782176_7	Pharmacodynamic_phenotype	78,81,95,103	MTX toxicity
24782176_7	Gene_or_protein	142,146	RFC1
24782176_7	Limited_variation	110,162	reduced folate carrier 1 gene ( RFC1 ) variant 80G>A
24782176_7	Limited_variation	182,191	rs1051266
24782176_7	Gene_or_protein	110,139	reduced folate carrier 1 gene
24782176_7	Pharmacodynamic_phenotype	78,90	MTX efficacy
27717041_2	Chemical	13,20	Alcohol
27717041_2	Limited_variation	55,96	single-nucleotide polymorphisms in GABRA2
27717041_2	Gene_or_protein	90,96	GABRA2
27717041_2	Disease	13,34	Alcohol use disorders
27717041_2	Gene_or_protein	121,146	GABAA receptor a2-subunit
12057079_3	Gene_or_protein	15,19	HER2
12057079_3	Chemical	192,207	hormonal agents
12057079_3	Phenotype	36,60	malignant transformation
12057079_3	Pharmacodynamic_phenotype	139,187	resistant to non- anthracycline -based therapies
12057079_3	Pharmacodynamic_phenotype	139,151,192,207	resistant to hormonal agents
12057079_3	Disease	102,115	breast cancer
12057079_3	Chemical	226,252	targeted molecular therapy
12057079_3	Chemical	152,187	non- anthracycline -based therapies
17062187_6	Limited_variation	20,25	M184V
17062187_6	Limited_variation	30,35	Q151M
17062187_6	Chemical	61,104	nucleoside reverse transcriptase inhibitors
17062187_6	Limited_variation	178,182	V71I
17062187_6	Limited_variation	187,191	L90M
17062187_6	Chemical	215,225	nelfinavir
17062187_6	Chemical	107,112	NRTIs
17062187_6	Disease	118,133	HIV-1 infection
17062187_6	Chemical	201,210	indinavir
17062187_6	Pharmacodynamic_phenotype	47,114	resistance to nucleoside reverse transcriptase inhibitors ( NRTIs )
17062187_6	Pharmacodynamic_phenotype	215,236	nelfinavir resistance
17062187_6	Pharmacodynamic_phenotype	201,210,226,236	indinavir resistance
16153394_11	Chemical	10,21	terbutaline
16153394_11	Gene_or_protein	52,60	beta2-AR
16153394_11	Haplotype	100,133	haplotype A ( Arg 16Gln27Thr164 )
16153394_11	Haplotype	171,203	haplotype B ( Gly16Gln27Thr164 )
16153394_11	Haplotype	247,279	haplotype C ( Gly16Glu27Thr164 )
16153394_11	Pharmacodynamic_phenotype	32,60	desensitizes venous beta2-AR
17190370_3	Gene_or_protein	68,73	ABCB1
17190370_3	Chemical	120,140	( R ) - lansoprazole
17190370_3	Phenotype	169,199	CYP2C19 extensive metabolizers
17190370_3	Phenotype	215,240	gastroesophageal symptoms
17190370_3	Chemical	282,292	tacrolimus
17190370_3	Limited_variation	68,92	ABCB1 C3435Tpolymorphism
17190370_3	Pharmacokinetic_phenotype	100,140	pharmacokinetics of ( R ) - lansoprazole
17190370_3	Phenotype	202,205	EMs
17190370_3	Gene_or_protein	169,176	CYP2C19
17190370_3	Disease	244,260	renal transplant
24886060_7	Phenotype	10,28	Expression of NQO1
24886060_7	Gene_or_protein	24,28	NQO1
24886060_7	Pharmacodynamic_phenotype	48,69	sensitivity to 17-AAG
24886060_7	Chemical	63,69	17-AAG
24886060_7	Disease	77,81	OSCC
24886060_7	Gene_or_protein	138,143	HSP90
24886060_7	Chemical	190,196	17-AAG
24886060_7	Phenotype	128,143	expressed HSP90
24886060_7	Pharmacodynamic_phenotype	177,196	resistant to 17-AAG
23959853_1	Chemical	38,48	cefadroxil
23959853_1	Gene_or_protein	94,99	PepT1
23959853_1	Pharmacokinetic_phenotype	23,48	disposition of cefadroxil
23959853_1	Limited_variation	80,89,94,99	wild-type PepT1
23959853_1	Genomic_variation	94,108	PepT1 knockout
23959853_1	Pharmacokinetic_phenotype	8,18,35,48	absorption of cefadroxil
19912163_13	Chemical	76,86	mizoribine
19912163_13	Limited_variation	124,129	G565A
19912163_13	Pharmacodynamic_phenotype	48,86	dose-normalized C ( 12 ) of mizoribine
19912163_13	Pharmacokinetic_phenotype	91,111	substitute CL ( MZ )
17548696_4	Phenotype	32,44	skin lesions
17548696_4	Gene_or_protein	100,132	glutathione S-transferase omega1
17548696_4	Gene_or_protein	137,172	methylenetetrahydrofolate reductase
17548696_4	Chemical	199,222	monomethylarsonous acid
17548696_4	Chemical	227,230	MMA
17548696_4	Chemical	262,265	DMA
17548696_4	Chemical	237,257	dimethylarsinic acid
17548696_4	Chemical	297,300	MMA
17548696_4	Chemical	314,321	arsenic
17548696_4	Chemical	326,329	DMA
17548696_4	Chemical	333,336	MMA
17548696_4	Limited_variation	79,132	polymorphisms in the glutathione S-transferase omega1
17548696_4	Limited_variation	79,99,137,172	polymorphisms in the methylenetetrahydrofolate reductase
17548696_4	Phenotype	287,321	ratios of MMA to inorganic arsenic
17548696_4	Phenotype	287,296,326,336	ratios of DMA to MMA
17548696_4	Phenotype	185,222,268,276	percentage of monomethylarsonous acid in urine
17548696_4	Phenotype	185,198,237,257,268,276	percentage of dimethylarsinic acid in urine
17548696_4	Phenotype	225,230	% MMA
17548696_4	Phenotype	260,265	% DMA
17586618_1	Chemical	0,12	Homocysteine
17586618_1	Phenotype	21,43	VCAM-1 gene expression
17586618_1	Gene_or_protein	21,27	VCAM-1
17586618_1	Phenotype	66,92	NAD(P)H oxidase activation
17586618_1	Gene_or_protein	66,81	NAD(P)H oxidase
17586618_1	Gene_or_protein	52,61	NF-kappaB
17586618_1	Phenotype	52,61,82,92	NF-kappaB activation
17586618_1	Chemical	133,158	polyphenolic antioxidants
12824799_5	Pharmacodynamic_phenotype	104,124	stavudine resistance
12824799_5	Limited_variation	31,50	Y181I /C RT changes
12824799_5	Gene_or_protein	40,42	RT
12824799_5	Chemical	63,73	nevirapine
12824799_5	Chemical	104,113	stavudine
12824799_5	Chemical	83,88	NNRTI
20306339_17	Chemical	49,61	capecitabine
20306339_17	Disease	73,90	pancreatic cancer
20306339_17	Gene_or_protein	114,118	TYMS
20306339_17	Limited_variation	114,136	TYMS * 2 / * 2 variant
20306339_17	Pharmacodynamic_phenotype	170,194	non-hematologic toxicity
17430486_2	Gene_or_protein	0,5	CYP3A
17430486_2	Chemical	37,40	TAC
17430486_2	Pharmacokinetic_phenotype	37,51	TAC metabolism
25261422_8	Chemical	64,73	tenofovir
25261422_8	Chemical	78,91	emtricitabine
25261422_8	Limited_variation	156,160	M41L
25261422_8	Disease	139,144	HIV-1
25261422_8	Disease	139,160	HIV-1 harbouring M41L
9761125_9	Limited_variation	26,38	p53 mutation
9761125_9	Gene_or_protein	26,29	p53
9761125_9	Chemical	98,108	phenacetin
9761125_9	Phenotype	98,114	phenacetin abuse
9761125_9	Phenotype	117,124	smoking
22501025_4	Chemical	108,115	alcohol
22501025_4	Limited_variation	138,157	variation in GABRA2
22501025_4	Gene_or_protein	151,157	GABRA2
22501025_4	Pharmacodynamic_phenotype	97,115	effects of alcohol
22501025_4	Phenotype	43,61	differences in SRs
8834564_2	Disease	33,53	spontaneous abortion
8834564_2	Gene_or_protein	87,112	glutathione S-transferase
8834564_2	Gene_or_protein	115,120	GSTM1
8834564_2	Gene_or_protein	150,154	NAT2
8834564_2	Gene_or_protein	127,147	N -acetyltransferase
8834564_2	Limited_variation	58,74,87,112	polymorphisms in glutathione S-transferase
8834564_2	Limited_variation	58,74,127,147	polymorphisms in N -acetyltransferase
8834564_2	Chemical	199,210	xenobiotics
8834564_2	Pharmacokinetic_phenotype	185,210	metabolism of xenobiotics
17558305_5	Haplotype	31,47	UGT1A haplotypes
17558305_5	Chemical	95,112	SN-38 glucuronide
17558305_5	Pharmacodynamic_phenotype	127,137	toxicities
17558305_5	Disease	168,174	cancer
17558305_5	Chemical	197,207	irinotecan
17558305_5	Pharmacokinetic_phenotype	56,123	area under concentration curve ratio ( SN-38 glucuronide / SN -38 )
17558305_5	Chemical	115,121	SN -38
17558305_5	Chemical	244,256	chemotherapy
17558305_5	Gene_or_protein	31,36	UGT1A
23617284_5	Gene_or_protein	58,87	xeroderma pigmentosum group A
23617284_5	Gene_or_protein	90,93	XPA
23617284_5	Gene_or_protein	108,137	xeroderma pigmentosum group D
23617284_5	Gene_or_protein	140,143	XPD
23617284_5	Chemical	220,247	platinum based chemotherapy
23617284_5	Disease	260,265	NSCLC
23617284_5	Limited_variation	108,195	xeroderma pigmentosum group D ( XPD ) codon751 single-nucleotide polymorphisms ( SNPs )
23617284_5	Limited_variation	58,103,155,195	xeroderma pigmentosum group A ( XPA ) codon23 single-nucleotide polymorphisms ( SNPs )
23617284_5	Pharmacodynamic_phenotype	208,247	response to platinum based chemotherapy
23617284_5	Chemical	220,228	platinum
17898154_8	Chemical	16,42	3'-azido-3'-deoxythymidine
17898154_8	Chemical	60,69	estradiol
17898154_8	Chemical	72,77	17-OH
17898154_8	Chemical	86,103	ethinyl estradiol
17898154_8	Chemical	106,111	17-OH
17898154_8	Limited_variation	179,194	UGT1A1 genotype
17898154_8	Gene_or_protein	179,185	UGT1A1
17898154_8	Chemical	0,13	Acetaminophen
17898154_8	Chemical	45,57	muraglitazar
17898154_8	Pharmacokinetic_phenotype	145,164	rates of metabolism
19549911_9	Chemical	15,26	fludarabine
19549911_9	Gene_or_protein	32,35	SYK
19549911_9	Disease	67,79	cytotoxicity
19549911_9	Chemical	94,105	fludarabine
19549911_9	Chemical	32,48	SYK Inhibitor II
19549911_9	Chemical	52,56	R406
19549911_9	Chemical	0,48	Combination of fludarabine with SYK Inhibitor II
19549911_9	Chemical	0,31,52,56	Combination of fludarabine with R406
21849660_11	Chemical	13,19	Statin
21849660_11	Phenotype	102,105	RFS
21849660_11	Phenotype	111,113	OS
21849660_11	Disease	131,153	stage III colon cancer
21849660_11	Limited_variation	170,190	KRAS mutation status
21849660_11	Gene_or_protein	170,174	KRAS
21849660_11	Phenotype	96,99	DFS
21849660_11	Chemical	50,62	chemotherapy
24901049_9	Chemical	0,10	Dabrafenib
24901049_9	Phenotype	40,115	Ser358 phosphorylation of mixed lineage kinase domain-like protein ( MLKL )
24901049_9	Gene_or_protein	25,29	RIP3
24901049_9	Gene_or_protein	66,106	mixed lineage kinase domain-like protein
24901049_9	Gene_or_protein	109,113	MLKL
24901049_9	Phenotype	134,167	interaction between RIP3 and MLKL
24901049_9	Gene_or_protein	154,158	RIP3
24901049_9	Gene_or_protein	163,167	MLKL
27573423_1	Chemical	0,6	AC0010
27573423_1	Gene_or_protein	25,29	EGFR
27573423_1	Gene_or_protein	70,74	EGFR
27573423_1	Limited_variation	90,95	T790M
27573423_1	Disease	137,148	Lung Cancer
27573423_1	Limited_variation	62,74	Mutated EGFR
27573423_1	Chemical	25,39	EGFR Inhibitor
27573423_1	Phenotype	90,115	T790M -Induced Resistance
27573423_1	Phenotype	105,115	Resistance
16485141_7	Phenotype	32,48,96,105	high- nic o tine consumers
16485141_7	Chemical	80,88	nicotine
16485141_7	Gene_or_protein	115,121	CYP2A5
16485141_7	Chemical	179,187	nicotine
16485141_7	Gene_or_protein	237,243	CYP2A5
16485141_7	Chemical	42,43	o
16485141_7	Phenotype	144,147,195,204	low consumers
14654666_9	Chemical	118,121	BH4
14654666_9	Pharmacodynamic_phenotype	164,177	Phe tolerance
14654666_9	Chemical	164,167	Phe
14654666_9	Chemical	219,222	Phe
14654666_9	Limited_variation	91,113	genotype Y414C / R408W
14654666_9	Pharmacodynamic_phenotype	213,246	blood Phe levels < 200 micromol/L
14654666_9	Phenotype	47,54	3 years
14654666_9	Pharmacodynamic_phenotype	11,24	nonresponders
14654666_9	Pharmacodynamic_phenotype	74,88	clear response
21672908_11	Chemical	50,58	warfarin
21672908_11	Pharmacodynamic_phenotype	137,157	warfarin stable dose
21672908_11	Gene_or_protein	182,188	VKORC1
21672908_11	Gene_or_protein	193,199	CYP2C9
21672908_11	Limited_variation	162,188	genetic variants in VKORC1
21672908_11	Limited_variation	162,181,193,199	genetic variants in CYP2C9
21672908_11	Chemical	137,145	warfarin
18281523_8	Chemical	0,9	Gefitinib
18281523_8	Disease	49,54	tumor
18281523_8	Limited_variation	113,124	EGFR status
18281523_8	Gene_or_protein	113,117	EGFR
18281523_8	Disease	132,138	tumors
18281523_8	Pharmacokinetic_phenotype	27,40	PK properties
18281523_8	Pharmacodynamic_phenotype	74,92	PD characteristics
20308030_10	Pharmacodynamic_phenotype	79,89	neuropathy
20308030_10	Chemical	58,69	oxaliplatin
20308030_10	Gene_or_protein	98,103	GSTP1
20308030_10	Gene_or_protein	124,128	AGXT
20308030_10	Pharmacodynamic_phenotype	58,89	oxaliplatin -induced neuropathy
20308030_10	Limited_variation	98,119	GSTP1 Ile ( 105 ) Val
20308030_10	Limited_variation	124,144	AGXT Ile ( 340 ) Met
21187469_8	Chemical	25,38	5-azacytidine
21187469_8	Gene_or_protein	56,64	p16INK4a
26313006_9	Gene_or_protein	14,22	CyclinB1
26313006_9	Chemical	36,49	Cycloheximide
26313006_9	Gene_or_protein	53,57	CDK1
26313006_9	Chemical	70,81	Roscovitine
26313006_9	Pharmacodynamic_phenotype	106,133	FQI -induced mitotic arrest
26313006_9	Phenotype	14,32	CyclinB1 induction
26313006_9	Phenotype	53,66	CDK1 activity
26313006_9	Chemical	106,109	FQI
26313006_9	Pharmacodynamic_phenotype	119,133	mitotic arrest
18282182_12	Gene_or_protein	0,6	MEK1/2
18282182_12	Gene_or_protein	34,40	ERK1/2
18282182_12	Chemical	64,71	PD98059
18282182_12	Gene_or_protein	49,53	MEK1
18282182_12	Phenotype	92,108	COX-2 expression
18282182_12	Gene_or_protein	92,97	COX-2
18282182_12	Chemical	136,141	U0126
18282182_12	Gene_or_protein	119,125	MEK1/2
18282182_12	Phenotype	171,187	COX-2 expression
18282182_12	Gene_or_protein	171,176	COX-2
18282182_12	Chemical	49,63	MEK1 inhibitor
18282182_12	Chemical	119,135	MEK1/2 inhibitor
19183407_9	Chemical	27,34	AKR-501
19183407_9	Chemical	55,58	TPO
19183407_9	Disease	129,145	thrombocytopenia
19183407_9	Gene_or_protein	55,67	TPO receptor
19042106_4	Gene_or_protein	0,28	Catechol-O-methyltransferase
19042106_4	Gene_or_protein	31,35	COMT
19042106_4	Chemical	71,78	Ecstasy
19042106_4	Pharmacokinetic_phenotype	57,78	catabolism of Ecstasy
10911933_8	Gene_or_protein	51,54	CYP
10911933_8	Gene_or_protein	104,110	CYP2D6
10911933_8	Chemical	104,137	CYP2D6 metabolized drugs of abuse
10911933_8	Limited_variation	51,54,69,77	CYP genotype
10911933_8	Phenotype	51,64	CYP phenotype
12095411_10	Gene_or_protein	96,111	angiotensinogen
12095411_10	Phenotype	189,197	stenosis
12095411_10	Limited_variation	77,116	235T allele of the angiotensinogen gene
12095411_10	Chemical	125,136	cholesterol
19671633_2	Gene_or_protein	68,105	delta-aminolevulinic acid dehydratase
19671633_2	Gene_or_protein	108,112	ALAD
19671633_2	Limited_variation	119,179	matrix gamma-carboxyglutamic acid ( MGP ) gene polymorphisms
19671633_2	Gene_or_protein	119,152	matrix gamma-carboxyglutamic acid
19671633_2	Gene_or_protein	155,158	MGP
19671633_2	Pharmacodynamic_phenotype	199,212	lead toxicity
19671633_2	Limited_variation	68,114,161,179	delta-aminolevulinic acid dehydratase ( ALAD ) gene polymorphisms
19671633_2	Chemical	199,203	lead
22179630_14	Limited_variation	34,55	C/T genotype of BAG-1
22179630_14	Gene_or_protein	50,55	BAG-1
22179630_14	Gene_or_protein	96,101	Bag-1
22179630_14	Limited_variation	80,111	C/C genotype at Bag-1 codon 324
22179630_14	Chemical	142,170	platinum -based chemotherapy
22179630_14	Pharmacodynamic_phenotype	129,170	responses to platinum -based chemotherapy
22179630_14	Chemical	142,150	platinum
23757001_2	Gene_or_protein	109,130	serotonin transporter
23757001_2	Gene_or_protein	213,218	HTR3A
23757001_2	Gene_or_protein	221,226	HTR3B
23757001_2	Gene_or_protein	233,239	SLC6A4
23757001_2	Chemical	273,280	alcohol
23757001_2	Disease	294,296	AD
23757001_2	Disease	273,291	alcohol dependence
23757001_2	Gene_or_protein	83,90	5-HT3AB
23757001_2	Phenotype	62,79	drinking behavior
23757001_2	Limited_variation	181,218	genetic variations in the genes HTR3A
23757001_2	Limited_variation	181,212,233,239	genetic variations in the genes SLC6A4
23757001_2	Limited_variation	181,212,221,226	genetic variations in the genes HTR3B
20205700_9	Gene_or_protein	44,51	ALDH1b1
20205700_9	Pharmacodynamic_phenotype	129,145	hypersensitivity
20205700_9	Pharmacodynamic_phenotype	112,145	alcohol -induced hypersensitivity
20205700_9	Chemical	112,119	alcohol
20205700_9	Limited_variation	31,65	SNP encoding ALDH1b1 ( rs2228093 )
20205700_9	Limited_variation	54,63	rs2228093
22379998_2	Chemical	30,43	carbamazepine
22379998_2	Gene_or_protein	74,79	HLA-A
22379998_2	Pharmacodynamic_phenotype	30,69	carbamazepine -induced hypersensitivity
22379998_2	Haplotype	74,86	HLA-A * 3101
22379998_2	Pharmacodynamic_phenotype	53,69	hypersensitivity
25565175_4	Gene_or_protein	14,19	HLA-B
25565175_4	Chemical	34,42	abacavir
25565175_4	Pharmacodynamic_phenotype	34,69	abacavir hypersensitivity reactions
25565175_4	Limited_variation	14,24	HLA-B 5701
18940228_4	Chemical	22,25	HCH
18940228_4	Chemical	132,143	glutathione
18940228_4	Chemical	146,149	GSH
18940228_4	Gene_or_protein	197,205	catalase
18940228_4	Gene_or_protein	210,243	glucose-6-phosphate dehydrogenase
18940228_4	Gene_or_protein	189,192	SOD
18940228_4	Phenotype	64,90	hepatic lipid peroxidation
18940228_4	Pharmacodynamic_phenotype	122,151	levels of glutathione ( GSH )
18940228_4	Phenotype	154,186	activity of superoxide dismutase
18940228_4	Phenotype	154,165,197,205	activity of catalase
18940228_4	Gene_or_protein	166,186	superoxide dismutase
18940228_4	Phenotype	154,165,210,243	activity of glucose-6-phosphate dehydrogenase
10716965_3	Gene_or_protein	40,44	CRBP
10716965_3	Pharmacokinetic_phenotype	116,122	uptake
10716965_3	Gene_or_protein	4,37	cellular retinol -binding protein
10716965_3	Pharmacokinetic_phenotype	127,137	metabolism
10716965_3	Chemical	53,62	vitamin A
17680654_7	Chemical	35,45	telaprevir
17680654_7	Chemical	60,70	telaprevir
17680654_7	Chemical	73,89	PEG-IFN-alpha-2a
17680654_7	Limited_variation	96,112	A156V /T variant
17680654_7	Chemical	35,45,55,89	telaprevir with telaprevir / PEG-IFN-alpha-2a
17680654_7	Phenotype	149,161	viral levels
9164419_8	Chemical	62,74	lansoprazole
9164419_8	Limited_variation	120,175	S-mephenytoin 4'-hydroxylation ( CYP2C19 ) polymorphism
9164419_8	Gene_or_protein	153,160	CYP2C19
9164419_8	Pharmacokinetic_phenotype	45,74	hydroxylation of lansoprazole
9164419_8	Pharmacokinetic_phenotype	120,150	S-mephenytoin 4'-hydroxylation
9164419_8	Chemical	120,133	S-mephenytoin
11122156_8	Phenotype	60,83	alpha-globin deficiency
11122156_8	Gene_or_protein	60,72	alpha-globin
11122156_8	Disease	128,135	anaemia
11122156_8	Disease	192,196	Hb H
11122156_8	Phenotype	86,102	high Hb H levels
11122156_8	Limited_variation	201,240	alpha-thalassaemic haemoglobin variants
11122156_8	Phenotype	162,180	tissue oxygenation
11122156_8	Phenotype	258,275	red cell survival
11122156_8	Gene_or_protein	220,231	haemoglobin
11122156_8	Disease	91,95	Hb H
19037200_5	Gene_or_protein	31,35	COMT
19037200_5	Gene_or_protein	0,28	Catechol-O-methyltransferase
19037200_5	Chemical	74,82	dopamine
19037200_5	Pharmacokinetic_phenotype	52,82	breakdown of cerebral dopamine
24905729_3	Gene_or_protein	117,136	pregnane X receptor
24905729_3	Gene_or_protein	139,142	PXR
24905729_3	Chemical	155,165	rifampicin
24905729_3	Disease	38,81	persistent hepatocellular secretory failure
24905729_3	Disease	84,88	PHSF
24905729_3	Chemical	117,152	pregnane X receptor ( PXR ) agonist
10945855_3	Chemical	20,36	p-fluorofentanyl
10945855_3	Gene_or_protein	69,74	GIRK2
10945855_3	Chemical	114,122	fentanyl
10945855_3	Chemical	136,144	p-fluoro
10945855_3	Chemical	217,225	fentanyl
10945855_3	Chemical	257,274	p- fluorofentanyl
10945855_3	Gene_or_protein	92,108	opioid receptors
10945855_3	Gene_or_protein	61,66	GIRK1
10945855_3	Chemical	92,98	opioid
10864974_1	Phenotype	0,21	Nigrostriatal lesions
10864974_1	Disease	28,43	oral dyskinesia
10864974_1	Phenotype	48,64	c-Fos expression
10864974_1	Gene_or_protein	48,53	c-Fos
10864974_1	Chemical	98,126	1-(m-chlorophenyl)piperazine
10864974_1	Chemical	80,97	serotonin agonist
22077505_8	Pharmacodynamic_phenotype	88,99	neutropenia
22077505_8	Chemical	68,78	irinotecan
22077505_8	Gene_or_protein	116,122	UGT1A1
22077505_8	Pharmacodynamic_phenotype	68,99	irinotecan -induced neutropenia
22077505_8	Haplotype	116,126	UGT1A1 * 6
23666583_9	Chemical	41,51	tacrolimus
23666583_9	Gene_or_protein	81,87	CYP3A5
23666583_9	Pharmacokinetic_phenotype	41,61	tacrolimus clearance
23666583_9	Limited_variation	81,96	CYP3A5 genotype
22842957_3	Gene_or_protein	52,58	CYP2C9
22842957_3	Limited_variation	63,84	SLCO1B1 polymorphisms
22842957_3	Gene_or_protein	63,70	SLCO1B1
22842957_3	Chemical	107,118	nateglinide
22842957_3	Limited_variation	52,58,71,84	CYP2C9 polymorphisms
22842957_3	Pharmacokinetic_phenotype	93,118	metabolism of nateglinide
21187469_5	Chemical	81,84	I3C
21187469_5	Chemical	97,100	I3C
21187469_5	Gene_or_protein	139,147	p16INK4a
21187469_5	Disease	117,122	tumor
21187469_5	Disease	151,168	pancreatic cancer
17094454_10	Limited_variation	27,52	PSA -158 G/A polymorphism
17094454_10	Gene_or_protein	27,30	PSA
17094454_10	Genomic_factor	74,86	PSA promoter
17094454_10	Phenotype	74,95	PSA promoter activity
17094454_10	Phenotype	133,148	serum PSA level
17094454_10	Limited_variation	206,225	GG genotype of ARE1
17094454_10	Gene_or_protein	221,225	ARE1
17094454_10	Pharmacodynamic_phenotype	238,276	sensitive to androgen ablation therapy
17094454_10	Chemical	251,276	androgen ablation therapy
17094454_10	Gene_or_protein	74,77	PSA
17094454_10	Gene_or_protein	139,142	PSA
18349392_2	Gene_or_protein	24,56	epidermal growth factor receptor
18349392_2	Gene_or_protein	59,63	EGFR
18349392_2	Chemical	141,150	cetuximab
18349392_2	Disease	176,204	metastatic colorectal cancer
18349392_2	Disease	207,211	MCRC
18349392_2	Pharmacodynamic_phenotype	129,158	activity of cetuximab therapy
27350677_12	Limited_variation	39,78	genetic variants within the PDLIM5 gene
27350677_12	Gene_or_protein	67,73	PDLIM5
27350677_12	Chemical	134,141	steroid
27350677_12	Disease	158,164	cancer
27350677_12	Limited_variation	104,129	PLDIM5 gene polymorphisms
27350677_12	Gene_or_protein	104,110	PLDIM5
21890455_6	Chemical	0,3	IMO
21890455_6	Gene_or_protein	20,24	EGFR
21890455_6	Phenotype	74,107	interaction between TLR9 and EGFR
21890455_6	Gene_or_protein	94,98	TLR9
21890455_6	Gene_or_protein	103,107	EGFR
21890455_6	Phenotype	20,45	EGFR -dependent signaling
22995765_7	Chemical	123,129	heroin
22995765_7	Limited_variation	52,79	AA homozygotes of rs6943555
22995765_7	Disease	123,139	heroin dependent
22995765_7	Limited_variation	70,79	rs6943555
22102708_4	Limited_variation	87,92	V617F
22102708_4	Disease	136,153	polycythemia vera
22102708_4	Chemical	275,286	hydroxyurea
22102708_4	Chemical	299,307	imatinib
22102708_4	Chemical	321,330	dasatinib
22102708_4	Chemical	343,351	busulfan
22102708_4	Chemical	368,390	radioactive phosphorus
22102708_4	Chemical	174,184	interferon
22102708_4	Chemical	187,220	rIFNa-2b : 28 , Peg-rIFNa-2a : 18
22102708_4	Chemical	226,246	non-interferon drugs
22102708_4	Pharmacodynamic_phenotype	50,71	hematologic responses
22102708_4	Pharmacodynamic_phenotype	37,45,62,71	clinical responses
21880305_9	Limited_variation	43,49	rs6265
21880305_9	Chemical	70,80	sertraline
21880305_9	Limited_variation	31,49	A allele of rs6265
21880305_9	Pharmacodynamic_phenotype	50,90	responded better to sertraline treatment
18377430_1	Gene_or_protein	13,18	ABCB1
18377430_1	Limited_variation	23,42	ABCG2 polymorphisms
18377430_1	Gene_or_protein	23,28	ABCG2
18377430_1	Chemical	46,57	doxorubicin
18377430_1	Disease	79,92	breast cancer
18377430_1	Limited_variation	13,18,29,42	ABCB1 polymorphisms
18377430_1	Pharmacokinetic_phenotype	46,69	doxorubicin disposition
22134241_7	Chemical	33,40	AZD7762
22134241_7	Gene_or_protein	97,100	p53
22134241_7	Chemical	45,53	olaparib
22134241_7	Chemical	18,53	combination of AZD7762 and olaparib
22134241_7	Disease	97,125	p53 mutant pancreatic cancer
22134241_7	Limited_variation	97,107	p53 mutant
22134241_7	Phenotype	75,93	radiosensitization
22134241_7	Genomic_factor	150,158	isogenic
22134241_7	Disease	150,165	isogenic cancer
17477907_6	Gene_or_protein	20,24	P-gp
17477907_6	Chemical	111,122	doxorubicin
17477907_6	Chemical	126,137	vinblastine
17477907_6	Phenotype	20,40	P-gp -expressing MDR
17477907_6	Pharmacodynamic_phenotype	89,103,111,122	sensitivity to doxorubicin
17477907_6	Pharmacodynamic_phenotype	89,103,126,137	sensitivity to vinblastine
17477907_6	Phenotype	263,276	MDR phenotype
17477907_6	Phenotype	54,79	serum from immunized mice
10785598_1	Phenotype	32,65	induction of thymidylate synthase
10785598_1	Gene_or_protein	45,65	thymidylate synthase
10785598_1	Gene_or_protein	90,93	p53
10785598_1	Disease	80,106	wild-type p53 colon cancer
10785598_1	Chemical	139,153	5-fluorouracil
10785598_1	Gene_or_protein	162,182	thymidylate synthase
10785598_1	Limited_variation	80,93	wild-type p53
10785598_1	Chemical	193,204	raltitrexed
10785598_1	Limited_variation	69,75,90,93	mutant p53
10785598_1	Genomic_variation	0,27	Molecular downstream events
10785598_1	Disease	69,75,90,106	mutant p53 colon cancer
10785598_1	Chemical	162,192	thymidylate synthase inhibitor
7748323_2	Phenotype	4,28	expression of c-fos mRNA
7748323_2	Gene_or_protein	18,23	c-fos
7748323_2	Chemical	98,118	N-methyl-D-aspartate
7748323_2	Chemical	121,125	NMDA
7748323_2	Chemical	206,214	caffeine
7748323_2	Gene_or_protein	179,198	glutamate receptors
7748323_2	Gene_or_protein	234,253	adenosine receptors
7748323_2	Genomic_factor	18,28	c-fos mRNA
7748323_2	Chemical	132,143	kainic acid
7748323_2	Chemical	220,253	antagonist of adenosine receptors
7748323_2	Chemical	146,198	agonists of different classes of glutamate receptors
17899045_8	Chemical	41,49	warfarin
17899045_8	Gene_or_protein	175,181	VKORC1
17899045_8	Gene_or_protein	248,254	CYP2C9
17899045_8	Gene_or_protein	259,265	VKORC1
17899045_8	Pharmacodynamic_phenotype	41,54	warfarin dose
17899045_8	Phenotype	134,140	weight
17899045_8	Limited_variation	175,190	VKORC1 genotype
17899045_8	Phenotype	235,241	weight
17899045_8	Limited_variation	248,274	CYP2C9 and VKORC1 genotype
17899045_8	Phenotype	229,232	age
17899045_8	Phenotype	96,99	age
22252093_2	Chemical	26,39	acenocoumarol
22252093_2	Limited_variation	130,136,148,157	CYP2C9 genotypes
22252093_2	Gene_or_protein	130,136	CYP2C9
22252093_2	Gene_or_protein	141,147	VKORC1
22252093_2	Phenotype	61,81	underanticoagulation
22252093_2	Phenotype	86,105	overanticoagulation
22252093_2	Limited_variation	141,157	VKORC1 genotypes
22252093_2	Pharmacodynamic_phenotype	17,44	required acenocoumarol dose
25367959_2	Gene_or_protein	75,79	EGFR
25367959_2	Chemical	19,44	erlotinib and bevacizumab
25367959_2	Phenotype	54,57	PFS
25367959_2	Limited_variation	75,87	EGFR -mutant
25367959_2	Disease	75,93	EGFR -mutant NSCLC
25367959_2	Chemical	19,28	erlotinib
25367959_2	Chemical	33,44	bevacizumab
23501331_2	Limited_variation	68,148	polymorphisms in genes involved in cholesterol homeostasis and statin metabolism
23501331_2	Chemical	103,114	cholesterol
23501331_2	Gene_or_protein	159,165	CYP3A4
23501331_2	Gene_or_protein	170,176	CYP3A5
23501331_2	Chemical	131,137	statin
23501331_2	Pharmacodynamic_phenotype	28,47	response to statins
23501331_2	Chemical	40,47	statins
23501331_2	Pharmacokinetic_phenotype	103,126	cholesterol homeostasis
23501331_2	Pharmacokinetic_phenotype	131,148	statin metabolism
25391641_1	Gene_or_protein	20,26	CYP2B6
25391641_1	Gene_or_protein	29,35	CYP2A6
25391641_1	Gene_or_protein	40,46	UGT2B7
25391641_1	Chemical	98,107	efavirenz
25391641_1	Chemical	112,122	nevirapine
25391641_1	Disease	50,53	HIV
25391641_1	Chemical	50,63	HIV treatment
17884271_6	Limited_variation	47,62	MAO-A genotypes
17884271_6	Gene_or_protein	47,52	MAO-A
17884271_6	Disease	279,295	Major Depression
17884271_6	Pharmacodynamic_phenotype	165,198	antidepressant treatment response
17884271_6	Chemical	165,179	antidepressant
17884271_6	Chemical	99,108	serotonin
17884271_6	Chemical	116,130	norepinephrine
17884271_6	Pharmacokinetic_phenotype	99,108,131,143	serotonin availability
17884271_6	Pharmacokinetic_phenotype	116,143	norepinephrine availability
25589623_11	Limited_variation	0,10	rs11085735
25589623_11	Phenotype	27,30	RFS
25589623_11	Chemical	42,51	tamoxifen
8873217_7	Limited_variation	11,17	6G-->T
8873217_7	Chemical	69,78	serotonin
8873217_7	Pharmacodynamic_phenotype	60,85	platelet serotonin levels
21623265_3	Chemical	36,46	crizotinib
21623265_3	Disease	86,112	non-small cell lung cancer
21623265_3	Gene_or_protein	71,74	ALK
21623265_3	Disease	115,120	NSCLC
21623265_3	Genomic_variation	71,85	ALK rearranged
21623265_3	Disease	71,122	ALK rearranged non-small cell lung cancer ( NSCLC )
22394056_8	Gene_or_protein	100,104	BDNF
22394056_8	Chemical	158,165	cocaine
22394056_8	Phenotype	19,45	deficit in fear extinction
22394056_8	Limited_variation	100,117	BDNF ( Val /Met )
22394056_8	Pharmacodynamic_phenotype	144,176	extinction of cocaine responding
16001112_10	Gene_or_protein	0,5	Beta2
16001112_10	Chemical	42,50	nicotine
16001112_10	Pharmacodynamic_phenotype	66,80	supersensitive
16001112_10	Limited_variation	0,11	Beta2 - / -
16001112_10	Pharmacodynamic_phenotype	99,108	tolerance
11287760_4	Limited_variation	59,82	MTHFR gene polymorphism
11287760_4	Gene_or_protein	59,64	MTHFR
11287760_4	Phenotype	140,187	intima-media thickness of common carotid artery
11287760_4	Phenotype	190,196	CC-IMT
11287760_4	Gene_or_protein	98,110	homocysteine
11287760_4	Gene_or_protein	113,116	Hcy
11287760_4	Phenotype	91,124	plasma homocysteine ( Hcy ) level
26411491_2	Chemical	7,23	6-mercaptopurine
26411491_2	Gene_or_protein	44,48	TPMT
26411491_2	Genomic_factor	70,83	TPMT promoter
26411491_2	Phenotype	44,64	TPMT gene expression
26411491_2	Gene_or_protein	70,74	TPMT
23337555_13	Limited_variation	32,47	alleles for CFH
23337555_13	Gene_or_protein	44,47	CFH
23337555_13	Gene_or_protein	50,55	ARMS2
23337555_13	Gene_or_protein	58,63	HTRA1
23337555_13	Disease	104,107	AMD
23337555_13	Gene_or_protein	149,183	vascular endothelial growth factor
23337555_13	Limited_variation	32,43,58,63	alleles for HTRA1
23337555_13	Limited_variation	32,43,50,55	alleles for ARMS2
23337555_13	Limited_variation	32,43,70,72	alleles for C3
23337555_13	Gene_or_protein	70,72	C3
23337555_13	Pharmacodynamic_phenotype	131,191	response to anti- vascular endothelial growth factor therapy
23337555_13	Chemical	143,191	anti- vascular endothelial growth factor therapy
17558310_2	Limited_variation	4,54	1976C>T polymorphism in the adenosine A2A receptor
17558310_2	Gene_or_protein	32,54	adenosine A2A receptor
17558310_2	Gene_or_protein	62,69	ADORA2A
17558310_2	Chemical	164,172	caffeine
17558310_2	Chemical	134,163	adenosine receptor antagonist
17558310_2	Pharmacodynamic_phenotype	86,111,164,172	psychological response to caffeine
24993285_12	Limited_variation	36,45	BDNF SNPs
24993285_12	Gene_or_protein	36,40	BDNF
24993285_12	Disease	107,120	schizophrenia
24993285_12	Disease	221,234	schizophrenia
24993285_12	Disease	76,120	comorbid alcohol dependence in schizophrenia
24993285_12	Chemical	85,92	alcohol
24993285_12	Chemical	177,184	alcohol
24993285_12	Disease	177,195	alcohol -dependent
24993285_12	Disease	85,103	alcohol dependence
24993285_12	Disease	177,234	alcohol -dependent patients who do not have schizophrenia
16144943_13	Chemical	68,102	SAHA in combination with docetaxel
16144943_13	Chemical	93,102	docetaxel
16144943_13	Disease	130,160	Her-2 -amplified breast cancer
16144943_13	Gene_or_protein	130,135	Her-2
16144943_13	Chemical	68,92,110,121	SAHA in combination with trastuzumab
16144943_13	Chemical	68,72	SAHA
16144943_13	Chemical	68,121	SAHA in combination with docetaxel and/or trastuzumab
16144943_13	Genomic_variation	130,146	Her-2 -amplified
10864974_5	Disease	80,95	oral dyskinesia
10864974_5	Phenotype	100,122	Fos protein expression
10864974_5	Gene_or_protein	100,103	Fos
10864974_5	Chemical	170,198	1-(m-chlorophenyl)piperazine
10864974_5	Chemical	201,206	m-CPP
10864974_5	Chemical	152,169	5-HT(2C ) agonist
10864974_5	Phenotype	30,76	unilateral lesions of nigrostriatal DA neurons
23598060_11	Phenotype	13,16	P50
23598060_11	Phenotype	21,24	PPI
23598060_11	Limited_variation	51,57	rs4680
23598060_11	Gene_or_protein	46,50	COMT
23598060_11	Disease	75,88	schizophrenia
23598060_11	Phenotype	122,125	P50
23598060_11	Gene_or_protein	149,153	COMT
23598060_11	Limited_variation	154,162	rs737865
23598060_11	Phenotype	181,184	PPI
23598060_11	Limited_variation	211,219	rs165599
23598060_11	Gene_or_protein	206,210	COMT
23598060_11	Disease	237,250	schizophrenia
23598060_11	Phenotype	297,357	reduction of the risk of P50 or PPI defects in schizophrenia
23598060_11	Disease	344,357	schizophrenia
23598060_11	Phenotype	322,325	P50
23598060_11	Phenotype	329,332	PPI
12509456_18	Phenotype	16,37	BRCA1 mRNA expression
12509456_18	Gene_or_protein	16,21	BRCA1
12509456_18	Disease	50,63	breast cancer
12509456_18	Gene_or_protein	110,115	BRCA1
12509456_18	Genomic_variation	86,115	C -terminally truncated BRCA1
12509456_18	Chemical	152,155	CL4
12509456_18	Chemical	145,148	LAM
12509456_18	Genomic_factor	16,26	BRCA1 mRNA
25666034_12	Gene_or_protein	37,40	TRb
25666034_12	Chemical	74,82	nicotine
25666034_12	Phenotype	86,114	hippocampus-dependent memory
25666034_12	Pharmacodynamic_phenotype	58,82	effect of acute nicotine
20871262_15	Gene_or_protein	40,44	EGFR
20871262_15	Chemical	99,109	everolimus
20871262_15	Disease	35,58	non- EGFR mutant tumors
20871262_15	Pharmacodynamic_phenotype	4,17	response rate
20871262_15	Limited_variation	35,51	non- EGFR mutant
21946895_6	Chemical	18,28	naltrexone
21946895_6	Chemical	60,67	alcohol
21946895_6	Gene_or_protein	85,90	OPRM1
21946895_6	Limited_variation	85,105	OPRM1 A118G genotype
21946895_6	Disease	60,78	alcohol dependence
17963417_12	Disease	75,92	diabetes mellitus
17963417_12	Chemical	111,119	acarbose
17963417_12	Gene_or_protein	151,162	adiponectin
17963417_12	Gene_or_protein	165,171	ADIPOQ
17963417_12	Phenotype	61,92	conversion to diabetes mellitus
17963417_12	Limited_variation	151,191	adiponectin ( ADIPOQ ) gene polymorphism
17963417_12	Limited_variation	30,42	polymorphism
22716779_2	Limited_variation	8,17	rs1260326
22716779_2	Limited_variation	32,41	rs1799884
22716779_2	Gene_or_protein	61,91	glucokinase regulatory protein
22716779_2	Gene_or_protein	94,98	GCKR
22716779_2	Gene_or_protein	105,116	glucokinase
22716779_2	Gene_or_protein	119,122	GCK
22716779_2	Chemical	194,197	TAG
22716779_2	Chemical	202,209	glucose
22716779_2	Pharmacodynamic_phenotype	194,197,210,224	TAG concentrations
22716779_2	Pharmacodynamic_phenotype	202,209,210,224	glucose concentrations
12149232_3	Gene_or_protein	23,26	HFE
12149232_3	Chemical	37,41	iron
12149232_3	Limited_variation	76,90	C282Y mutation
12149232_3	Phenotype	123,178	expression of the human hemachromatosis protein ( HFE )
12149232_3	Chemical	202,206	iron
12149232_3	Gene_or_protein	141,170	human hemachromatosis protein
12149232_3	Gene_or_protein	173,176	HFE
12149232_3	Pharmacokinetic_phenotype	183,206	hyperabsorption of iron
12149232_3	Pharmacokinetic_phenotype	37,52	iron absorption
16940443_5	Chemical	33,49	prostaglandin E2
16940443_5	Chemical	86,108	dibutyryl ( Bt2 ) cAMP
16940443_5	Chemical	114,138	phorbol 12, 13-diacetate
16940443_5	Chemical	141,144	PDA
16940443_5	Phenotype	169,181	BRCA1 levels
16940443_5	Gene_or_protein	169,174	BRCA1
16940443_5	Gene_or_protein	194,203	aromatase
16940443_5	Phenotype	194,215	aromatase mRNA levels
16940443_5	Chemical	86,146	dibutyryl ( Bt2 ) cAMP plus phorbol 12, 13-diacetate ( PDA )
16940443_5	Genomic_factor	194,208	aromatase mRNA
16940443_5	Disease	23,27	BAFs
16184603_4	Limited_variation	52,86	prodynorphin promoter polymorphism
16184603_4	Gene_or_protein	52,64	prodynorphin
16184603_4	Chemical	90,97	cocaine
16184603_4	Disease	90,107	cocaine dependent
16184603_4	Genomic_factor	52,73	prodynorphin promoter
12768192_8	Gene_or_protein	28,34	ICAM-1
12768192_8	Chemical	148,153	DMXAA
12768192_8	Phenotype	103,121	antitumor immunity
12768192_8	Genomic_variation	14,34	nonfunctional ICAM-1
24733796_3	Disease	37,51,69,82	HER2 -positive breast cancer
24733796_3	Gene_or_protein	37,41	HER2
24733796_3	Disease	37,51,86,89	HER2 -positive MBC
24733796_3	Phenotype	37,51	HER2 -positive
24733796_3	Chemical	121,140	DM1 plus pertuzumab
23147740_1	Chemical	0,12	Posaconazole
23147740_1	Gene_or_protein	72,77	Cyp51
23147740_1	Disease	142,174	invasive pulmonary aspergillosis
23147740_1	Limited_variation	72,84	Cyp51 mutant
23147740_1	Limited_variation	58,67,72,77	wild-type Cyp51
19031955_1	Disease	6,20	encephalopathy
19031955_1	Chemical	33,36	MTX
19031955_1	Chemical	63,75	methotrexate
19031955_1	Limited_variation	95,138	homozygous for the MTHFR C677T polymorphism
19031955_1	Gene_or_protein	114,119	MTHFR
19031955_1	Pharmacokinetic_phenotype	33,46	MTX clearance
26402671_3	Phenotype	182,218	BCR - ABL 1 tyrosine kinase activity
26402671_3	Gene_or_protein	182,185	BCR
26402671_3	Chemical	232,236	TKIs
26402671_3	Chemical	182,229	BCR - ABL 1 tyrosine kinase activity inhibitors
26402671_3	Gene_or_protein	188,191	ABL
26402671_3	Pharmacodynamic_phenotype	162,229	pharmacodynamics of BCR - ABL 1 tyrosine kinase activity inhibitors
26402671_3	Pharmacokinetic_phenotype	141,157,179,229	pharmacokinetics of BCR - ABL 1 tyrosine kinase activity inhibitors
26402671_3	Gene_or_protein	59,64	genes
26402671_3	Limited_variation	73,81	variants
26402671_3	Limited_variation	91,104	polymorphisms
26402671_3	Gene_or_protein	125,133	proteins
16357205_4	Chemical	50,62	tetracycline
16357205_4	Phenotype	134,170	hematopoietic mesoderm specification
16357205_4	Phenotype	183,217	hematopoietic progenitor formation
16357205_4	Phenotype	257,295	multilineage hematopoietic engraftment
16357205_4	Gene_or_protein	74,78	Cdx4
16357205_4	Gene_or_protein	109,113	Cdx4
16357205_4	Phenotype	109,124	Cdx4 expression
16357205_4	Gene_or_protein	240,245	HoxB4
16357205_4	Genomic_factor	50,78	tetracycline -inducible Cdx4
16357205_4	Phenotype	109,124,226,245	Cdx4 expression together with HoxB4
24769646_6	Chemical	13,41	dimethyl histone H3 lysine 4
24769646_6	Gene_or_protein	61,65	RARa
24769646_6	Gene_or_protein	89,93	PU.1
24769646_6	Gene_or_protein	133,138	RUNX1
24769646_6	Gene_or_protein	181,184	MLL
24769646_6	Gene_or_protein	187,190	AF9
24769646_6	Gene_or_protein	215,218	MLL
24769646_6	Gene_or_protein	221,224	AF4
24769646_6	Pharmacodynamic_phenotype	351,367	ATRA sensitivity
24769646_6	Chemical	351,355	ATRA
24769646_6	Gene_or_protein	371,374	MLL
24769646_6	Gene_or_protein	377,380	AF4
24769646_6	Chemical	44,51	H3K4me2
24769646_6	Genomic_factor	89,128	PU.1 upstream regulatory region ( URE )
24769646_6	Genomic_factor	133,166	RUNX1 +24 / +25 intronic enhancer
24769646_6	Gene_or_protein	258,288	lysine -specific demethylase 1
24769646_6	Genomic_factor	61,86	RARa gene-promoter region
24769646_6	Pharmacodynamic_phenotype	4,53	level of dimethyl histone H3 lysine 4 ( H3K4me2 )
24769646_6	Phenotype	371,390	MLL - AF4 -positive
24769646_6	Phenotype	181,200	MLL - AF9 -positive
24769646_6	Phenotype	215,234	MLL - AF4 -positive
26086347_5	Gene_or_protein	24,29	ABCG2
26086347_5	Pharmacodynamic_phenotype	94,126	atorvastatin dose-dependent ADRs
26086347_5	Chemical	94,106	atorvastatin
26086347_5	Gene_or_protein	192,197	ABCG2
26086347_5	Limited_variation	24,36	ABCG2 421 CA
26086347_5	Limited_variation	192,203	ABCG2 421CC
26086347_5	Limited_variation	24,33,40,42	ABCG2 421 AA
26086347_5	Pharmacodynamic_phenotype	122,126	ADRs
12361551_1	Disease	55,64	alcoholic
12361551_1	Chemical	90,94	iron
12361551_1	Phenotype	90,103	iron overload
12361551_1	Gene_or_protein	19,22	HFE
12361551_1	Limited_variation	2,27,30,35	Mutations in the HFE gene C282Y
12361551_1	Limited_variation	2,27,38,42	Mutations in the HFE gene H63D
12361551_1	Limited_variation	2,27,45,49	Mutations in the HFE gene S65C
9724909_1	Gene_or_protein	42,46	MDR1
9724909_1	Chemical	21,31	adriamycin
9724909_1	Disease	82,99	ovarian carcinoma
9724909_1	Phenotype	42,70	MDR1 gene encoded resistance
9724909_1	Chemical	0,31	HPMA copolymer bound adriamycin
19712599_4	Chemical	97,105	abacavir
19712599_4	Gene_or_protein	120,125	HLA-B
19712599_4	Pharmacodynamic_phenotype	68,105	hypersensitivity reaction to abacavir
19712599_4	Haplotype	120,132	HLA-B * 5701
26566708_5	Limited_variation	55,81	HO-1 ( GT ) n polymorphism
26566708_5	Gene_or_protein	55,59	HO-1
26566708_5	Disease	86,92	cancer
26566708_5	Chemical	109,116	arsenic
23982599_5	Chemical	5,13	afatinib
23982599_5	Chemical	16,24	Gilotrif
23982599_5	Disease	112,138	non-small-cell lung cancer
23982599_5	Disease	141,146	NSCLC
23982599_5	Disease	158,165	tumours
23982599_5	Gene_or_protein	171,175	EGFR
23982599_5	Limited_variation	171,193	EGFR exon 19 deletions
23982599_5	Limited_variation	171,175,197,227	EGFR exon 21 ( L858R ) substitution
23982599_5	Genomic_factor	171,183	EGFR exon 19
19578241_10	Chemical	34,37	3TC
19578241_10	Limited_variation	117,125	rtA 181T
19578241_10	Gene_or_protein	117,120	rtA
19578241_10	Pharmacodynamic_phenotype	34,48	3TC resistance
19578241_10	Chemical	7,10	ADV
19578241_10	Chemical	171,174	ADV
19578241_10	Pharmacodynamic_phenotype	171,185	ADV -resistant
19578241_10	Limited_variation	0,68	Before ADV treatment , apart from 3TC resistance signature mutations
26603945_15	Gene_or_protein	79,83	DPYD
26603945_15	Limited_variation	79,83,93,102	DPYD c.2846A>T
26603945_15	Disease	159,165	cancer
26603945_15	Chemical	179,196	fluoropyrimidines
26603945_15	Haplotype	79,88	DPYD * 2A
26239294_9	Limited_variation	58,80	CHRNA5 coding variants
26239294_9	Gene_or_protein	58,64	CHRNA5
26239294_9	Chemical	115,123	nicotine
26239294_9	Disease	115,134	nicotine dependence
16251483_10	Chemical	9,16	arsenic
16251483_10	Gene_or_protein	75,78	p53
16251483_10	Gene_or_protein	83,86	p16
16251483_10	Disease	112,126	carcinogenesis
16251483_10	Phenotype	42,78	DNA methylation patterns in gene p53
16251483_10	Phenotype	42,74,83,86	DNA methylation patterns in gene p16
11587712_3	Chemical	82,101	naloxone methiodide
11587712_3	Phenotype	114,128	Fos expression
11587712_3	Gene_or_protein	114,117	Fos
11587712_3	Chemical	234,242	naloxone
11587712_3	Chemical	62,79	opioid antagonist
11587712_3	Phenotype	169,188	neuronal activation
21531995_4	Limited_variation	5,16	SCARB1 SNPs
21531995_4	Gene_or_protein	5,11	SCARB1
21531995_4	Pharmacodynamic_phenotype	36,55	progesterone levels
23739923_9	Phenotype	0,16	IFN-a production
23739923_9	Gene_or_protein	0,5	IFN-a
23739923_9	Chemical	76,97	deferoxamine mesylate
23739923_9	Gene_or_protein	137,154	von Hippel-Lindau
23739923_9	Gene_or_protein	157,160	VHL
23739923_9	Gene_or_protein	231,234	VHL
23739923_9	Limited_variation	224,234	mutant VHL
23739923_9	Limited_variation	127,154	wild-type von Hippel-Lindau
23739923_9	Disease	51,58	hypoxia
15944732_4	Gene_or_protein	59,69	HER2 / neu
15944732_4	Chemical	95,102	S-27609
15944732_4	Disease	153,168	mammary tumours
15944732_4	Chemical	82,91	Imiquimod
15944732_4	Phenotype	153,168,189,198	mammary tumours incidence
15944732_4	Chemical	21,102	DNA vaccine encoding a portion of rat HER2 / neu with either Imiquimod or S-27609
15944732_4	Chemical	220,235	DNA vaccination
28258422_9	Gene_or_protein	22,26	EGFR
28258422_9	Disease	166,169	ILD
28258422_9	Chemical	199,211	prednisolone
28258422_9	Chemical	22,31	EGFR -TKI
28258422_9	Pharmacodynamic_phenotype	4,31	adverse events of EGFR -TKI
28258422_9	Gene_or_protein	84,88	EGFR
28258422_9	Chemical	84,93	EGFR -TKI
21692767_12	Gene_or_protein	62,66	IL18
21692767_12	Disease	109,137	acute cutaneous inflammation
21692767_12	Chemical	151,158	aspirin
21692767_12	Pharmacodynamic_phenotype	201,205	AIAU
21692767_12	Haplotype	44,66	ht1 [ CG ] of the IL18
21692767_12	Pharmacodynamic_phenotype	109,158	acute cutaneous inflammation sensitive to aspirin
18754843_2	Limited_variation	53,80	CYP2D6 genetic polymorphism
18754843_2	Gene_or_protein	53,59	CYP2D6
18754843_2	Chemical	108,118	flecainide
18754843_2	Chemical	169,179	paroxetine
18754843_2	Gene_or_protein	185,191	CYP2D6
18754843_2	Pharmacokinetic_phenotype	88,118	pharmacokinetics of flecainide
18754843_2	Chemical	185,201	CYP2D6 inhibitor
15163695_4	Gene_or_protein	18,22	CREB
15163695_4	Chemical	81,88	ethanol
15163695_4	Phenotype	66,80,101,108	preference for sucrose
15163695_4	Genomic_variation	18,38	CREB -haplodeficient
15163695_4	Phenotype	66,88	preference for ethanol
15163695_4	Chemical	101,108	sucrose
15163695_4	Genomic_variation	123,132	wild-type
19448895_12	Limited_variation	52,54,62,78	AC CYP7A1 genotypes
19448895_12	Gene_or_protein	62,68	CYP7A1
19448895_12	Chemical	110,122	triglyceride
19448895_12	Chemical	188,200	triglyceride
19448895_12	Limited_variation	59,78	CC CYP7A1 genotypes
19448895_12	Pharmacodynamic_phenotype	110,136	triglyceride concentration
19448895_12	Pharmacodynamic_phenotype	188,214	triglyceride concentration
22348413_12	Chemical	28,35	statins
22348413_12	Gene_or_protein	40,46	CYP3A4
22348413_12	Pharmacokinetic_phenotype	5,35	interactions affecting statins
22348413_12	Chemical	63,75	transporters
17596442_8	Chemical	0,7	Cocaine
17596442_8	Gene_or_protein	53,73	glutamate receptor 1
17596442_8	Gene_or_protein	105,110	CB1-R
17596442_8	Chemical	134,139	AM251
17596442_8	Pharmacodynamic_phenotype	0,73	Cocaine -induced c AMP -dependent phosphorylation of glutamate receptor 1
17596442_8	Limited_variation	105,117	CB1-R mutant
17596442_8	Chemical	17,22	c AMP
17596442_8	Pharmacodynamic_phenotype	17,73	c AMP -dependent phosphorylation of glutamate receptor 1
17596442_8	Pharmacodynamic_phenotype	34,73	phosphorylation of glutamate receptor 1
20694283_8	Limited_variation	5,15	rs11676382
20694283_8	Gene_or_protein	0,4	GGCX
20694283_8	Chemical	60,68	warfarin
20694283_8	Pharmacodynamic_phenotype	60,73	warfarin dose
9205829_7	Chemical	14,23	Proguanil
9205829_7	Limited_variation	68,96	CYP2C19 genetic polymorphism
9205829_7	Gene_or_protein	68,75	CYP2C19
9205829_7	Pharmacokinetic_phenotype	176,180,195,207	poor metabolisers
9205829_7	Pharmacokinetic_phenotype	185,207	extensive metabolisers
9205829_7	Phenotype	133,156	urinary metabolic ratio
24322002_4	Limited_variation	71,90	FCGR3A polymorphism
24322002_4	Gene_or_protein	71,77	FCGR3A
24322002_4	Chemical	204,209	r-ATG
24322002_4	Phenotype	108,128	lymphocyte depletion
24322002_4	Chemical	172,201	rabbit antithymocyte globulin
24322002_4	Disease	132,149	kidney transplant
24152157_15	Chemical	87,98	allopurinol
24152157_15	Chemical	139,149	oxypurinol
24152157_15	Pharmacodynamic_phenotype	34,63	Type B adverse drug reactions
24152157_15	Pharmacodynamic_phenotype	87,115	allopurinol hypersensitivity
24152157_15	Pharmacodynamic_phenotype	139,175	oxypurinol -specific T cell response
24152157_15	Haplotype	235,248	HLA-B * 58:01
24152157_15	Gene_or_protein	235,240	HLA-B
25499099_6	Chemical	27,37	S-warfarin
25499099_6	Limited_variation	79,88	rs7089580
25499099_6	Pharmacokinetic_phenotype	9,37	oral clearance of S-warfarin
25499099_6	Limited_variation	79,101	rs7089580 allele ( T )
25499099_6	Limited_variation	116,137	wild-type homozygotes
21709633_9	Phenotype	56,59	FPG
21709633_9	Chemical	84,132	sulphonylurea treatment in addition to metformin
21709633_9	Disease	150,165	type 2 diabetes
21709633_9	Gene_or_protein	197,202	KCNQ1
21709633_9	Limited_variation	184,202	variation in KCNQ1
21709633_9	Chemical	84,97	sulphonylurea
21709633_9	Chemical	123,132	metformin
2134689_3	Chemical	34,47	S-mephenytoin
2134689_3	Chemical	61,75	R- mephenytoin
2134689_3	Gene_or_protein	111,135	cytochrome P-450 human-2
2134689_3	Pharmacokinetic_phenotype	17,47	hydroxylation of S-mephenytoin
2134689_3	Pharmacokinetic_phenotype	17,33,61,75	hydroxylation of R- mephenytoin
19929252_7	Limited_variation	26,44	DRD2 polymorphisms
19929252_7	Gene_or_protein	26,30	DRD2
19929252_7	Pharmacodynamic_phenotype	113,153	response to dopamine -agonists treatment
19929252_7	Chemical	125,153	dopamine -agonists treatment
19929252_7	Pharmacodynamic_phenotype	94,108,122,153	susceptibility to dopamine -agonists treatment
17042920_15	Chemical	14,26	cyclosporine
17042920_15	Gene_or_protein	58,64	CYP3A5
17042920_15	Disease	120,141	renal transplantation
17042920_15	Phenotype	58,79	CYP3A5 non-expressors
17042920_15	Pharmacokinetic_phenotype	14,43	cyclosporine dose-adjusted C0
17042920_15	Phenotype	58,64,85,95	CYP3A5 expressors
24681963_1	Limited_variation	17,44	Gly16Arg ADRB2 polymorphism
24681963_1	Gene_or_protein	26,31	ADRB2
24681963_1	Chemical	61,71	salmeterol
24681963_1	Chemical	75,86	montelukast
24681963_1	Disease	129,135	asthma
24681963_1	Pharmacodynamic_phenotype	48,71	responses to salmeterol
24681963_1	Pharmacodynamic_phenotype	48,60,75,86	responses to montelukast
23702428_7	Chemical	38,44	heroin
23702428_7	Phenotype	67,84	expression of MOR
23702428_7	Gene_or_protein	81,84	MOR
23702428_7	Gene_or_protein	211,215	ELK1
23702428_7	Disease	38,52	heroin abusers
23702428_7	Phenotype	89,138	extracellular regulated kinase signaling networks
23702428_7	Phenotype	158,215	dysregulation of the downstream transcription factor ELK1
23702428_7	Gene_or_protein	89,119	extracellular regulated kinase
12125044_5	Gene_or_protein	19,22	Jun
12125044_5	Chemical	84,95	amphetamine
12125044_5	Chemical	137,148	haloperidol
12125044_5	Gene_or_protein	27,37	35-kDa FRA
18991847_9	Limited_variation	43,77	genetic variant of the CSNK1E gene
18991847_9	Gene_or_protein	66,72	CSNK1E
18991847_9	Chemical	111,126	methamphetamine
18991847_9	Disease	141,150	psychosis
18991847_9	Disease	111,137	methamphetamine dependence
27498738_5	Gene_or_protein	0,31	Thiopurine S-methyl transferase
27498738_5	Gene_or_protein	34,38	TPMT
27498738_5	Chemical	73,89	6-mercaptopurine
27498738_5	Chemical	92,96	6-MP
27498738_5	Pharmacodynamic_phenotype	73,110	6-mercaptopurine ( 6-MP ) sensitivity
21366650_6	Chemical	183,193	tacrolimus
21366650_6	Gene_or_protein	202,209	CYP2C19
21366650_6	Gene_or_protein	275,281	CYP3A5
21366650_6	Limited_variation	202,218	CYP2C19 genotype
21366650_6	Pharmacodynamic_phenotype	137,165,180,193	maximum plasma concentration of tacrolimus
21366650_6	Pharmacokinetic_phenotype	69,115,183,193	area under the plasma concentration-time curve tacrolimus
21366650_6	Limited_variation	275,291	CYP3A5 genotypes
21366650_6	Chemical	497,509	lansoprazole
12851836_12	Limited_variation	38,51	DPYD mutation
12851836_12	Gene_or_protein	38,42	DPYD
12851836_12	Phenotype	68,88	lack of DPD activity
12851836_12	Gene_or_protein	76,79	DPD
12851836_12	Disease	180,186	cancer
12851836_12	Chemical	225,229	5-FU
12851836_12	Limited_variation	167,176	mutations
16595709_5	Limited_variation	26,40	UGT1A9 I399C>T
16595709_5	Gene_or_protein	26,32	UGT1A9
16595709_5	Chemical	109,115	SN-38G
16595709_5	Chemical	89,106	SN-38-glucuronide
16595709_5	Pharmacodynamic_phenotype	79,117	change in SN-38-glucuronide ( SN-38G )
16595709_5	Limited_variation	11,19	variants
22989574_5	Chemical	0,10	Crizotinib
22989574_5	Gene_or_protein	43,46	ALK
22989574_5	Disease	74,79	tumor
22989574_5	Gene_or_protein	110,113	ALK
22989574_5	Gene_or_protein	51,54	MET
22989574_5	Gene_or_protein	118,121	MET
22989574_5	Chemical	51,64	MET inhibitor
22989574_5	Chemical	43,46,55,64	ALK inhibitor
22989574_5	Limited_variation	96,113	alteration in ALK
22989574_5	Limited_variation	96,109,118,121	alteration in MET
21723857_2	Phenotype	22,37	TPMT deficiency
21723857_2	Gene_or_protein	22,26	TPMT
21723857_2	Chemical	72,75	AZA
21723857_2	Chemical	57,69	azathioprine
21723857_2	Pharmacodynamic_phenotype	57,111	azathioprine ( AZA ) - induced myelosuppression ( MS )
21723857_2	Pharmacodynamic_phenotype	107,109	MS
21723857_2	Pharmacodynamic_phenotype	88,104	myelosuppression
25495407_5	Chemical	10,20	paclitaxel
25495407_5	Gene_or_protein	32,38	CYP2C8
25495407_5	Limited_variation	48,64	CYP2C8 rs1934951
25495407_5	Gene_or_protein	48,54	CYP2C8
25495407_5	Disease	86,92	anemia
25495407_5	Limited_variation	99,114	ERCC1 Gln504Lys
25495407_5	Gene_or_protein	99,104	ERCC1
25495407_5	Disease	120,130	neuropathy
25495407_5	Pharmacodynamic_phenotype	10,29	paclitaxel toxicity
25495407_5	Limited_variation	32,43	CYP2C8 HapC
23147740_4	Chemical	44,56	posaconazole
23147740_4	Chemical	97,100	IPA
23147740_4	Gene_or_protein	148,153	Cyp51
23147740_4	Limited_variation	197,212	Cyp51 mutations
23147740_4	Gene_or_protein	197,202	Cyp51
23147740_4	Chemical	224,229	azole
23147740_4	Pharmacodynamic_phenotype	224,240	azole resistance
23147740_4	Limited_variation	148,163	Cyp51 wild-type
12518032_6	Chemical	31,39	T0901317
12518032_6	Gene_or_protein	54,57	LXR
12518032_6	Gene_or_protein	117,124	Angptl3
12518032_6	Phenotype	89,112	levels of plasma lipids
12518032_6	Phenotype	89,98,117,129	levels of Angptl3 mRNA
12518032_6	Chemical	54,76	LXR -selective agonist
12518032_6	Genomic_factor	117,129	Angptl3 mRNA
14683587_2	Gene_or_protein	61,64	p53
14683587_2	Limited_variation	61,67	p53 wt
14683587_2	Chemical	91,100	cisplatin
14683587_2	Limited_variation	211,221	p53 status
14683587_2	Disease	146,155,175,184	prostatic carcinoma
14683587_2	Gene_or_protein	211,214	p53
14683587_2	Disease	108,118,175,184	colorectal carcinoma
24702251_4	Chemical	0,11	Hydralazine
24702251_4	Gene_or_protein	53,74	N-acetyltransferase 2
26518936_1	Gene_or_protein	50,56	Cyp3a5
26518936_1	Chemical	91,101	Tacrolimus
26518936_1	Haplotype	50,60	Cyp3a5 * 1
26518936_1	Pharmacodynamic_phenotype	72,101	Need More Doses of Tacrolimus
21995462_17	Limited_variation	86,96	IVS4+76G>A
21995462_17	Limited_variation	99,119	699G>A ( Met233Ile )
21995462_17	Limited_variation	122,135	IVS12-5676A>G
21995462_17	Limited_variation	142,155	*347_*348insA
21995462_17	Chemical	215,224	docetaxel
21995462_17	Pharmacokinetic_phenotype	200,236	variability in docetaxel disposition
21995462_17	Pharmacokinetic_phenotype	239,248	clearance
21995462_17	Pharmacokinetic_phenotype	253,299	area under the plasma concentration-time curve
20159992_1	Limited_variation	4,45	FLT3 internal tandem duplication mutation
20159992_1	Gene_or_protein	4,8	FLT3
20159992_1	Chemical	101,113	AZD1152-HQPA
20159992_1	Disease	117,143	acute myelogenous leukemia
20159992_1	Gene_or_protein	75,90	aurora B kinase
20159992_1	Chemical	75,100	aurora B kinase inhibitor
17030231_4	Gene_or_protein	66,91	beta2-adrenergic receptor
17030231_4	Gene_or_protein	99,104	ADRB2
17030231_4	Limited_variation	49,106	variation in the beta2-adrenergic receptor gene ( ADRB2 )
17030231_4	Chemical	131,182	salmeterol administered with fluticasone propionate
17030231_4	Pharmacodynamic_phenotype	119,182	response to salmeterol administered with fluticasone propionate
17030231_4	Chemical	131,141	salmeterol
17030231_4	Chemical	160,182	fluticasone propionate
11491416_8	Chemical	77,87	zidovudine
11491416_8	Limited_variation	159,168	wild-type
11491416_8	Limited_variation	77,108	zidovudine -associated mutation
11491416_8	Limited_variation	113,118	M184V
11491416_8	Phenotype	25,45	replication capacity
18794726_7	Chemical	24,32	atenolol
18794726_7	Limited_variation	93,126	beta1-AR ( Ser49Gly , Arg389Gly )
18794726_7	Gene_or_protein	93,101	beta1-AR
18794726_7	Gene_or_protein	131,141	alpha2C-AR
18794726_7	Limited_variation	131,156	alpha2C-AR ( del322-325 )
18794726_7	Pharmacodynamic_phenotype	17,47	plasma atenolol concentrations
20043790_1	Chemical	28,36	spinosad
20043790_1	Chemical	41,59	milbemycin 5-oxime
20043790_1	Limited_variation	100,118	MDR1 gene mutation
20043790_1	Gene_or_protein	100,104	MDR1
20043790_1	Pharmacodynamic_phenotype	18,36	safety of spinosad
20043790_1	Pharmacodynamic_phenotype	18,27,41,59	safety of milbemycin 5-oxime
19021634_8	Limited_variation	13,27	CHEK2 mutation
19021634_8	Gene_or_protein	13,18	CHEK2
19021634_8	Gene_or_protein	68,70	ER
19021634_8	Chemical	123,132	tamoxifen
19021634_8	Disease	68,94	ER -positive breast cancer
19021634_8	Phenotype	68,80	ER -positive
19021634_8	Chemical	123,148	tamoxifen chemoprevention
22394227_9	Gene_or_protein	115,118	AhR
22394227_9	Chemical	234,244	polyphenol
22394227_9	Chemical	115,130	AhR antagonists
22394227_9	Pharmacodynamic_phenotype	207,229	antioxidative activity
26450446_1	Chemical	0,7	AZD9291
26450446_1	Gene_or_protein	11,15	EGFR
26450446_1	Disease	11,59	EGFR -mutant advanced non-small-cell lung cancer
26450446_1	Limited_variation	11,23	EGFR -mutant
23737969_11	Gene_or_protein	43,49	UGT1A1
23737969_11	Haplotype	43,53	UGT1A1 * 6
23737969_11	Phenotype	75,95	creatinine elevation
23737969_11	Phenotype	0,21	Body weight > = 40 kg
11888518_8	Chemical	30,36	BO-653
11888518_8	Chemical	47,55	probucol
11888518_8	Phenotype	82,97	c-myc induction
11888518_8	Gene_or_protein	82,87	c-myc
11888518_8	Phenotype	12,27	gene expression
12958193_8	Gene_or_protein	46,53	CYP3a13
12958193_8	Chemical	57,70	dexamethasone
12958193_8	Gene_or_protein	89,108	pregnane X receptor
12958193_8	Pharmacodynamic_phenotype	33,70	induction of CYP3a13 by dexamethasone
12958193_8	Genomic_variation	89,113	pregnane X receptor null
21107535_6	Chemical	26,33	MnCl(2)
21107535_6	Gene_or_protein	103,107	Nrf2
21107535_6	Gene_or_protein	136,140	Nrf2
21107535_6	Gene_or_protein	148,152	HO-1
21107535_6	Phenotype	185,198,225,229	expression of HO-1
21107535_6	Gene_or_protein	202,222	Nrf2 -regulated gene
21107535_6	Gene_or_protein	225,229	HO-1
21107535_6	Phenotype	65,74,87,107	cytosolic accumulation of Nrf2
21107535_6	Phenotype	79,107	nuclear accumulation of Nrf2
21107535_6	Phenotype	125,152	binding of Nrf2 to the HO-1
21107535_6	Gene_or_protein	202,206	Nrf2
19000371_7	Phenotype	4,19,38,42	levels of c-fos mRNA
19000371_7	Gene_or_protein	14,19	c-fos
19000371_7	Gene_or_protein	22,27	c-jun
19000371_7	Chemical	169,180	doxorubicin
19000371_7	Phenotype	4,13,22,27,38,42	levels of c-jun mRNA
19000371_7	Gene_or_protein	70,75	rsGFP
19000371_7	Phenotype	60,83	levels of rsGFP protein
19000371_7	Phenotype	4,13,32,42	levels of rsGFP mRNA
19000371_7	Gene_or_protein	32,37	rsGFP
19000371_7	Genomic_factor	32,42	rsGFP mRNA
19000371_7	Genomic_factor	22,27,38,42	c-jun mRNA
19000371_7	Genomic_factor	14,19,38,42	c-fos mRNA
8530458_13	Chemical	25,39	streptozotocin
8530458_13	Genomic_factor	126,138	FAS promoter
8530458_13	Chemical	0,7	Insulin
8530458_13	Gene_or_protein	75,78	CAT
8530458_13	Phenotype	75,87	CAT activity
8530458_13	Phenotype	92,107	CAT mRNA levels
8530458_13	Gene_or_protein	92,95	CAT
8530458_13	Disease	25,50	streptozotocin - diabetic
8530458_13	Gene_or_protein	126,129	FAS
8530458_13	Genomic_factor	92,100	CAT mRNA
23752130_11	Chemical	32,44	butyric acid
23752130_11	Gene_or_protein	98,104	MFG-E8
23752130_11	Disease	141,148	colitis
23752130_11	Pharmacodynamic_phenotype	108,148	DSS -induced murine experimental colitis
23752130_11	Chemical	108,111	DSS
23752130_11	Pharmacodynamic_phenotype	61,86	anti-inflammatory effects
15717164_13	Gene_or_protein	8,14	GST-M1
15717164_13	Chemical	34,50	cyclophosphamide
15717164_13	Limited_variation	62,81	GST-P1 polymorphism
15717164_13	Gene_or_protein	62,68	GST-P1
15717164_13	Limited_variation	8,19	GST-M1 null
15717164_13	Pharmacodynamic_phenotype	34,59	cyclophosphamide efficacy
15717164_13	Phenotype	114,148	susceptibility to further relapses
15998902_8	Chemical	0,12	Temsirolimus
15998902_8	Chemical	47,56	sirolimus
15998902_8	Gene_or_protein	143,147	p450
15998902_8	Pharmacodynamic_phenotype	0,40	Temsirolimus peak concentration ( Cmax )
15998902_8	Pharmacodynamic_phenotype	47,61	sirolimus Cmax
15998902_8	Pharmacokinetic_phenotype	47,56,66,105	sirolimus area under the concentration-time curve
15998902_8	Chemical	143,179	p450 enzyme-inducing anticonvulsants
15998902_8	Chemical	182,187	EIACs
23756537_2	Gene_or_protein	45,49	MDR1
23756537_2	Limited_variation	45,56	MDR1 C3435T
23756537_2	Chemical	130,142	cyclosporine
23756537_2	Chemical	145,148	CsA
23756537_2	Disease	212,232	gingival hyperplasia
23756537_2	Disease	235,237	GH
23756537_2	Phenotype	202,232	degree of gingival hyperplasia
23756537_2	Disease	91,107	renal transplant
18161298_22	Phenotype	4,35	expression of cleaved Caspase-3
18161298_22	Gene_or_protein	26,35	Caspase-3
18161298_22	Chemical	39,42	WCA
18161298_22	Chemical	53,57	5-FU
18161298_22	Genomic_factor	18,35	cleaved Caspase-3
23225895_8	Gene_or_protein	41,47	pfmdr1
23225895_8	Chemical	96,108	lumefantrine
23225895_8	Pharmacodynamic_phenotype	96,129	lumefantrine blood concentrations
23225895_8	Haplotype	41,72	pfmdr1 N86/184F/D1246 haplotype
23225895_8	Haplotype	165,189	86Y/Y184/1246Y haplotype
24673480_4	Gene_or_protein	87,93	CYP2D6
24673480_4	Pharmacodynamic_phenotype	12,26	effective dose
24673480_4	Pharmacodynamic_phenotype	42,64	adverse drug reactions
24673480_4	Pharmacodynamic_phenotype	67,71	ADRs
24673480_4	Limited_variation	87,102	CYP2D6 genotype
24673480_4	Chemical	112,122	carvedilol
24458010_2	Chemical	0,7	Codeine
24458010_2	Chemical	27,35	morphine
24458010_2	Gene_or_protein	79,98	cytochrome P450 2D6
24458010_2	Gene_or_protein	101,107	CYP2D6
24458010_2	Chemical	147,154	codeine
24458010_2	Phenotype	171,186	CYP2D6 activity
24458010_2	Gene_or_protein	171,177	CYP2D6
24458010_2	Chemical	47,53	opioid
24458010_2	Chemical	47,61	opioid agonist
24458010_2	Pharmacodynamic_phenotype	124,132,144,154	efficacy of codeine
24458010_2	Pharmacodynamic_phenotype	137,154	safety of codeine
15265979_11	Chemical	97,107	amiodarone
15265979_11	Gene_or_protein	126,135	PPARalpha
15265979_11	Chemical	153,163	amiodarone
15265979_11	Pharmacodynamic_phenotype	74,107	hepatotoxic effects of amiodarone
15265979_11	Pharmacodynamic_phenotype	153,187	amiodarone -induced hepatotoxicity
15265979_11	Disease	173,187	hepatotoxicity
12021632_1	Gene_or_protein	40,49	MDR1 gene
12021632_1	Chemical	54,66	cyclosporine
12021632_1	Genomic_factor	19,49	exon 26 of the human MDR1 gene
12021632_1	Limited_variation	0,49	C3435T mutation in exon 26 of the human MDR1 gene
12021632_1	Pharmacokinetic_phenotype	54,83	cyclosporine pharmacokinetics
20216107_11	Gene_or_protein	23,27	COMT
20216107_11	Chemical	77,88	propranolol
20216107_11	Phenotype	92,107	pain perception
20216107_11	Haplotype	23,51	COMT high activity haplotype
20216107_11	Limited_variation	201,214	heterozygotes
20216107_11	Limited_variation	249,260	homozygotes
20216107_11	Pharmacodynamic_phenotype	67,107	effect of propranolol on pain perception
20216107_11	Haplotype	148,157	haplotype
15217301_7	Pharmacokinetic_phenotype	129,149	disposition kinetics
15217301_7	Gene_or_protein	54,58	MDR1
15217301_7	Chemical	224,236	fexofenadine
15217301_7	Chemical	239,250	ciclosporin
15217301_7	Chemical	255,264	talinolol
15217301_7	Limited_variation	33,58	polymorphisms of the MDR1
15217301_7	Chemical	214,221	digoxin
22811313_10	Chemical	6,14	androgen
22811313_10	Limited_variation	100,114	FMR1 genotypes
22811313_10	Gene_or_protein	100,104	FMR1
22811313_10	Chemical	163,175	testosterone
22811313_10	Pharmacodynamic_phenotype	6,29	androgen concentrations
22811313_10	Phenotype	55,64	pregnancy
22811313_10	Limited_variation	140,155	normal genotype
22811313_10	Phenotype	208,227	pregnancy potential
24977443_10	Gene_or_protein	120,126	UGT1A1
24977443_10	Chemical	214,224	irinorecan
24977443_10	Chemical	272,282	irinotecan
24977443_10	Disease	310,327	colorectal cancer
24977443_10	Phenotype	120,137	UGT1A1 deficiency
24704376_7	Limited_variation	20,30	rs35349697
24704376_7	Disease	77,93	opioid addiction
24704376_7	Disease	110,127	alcohol addiction
24704376_7	Chemical	110,117	alcohol
24704376_7	Chemical	77,83	opioid
24704376_7	Limited_variation	4,17	SNP in exon 3
24704376_7	Genomic_factor	11,17	exon 3
22771883_2	Chemical	165,179	gadoxetic acid
22771883_2	Chemical	273,287	gadoxetic acid
22771883_2	Limited_variation	26,119,128,135	genetic polymorphisms of liver-specific human organic anion transporting polypeptide ( OATP ) OATP1B3
22771883_2	Gene_or_protein	113,117	OATP
22771883_2	Limited_variation	26,123	genetic polymorphisms of liver-specific human organic anion transporting polypeptide ( OATP ) 1B1
22771883_2	Pharmacokinetic_phenotype	155,179	uptake of gadoxetic acid
22771883_2	Pharmacodynamic_phenotype	252,287	liver enhancement by gadoxetic acid
22771883_2	Gene_or_protein	72,110	organic anion transporting polypeptide
20226083_1	Limited_variation	0,44	RRM1 single nucleotide polymorphism -37C-->A
20226083_1	Gene_or_protein	0,4	RRM1
20226083_1	Disease	90,95	NSCLC
20226083_1	Chemical	111,122	gemcitabine
20226083_1	Phenotype	61,86	progression-free survival
20226083_1	Chemical	111,142	gemcitabine -based chemotherapy
19176891_5	Chemical	64,67	CCK
19176891_5	Chemical	222,225	CCK
19176891_5	Gene_or_protein	249,255	ERK1/2
19176891_5	Gene_or_protein	143,149	ERK1/2
19176891_5	Genomic_factor	152,159	pERK1/2
19176891_5	Genomic_factor	128,149	phosphorylated ERK1/2
19176891_5	Pharmacodynamic_phenotype	222,255	CCK -induced expression of ERK1/2
19176891_5	Pharmacodynamic_phenotype	235,255	expression of ERK1/2
19176891_5	Gene_or_protein	272,292	tyrosine hydroxylase
19176891_5	Phenotype	272,308	tyrosine hydroxylase -immunoreactive
15010519_9	Chemical	13,25	Lansoprazole
15010519_9	Gene_or_protein	56,63	CYP2C19
15010519_9	Gene_or_protein	68,74	CYP3A4
18805405_1	Phenotype	14,50	transcriptional activation of CYP3A4
18805405_1	Gene_or_protein	0,3	PXR
18805405_1	Gene_or_protein	44,50	CYP3A4
18805405_1	Chemical	54,70	cryptotanshinone
18805405_1	Chemical	75,89	tanshinone IIA
15020609_2	Gene_or_protein	42,69	multidrug resistance gene-1
15020609_2	Chemical	102,109	PSC 833
15020609_2	Gene_or_protein	72,77	MDR-1
15020609_2	Disease	223,245	acute myeloid leukemia
15020609_2	Disease	248,251	AML
15020609_2	Disease	268,292	myelodysplastic syndrome
15020609_2	Disease	295,298	MDS
15020609_2	Chemical	90,99	valspodar
15020609_2	Chemical	31,169	adding the multidrug resistance gene-1 ( MDR-1 ) modulator valspodar ( PSC 833 ; Novartis Pharmaceuticals , Hanover , NJ ) to chemotherapy
15020609_2	Pharmacodynamic_phenotype	179,195	clinical benefit
24293093_1	Gene_or_protein	27,33	CYP2B6
24293093_1	Disease	101,125	chronic myeloid leukemia
24293093_1	Chemical	148,156	imatinib
24293093_1	Limited_variation	0,41	Functional polymorphism of CYP2B6 G15631T
24293093_1	Pharmacodynamic_phenotype	77,97	cytogenetic response
24293093_1	Pharmacodynamic_phenotype	61,72,89,97	hematologic response
11849656_2	Disease	349,359	restenosis
11849656_2	Gene_or_protein	102,131	angiotensin converting enzyme
11849656_2	Gene_or_protein	134,137	ACE
11849656_2	Gene_or_protein	169,184	angiotensinogen
11849656_2	Gene_or_protein	187,190	AGT
11849656_2	Limited_variation	169,198	angiotensinogen ( AGT ) M253T
11849656_2	Gene_or_protein	203,233	angiotensin II type 1 receptor
11849656_2	Gene_or_protein	236,240	AT1R
11849656_2	Limited_variation	203,249	angiotensin II type 1 receptor ( AT1R ) A1166C
11849656_2	Chemical	270,279	quinapril
11849656_2	Gene_or_protein	285,288	ACE
11849656_2	Limited_variation	102,158	angiotensin converting enzyme ( ACE ) insertion/deletion
11849656_2	Pharmacodynamic_phenotype	260,279	effect of quinapril
11849656_2	Gene_or_protein	32,77	renin-angiotensin system ( RAS ) related gene
11849656_2	Limited_variation	32,91	renin-angiotensin system ( RAS ) related gene polymorphisms
11849656_2	Chemical	285,298	ACE inhibitor
11849656_2	Disease	366,400	percutaneous coronary intervention
11849656_2	Disease	403,406	PCI
26505400_7	Limited_variation	0,9	rs2115819
26505400_7	Limited_variation	12,21	rs9934438
26505400_7	Limited_variation	28,36	rs689466
26505400_7	Gene_or_protein	54,59	ALOX5
26505400_7	Gene_or_protein	62,89	arachidonate 5-lipoxygenase
26505400_7	Gene_or_protein	94,100	VKORC1
26505400_7	Chemical	103,120	vitamin K epoxide
26505400_7	Gene_or_protein	157,162	PTGS2
26505400_7	Gene_or_protein	165,202	prostaglandin-endoperoxide synthase 2
26505400_7	Gene_or_protein	103,150	vitamin K epoxide reductase complex , subunit 1
12846271_3	Limited_variation	26,63	aromatase gene ( CYP19 ) polymorphism
12846271_3	Gene_or_protein	43,48	CYP19
12846271_3	Chemical	84,93	estradiol
12846271_3	Phenotype	110,130	bone mineral density
12846271_3	Phenotype	133,136	BMD
12846271_3	Phenotype	155,163	fracture
12846271_3	Pharmacodynamic_phenotype	72,107	circulating estradiol ( E2 ) levels
12846271_3	Phenotype	141,151	BMD change
12846271_3	Gene_or_protein	26,40	aromatase gene
12846271_3	Chemical	96,98	E2
23030234_8	Chemical	19,23	MDMA
23030234_8	Gene_or_protein	183,213	serotonin reuptake transporter
23030234_8	Gene_or_protein	216,220	SERT
23030234_8	Pharmacodynamic_phenotype	19,37	MDMA plasma levels
23030234_8	Phenotype	64,78	blood pressure
23030234_8	Phenotype	81,91	heart rate
23030234_8	Phenotype	94,110	body temperature
23030234_8	Chemical	0,5	SSRIs
23030234_8	Pharmacodynamic_phenotype	148,222	pharmacodynamic interaction at the serotonin reuptake transporter ( SERT )
23030234_8	Pharmacodynamic_phenotype	19,23,40,56	MDMA clinical effects
23115637_2	Limited_variation	42,74	polymorphisms of the GABRA2 gene
23115637_2	Gene_or_protein	63,69	GABRA2
23115637_2	Gene_or_protein	88,109	GABA ( A ) a2-subunit
23115637_2	Chemical	130,137	ethanol
23115637_2	Disease	130,148	ethanol dependence
26240276_10	Phenotype	14,29	HAGE expression
26240276_10	Gene_or_protein	14,18	HAGE
26240276_10	Chemical	94,107	anthracycline
26240276_10	Disease	121,125	TNBC
26240276_10	Pharmacodynamic_phenotype	82,117	response to anthracycline treatment
28213291_1	Disease	55,93	oxidative stress -induced liver damage
28213291_1	Chemical	27,46	2'-O-galloylhyperin
28213291_1	Gene_or_protein	115,119	Nrf2
28213291_1	Pharmacodynamic_phenotype	0,46	Hepatoprotective effect of 2'-O-galloylhyperin
16402341_5	Disease	43,45	TD
16402341_5	Chemical	61,74	phenylalanine
16402341_5	Gene_or_protein	134,159	phenylalanine hydroxylase
16402341_5	Gene_or_protein	162,165	PAH
16402341_5	Chemical	216,229	phenylalanine
16402341_5	Disease	257,259	TD
16402341_5	Pharmacokinetic_phenotype	61,85	phenylalanine metabolism
16402341_5	Limited_variation	109,167	variants in the gene for phenylalanine hydroxylase ( PAH )
16402341_5	Pharmacokinetic_phenotype	202,229	catabolism of phenylalanine
27525598_2	Gene_or_protein	40,60	interleukin (IL)-28B
27525598_2	Chemical	170,196	pegylated interferon-alpha
27525598_2	Chemical	201,210	ribavirin
27525598_2	Disease	303,306	CHC
27525598_2	Limited_variation	15,60	polymorphism upstream of interleukin (IL)-28B
27525598_2	Disease	281,300	chronic hepatitis C
27525598_2	Chemical	170,210	pegylated interferon-alpha and ribavirin
27525598_2	Pharmacodynamic_phenotype	130,158,167,210	sustained virologic response to pegylated interferon-alpha and ribavirin
27525598_2	Disease	281,345	chronic hepatitis C ( CHC ) virus genotype 1 ( HCV-1 ) infection
27525598_2	Phenotype	161,164	SVR
27525598_2	Phenotype	130,158	sustained virologic response
20005399_5	Chemical	21,33	nitric oxide
20005399_5	Limited_variation	64,117	genetic variation in endothelial NO synthase ( eNOS )
20005399_5	Gene_or_protein	111,115	eNOS
20005399_5	Disease	145,157	hypertension
20005399_5	Disease	160,170	thrombosis
20005399_5	Disease	173,182	vasospasm
20005399_5	Disease	189,204	atherosclerosis
20005399_5	Disease	246,249	CAN
20005399_5	Chemical	36,38	NO
20005399_5	Gene_or_protein	85,108	endothelial NO synthase
20005399_5	Pharmacokinetic_phenotype	21,48	nitric oxide ( NO ) release
23515284_5	Chemical	0,3	PTH
23515284_5	Chemical	72,74	Pi
23515284_5	Chemical	102,104	Pi
23515284_5	Limited_variation	108,110	DD
23515284_5	Limited_variation	78,80	Wt
23515284_5	Pharmacodynamic_phenotype	66,74	serum Pi
23515284_5	Pharmacodynamic_phenotype	96,104	serum Pi
27217047_10	Chemical	69,79	tacrolimus
27217047_10	Gene_or_protein	151,157	CYP3A5
27217047_10	Gene_or_protein	233,239	CYP3A5
27217047_10	Gene_or_protein	295,301	CYP3A5
27217047_10	Haplotype	295,305	CYP3A5 * 1
27217047_10	Haplotype	113,129	CYP3A5 * 3 / * 3
27217047_10	Haplotype	151,161	CYP3A5 * 1
27217047_10	Haplotype	233,249	CYP3A5 * 3 / * 3
27217047_10	Chemical	47,49	AZ
27217047_10	Pharmacodynamic_phenotype	56,79	C0 values of tacrolimus
27217047_10	Pharmacodynamic_phenotype	194,215	daily doses of Tac-QD
27217047_10	Chemical	209,215	Tac-QD
27217047_10	Gene_or_protein	113,119	CYP3A5
9795138_10	Genomic_factor	107,119	zif/268 mRNA
9795138_10	Gene_or_protein	107,114	zif/268
9795138_10	Chemical	147,159	PVP and oPRL
9795138_10	Phenotype	60,119	average number of cells/animal which expressed zif/268 mRNA
21734808_2	Limited_variation	28,67	cytosine deaminase ( bCD ) mutant D314A
21734808_2	Chemical	72,88	5-fluorocytosine
21734808_2	Chemical	91,95	5-FC
21734808_2	Disease	115,127	colon cancer
21734808_2	Gene_or_protein	49,52	bCD
21734808_2	Gene_or_protein	28,46	cytosine deaminase
20512075_2	Chemical	50,59	gefitinib
20512075_2	Chemical	64,73	erlotinib
20512075_2	Disease	91,118	non-small cell lung cancers
20512075_2	Disease	121,127	NSCLCs
20512075_2	Limited_variation	135,191	epidermal growth factor receptor ( EGFR ) gene mutations
20512075_2	Gene_or_protein	135,167	epidermal growth factor receptor
20512075_2	Gene_or_protein	170,174	EGFR
20512075_2	Chemical	14,40	tyrosine kinase inhibitors
20512075_2	Chemical	43,47	TKIs
20512075_2	Gene_or_protein	14,29	tyrosine kinase
15099407_2	Gene_or_protein	0,21	Alcohol dehydrogenase
15099407_2	Gene_or_protein	24,27	ADH
15099407_2	Gene_or_protein	73,78	ALDH2
15099407_2	Chemical	126,133	ethanol
15099407_2	Chemical	210,217	ethanol
15099407_2	Gene_or_protein	34,70	mitochondrial aldehyde dehydrogenase
15099407_2	Pharmacokinetic_phenotype	210,229	ethanol elimination
8970671_3	Pharmacodynamic_phenotype	0,24	RESISTANCE TO SAQUINAVIR
8970671_3	Chemical	14,24	SAQUINAVIR
8970671_3	Pharmacodynamic_phenotype	27,51	Resistance to saquinavir
8970671_3	Chemical	41,51	saquinavir
8970671_3	Limited_variation	102,106,116,131	L90M in HIV protease
8970671_3	Limited_variation	111,131	G48V in HIV protease
8970671_3	Disease	119,122	HIV
8970671_3	Gene_or_protein	119,131	HIV protease
16485141_1	Chemical	0,8	Nicotine
16485141_1	Chemical	65,73	nicotine
16485141_1	Gene_or_protein	90,96	CYP2A5
16485141_1	Pharmacokinetic_phenotype	56,86	rates of nicotine inactivation
16485141_1	Phenotype	0,28	Nicotine self-administration
19620488_3	Gene_or_protein	32,36	HER2
19620488_3	Gene_or_protein	41,46	TOP2A
19620488_3	Disease	74,87	breast cancer
19620488_3	Chemical	141,157	cyclophosphamide
19620488_3	Chemical	119,130	doxorubicin
19620488_3	Genomic_variation	18,36	status of the HER2
19620488_3	Genomic_variation	18,31,41,46	status of the TOP2A
23569304_9	Pharmacodynamic_phenotype	9,34	resistance to vemurafenib
23569304_9	Chemical	23,34	vemurafenib
23569304_9	Phenotype	106,135	ERK1/2 phosphorylation levels
23569304_9	Gene_or_protein	106,112	ERK1/2
23569304_9	Gene_or_protein	191,195	NRAS
23569304_9	Gene_or_protein	217,221	MEK1
23569304_9	Limited_variation	217,230,247,256	MEK1 ( Q56P ) mutations
23569304_9	Gene_or_protein	234,244	MEK1(E203K
23569304_9	Gene_or_protein	67,71	MAPK
23569304_9	Phenotype	51,81	reactivation of MAPK signaling
23569304_9	Limited_variation	191,213	NRAS ( Q61 ) mutations
23569304_9	Limited_variation	234,256	MEK1(E203K ) mutations
22300961_11	Chemical	57,72	25-OH vitamin D
22300961_11	Gene_or_protein	163,168	NR1I1
22300961_11	Haplotype	163,172	NR1I1 CCA
22300961_11	Phenotype	93,113	virological response
22300961_11	Pharmacodynamic_phenotype	53,79	low 25-OH vitamin D levels
22300961_11	Haplotype	175,178	bAt
21139584_10	Chemical	13,19	GUT-70
21139584_10	Disease	64,80	MCL with mt- p53
21139584_10	Gene_or_protein	77,80	p53
21139584_10	Disease	122,125	MCL
21139584_10	Phenotype	136,152	Hsp90 inhibition
21139584_10	Gene_or_protein	136,141	Hsp90
21139584_10	Limited_variation	73,80	mt- p53
19695401_17	Gene_or_protein	78,82	TPMT
19695401_17	Chemical	121,133	azathioprine
19695401_17	Haplotype	78,87	TPMT * 3C
19695401_17	Pharmacodynamic_phenotype	121,159	azathioprine -induced myelosuppression
19695401_17	Disease	22,39	kidney transplant
19695401_17	Pharmacodynamic_phenotype	143,159	myelosuppression
26743855_3	Disease	85,99	adenocarcinoma
26743855_3	Gene_or_protein	131,135	EGFR
26743855_3	Chemical	205,234	platinum doublet chemotherapy
26743855_3	Limited_variation	131,151	EGFR mutation status
26743855_3	Phenotype	274,291	clinical outcomes
26743855_3	Phenotype	296,315	recurrence patterns
26743855_3	Chemical	205,213	platinum
26743855_3	Limited_variation	329,344	mutation status
17555608_2	Chemical	134,142	propofol
17555608_2	Chemical	225,233	propofol
17555608_2	Limited_variation	366,374,412,417	genotype GABRE
17555608_2	Gene_or_protein	412,417	GABRE
17555608_2	Limited_variation	520,528,556,562	genotype CYP2B6
17555608_2	Gene_or_protein	556,562	CYP2B6
17555608_2	Pharmacodynamic_phenotype	193,212	time to eye opening
17555608_2	Pharmacodynamic_phenotype	308,345	time to achieve bispectral index < 70
17555608_2	Pharmacokinetic_phenotype	475,494	time to eye opening
17555608_2	Pharmacodynamic_phenotype	165,186	bispectral index < 70
17555608_2	Pharmacokinetic_phenotype	459,468	clearance
25194407_11	Phenotype	45,63	serum level of PTH
25194407_11	Gene_or_protein	60,63	PTH
25194407_11	Gene_or_protein	78,86	fetuin-A
25194407_11	Chemical	91,100	vitamin D
25194407_11	Gene_or_protein	193,196	VDR
25194407_11	Phenotype	78,86,101,107	fetuin-A levels
25194407_11	Pharmacodynamic_phenotype	91,107	vitamin D levels
25194407_11	Disease	139,154	atherosclerosis
25194407_11	Limited_variation	193,206,216,229	VDR gene FokI polymorphisms
25194407_11	Limited_variation	193,201,211,229	VDR gene ApaI polymorphisms
16297086_5	Chemical	0,9	Tamoxifen
16297086_5	Disease	30,43	breast cancer
16297086_5	Gene_or_protein	47,53	BRCA-2
16297086_5	Gene_or_protein	85,91	BRCA-1
16297086_5	Limited_variation	47,62	BRCA-2 mutation
16297086_5	Limited_variation	85,100	BRCA-1 mutation
20487194_4	Gene_or_protein	109,114	HLA-B
20487194_4	Chemical	180,188	abacavir
20487194_4	Gene_or_protein	191,221	thiopurine S-methyltransferase
20487194_4	Gene_or_protein	224,228	TPMT
20487194_4	Chemical	251,261	thiopurine
20487194_4	Gene_or_protein	277,283	CYP2C9
20487194_4	Gene_or_protein	288,294	VKORC1
20487194_4	Chemical	345,353	warfarin
20487194_4	Haplotype	109,121	HLA-B * 5701
20487194_4	Pharmacodynamic_phenotype	141,188	hypersensitivity to the antiretroviral abacavir
20487194_4	Pharmacodynamic_phenotype	251,270	thiopurine toxicity
20487194_4	Pharmacodynamic_phenotype	317,353	dosing of the anticoagulant warfarin
20487194_4	Limited_variation	191,241	thiopurine S-methyltransferase ( TPMT ) genotyping
20487194_4	Limited_variation	288,305	VKORC1 genotyping
20487194_4	Limited_variation	277,283,295,305	CYP2C9 genotyping
20487194_4	Chemical	331,344	anticoagulant
26556583_1	Gene_or_protein	16,34	cytidine deaminase
26556583_1	Chemical	65,76	azacitidine
26556583_1	Pharmacodynamic_phenotype	53,76	response to azacitidine
18433425_8	Gene_or_protein	3,18	cytochrome P450
18433425_8	Chemical	38,47	yohimbine
18433425_8	Limited_variation	50,64	P450 genotypes
18433425_8	Gene_or_protein	50,54	P450
18433425_8	Gene_or_protein	67,73	CYP2D6
18433425_8	Gene_or_protein	78,84	CYP3A4
18429967_8	Gene_or_protein	3,9	CYP3A5
18429967_8	Gene_or_protein	32,38	CYP3A5
18429967_8	Gene_or_protein	325,331	CYP3A5
18429967_8	Limited_variation	363,387	CYP3A5 genetic variation
18429967_8	Gene_or_protein	363,369	CYP3A5
18429967_8	Chemical	406,416	tacrolimus
18429967_8	Haplotype	3,13	CYP3A5 * 1
18429967_8	Pharmacokinetic_phenotype	80,89	clearance
18429967_8	Pharmacokinetic_phenotype	406,439	tacrolimus chronopharmacokinetics
18429967_8	Phenotype	32,49	CYP3A5 expressers
18429967_8	Phenotype	325,346	CYP3A5 non-expressers
23962279_13	Gene_or_protein	0,4	TPMT
23962279_13	Gene_or_protein	82,86	TPMT
23962279_13	Chemical	130,140	thiopurine
23962279_13	Phenotype	82,96	TPMT deficient
15386371_15	Chemical	55,59	5-FU
15386371_15	Gene_or_protein	104,106	TS
15386371_15	Limited_variation	141,145	VNTR
15386371_15	Limited_variation	154,185	SNP located within the promoter
15386371_15	Limited_variation	104,115	TS genotype
19212337_5	Disease	47,66	CEL in blast crisis
19212337_5	Gene_or_protein	22,28	FIP1L1
19212337_5	Chemical	85,94	sorafenib
19212337_5	Limited_variation	22,46	FIP1L1 -PDGFRalpha T674I
19212337_5	Chemical	97,104	Nexavar
10911933_12	Gene_or_protein	11,17	CYP2A6
10911933_12	Chemical	25,40	tranylcypromine
10911933_12	Chemical	43,54	methoxsalen
10911933_12	Phenotype	83,111	activation of procarcinogens
10911933_12	Phenotype	67,74	smoking
11167824_1	Chemical	17,39	5-aza-2'-deoxycytidine
11167824_1	Disease	43,52	leukaemia
11167824_1	Gene_or_protein	64,67	MLL
11167824_1	Chemical	117,140	all-trans retinoic acid
11167824_1	Chemical	145,174	1alpha,25-dihydroxyvitamin D3
11167824_1	Genomic_variation	64,81	MLL abnormalities
11167824_1	Pharmacodynamic_phenotype	98,140	differentiation by all-trans retinoic acid
11167824_1	Pharmacodynamic_phenotype	98,116,145,174	differentiation by 1alpha,25-dihydroxyvitamin D3
11167824_1	Pharmacodynamic_phenotype	0,39	Sensitization by 5-aza-2'-deoxycytidine
22935916_9	Gene_or_protein	4,8	COMT
22935916_9	Limited_variation	4,42	COMT gene polymorphism , SNP rs9606186
22935916_9	Chemical	64,75	risperidone
22935916_9	Pharmacodynamic_phenotype	64,94	risperidone therapy efficiency
22935916_9	Limited_variation	33,42	rs9606186
21890455_1	Chemical	29,58	IMO cooperates with cetuximab
21890455_1	Gene_or_protein	0,20	Toll-like receptor 9
21890455_1	Gene_or_protein	62,67	K-ras
21890455_1	Limited_variation	62,74	K-ras mutant
21890455_1	Chemical	49,58	cetuximab
21890455_1	Chemical	29,32	IMO
21890455_1	Chemical	0,28	Toll-like receptor 9 agonist
21890455_1	Disease	62,85,101,108	K-ras mutant colorectal cancers
21890455_1	Disease	62,74,90,108	K-ras mutant pancreatic cancers
20680652_3	Limited_variation	34,48	rs622342 A > C
20680652_3	Chemical	110,119	metformin
20680652_3	Gene_or_protein	85,90	HbA1c
20680652_3	Phenotype	85,106	HbA1c lowering effect
20680652_3	Limited_variation	34,42	rs622342
16043828_13	Gene_or_protein	14,18	KRAS
16043828_13	Chemical	83,92	erlotinib
16043828_13	Limited_variation	14,26	KRAS -mutant
16043828_13	Chemical	97,109	chemotherapy
16043828_13	Chemical	83,109	erlotinib and chemotherapy
16043828_13	Pharmacodynamic_phenotype	47,64	clinical outcomes
16043828_13	Disease	14,32	KRAS -mutant NSCLC
17009149_5	Disease	88,105	colorectal cancer
17009149_5	Limited_variation	179,216	MTHFR polymorphisms in the MTHFR gene
17009149_5	Gene_or_protein	179,184	MTHFR
17009149_5	Limited_variation	219,227	677C-->T
17009149_5	Gene_or_protein	206,211	MTHFR
17009149_5	Limited_variation	230,239	Ala-->Val
17009149_5	Gene_or_protein	255,260	XRCC1
17009149_5	Limited_variation	255,303	XRCC1 gene ( Arg-->Gln substitution in exon 10 )
17009149_5	Phenotype	59,82	unresectable metastases
17009149_5	Chemical	146,152	FOLFOX
17009149_5	Chemical	124,160	chemotherapy with the FOLFOX regimen
17009149_5	Genomic_factor	294,301	exon 10
22486182_10	Gene_or_protein	96,102	VKORC1
22486182_10	Limited_variation	107,123	CYP2C9 genotypes
22486182_10	Gene_or_protein	107,113	CYP2C9
22486182_10	Chemical	187,200	acenocoumarol
22486182_10	Limited_variation	96,102,114,123	VKORC1 genotypes
22486182_10	Pharmacodynamic_phenotype	187,217	acenocoumarol dose requirement
22486182_10	Phenotype	63,93	International Normalized Ratio
16163519_2	Gene_or_protein	12,37	Dopamine beta-hydroxylase
16163519_2	Gene_or_protein	40,43	DBH
16163519_2	Chemical	55,63	dopamine
16163519_2	Chemical	74,88	norepinephrine
16163519_2	Chemical	130,143	catecholamine
16163519_2	Pharmacokinetic_phenotype	130,154	catecholamine metabolism
16163519_2	Chemical	66,68	DA
16163519_2	Chemical	91,93	NE
22085575_9	Gene_or_protein	49,59	EML4 - ALK
22085575_9	Genomic_variation	49,73	EML4 - ALK translocation
22085575_9	Gene_or_protein	110,113	ALK
22085575_9	Chemical	126,136	crozotinib
22085575_9	Chemical	110,123	ALK inhibitor
16084852_3	Haplotype	24,40	ABCB1 haplotypes
16084852_3	Gene_or_protein	24,29	ABCB1
16084852_3	Gene_or_protein	159,173	P-glycoprotein
16084852_3	Chemical	216,225	verapamil
16084852_3	Pharmacokinetic_phenotype	86,126	central nervous system drug distribution
16084852_3	Pharmacokinetic_phenotype	129,147	brain distribution
16084852_3	Chemical	153,183	model P-glycoprotein substrate
16084852_3	Chemical	190,215	calcium channel inhibitor
25902899_1	Chemical	23,32	pazopanib
25902899_1	Chemical	37,47	everolimus
25902899_1	Gene_or_protein	51,57	PIK3CA
25902899_1	Gene_or_protein	77,81	PTEN
25902899_1	Disease	110,122	solid tumors
25902899_1	Chemical	23,47	pazopanib and everolimus
25902899_1	Limited_variation	51,86	PIK3CA mutation positive/ PTEN loss
25902899_1	Pharmacodynamic_phenotype	110,153	solid tumors refractory to standard therapy
